US20060122243A1 - Antiallergic - Google Patents

Antiallergic Download PDF

Info

Publication number
US20060122243A1
US20060122243A1 US10/515,623 US51562305A US2006122243A1 US 20060122243 A1 US20060122243 A1 US 20060122243A1 US 51562305 A US51562305 A US 51562305A US 2006122243 A1 US2006122243 A1 US 2006122243A1
Authority
US
United States
Prior art keywords
group
substituted
formula
trifluoromethyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/515,623
Inventor
Susumu Muto
Akiko Itai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Medicinal Molecular Design Inc IMMD
Original Assignee
Institute of Medicinal Molecular Design Inc IMMD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Medicinal Molecular Design Inc IMMD filed Critical Institute of Medicinal Molecular Design Inc IMMD
Assigned to INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. reassignment INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ITAI, AKIKO, MUTO, SUSUMU
Publication of US20060122243A1 publication Critical patent/US20060122243A1/en
Priority to US11/783,324 priority Critical patent/US7700655B2/en
Priority to US11/783,325 priority patent/US20070185059A1/en
Priority to US11/952,686 priority patent/US20080090779A1/en
Assigned to INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. reassignment INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER LISTED ON THE NOTICE OF RECORDATION PREVIOUSLY RECORDED ON REEL 016709 FRAME 0934. ASSIGNOR(S) HEREBY CONFIRMS THE SERIAL NUMBER SHOULD READ "10/515,623". Assignors: ITAI, AKIKO, MUTO, SUSUMU
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Definitions

  • the present invention relates to pharmaceutical compositions effective for preventive and/or therapeutic treatment of allergic diseases such as pollinosis, bronchial asthma, atopic dermatitis, urticaria; endometriosis, and hysteromyoma.
  • allergic diseases such as pollinosis, bronchial asthma, atopic dermatitis, urticaria; endometriosis, and hysteromyoma.
  • Allergic diseases are understood to be caused by production of IgE by an antigen stimulation invaded in a body, and successive release of various chemical mediators such as inflammatory cytokine, histamine, leukotriene and the like by a degranulation from an activated mast cell stimulated by a complex of the antigen and IgE, thereby constriction of airway, accentuation of vascular permeability, inflammation of skin, bronchi and the like are induced.
  • antiallergic agents are understood mainly as drugs inhibiting allergic reaction type I and successively-induced allergic inflammation, particularly as drugs inhibiting the production and release of the mediators from mast cells, or those as being antagonists against the aforementioned actions.
  • steroids antihistaminic drugs
  • suppressants or inhibitors of the release of mediators and the like have been used as antiallergic agents.
  • steroids are very effective drugs, they have a problem of side effects.
  • Antihistaminic drugs are only for symptomatic therapies and fail to achieve radical therapy.
  • Suppressants or inhibitors of the release of mediators are considered to have a high effectiveness.
  • some of them lack immediate effectiveness or have central side effects. Accordingly, the antiallergic drugs currently available are not fully satisfactory as they are.
  • Endometriosis Patients with endometriosis are increasing in recent years, and currently, 10 to 14% of females are considered to be suffered from the disease. Endometriosis has been focused as a cause of sterility, as well as the disease lowers the quality of life of patients with severe pains during menstruation and coitus.
  • a therapy by using a hormone drug has been currently applied as a pseudo menopausal therapy.
  • the aforementioned therapy induces strong side effects, and it also has a risk of causing osteoporosis during a long-term administration. Therefore, at present, a drug or a method for treatment with safety and high efficacy is not available.
  • mast cells exist apparently with high density in the lesion of endometriosis (American Journal of Reproductive Immunology (New York: 1998), (Denmark), Vol. 40, No. 4, p. 291-294), and that mast cells are activated to lead degranulation (Nikkei Medical, 2002, No. 415, p. 28; Fertility and Sterility, (USA), 2002, Vol. 78, No. 4, p. 782-786).
  • an antiallergic drug which strongly inhibits activation of mast cells and can be used as a therapeutic agent for radical treatment of allergic diseases, is usable as an effective therapeutic agent for endometriosis.
  • an antiallergic agent which can be used as a therapeutic agent for radical treatment of allergic diseases, is useful as a therapeutic agent for hysteromyoma.
  • N-phenylsalicylamide derivatives are disclosed as a plant growth inhibitor in the specification of U.S. Pat. No.4,358,443.
  • said derivatives are disclosed as anti-inflammatory agents in the specification of European Patent No. 0,221,211, Japanese Patent Unexamined Publication (KOKAI) No. (Sho)62-99329, and the specification of U.S. Pat. No. 6,117,859.
  • they are disclosed as NF- ⁇ B inhibitors in the pamphlets of International Publication WO99/65499, International Publication WO02/49632, and International Publication WO02/076918, and as inhibitors against the production of cytokines in the pamphlet of International Publication WO02/051397.
  • An object of the present invention is to provide medicaments that enable radical preventive and/or therapeutic treatment of allergy by an inhibition of allergic reactions.
  • the inventors of the present invention conducted various researches on the antiallergic actions of salicylamide derivatives which are generally believed to have low toxicity.
  • N-substituted salicylamide derivatives particularly N-arylsalicylamide derivatives, specifically N-phenylsalicylamide derivatives wherein aniline moiety is substituted in both of 2- and 5-positions or in both of 3- and 5-positions
  • N-thiazol-2-yl-salicylamide derivatives wherein thiazole ring is substituted in both of 4- and 5-positions
  • the inventors also conducted researches on hydroxyaryl derivatives which are analogous compounds thereof. The present invention was achieved on the basis of these findings.
  • the present invention thus provides:
  • Examples of preferred medicaments provided by the present invention include:
  • the present invention provides use of each of the aforementioned substances for manufacture of the medicament according to the aforementioned (1) to (13).
  • the present invention further provides a method for preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma in a mammal including a human, which comprises the step of administering preventively and/or therapeutically effective amount of the aforementioned substances to a mammal including a human.
  • the present invention further provides:
  • the present invention provides:
  • the present invention provides:
  • the present invention also provides:
  • FIG. 1 shows inhibitory effect of the medicament of the present invention (compound No. 50) against immediate type allergy.
  • FIG. 2 shows inhibitory effect of the medicament of the present invention (compound No. 50) against dermatitis with an atopic dermatitis model.
  • any of fluorine atom, chlorine atom, bromine atom, or iodine atom may be used unless otherwise specifically referred to.
  • hydrocarbon group examples include, for example, an aliphatic hydrocarbon group, an aryl group, an arylene group, an aralkyl group, a bridged cyclic hydrocarbon group, a spiro cyclic hydrocarbon group, and a terpene hydrocarbon.
  • aliphatic hydrocarbon group examples include, for example, alkyl group, alkenyl group, alkynyl group, alkylene group, alkenylene group, alkylidene group and the like which are straight chain or branched chain monovalent or bivalent acyclic hydrocarbon groups; cycloalkyl group, cycloalkenyl group, cycloalkanedienyl group, cycloalkyl-alkyl group, cycloalkylene group, and cycloalkenylene group, which are saturated or unsaturated monovalent or bivalent alicyclic hydrocarbon groups.
  • alkyl group examples include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, 1-methylbutyl, neopentyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1-ethylbutyl, 1-ethyl-1-methylpropyl, n-heptyl, n-octyl, methyl
  • alkenyl group examples include, for example, vinyl, prop-1-en-1-yl, allyl, isopropenyl, but-1-en-1-yl, but-2-en-1-yl, but-3-en-1-yl, 2-methylprop-2-en-1-yl, 1-methylprop-2-en-1-yl, pent-1-en-1-yl, pent-2-en-1-yl, pent-3-en-1-yl, pent-4-en-1-yl, 3-methylbut-2-en-1-yl, 3-methylbut-3-en-1-yl, hex-1-en-1-yl, hex-2-en-1-yl, hex-3-en-1-yl, hex-4-en-1-yl, hex-5-en-1-yl, 4-methylpent-3-en-1-yl, 4-methylpent-3-en-1-yl, 4-methylpent-3-en-1-yl, 4-methylpent-3-en-1-yl, 4-methylpent-3-en
  • alkynyl group examples include, for example, ethynyl, prop-1-yn-1-yl, prop-2-yn-1-yl, but-1-yn-1-yl, but-3-yn-1-yl, 1-methylprop-2-yn-1-yl, pent-1-yn-1-yl, pent-4-yn-1-yl, hex-1-yn-1-yl, hex-5-yn-1-yl, hept-1-yn-1-yl, hept-6-yn-1-yl, oct-1-yn-1-yl, oct-7-yn-1-yl, non-1-yn-1-yl, non-8-yn-1-yl, dec-1-yn-1-yl, dec-9-yn-1-yl, undec-1-yn-1-yl, undec-10-yn-1-yl, dodec-1-yn-1-yl, dodec-11-yn-1-y
  • alkylene group examples include, for example, methylene, ethylene, ethane-1,1-diyl, propane-1,3-diyl, propane-1,2-diyl, propane-2,2-diyl, butane-1,4-diyl, pentane-1,5-diyl, hexane-1,6-diyl, and 1,1,4,4-tetramethylbutane-1,4-diyl group, which are C 1 to C 8 straight chain or branched chain alkylene groups.
  • alkenylene group examples include, for example, ethene-1,2-diyl, propene-1,3-diyl, but-1-ene-1,4-diyl, but-2-ene-1,4-diyl, 2-methylpropene-1,3-diyl, pent-2-ene-1,5-diyl, and hex-3-ene-1,6-diyl, which are C 1 to C 6 straight chain or branched chain alkylene groups.
  • alkylidene group examples include, for example, methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene, and hexylidene, which are C 1 to C 6 straight chain or branched chain alkylidene groups.
  • cycloalkyl group examples include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, which are C 3 to C 8 cycloalkyl groups.
  • the aforementioned cycloalkyl group may be fused with benzene ring, naphthalene ring and the like, and examples include, for example, 1-indanyl, 2-indanyl, 1,2,3,4-tetrahydronaphthalen-1-yl, and 1,2,3,4-tetrahydronaphthalen-2-yl.
  • cycloalkenyl group examples include, for example, 2-cyclopropen-1-yl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 1-cyclobuten-1-yl, and 1-cyclopenten-1-yl, which are C 3 to C 6 cycloalkenyl groups.
  • the aforementioned cycloalkenyl group may be fused with benzene ring, naphthalene ring and the like, and examples include, for example, 1-indanyl, 2-indanyl, 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 1-indenyl, and 2-indenyl.
  • cycloalkanedienyl group examples include, for example, 2,4-cyclopentadien-1-yl, 2,4-cyclohexanedien-1-yl, and 2,5-cyclohexanedien-1-yl, which are C 5 to C 6 cycloalkanedienyl groups.
  • the aforementioned cycloalkanedienyl group may be fused with benzene ring, naphthalene ring and the like, and examples include, for example, 1-indenyl and 2-indenyl.
  • Examples of the cycloalkyl-alkyl group include the groups in which one hydrogen atom of the alkyl group is substituted with a cycloalkyl group, and include, for example, cyclopropylmethyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 3-cyclopropylpropyl, 4-cyclopropylbutyl, 5-cyclopropylpentyl, 6-cyclopropylhexyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylpropyl, cyclohexylbutyl, cycloheptylmethyl, cyclooctylmethyl, and 6-cyclooctylhexyl, which are C 4 to C 14 cycloalkyl-alkyl groups.
  • cycloalkylene group examples include, for example, cyclopropane-1,1-diyl, cyclopropane-1,2-diyl, cyclobutane-1,1-diyl, cyclobutane-1,2-diyl, cyclobutane-1,3-diyl, cyclopentane-1,1-diyl, cyclopentane-1,2-diyl, cyclopentane-1,3-diyl, cyclohexane-1,1-diyl, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl, cyclohexane-1,4-diyl, cycloheptane-1,1-diyl, cycloheptane-1,2-diyl, cyclooctane-1,1-diyl, and cyclooctane-1,2-
  • Examples of the cycloalkenylene group include, for example, 2-cyclopropene-1,1-diyl, 2-cyclobutene-1,1-diyl, 2-cyclopentene-1,1-diyl, 3-cyclopentene-1,1-diyl, 2-cyclohexene-1,1-diyl, 2-cyclohexene-1,2-diyl, 2-cyclohexene-1,4-diyl, 3-cyclohexene-1,1-diyl, 1-cyclobutene-1,2-diyl, 1-cyclopentene-1,2-diyl, and 1-cyclohexene-1,2-diyl, which are C 3 to C 6 cycloalkenylene groups.
  • aryl group examples include a monocyclic or a fused polycyclic aromatic hydrocarbon group, and include, for example, phenyl, 1-naphthyl, 2-naphthyl, anthryl, phenanthryl, and acenaphthylenyl, which are C 6 to C 14 aryl groups.
  • the aforementioned aryl group may be fused with the aforementioned C 3 to C 8 cycloalkyl group, C 3 to C 6 cycloalkenyl group, C 5 to C 6 cycloalkanedienyl group or the like, and examples include, for example, 4-indanyl, 5-indanyl, 1,2,3,4-tetrahydronaphthalen-5-yl, 1,2,3,4-tetrahydronaphthalen-6-yl, 3-acenaphthenyl, 4-acenaphthenyl, inden-4-yl, inden-5-yl, inden-6-yl, inden-7-yl, 4-phenalenyl, 5-phenalenyl, 6-phenalenyl, 7-phenalenyl, 8-phenalenyl, and 9-phenalenyl.
  • arylene group examples include, for example, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, naphthalene-1,2-diyl, naphthalene-1,3-diyl, naphthalene-1,4-diyl, naphthalene-1,5-diyl, naphthalene-1,6-diyl, naphthalene-1,7-diyl, naphthalene-1,8-diyl, naphthalene-2,3-diyl, naphthalene-2,4-diyl, naphthalene-2,5-diyl, naphthalene-2,6-diyl, naphthalene-2,7-diyl, naphthalene-2,8-diyl, and anthracene-1,4-diyl, which are C 6 to C 14 arylene groups.
  • aralkyl group examples include the groups in which one hydrogen atom of the alkyl group is substituted with an aryl group, and include, for example, benzyl, 1-naphthylmethyl, 2-naphthylmethyl, anthracenylmethyl, phenanthrenylmethyl, acenaphthylenylmethyl, diphenylmethyl, 1-phenethyl, 2-phenethyl, 1-(1-naphthyl)ethyl, 1-(2-naphthyl)ethyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl, 3-phenylpropyl, 3-(1-naphthyl)propyl, 3-(2-naphthyl)propyl, 4-phenylbutyl, 4-(1-naphthyl)butyl, 4-(2-naphthyl)but
  • bridged cyclic hydrocarbon group examples include, for example, bicyclo[2.1.0]pentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]octyl, and adamantyl.
  • spiro cyclic hydrocarbon group examples include, for example, spiro[3.4]octyl, and spiro[4.5]deca-1,6-dienyl.
  • terpene hydrocarbon examples include, for example, geranyl, neryl, linalyl, phytyl, menthyl, and bornyl.
  • halogenated alkyl group examples include the groups in which one hydrogen atom of the alkyl group is substituted with a halogen atom, and include, for example, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, iodomethyl, diiodomethyl, triiodomethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl, heptafluoropropyl, heptafluoroisopropyl, nonafluorobutyl, and perfluorohexyl, which are C 1 to C 6 straight chain or branched chain halogenated alkyl groups substituted with 1 to 13 halogen atoms.
  • heterocyclic group examples include, for example, a monocyclic or a fused polycyclic hetero aryl group which comprises at least one atom of 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like as ring-constituting atoms (ring forming atoms), and a monocyclic or a fused polycyclic non-aromatic heterocyclic group which comprises at least one atom of 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like as ring-constituting atoms (ring forming atoms).
  • Examples of the monocyclic heteroaryl group include, for example, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, (1,2,3-oxadiazol)-4-yl, (1,2,3-oxadiazol)-5-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-5-yl,
  • fused polycyclic heteroaryl group examples include, for example, 2-benzofuranyl, 3-benzofuranyl, 4-benzofuranyl, 5-benzofuranyl, 6-benzofuranyl, 7-benzofuranyl, 1-isobenzofuranyl, 4-isobenzofuranyl, 5-isobenzofuranyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 4-benzo[b]thienyl, 5-benzo[b]thienyl, 6-benzo[b]thienyl, 7-benzo[b]thienyl, 1-benzo[c]thienyl, 4-benzo[c]thienyl, 5-benzo[c]thienyl, 1-indolyl, 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, (2H-isoindol)-1
  • Examples of the monocyclic non-aromatic heterocyclic group include, for example, 1-aziridinyl, 1-azetidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrofuryl, 3-tetrahydrofuryl, thiolanyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 1-(2-pyrrolinyl), 1-(2-imidazolinyl), 2-(2-imidazolinyl), 1-(2-pyrazolinyl), 3-(2-pyrazolinyl), piperidino, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-homopiperidinyl, 2-tetrahydropyranyl, morpholino, (thiomorpholin)-4-yl, 1-piperazinyl
  • fused polycyclic non-aromatic heterocyclic group examples include, for example, 2-quinuclidinyl, 2-chromanyl, 3-chromanyl, 4-chromanyl, 5-chromanyl, 6-chromanyl, 7-chromanyl, 8-chromanyl, 1-isochromanyl, 3-isochromanyl, 4-isochromanyl, 5-isochromanyl, 6-isochromanyl, 7-isochromanyl, 8-isochromanyl, 2-thiochromanyl, 3-thiochromanyl, 4-thiochromanyl, 5-thiochromanyl, 6-thiochromanyl, 7-thiochromanyl, 8-thiochromanyl, 1-isothiochromanyl, 3-isothiochromanyl, 4-isothiochromanyl, 5-isothiochromanyl, 6-isothiochromanyl, 7-isothiochromanyl, 8-thio
  • a monocyclic or a fused polycyclic hetero aryl groups which may have 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, in addition to the nitrogen atom that has the bond, as ring-constituting atoms (ring forming atoms)
  • a monocyclic or a fused polycyclic non-aromatic heterocyclic groups which may have 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, in addition to the nitrogen atom that has the bond, as ring-constituting atoms (ring forming atoms) are referred to as “cyclic amino group.”
  • Examples include, for example, 1-pyrrolidinyl, 1-imidazolidinyl, 1-pyrazolidinyl, 1-oxazolidinyl, 1-thiazolidinyl, piperidino, morpholino, 1-piperazinyl, thiomorpholin
  • cyclic group The aforementioned cycloalkyl group, cycloalkenyl group, cycloalkanedienyl group, aryl group, cycloalkylene group, cycloalkenylene group, arylene group, bridged cyclic hydrocarbon group, spiro cyclic hydrocarbon group, and heterocyclic group are generically referred to as “cyclic group.” Furthermore, among said cyclic groups, particularly, aryl group, arylene group, monocyclic heteroaryl group, and fused polycyclic heteroaryl group are generically referred to as “aromatic ring group.”
  • hydrocarbon-oxy group examples include the groups in which a hydrogen atom of the hydroxy group is substituted with a hydrocarbon group, and examples of the hydrocarbon include similar groups to the aforementioned hydrocarbon groups.
  • hydrocarbon-oxy group examples include, for example, alkoxy group (alkyl-oxy group), alkenyl-oxy group, alkynyl-oxy group, cycloalkyl-oxy group, cycloalkyl-alkyl-oxy group and the like, which are aliphatic hydrocarbon-oxy groups; aryl-oxy group; aralkyl-oxy group; and alkylene-dioxy group.
  • alkoxy examples include, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, 2-methylbutoxy, 1-methylbutoxy, neopentyloxy, 1,2-dimethylpropoxy, 1-ethylpropoxy, n-hexyloxy, 4-methylpentyloxy, 3-methylpentyloxy, 2-methylpentyloxy, 1-methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethybutoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy, 2-ethylbutoxy, 1-ethyl-1-methylpropoxy, n-heptyloxy, n-octyloxy, n
  • alkenyl-oxy group examples include, for example, vinyloxy, (prop-1-en-1-yl)oxy, allyloxy, isopropenyloxy, (but-1-en-1-yl)oxy, (but-2-en-1-yl)oxy, (but-3-en-1-yl)oxy, (2-methylprop-2-en-1-yl)oxy, (1-methylprop-2-en-1-yl)oxy, (pent-1-en-1-yl)oxy, (pent-2-en-1-yl)oxy, (pent-3-en-1-yl)oxy, (pent-4-en-1-yl)oxy, (3-methylbut-2-en-1-yl)oxy, (3-methylbut-3-en-1-yl)oxy, (hex-1-en-1-yl)oxy, (hex-2-en-1-yl)oxy, (hex-3-en-1-yl)oxy, (hex-4-en-1-yl)oxy, (hex-5-en-1-yl)oxy, (4-methyl
  • alkynyl-oxy group examples include, for example, ethynyloxy, (prop-1-yn-1-yl)oxy, (prop-2-yn-1-yl)oxy, (but-1-yn-1-yl)oxy, (but-3-yn-1-yl)oxy, (1-methylprop-2-yn-1-yl)oxy, (pent-1-yn-1-yl)oxy, (pent-4-yn-1-yl)oxy, (hex-1-yn-1-yl)oxy, (hex-5-yn-1-yl)oxy, (hept-1-yn-1-yl)oxy, (hept-6-yn-1-yl)oxy, (oct-1-yn-1-yl)oxy, (oct-7-yn-1-yl)oxy, (non-1-yn-1-yl)oxy, (non-8-yn-1-yl)oxy, (dec-1-yn-1-yl)oxy, (dec-9-yny
  • cycloalkyl-oxy group examples include, for example, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and cyclooctyloxy, which are C 3 to C 8 cycloalkyl-oxy groups.
  • cycloalkyl-alkyl-oxy group examples include, for example, cyclopropylmethoxy, 1-cyclopropylethoxy, 2-cyclopropylethoxy, 3-cyclopropylpropoxy, 4-cyclopropylbutoxy, 5-cyclopropylpentyloxy, 6-cyclopropylhexyloxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-cyclohexylethoxy, 3-cyclohexylpropoxy, 4-cyclohexylbutoxy, cycloheptylmethoxy, cyclooctylmethoxy, and 6-cyclooctylhexyloxy, which are C 4 to C 14 cycloalkyl-alkyl-oxy groups.
  • aryl-oxy group examples include, for example, phenoxy, 1-naphthyloxy, 2-naphthyloxy, anthryloxy, phenanthryloxy, and acenaphthylenyloxy, which are C 6 to C 14 aryl-oxy groups.
  • aralkyl-oxy group examples include, for example, benzyloxy, 1-naphthylmethoxy, 2-naphthylmethoxy, anthracenylmethoxy, phenanthrenylmethoxy, acenaphthylenylmethoxy, diphenylmethoxy, 1-phenethyloxy, 2-phenethyloxy, 1-(1-naphthyl)ethoxy, 1-(2-naphthyl)ethoxy, 2-(1-naphthyl)ethoxy, 2-(2-naphthyl)ethoxy, 3-phenylpropoxy, 3-(1-naphthyl)propoxy, 3-(2-naphthyl)propoxy, 4-phenylbutoxy, 4-(1-naphthyl)butoxy, 4-(2-naphthyl)butoxy, 5-phenylpentyloxy, 5-(1-n-
  • alkylenedioxy group examples include, for example, methylenedioxy, ethylenedioxy, 1-methylmethylenedioxy, and 1,1-dimethylmethylenedioxy.
  • halogenated alkoxy group examples include the groups in which a hydrogen atom of the hydroxy group is substituted with a halogenated alkyl group, and include, for example, fluoromethoxy, difluoromethoxy, chloromethoxy, bromomethoxy, iodomethoxy, trifluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, 3,3,3-trifluoropropoxy, heptafluoropropoxy, heptafluoroisopropoxy, nonafluorobutoxy, and perfluorohexyloxy, which are C 1 to C 6 straight chain or branched chain halogenated alkoxy groups substituted with 1 to 13 halogen atoms.
  • heterocyclic-oxy group examples include the groups in which a hydrogen atom of the hydroxy group is substituted with a heterocyclic group, and examples of the heterocyclic ring include similar groups to the aforementioned heterocyclic groups.
  • heterocyclic-oxy group examples include, for example, a monocyclic heteroaryl-oxy group, a fused polycyclic heteroaryl-oxy group, a monocyclic non-aromatic heterocyclic-oxy group, and a fused polycyclic non-aromatic heterocyclic-oxy group.
  • Examples of the monocyclic heteroaryl-oxy group include, for example, 3-thienyloxy, (isoxazol-3-yl)oxy, (thiazol-4-yl)oxy, 2-pyridyloxy, 3-pyridyloxy, 4-pyridyloxy, and (pyrimidin-4-yl)oxy.
  • fused polycyclic heteroaryl-oxy group examples include, for example, 5-indolyloxy, (benzimidazol-2-yl)oxy, 2-quinolyloxy, 3-quinolyloxy, and 4-quinolyloxy.
  • Examples of the monocyclic non-aromatic heterocyclic-oxy group include, for example, 3-pyrrolidinyloxy, and 4-piperidinyloxy.
  • fused polycyclic non-aromatic heterocyclic-oxy group examples include, for example, 3-indolynyloxy, and 4-chromanyloxy.
  • hydrocarbon-sulfanyl group examples include the groups in which a hydrogen atom of the sulfanyl group is substituted with a hydrocarbon group, and examples of the hydrocarbon include similar groups to the aforementioned hydrocarbon groups.
  • hydrocarbon-sulfanyl groups include, for example, alkyl-sulfanyl group, alkenyl-sulfanyl group, alkynyl-sulfanyl group, cycloalkyl-sulfanyl group, cycloalkyl-alkyl-sulfanyl group and the like, which are aliphatic hydrocarbon-sulfanyl groups; aryl-sulfanyl group, and aralkyl-sulfanyl group.
  • alkyl-sulfanyl group examples include, for example, methylsulfanyl, ethylsulfanyl, n-propylsulfanyl, isopropylsulfanyl, n-butylsulfanyl, isobutylsulfanyl, sec-butylsulfanyl, tert-butylsulfanyl, n-pentylsulfanyl, isopentylsulfanyl, (2-methylbutyl)sulfanyl, (1-methylbutyl)sulfanyl, neopentylsulfanyl, (1,2-dimethylpropyl)sulfanyl, (1-ethylpropyl)sulfanyl, n-hexylsulfanyl, (4-methylpentyl)sulfanyl, (3-methylpentyl)sulfanyl, (2-methylpentyl)sulfanyl
  • alkenyl-sulfanyl group examples include, for example, vinylsulfanyl, (prop-1-en-1-yl)sulfanyl, allylsulfanyl, isopropenylsulfanyl, (but-1-en-1-yl)sulfanyl, (but-2-en-1-yl)sulfanyl, (but-3-en-1-yl)sulfanyl, (2-methylprop-2-en-1-yl)sulfanyl, (1-methylprop-2-en-1-yl)sulfanyl, (pent-1-en-1-yl)sulfanyl, (pent-2-en-1-yl)sulfanyl, (pent-3-en-1-yl)sulfanyl, (pent-4-en-1-yl)sulfanyl, (3-methylbut-2-en-1-yl)sulfanyl, (3-methylbut-3-en-1-yl)sulfanyl, (hex-1
  • alkynyl-sulfanyl group examples include, for example, ethynylsulfanyl, (prop-1-yn-1-yl)sulfanyl, (prop-2-yn-1-yl)sulfanyl, (but-1-yn-1-yl)sulfanyl, (but-3-yn-1-yl)sulfanyl, (1-methylprop-2-yn-1-yl)sulfanyl, (pent-1-yn-1-yl)sulfanyl, (pent-4-yn-1-yl)sulfanyl, (hex-1-yn-1-yl)sulfanyl, (hex-5-yn-1-yl)sulfanyl, (hept-1-yn-1-yl)sulfanyl, (hept-6-yn-1-yl)sulfanyl, (oct-1-yn-1-yl)sulfanyl, (oct-7-yn
  • cycloalkyl-sulfanyl group examples include, for example, cyclopropylsulfanyl, cyclobutylsulfanyl, cyclopentylsulfanyl, cyclohexylsulfanyl, cycloheptylsulfanyl, and cyclooctylsulfanyl, which are C 3 to C 8 cycloalkyl-sulfanyl groups.
  • cycloalkyl-alkyl-sulfanyl group examples include, for example, (cyclopropylmethyl)sulfanyl, (1-cyclopropylethyl)sulfanyl, (2-cyclopropylethyl)sulfanyl, (3-cyclopropylpropyl)sulfanyl, (4-cyclopropylbutyl)sulfanyl, (5-cyclopropylpentyl)sulfanyl, (6-cyclopropylhexyl)sulfanyl, (cyclobutylmethyl)sulfanyl, (cyclopentylmethyl)sulfanyl, (cyclobutylmethyl)sulfanyl, (cyclopentylmethyl)sulfanyl, (cyclohexylmethyl)sulfanyl, (2-cyclohexylethyl)sulfanyl, (3-cyclohexylpropyl)sulfanyl, (4-cyclohex
  • aryl-sulfanyl group examples include, for example, phenylsulfanyl, 1-naphthylsulfanyl, 2-naphthylsulfanyl, anthrylsulfanyl, fenanthrylsulfanyl, and acenaphthylenylsulfanyl, which are C 6 to C 14 aryl-sulfanyl groups.
  • aralkyl-sulfanyl group examples include, for example, benzylsulfanyl, (1-naphthylmethyl)sulfanyl, (2-naphthylmethyl)sulfanyl, (anthracenylmethyl)sulfanyl, (phenanthrenylmethyl)sulfanyl, (acenaphthylenylmethyl)sulfanyl, (diphenylmethyl)sulfanyl, (1-phenethyl)sulfanyl, (2-phenethyl)sulfanyl, (1-(1-naphthyl)ethyl)sulfanyl, (1-(2-naphthyl)ethyl)sulfanyl, (2-(1-naphthyl)ehyl)sulfanyl, (2-(2-naphthyl)ethyl)sulfanyl, (3-phenylpropy
  • halogenated alkyl-sulfanyl group examples include the groups in which a hydrogen atom of the sulfanyl group is substituted with a halogenated alkyl group, and include, for example, (fluoromethyl)sulfanyl, (chloromethyl)sulfanyl, (bromomethyl)sulfanyl, (iodomethyl)sulfanyl, (difluoromethyl)sulfanyl, (trifluoromethyl)sulfanyl, (trichloromethyl)sulfanyl, (2,2,2-trifluoroethyl)sulfanyl, (pentafluoroethyl)sulfanyl, (3,3,3-trifluoropropyl)sulfanyl, (heptafluoropropyl)sulfanyl, (heptafluoroisopropyl)sulfanyl, (nonafluorobutyl)sulfanyl, and
  • heterocyclic-sulfanyl group examples include the groups in which a hydrogen atom of the sulfanyl group is substituted with a heterocyclic group, and examples of the heterocyclic ring include similar groups to the aforementioned heterocyclic groups.
  • heterocyclic-sulfanyl group examples include, for example, a monocyclic heteroaryl-sulfanyl group, a fused polycyclic heteroaryl-sulfanyl group, a monocyclic non-aromatic heterocyclic-sulfanyl group, and a fused polycyclic non-aromatic heterocyclic-sulfanyl group.
  • Examples of the monocyclic heteroaryl-sulfanyl group include, for example, (imidazol-2-yl)sulfanyl, (1,2,4-triazol-2-yl)sulfanyl, (pyridin-2-yl)sulfanyl, (pyridin-4-yl)sulfanyl, and (pyrimidin-2-yl)sulfanyl.
  • fused polycyclic heteroaryl-sulfanyl group examples include, for example, (benzimidazol-2-yl)sulfanyl, (quinolin-2-yl)sulfanyl, and (quinolin-4-yl)sulfanyl.
  • Examples of the monocyclic non-aromatic heterocyclic-sulfanyl groups include, for example, (3-pyrrolidinyl)sulfanyl, and (4-piperidinyl)sulfanyl.
  • fused polycyclic non-aromatic heterocyclic-sulfanyl group examples include, for example, (3-indolinyl)sulfanyl, and (4-chromanyl)sulfanyl.
  • acyl group examples include, for example, formyl group, glyoxyloyl group, thioformyl group, carbamoyl group, thiocarbamoyl group, sulfamoyl group, sulfinamoyl group, carboxy group, sulfo group, phosphono group, and groups represented by the following formulas:
  • hydrocarbon-carbonyl group examples include, for example, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, lauroyl, myristoryl, palmitoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, isocrotonoyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, 1-naphthoyl, 2-naphthoyl, and phenylacetyl, and those groups in which R a1 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl group” whose examples include, for example, 2-thenoyl,
  • hydrocarbon-oxy-carbonyl group examples include, for example, methoxycarbonyl, ethoxycarbonyl, phenoxycarbonyl, and benzyloxycarbonyl
  • heterocyclic ring-oxy-carbonyl group examples include, for example, 3-pyridyloxycarbonyl.
  • hydrocarbon-carbonyl-carbonyl group whose examples include, for example, pyruvoyl
  • heterocyclic ring-carbonyl-carbonyl group examples include, for example, pyruvoyl
  • hydrocarbon-oxy-carbonyl-carbonyl group examples include, for example, methoxalyl and ethoxalyl groups
  • heterocyclic ring-oxy-carbonyl-carbonyl group examples include, for example, methoxalyl and ethoxalyl groups
  • N-hydrocarbon-carbamoyl group whose examples include, for example, N-methylcarbamoyl group
  • R a1 is a heterocyclic group
  • N-hydrocarbon-sulfamoyl group those groups in which R a1 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfamoyl group,” and those groups in which R a1 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfamoyl group.”
  • N-hydrocarbon-sulfinamoyl group those groups in which R a1 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfinamoyl group,” and those groups in which R a1 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfinamoyl group.”
  • hydrocarbon-sulfonyl group whose examples include, for example, methanesulfonyl and benzenesulfonyl
  • heterocyclic ring-sulfonyl group examples include, for example, methanesulfonyl and benzenesulfonyl
  • hydrocarbon-sulfinyl group whose examples include, for example, methylsulfinyl and benzenesulfinyl
  • heterocyclic ring-sulfinyl group examples include, for example, methylsulfinyl and benzenesulfinyl
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas ( ⁇ -1A) through ( ⁇ -21A) include the similar groups to the aforementioned hydrocarbon group.
  • Examples of the hydrocarbon-carbonyl group represented by the formula ( ⁇ -1A) include, for example, an alkyl-carbonyl group, an alkenyl-carbonyl group, an alkynyl-carbonyl group, a cycloalkyl-carbonyl group, a cycloalkenyl-carbonyl group, a cycloalkanedienyl-carbonyl group, a cycloalkyl-alkyl-carbonyl group, which are aliphatic hydrocarbon-carbonyl groups; an aryl-carbonyl group; an aralkyl-carbonyl group; a bridged cyclic hydrocarbon-carbonyl group; a spirocyclic hydrocarbon-carbonyl group; and a terpene family hydrocarbon-carbonyl group.
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas ( ⁇ -1A) through ( ⁇ -21A) include similar groups to the aforementioned heterocyclic group.
  • Examples of the heterocyclic ring-carbonyl group represented by the formula ( ⁇ -1A) include, for example, a monocyclic heteroaryl-carbonyl group, a fused polycyclic heteroaryl-carbonyl group, a monocyclic non-aromatic heterocyclic ring-carbonyl group, and a fused polycyclic non-aromatic heterocyclic ring-carbonyl group.
  • groups represented by the formulas ( ⁇ -2A) through ( ⁇ -21A) are similar to those explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas ( ⁇ -10A) through ( ⁇ -16A) include similar groups to the aforementioned cyclic amino group.
  • substituent existing in the functional group examples include, for example, halogen atoms, oxo group, thioxo group, nitro group, nitroso group, cyano group, isocyano group, cyanato group, thiocyanato group, isocyanato group, isothiocyanato group, hydroxy group, sulfanyl group, carboxy group, sulfanylcarbonyl group, oxalo group, methooxalo group, thiocarboxy group, dithiocarboxy group, carbamoyl group, thiocarbamoyl group, sulfo group, sulfamoyl group, sulfino group, sulfinamoyl group, sulfeno group, sulfenamoyl group, phosphono group, hydroxyphosphonyl group, hydrocarbon group, heterocyclic group, hydrocarbon-oxy group, heterocyclic ring-oxy group
  • substituents When two or more substituents exist according to the aforementioned definition of “which may be substituted,” said two or more substituents may combine to each other, together with atom(s) to which they bind, to form a ring.
  • substituents for these cyclic groups, as ring-constituting atoms (ring forming atoms), one to three kinds of one or more hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like may be included, and one or more substituents may exist on the ring.
  • the ring may be monocyclic or fused polycyclic, and aromatic or non-aromatic.
  • substituents according to the aforementioned definition of “which may be substituted” may further be substituted with the aforementioned substituents at the chemically substitutable positions on the substituent.
  • Kind of substituents, number of substituents, and positions of substituents are not particularly limited, and when the substituents are substituted with two or more substituents, they may be the same or different.
  • substituents include, for example, a halogenated alkyl-carbonyl group whose examples include, for example, trifluoroacetyl, a halogenated alkyl-sulfonyl group whose examples include, for example, trifluoromethanesulfonyl, an acyl-oxy group, an acyl-sulfanyl group, an N-hydrocarbon-amino group, an N,N-di(hydrocarbon)-amino group, an N-heterocyclic ring-amino group, an N-hydrocarbon-N-heterocyclic ring-amino group, an acyl-amino group, and a di(acyl)-amino group.
  • substitution on the aforementioned substituents may be repeated multiple orders.
  • acyl-oxy group examples include the groups in which hydrogen atom of hydroxy group is substituted with acyl group, and include, for example, formyloxy group, glyoxyloyloxy group, thioformyloxy group, carbamoloxy group, thiocarbamoyloxy group, sulfamoyloxy group, sulfinamoloxy group, carboxyoxy group, sulphooxy group, phosphonooxy group, and groups represented by the following formulas:
  • acyl-oxy group among the groups represented by the formula ( ⁇ -1B), those groups in which R a2 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-oxy group” whose examples include, for example, acetoxy and benzoyloxy, and those groups in which R a2 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl-oxy group.”
  • N-hydrocarbon-carbamoyl-oxy group those groups in which R a2 is a hydrocarbon group are referred to as “N-hydrocarbon-carbamoyl-oxy group,” and those groups in which R a2 is a heterocyclic group are referred to as “N-heterocyclic ring-carbamoyl-oxy group.”
  • N-hydrocarbon-sulfamoyl-oxy group those groups in which R a2 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfamoyl-oxy group,” and those groups in which R a2 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfamoyl-oxy group.”
  • N-hydrocarbon-sulfinamoyl-oxy group those groups in which R a2 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfinamoyl-oxy group,” and those groups where R a2 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfinamoyl-oxy group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas ( ⁇ -1B) through ( ⁇ -21B) include the similar groups to the aforementioned hydrocarbon group.
  • Examples of the hydrocarbon-carbonyl-oxy group represented by the formula ( ⁇ -1B) include, for example, an alkyl-carbonyl-oxy group, an alkenyl-carbonyl-oxy group, an alkynyl-carbonyl-oxy group, a cycloalkyl-carbonyl-oxy group, a cycloalkenyl-carbonyl-oxy group, a cycloalkanedienyl-carbonyl-oxy group, and a cycloalkyl-alkyl-carbonyl-oxy group, which are aliphatic hydrocarbon-carbonyl-oxy groups; an aryl-carbonyl-oxy group; an aralkyl-carbonyl-oxy group; a bridged cyclic hydrocarbon-carbonyl-oxy group; a spirocyclic hydrocarbon-carbonyl
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas ( ⁇ -1B) through ( ⁇ -21B) include similar groups to the aforementioned heterocyclic group.
  • Examples of the heterocyclic ring-carbonyl group represented by the formula ( ⁇ -1B) include, for example, a monocyclic heteroaryl-carbonyl group, a fused polycyclic heteroaryl-carbonyl group, a monocyclic non-aromatic heterocyclic ring-carbonyl group, and a fused polycyclic non-aromatic heterocyclic ring-carbonyl group.
  • groups represented by the formulas ( ⁇ -2B) through ( ⁇ -21B) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas ( ⁇ -10B) through ( ⁇ -16B) include similar groups to the aforementioned cyclic amino group.
  • acyl-oxy group hydrocarbon-oxy group, and heterocyclic-oxy group are generically referred to as “substituted oxy group.”
  • substituted oxy group hydrocarbon-oxy group, and heterocyclic-oxy group are generically referred to as “substituted oxy group.”
  • substituted oxy group and hydroxy group are generically referred to as “hydroxy group which may be substituted.”
  • acyl-sulfanyl group examples include the groups in which hydrogen atom of sulfanyl group is substituted with acyl group, and include, for example, formylsulfanyl group, glyoxyloylsulfanyl group, thioformylsulfanyl group, carbamoyloxy group, thicarbamoyloxy group, sulfamoyloxy group, sulfinamoyloxy group, carboxyoxy group, sulphooxy group, phosphonooxy group, and groups represented by the following formulas:
  • acyl-sulfanyl group among the groups represented by the formula ( ⁇ -1C), those groups in which R a3 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-sulfanyl group,” and those groups in which R a3 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl-sulfanyl group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas ( ⁇ -1C) through ( ⁇ -21C) include similar groups to the aforementioned hydrocarbon group.
  • Examples of the hydrocarbon-carbonyl-sulfanyl group represented by the formula ( ⁇ -1C) include, for example, an alkyl-carbonyl-sulfanyl group, an alkenyl-carbonyl-sulfanyl group, an alkynyl-carbonyl-sulfanyl group, a cycloalkyl-carbonyl-sulfanyl group, a cycloalkenyl-carbonyl-sulfanyl group, a cycloalkanedienyl-carbonyl-sulfanyl group, a cycloalkyl-alkyl-carbonyl-sulfanyl group which are aliphatic hydrocarbon-carbonyl-sulfanyl groups; an aryl-carbonyl-sulfanyl group; an aralkyl-carbon
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas ( ⁇ -1C) through ( ⁇ -21C) include similar groups to the aforementioned heterocyclic group.
  • Examples of the heterocyclic ring-carbonyl-sulfanyl group represented by the formula ( ⁇ -1C) include, for example, a monocyclic heteroaryl-carbonyl-sulfanyl group, a fused polycyclic heteroaryl-carbonyl-sulfanyl group, a monocyclic non-aromatic heterocyclic ring-carbonyl-sulfanyl group, and a fused polycyclic non-aromatic heterocyclic ring-carbonyl-sulfanyl group.
  • groups represented by the formula ( ⁇ -2C) through ( ⁇ -21C) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas ( ⁇ -1C) through ( ⁇ -16C) include similar groups to the aforementioned cyclic amino group.
  • acyl-sulfanyl group hydrocarbon-sulfanyl group, and heterocyclic-sulfanyl group are generically referred to as “substituted sulfanyl group.”
  • substituted sulfanyl group and sulfanyl group are generically referred to as “sulfanyl group which may be substituted.”
  • N-hydrocarbon-amino group examples include the groups in which one hydrogen atom of amino group is substituted with a hydrocarbon group, and include, for example, an N-alkyl-amino group, an N-alkenyl-amino group, an N-alkynyl-amino group, an N-cycloalkyl-amino group, an N-cycloalkyl-alkyl-amino group, an N-aryl-amino group, and an N-aralkyl-amino group.
  • N-alkyl-amino group examples include, for example, methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, tert-butylamino, n-pentylamino, isopentylamino, (2-methylbutyl)amino, (1-methylbutyl)amino, neopentylamino, (1,2-dimethylpropyl)amino, (1-ethylpropyl)amino, n-hexylamino, (4-methylpentyl)amino, (3-methylpentyl)amino, (2-methylpentyl)amino, (1-methylpentyl)amino, (3,3-dimethylbutyl)amino, (2,2-dimethylbutyl)amino, (1,1-di
  • N-alkenyl-amino group examples include, for example, vinyl amino, (prop-1-en-1-yl)amino, allylamino, isopropenylamino, (but-1-en-1-yl)amino, (but-2-en-1-yl)amino, (but-3-en-1-yl)amino, (2-methylprop-2-en-1-yl)amino, (1-methylprop-2-en-1-yl)amino, (pent-1-en-1-yl)amino, (pent-2-en-1-yl)amino, (pent-3-en-1-yl)amino, (pent-4-en-1-yl)amino, (3-methylbut-2-en-1-yl)amino, (3-methylbut-3-en-1-yl)amino, (hex-1-en-1-yl)amino, (hex-2-en-1-yl)amino, (hex-3-en-1-y
  • N-alkynyl-amino group examples include, for example, ethynylamino, (prop-1-yn-1-yl)amino, (prop-2-yn-1-yl)amino, (but-1-yn-1-yl)amino, (but-3-yn-1-yl)amino, (1-methylprop-2-yn-1-yl)amino, (pent-1-yn-1-yl)amino, (pent-4-yn-1-yl)amino, (hex-1-yn-1-yl)amino, (hex-5-yn-1-yl)amino, (hept-1-yn-1-yl)amino, (hept-6-yn-1-yl)amino, (oct-1-yn-1-yl)amino, (oct-7-yn-1-yl)amino, (non-1-yn-1-yl)amino, (n
  • N-cycloalkyl-amino group examples include, for example, cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, and cyclooctylamino, which are C 3 to C 8 N-cycloalkyl-amino groups.
  • N-cycloalkyl-alkyl-amino group examples include, for example, (cyclopropylmethyl)amino, (1-cyclopropylethyl)amino, (2-cyclopropylethyl)amino, (3-cyclopropylpropyl)amino, (4-cyclopropylbutyl)amino, (5-cyclopropylpentyl)amino, (6-cyclopropylhexyl)amino, (cyclobutylmethyl)amino, (cyclopentylmethyl)amino, (cyclobutylmethyl)amino, (cyclopentylmethyl)amino, (cyclohexylmethyl)amino, (2-cyclohexylethyl)amino, (3-cyclohexylpropyl)amino, (4-cyclohexylbutyl)amino, (cycloheptylmethyl)amino, (cyclooc
  • N-aryl-amino group examples include, for example, phenylamino, 1-naphthylamino, 2-naphtylamino, anthrylamino, phenanthrylamino, and acenaphthylenylamino, which are C 6 to C 14 N-mono-arylamino groups.
  • N-aralkyl-amino group examples include, for example, benzylamino, (1-naphthylmethyl)amino, (2-naphthylmethyl)amino, (anthracenylmethyl)amino, (phenanthrenylmethyl)amino, (acenaphthylenylmethyl)amino, (diphenylmethyl)amino, (1-phenethyl)amino, (2-phenethyl)amino, (1-(1-naphthyl)ethyl)amino, (1-(2-naphthyl)ethyl)amino, (2-(1-naphthyl)ethyl)amino, (2-(2-naphthyl)ethyl)amino, (3-phenylpropyl)amino, (3-(1-naphthyl)propyl)amino, (3-
  • N,N-di(hydrocarbon)-amino group examples include the groups in which two hydrogen atoms of amino group are substituted with hydrocarbon groups, and include, for example, N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino, N,N-di-n-propylamino, N,N-diisopropylamino, N-allyl-N-methylamino, N-(prop-2-yn-1-yl)-N-methylamino, N,N-dicyclohexylamino, N-cyclohexyl-N-methylamino, N-cyclohexylmethylamino-N-methylamino, N,N-diphenylamino, N-methyl-N-phenylamino, N,N-dibenzylamino, and N-benzyl-N-methylamino.
  • N-heterocyclic ring-amino group examples include the groups in which one hydrogen atom of amino group is substituted with a heterocyclic group, and include, for example, (3-pyrrolizinyl)amino, (4-piperidinyl)amino, (2-tetrahydropyranyl)amino, (3-indolinyl)amino, (4-chromanyl)amino, (3-thienyl)amino, (3-pyridyl)amino, (3-quinolyl)amino, and (5-indolyl)amino.
  • N-hydrocarbon-N-heterocyclic ring-amino group examples include the groups in which two hydrogen atoms of amino group are substituted with hydrocarbon group and heterocyclic group respectively, and include, for example, N-methyl-N-(4-piperidinyl)amino, N-(4-chromanyl)-N-methylamino, N-methyl-N-(3-thienyl)amino, N-methyl-N-(3-pyridyl)amino, N-methyl-N-(3-quinolyl)amino.
  • acyl-amino group examples include the groups in which one hydrogen atom of the amino group is substituted with an acyl group, and include, for example, formylamino group, glyoxyloylamino group, thioformylamino group, carbamoylamino group, thiocarbamoylamino group, sulfamoylamino group, sulfinamoylamino group, carboxyamino group, sulphoamino group, phosphonoamino group, and groups represented by the following formulas:
  • acyl-amino group among the groups represented by the formula ( ⁇ -1D), those groups in which R a4 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-amino group,” and those groups in which R a4 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl-amino group.”
  • N-hydrocarbon-carbamoyl group those groups in which R a4 is a hydrocarbon group are referred to as “N-hydrocarbon-carbamoyl group,” and those groups in which R a4 is a heterocyclic group are referred to as “N-heterocyclic ring-carbamoyl-amino group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas ( ⁇ -1D) through ( ⁇ -21D) include the similar groups to the aforementioned hydrocarbon group.
  • Examples of the hydrocarbon-carbonyl-amino groups represented by the formula ( ⁇ -1D) include, for example, an alkyl-carbonyl-amino group, an alkenyl-carbonyl-amino group, an alkynyl-carbonyl-amino group, a cycloalkyl-carbonyl-amino group, a cycloalkenyl-carbonyl-amino group, a cycloalkanedienyl-carbonyl-amino group, a cycloalkyl-alkyl-carbonyl-amino group which are aliphatic hydrocarbon-carbonyl-amino groups; an aryl-carbonyl-amino group; an aralkyl-carbonyl-amino group; a bridged cyclic hydrocarbon-carbon
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas ( ⁇ -1D) through ( ⁇ -21D) include similar groups to the aforementioned heterocyclic group.
  • Examples of the heterocyclic ring-carbonyl-amino group represented by the formula ( ⁇ -1D) include, for example, a monocyclic heteroaryl-carbonyl-amino group, a fused polycyclic heteroaryl-carbonyl-amino group, a monocyclic non-aromatic heterocyclic-carbonyl-amino group, and a fused polycyclic non-aromatic heterocyclic-carbonyl-amino group.
  • groups represented by the formulas ( ⁇ -2D) through ( ⁇ -21D) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas ( ⁇ -10D) through ( ⁇ -16D) include similar groups to the aforementioned cyclic amino group.
  • di(acyl)-amino group examples include the groups in which two hydrogen atoms of amino group are substituted with acyl groups in the definitions of the aforementioned substituents according to “which may be substituted.” Examples include, for example, di(formyl)-amino group, di(glyoxyloyl)-amino group, di(thioformyl)-amino group, di(carbamoyl)-amino group, di(thiocarbamoyl)-amino group, di(sulfamoyl)-amino group, di(sulfinamoyl)-amino group, di(carboxy)-amino group, di(sulfo)-amino group, di(phosphono)-amino group, and groups represented by the following formulas:
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas ( ⁇ -1E) through ( ⁇ -21E) include the similar groups to the aforementioned hydrocarbon group.
  • Examples of the bis(hydrocarbon-carbonyl)-amino groups represented by the formula ( ⁇ -1E) include, for example, a bis(alkyl-carbonyl)-amino group, a bis(alkenyl-carbonyl)-amino group, a bis(alkynyl-carbonyl)-amino group, a bis(cycloalkyl-carbonyl)-amino group, a bis(cycloalkenyl-carbonyl)-amino group, a bis(cycloalkanedienyl-carbonyl)-amino group, a bis(cycloalkyl-alkyl-carbonyl)-amino group which are bis(aliphatic hydrocarbon-carbonyl)-amino groups; a bis(aryl-carbonyl)-amino
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas ( ⁇ -1E) through ( ⁇ -21E) include similar groups to the aforementioned heterocyclic group.
  • Examples of the bis(heterocyclic ring-carbonyl)-amino group represented by the formula ( ⁇ -1E) include, for example, a bis(monocyclic heteroaryl-carbonyl)-amino group, a bis(fused polycyclic heteroaryl-carbonyl)-amino group, a bis(monocyclic non-aromatic heterocyclic-carbonyl)-amino group, and a bis(fused polycyclic non-aromatic heterocyclic-carbonyl)-amino group.
  • groups represented by the formulas ( ⁇ -2E) through ( ⁇ -21E) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas ( ⁇ -10E) through ( ⁇ -16E) include similar groups to the aforementioned cyclic amino group.
  • acyl-amino group and di(acyl)-amino group are generically referred to as “acyl substituted amino group.”
  • acyl substituted amino group N-hydrocarbon-amino group, N,N-di(hydrocarbon)-amino group, N-heterocyclic-amino group, N-hydrocarbon-N-heterocyclic-amino group, cyclic amino group, acyl-amino group, and di(acyl)-amino group.
  • Connecting group whose number of atoms of main chain is 2 to 5” in the definition of X means connecting groups wherein 2 to 5 atoms in a main chain link together between rings Z and E.
  • the aforementioned “number of atoms of the main chain” is counted so as to minimize the number of connecting atoms existing between the rings Z and E, regardless of the presence or absence of hetero atom(s). For example, the number of atoms of 1,2-cyclopentylene is counted as 2, the number of atoms of 1,3-cyclopentylene is counted as 3, the number of atoms of 1,4-phenylene is counted as 4, and the number of atoms of 2,6-pyridine-diyl is counted as 3.
  • the aforementioned “connecting group whose number of atoms of main chain is 2 to 5” is formed by one functional group selected from the following group of divalent group ⁇ -1, or formed by combining 2 to 4 functional groups of 1 to 4 kinds selected from the following divalent group ⁇ -2.
  • connecting group wherein the number of atoms of the main chain is 2 to 5
  • connecting group ⁇ is preferably a group selected from the following “connecting group ⁇ .”
  • Examples of the substituent according to “connecting group which may be substituted” in the definition of “a connecting group whose number of atoms of the main chain is 2 to 5,” include similar groups to the substituents in the definition of the aforementioned “which may be substituted.”
  • a C 1 to C 6 alkyl group is preferred, and a methyl group is more preferred.
  • the substituent may combine with a substituent of the ring E or Z, together with atoms to which they bind, to form a cyclic group which may be substituted. Examples include the compounds represented by the general formula (I) being those represented by the following formulas:
  • examples of A include hydrogen atom or acetyl group, and hydrogen atom is preferred.
  • Examples of the “arene” in “an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the definition of ring Z include a monocyclic or fused heterocyclic aromatic hydrocarbon, and include, for example, benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, and acenaphylene ring.
  • C 6 to C 10 arenes such as benzene ring, naphthalene ring and the like are preferred, benzene ring and naphthalene ring are more preferred, and benzene ring is most preferred.
  • Examples of the substituent in the definition of “an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z include similar groups to the substituent explained for the definition “which may be substituted.”
  • the position of substituents existing on the arene is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • substituents include groups selected from the following Substituent Group ⁇ -1z. Halogen atom and tert-butyl group [(1,1-dimethyl)ethyl group] are more preferred, and halogen atom is most preferred.
  • naphthalene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z is “a naphthalene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above,” naphthalene ring is preferred.
  • hetero arene in “a hetero arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z include a monocyclic or a fused polycyclic aromatic heterocyclic rings containing at least one of 1 to 3 kinds of heteroatoms selected from oxygen atom, sulfur atom and nitrogen atom and the like as ring-constituting atoms (ring forming atoms), and include, for example, furan ring, thiophene ring, pyrrole ring, oxazole ring, isoxazole ring, thiazole ring, isothiazole ring, imidazole ring, pyrazole ring, 1,2,3-oxadiazole ring, 1,2,3-thiadiazole ring, 1,2,3
  • Examples of the substituent in the definition of “a hetero arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z include similar groups to the substituent explained for the aforementioned definition “which may be substituted.”
  • the position of substituents existing on the hetero arene is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • Halogen atoms are preferred as the substituent in the definition of “a hetero arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z.
  • Examples of the aryl group of “an aryl group which may be substituted” in the definition of E include similar groups to the aryl group in the definition of the aforementioned “hydrocarbon group,” and C 6 to C 10 aryl groups such as phenyl group, 1-naphthyl group, 2-naphthyl group and the like are preferred, and phenyl group is most preferred.
  • Examples of the substituent in the definition of “an aryl group which may be substituted” in the definition of E include similar groups to the substituent explained for the definition “which may be substituted.”
  • the position of substituents existing on the aryl group is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • an aryl group which may be substituted in the aforementioned definition of E is “a phenyl group which may be substituted,” “a mono-substituted phenyl group,” “a di-substituted phenyl group,” and “a phenyl group which has three or more substituents” are preferred, and “a di-substituted phenyl group” is more preferred.
  • an aryl group which may be substituted in the aforementioned definition of E is “a di-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group ⁇ -1e.
  • an aryl group which may be substituted in the aforementioned definition of E is “a di-substituted phenyl group,” “a 2,5-di-substituted phenyl group,” and “a 3,5-di-substituted phenyl group” are preferred.
  • an aryl group which may be substituted in the aforementioned definition of E is “a 2,5-di-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group ⁇ -2e.
  • an aryl group which may be substituted in the aforementioned definition of E is “a 2,5-di-substituted phenyl group,” “a 2,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group” is more preferred, a group selected from the following Substituent Group ⁇ -3e is further preferred, and 2,5-bis(trifluoromethyl)phenyl group is most preferred.
  • an aryl group which may be substituted in the aforementioned definition of E is “a 3,5-di-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group ⁇ -4e.
  • an aryl group which may be substituted in the aforementioned definition of E is “a 3,5-di-substituted phenyl group,” “a 3,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group” is more preferred, a group selected from the following Substituent Group ⁇ -5e is further preferred, and 3,5-bis(trifluoromethyl)phenyl group is most preferred.
  • an aryl group which may be substituted in the aforementioned definition of E is “a mono-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group ⁇ -6e.
  • an aryl group which may be substituted in the aforementioned definition of E is “a phenyl group which has three or more substituents,” preferred examples of the group include groups represented by the following Substituent Group ⁇ -7e.
  • an aryl group which may be substituted in the aforementioned definition of E is “a naphthyl group which may be substituted,” preferred examples of the group include 1-naphthyl group, 4-methoxynaphthalen-2-yl group, and 4-hydroxy-3-methylnaphthalen-1-yl group.
  • heteroaryl group in “a heteroaryl group which may be substituted” in the definition of E include similar groups to the “monocyclic heteroaryl group” and “fused polycyclic heteroaryl group” in the definition of the aforementioned “heterocyclic group.”
  • a 5 to 13-membered heteroaryl group is preferred, and preferred examples of the group include thienyl group, pyrazolyl group, oxazolyl group, 1,3,4-thiadiazolyl group, pyridyl group, pyrimidinyl group, indolyl group, quinolyl group, carbazolyl group, thiazolyl group, and pyrazinyl group.
  • a 5-membered heteroaryl group is more preferred as the “heteroaryl group” in “a heteroaryl group which may be substituted” in the definition of E.
  • Thienyl group, pyrazolyl group, oxazolyl group, 1,3,4-thiadiazolyl group, and thiazolyl group are further preferred, and thiazolyl group is most preferred.
  • Examples of the substituent in the definition of “a heteroaryl group which may be substituted” in the aforementioned definition of E include similar groups to the substituent explained for the definition “which may be substituted.”
  • the position of substituents existing on the heteroaryl group is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • a heteroaryl group which may be substituted in the aforementioned definition of E is “a thiazolyl group which may be substituted,” “a thiazol-2-yl group which may be substituted.” “A mono-substituted thiazol-2-yl group” and “a di-substituted thiazol-2-yl group” are more preferred, and “a di-substituted thiazol-2-yl group” is further preferred.
  • a heteroaryl group which may be substituted in the aforementioned definition of E is “a di-substituted thiazol-2-yl group,” a group selected from the following Substituent Group ⁇ -8e is preferred, and 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group is most preferred.
  • a heteroaryl group which may be substituted in the aforementioned definition of E is “a mono-substituted thiazol-2-yl group,” preferred examples of the group include groups represented by the following Substituent Group ⁇ -9e.
  • Preferred examples of the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position ” in the definition of Z 1 include a group selected from the following Substituent Group ⁇ 1 -1z. A halogen atom and tert-butyl group are more preferred, and a halogen atom is most preferred.
  • a halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z 1 .
  • Examples of the substituent in the definition of “a phenyl group which may be substituted” in the definition of E 1 include similar groups to the substituents explained for the definition “which may be substituted.”
  • a position of a substituent existing on the phenyl group is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • a phenyl group which may be substituted in the definition of E 1 include 3,5-bis(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl group, a phenyl group which has three or more substituents wherein at least one of said substituents is trifluoromethyl group, and a di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, (provided that a 2,5-di-substituted phenyl group and a 3,5-di-substituted phenyl group are excluded as said di-substituted phenyl group.) 3,5-Bis(trifluoromethyl)phenyl group and 2,5-bis(trifluoromethyl)phenyl group are more preferred.
  • a phenyl group which may be substituted in the definition of E 1 is “a phenyl group which has three or more substituents wherein at least one of said substituents is trifluoromethyl group,” preferred examples of the group include groups represented by the following Substituent Group ⁇ 1 -1e.
  • a phenyl group which may be substituted in the definition of E 1 is “a di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, (provided that a 2,5-di-substituted phenyl group and a 3,5-di-substituted phenyl group are excluded from said di-substituted phenyl group)” preferred examples of the group include groups represented by the following Substituent Group ⁇ 1 -2e.
  • a halogen atom, nitro group, methyl group, and methoxy group are preferred as the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position” in the definition of Z 2 , and a halogen atom is most preferred.
  • a halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z 2 .
  • Examples of the substituent in the definition of “a 2,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” and “a 3,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” in the definition of E 2 include similar groups to the substituent explained for the definition “which may be substituted.”
  • a group selected from the following Substituent Group ⁇ 2 -1e is preferred as “a 2,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” in the definition of E 2 .
  • a group selected from the following Substituent Group ⁇ 2 -2e is preferred as “a 3,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” in the definition of E 2 .
  • a halogen atom, nitro group, methyl group and methoxy group are preferred as the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position” in the definition of Z 3 , and a halogen atom is most preferred.
  • a halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z 3 .
  • Examples of the substituent in the definition of “a hydrocarbon group which may be substituted” in the definition of R 3e2 and R 3e3 and “a C 2 to C 6 hydrocarbon group which may be substituted” in the definition of R 3e5 include similar groups to the substituent explained for the definition “which may be substituted.”
  • hydrocarbon group in the definition of “a hydrocarbon group which may be substituted” in the definition of R 3e2 and R 3e3 and “a C 2 to C 6 hydrocarbon group which may be substituted” in the definition of R 3e5 include similar groups to the “hydrocarbon group” in the aforementioned definition.
  • Examples of the “hydroxy group which may be substituted” in the definition of R 3e2 and R 3e3 include similar groups to the “hydroxy group which may be substituted” explained for the definition “which may be substituted.”
  • a halogen atom, phenyl group, 4-fluorophenyl group, 2,4-difluorophenyl group, 4-(trifluoromethyl)phenyl group, 1-pyrrolyl group and 2-thienyl group are preferred as the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position” in the definition of Z 4 , and a halogen atom is most preferred.
  • a halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z 4 .
  • Examples of the substituent in the definition of “a hydrocarbon group which may be substituted” in the definition of R 4e4 , and “an acyl group which may be substituted” and “a heterocyclic group which may be substituted” in the definition of R 4e5 include similar groups to the substituent explained for the definition “which may be substituted.”
  • hydrocarbon group in the definition of “a hydrocarbon group which may be substituted” in the definition of R 4e4 include similar groups to the “hydrocarbon group” in the aforementioned definition.
  • acyl group in the definition of “an acyl group which may be substituted” in the definition of R 4e5 include similar groups to the “acyl group” in the aforementioned definition.
  • heterocyclic group in the definition of “a heterocyclic group which may be substituted” in the definition of R 4e5 include similar groups to the “heterocyclic group” in the aforementioned definition.
  • a group selected from the following Substituent Group ⁇ 4 -1e is preferred as E 4 , and 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group is most preferred.
  • preferred compounds are those other than “substituted benzoic acid derivatives represented by the following general formula (X-1) and/or compounds represented by the following Compound Group ⁇ -1.”
  • Each compound defined by the aforementioned general formulas (I-1), (I-2), (I-3), and (I-4), or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof is novel.
  • Uses of the compound according to the aforementioned chemical substance invention are not particularly limited.
  • the compounds represented by the aforementioned general formulas (I), (I-1), (I-2), (I-3) and (1-4) may form salts.
  • pharmacologically acceptable salts include, when acidic groups exist, metal salts such as lithium salt, sodium salt, potassium salt, magnesium salt, calcium salts, or ammonium salts such as ammonium salt, methylammonium salt, dimethylammonium salt, trimethylammonium salt, dicyclohexylammonium salt, and when basic groups exist, mineral acid salts such as hydrochloride, oxalate, hydrosulfate, nitrate, phosphate, or organic acid salts such as methane sulfonate, benzene sulfonate, para-toluene sulfonate, acetate, propionate, tartrate, fumarate, maleate, malate, oxalate, succinate, citrate, benzoate, mandelate, cinnamate, lactate. Salts may sometimes
  • the compounds or salts thereof represented by the aforementioned general formulas (I), (I-1), (I-2), (1-3) and (1-4) may exist as hydrates or solvates.
  • any of the aforementioned substances may be used.
  • the compounds represented by the aforementioned general formulas (I), (I-1), (I-2), (I-3) and (I-4) may sometimes have one or more asymmetric carbons, and may exist as steric isomers such as optically active substance and diastereomer.
  • active ingredients of the medicament of the present invention pure forms of stereoisomers, arbitrary mixture of enantiomers or diastereomers, and racemates may be used.
  • the compounds represented by the general formulas (I), (I-1), (I-2), (1-3) and (I-4) has, for example, 2-hydroxypyridine form
  • the compounds may exist as 2-pyridone form which is a tautomer.
  • active ingredients of the medicament of the present invention pure forms of tautomers or a mixture thereof may be used.
  • the compounds represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) have olefinic double bonds, the configuration may be in either E or Z, and as active ingredients of the medicament of the present invention, geometrical isomer in either of the configurations or a mixture thereof may be used.
  • the compounds represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) can be prepared, for example, by methods shown bellow.
  • the compounds represented by the general formula (I), wherein X is —CONH— (the hydrogen atom on the nitrogen may be substituted) and the compounds represented by the general formulas (I-1), (I-2), (I-3) and (I-4) can be prepared, for example, by a method described in the reaction scheme 1.
  • a 101 represents a hydrogen atom or protecting groups of hydroxy group (preferably, an alkyl group such as methyl group and the like; an aralkyl group such as benzyl group and the like; an acetyl group, an alkoxyalkyl group such as methoxymethyl group and the like; a substituted silyl group such as trimethylsilyl group or the like), each of R and R 101 represents a hydrogen atom, a C 1 to C 6 alkyl group or the like, E 101 represents E or precursor of E in the definition of the general formula (I), G represents a hydroxy group, halogen atoms (preferably, a chlorine atom), a hydrocarbon-oxy group (preferably, an aryl-oxy group which may be substituted by halogen atom), an acyl-oxy group, an imido-oxy group or the like.
  • the amide (3) can be prepared by dehydrocondensation of the carboxylic acid derivative (1) and the amine (2). This reaction is carried out at a reaction temperature of from 0° C. to 180° C., without solvent or in an aprotic solvent, in the presence of an acid halogenating agent or a dehydrocondensing agent, and in the presence or absence of a base.
  • examples include, for example, thionyl chloride, thionyl bromide, sulfuryl chloride, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride or the like.
  • a 101 is hydrogen atom
  • phosphorus trichloride is preferable
  • a 101 is acetyl group or the like
  • phosphorus oxychloride is preferable.
  • examples include, for example, N,N′-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, diphenylphosphorylazide or the like.
  • examples include inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic bases such as pyridine, triethylamine, N,N′-diethylaniline or the like.
  • examples include dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 1,4-dioxane, benzene, toluene, monochlorobenzene, o-dichlorobenzene, N,N′-dimethylformamide, N-methylpyrrolidone or the like, when the reaction is carried out in the presence of the acid halogenating agent, particularly, toluene, monochlorobenzene, o-dichlorobenzene are preferable.
  • a target compound can also be prepared, for example, by a method or similar method described in Journal of Medicinal Chemistry, (USA), 1998, Vol. 41, No. 16, p. 2939-2945, in which the acid chloride is prepared and isolated beforehand from carboxylic acid, then the result is made to react with an amine having E 101 .
  • the final target compound (4) can be prepared by a reaction for deprotection and/or functional group modification in this step.
  • a reaction for deprotection and/or functional group modification for example, methods described in “Protective Groups in Organic Syntheses”, (USA), Theodra W. Green, Peter G. M.
  • X is other connecting group, for example, —SO 2 NH—, —NHCO—, —NHSO 2 —, —CONHCH 2 —, —CONHCH 2 CH 2 —, —CONHCH 2 CONH—, —CONHNHCO—, —CONHNHCH 2 —, —COO—, —CONHNH—; wherein the hydrogen atom on said connecting group may be substituted.
  • the target compound when X is the formula: —CONHCH 2 — wherein the hydrogen atom on said connecting group may be substituted, the target compound can be prepared by using an amine represented by the formula: H 2 N—CH 2 -E 101 , wherein E 101 has the same meaning as that defined above, instead of the amine (2).
  • the target compound when X is the formula: —CONHCH 2 CH 2 — wherein the hydrogen atom on said connecting group may be substituted, the target compound can be prepared by using an amine represented by the formula: H 2 N—CH 2 CH 2 -E 101 , wherein E 101 has the same meaning as that defined above, instead of the amine (2).
  • the target compound when X is the formula: —SO 2 NH—, the target compound can be prepared by using a sulfonyl chloride represented by the formula: A 101 -O-(ring Z)-SO 2 Cl, wherein each of A 101 and ring Z has the same meaning as that defined above, instead of the carboxylic acid derivative (1).
  • the target compound when X is the formula: —NHCO—, the target compound can be prepared by using an amine represented by the formula: A 101 -O-(ring Z)-NH 2 , wherein each of A 101 and ring Z has the same meaning as that defined above, and a carboxylic acid represented by the formula: E 101 -COOH, wherein -E 101 has the same meaning as that defined above, or a carboxylic acid chloride represented by the formula: E 101 -COCl, wherein -E 101 has the same meaning as that defined above.
  • the target compound when X is the formula: —NHSO 2 —, wherein said connecting group may be substituted, the target compound can be prepared by using an amine represented by the formula: HO-(ring Z)-NH 2 , wherein ring Z has the same meaning as that defined above, and a sulfonyl chloride represented by the formula: E 101 -SO 2 Cl, wherein E 101 has the same meaning as that defined above.
  • the target compound when X is the formula: —CONHNHCO—, the target compound can be prepared by using a hydrazide represented by the formula: HO-(ring Z)-CONHNH 2 , wherein ring Z has the same meaning as that defined above, and a carboxylic acid chloride represented by the formula: E 101 -COCl, wherein -E 101 has the same meaning as that defined above.
  • the target compound when X is the formula: —COO—, the target compound can be prepared by using a phenol derivative represented by the formula: HO-E 101 , wherein -E 101 has the same meaning as that defined above, instead of the amine (2).
  • the target compound when X is the formula: —CONHNH—, the target compound can be prepared by using a hydrazine represented by the formula: H 2 N—NH-E 101 , wherein E 101 has the same meaning as that defined above, instead of the amine (2).
  • the target compound when X is the formula: —CONHCH 2 CONH—, the target compound can be prepared by using an amine represented by the formula: H 2 N—CH 2 CONH-E 101 , wherein E 101 has the same meaning as that defined above, instead of the amine (2).
  • the amine represented by the formula: H 2 N—CH 2 CONH-E 101 can be prepared, for example, by condensation of the amine (2) and a N-protected amino acid (for example, N-(tert-butoxycarbonyl)glycine), according to the aforementioned method 1, followed by a deprotection reaction.
  • a N-protected amino acid for example, N-(tert-butoxycarbonyl)glycine
  • the target compound when X is the following formula: wherein said connecting group may be substituted, the target compound can be prepared by using an amine represented by the following formula: wherein ring Z has the same meaning as that defined above, and a carboxylic acid represented by the formula: E 101 -COOH, wherein E 101 has the same meaning as that defined above, or a carboxylic acid chloride represented by the formula: E 101 -COCl, wherein E 101 has the same meaning as that defined above.
  • the amine represented by the following formula: can be prepared, for example, by a method described in the reaction scheme 1-2. wherein ring Z has the same meaning as that defined above.
  • the bromoacetophenone (20) can be prepared by bromination of the acetophenone (19).
  • This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in a solvent, in the presence of a brominating agent.
  • phenyltrimethylammonium tribromide can preferably be used.
  • reaction solvent any solvent can be used as long as it does not inhibit the reaction, for example, ethers such as tetrahydrofuran can be used.
  • the amine (21) can be prepared by reacting the bromoacetophenone (20) with thiourea.
  • This reaction is carried out at a reaction temperature of from 0° C. to 120° C. in a solvent.
  • reaction solvent any solvent can be used as long as it does not inhibit the reaction, for example, alcohols such as ethanol can be used.
  • the imine derivative of the formula (7) can be prepared by dehydrocondensation of the aldehyde (5) and the amine (6). This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in a solvent, in the presence or absence of a dehydrating agent.
  • a dehydrating agent examples include anhydrous magnesium sulfate, molecular sieves or the like.
  • the solvent examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable.
  • X is other connecting group, for example, —CONHN ⁇ CH—, —CH ⁇ NNHCO—, —CHNNH—; wherein the hydrogen atom on said connecting group may be substituted.
  • the target compound when X is the formula: —CONHN ⁇ CH—, the target compound can be prepared by using a hydrazide represented by the formula: HO-(ring Z)-CONHNH 2 , wherein ring Z has the same meaning as that defined above, and an aldehyde represented by the formula: E-CHO, wherein E has the same meaning as that defined above.
  • the target compound when X is the formula: —CH ⁇ NNHCO—, the target compound can be prepared by using an aldehyde represented by the formula: HO-(ring Z)-CHO, wherein ring Z has the same meaning as that defined above, and a hydrazide represented by the formula: E-CONHNH 2 , wherein E has the same meaning as that defined above.
  • the target compound when X is the formula: —CH ⁇ NNH—, the target compound can be prepared by using an aldehyde represented by the formula: HO-(ring Z)-CHO, wherein ring Z has the same meaning as that defined above, and a hydrazine represented by the formula: E-NHNH 2 , wherein E has the same meaning as that defined above.
  • the target compound (8) can be prepared by reduction of the imine derivative (7). This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in a solvent, in the presence of a reducing agent.
  • a reducing agent examples include sodium borohydride, lithium borohydride or the like.
  • the solvent examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable.
  • This reaction can also be carried out by a method of catalytic hydrogenation.
  • the catalyst examples include palladium carbon, platinum carbon, palladium hydroxide, palladium black or the like.
  • solvent examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable.
  • the reaction is carried out at a reaction temperature of from 0° C. to 200° C., and the hydrogen pressure may be an ordinary pressure or a positive pressure.
  • the target compound (11) can be prepared by dehydrocondensation of the aldehyde (9-1) and the phosphorus compound (10-1). This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence of a base.
  • a base examples include inorganic base such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic base such as pyridine, triethylamine, N,N-diethylaniline or the like.
  • the solvent examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water or the like are preferable.
  • W 302 represents halogen atoms (preferably, iodine atom and bromine atom), (trifluoromethanesulfonyl)oxy group and the like.
  • the target compound (11) can be prepared by reacting the halogenated compound (9-2) with the styrene compound (10-2) in the presence of a transition-metal complex catalyst. This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence or absence of a ligand and/or a base.
  • a transition-metal complex catalyst examples include palladium catalyst such as palladium acetate and dichlorobis(triphenylphosphine)palladium.
  • the ligand examples include phosphine ligand such as triphenylphosphine.
  • examples include inorganic base such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate, or organic base such as pyridine, triethylamine, and N,N-diethylaniline.
  • examples include inert solvents, and N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane or the like are preferable.
  • the target compound enone (14) can be prepared by dehydrocondensation of the ketone (12) and the aldehyde (13). This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence of a base.
  • a base examples include inorganic base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic base such as pyridine, triethylamine, N,N-diethylaniline or the like.
  • examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water or the like are preferable.
  • the target compound (15) can be prepared by reduction of the enone (14).
  • This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in solvent, in the presence of a reducing agent.
  • a reducing agent examples include sodium borohydride, lithium borohydride or the like.
  • the solvent examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable.
  • this reaction is carried out by a method of catalytic hydrogenation also.
  • the catalyst examples include palladium carbon, platinum carbon, palladium hydroxide, palladium black or the like.
  • solvent examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable.
  • the reaction is carried out at a reaction temperature of from 0° C. to 200° C., and the hydrogen pressure is at normal pressure or applied pressure.
  • the target compound urea (18) can be prepared by reacting the amine (16) with the isocyanate (17). This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence or absence of a base.
  • a base examples include inorganic base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic base such as pyridine, triethylamine, N,N-diethylaniline or the like.
  • examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water or the like are preferable.
  • the target compound hydrazide (24) can be prepared by reacting the hydrazide (22) with the benzyl derivative (23).
  • This reaction is carried out at a reaction temperature of from 0° C. to 180° C. in a solvent, in the presence or absence of a base.
  • organic base such as pyridine, triethylamine or the like can preferably be used.
  • reaction solvent any solvent can be used as long as it does not inhibit the reaction, for example, halogenated solvent such as dichloromethane; ethers such as tetrahydrofuran; and hydrocarbon solvent such as toluene can be used.
  • halogenated solvent such as dichloromethane
  • ethers such as tetrahydrofuran
  • hydrocarbon solvent such as toluene
  • the target compound 5-(benzylidene)-3-benzylthiazolidin-2,4-dione derivative (26) can be prepared by reacting the aldehyde (9-1) with the 3-benzylthiazolidin-2,4-dione derivative (25).
  • This reaction is carried out at a reaction temperature of from 0° C. to 180° C. in a solvent, in the presence of a catalyst.
  • a catalyst for example, a mixture of piperidine/acetic acid can preferably be used.
  • the reaction solvent any solvent can be used as long as it does not inhibit the reaction, for example, hydrocarbon solvent such as toluene can be used.
  • the target compound 3-benzylthiazolidine-2,4-dione derivative (28) can be prepared by reacting thiazolidine-2,4-dione (30) with the benzyl derivative (23).
  • This reaction is carried out at a reaction temperature of from 0° C. to 180° C. in a solvent, in the presence of a base.
  • a base for example, inorganic base such as sodium hydroxide, potassium carbonate or the like, or organic base such as pyridine, triethylamine or the like can preferably be used.
  • reaction solvent any solvent can be used as long as it does not inhibit the reaction, for example, water; alcohols such as ethanol or the like; halogenated solvent such as dichloromethane or the like; ethers such as tetrahydrofuran or the like; or amides such as N,N-dimethylformamide or the like can be used.
  • the compounds represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) prepared by the aforementioned methods can be isolated and purified by methods widely known by those skilled in the art, for example, extraction, precipitation, fractional chromatography, fractional crystallization, suspension and washing, and recrystallization. Furthermore, each of the pharmaceutically acceptable salt of the compound of the present invention, the hydrate thereof and the solvate thereof can be prepared by methods widely known by those skilled in the art.
  • the compounds represented by the general formulas (I), (I-1), (I-2), (I-3), and (I-4) have antiallergic action, and accordingly, they are useful as active ingredients of the medicaments for the preventive and/or therapeutic treatment of allergic diseases.
  • the aforementioned medicaments have inhibitory activity against the proliferation of mast cells, inhibitory activity against the production of IgE from activated B cells, and inhibitory activity against the degranulation from activated mast cells. Therefore, they can be suitably used as a suppressant against allergic reaction expression.
  • the medicaments of the present invention are useful for the preventive and/or therapeutic treatment of the following diseases wherein allergic reaction is believed to be involved, for example, allergic diseases such as contact dermatitis, atopic dermatitis, eczema, pruritus, pollinosis, asthma, bronchitis, urticaria, vasculitis, rhinitis, gastrointestinal symptoms, diarrhea, interstitial pneumonia, arthritis, ophthalmia, conjunctivitis, neuritis, otitis media, granulomatosis, encephalomyelitis, cystitis, laryngitis, peliosis, food allergy, insect allergy, drug allergy, metal allergy, anaphylactic shock and the like, and/or endometriosis and/or hysteromyoma.
  • allergic diseases such as contact dermatitis, atopic dermatitis, eczema, pruritus, pollinosis, asthma, bronchitis, urtic
  • endometriosis it is known that an adhesion of the uterus with its peripheral tissue frequently occurs due to an abnormal proliferation of endometrial tissue outside the uterus. It is known that this is caused by an inflammatory reaction by allergy and the like, and a phenomenon called as “remodeling” including fibrosis and hyperplasia of tissue as typical examples occurs (Frontiers in Bioscience, (USA), 2002, Vol. 7, the April 1 issue, p.e 91-115).
  • the fibrosis of tissue it is widely known that one of the causes is a production of a large amount of collagen, which is triggered by infiltration of effecter cells and activation of proliferation of fibroblast by inflammation.
  • This remodeling phenomenon is considered to be occurred on the basis of a mechanism common in the remodeling of cardiac muscle after myocardial infarction, the remodeling of a vessel by arteriosclerosis, the remodeling of bronchus by bronchial asthma or the like, as well as in the adhesion of a tissue in endometriosis. Accordingly, an inhibitor against the proliferation or activation of a fibroblast is considered to be useful as a therapeutic drug not only for endometriosis but for diseases in which fibrosis or remodeling of a tissue is believed to be involved, for example, myocardial infarction, arteriosclerosis, asthma, nephritis, interstitial pneumonia, pulmonary fibrosis, hepatic cirrhosis and the like.
  • the compounds of the present invention was found to inhibit cell proliferation of HT-1080, which is a fibrosarcoma cell having properties similar to those of fibroblast and collagen productivity, under proliferative stimulation by PDGF (platelet-derived growth factor). Therefore, they are considered to be useful as a therapeutic drug and/or a preventive drug for diseases in which fibrosis or remodeling of tissue is involved.
  • HT-1080 is a fibrosarcoma cell having properties similar to those of fibroblast and collagen productivity
  • PDGF platelet-derived growth factor
  • the active ingredient of the medicament on the present invention one or more kinds of substances selected from the group consisting of the compound represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof may be used.
  • the aforementioned substance, per se, may be administered as the medicament of the present invention, however, preferably, the medicament of the present invention is provided in the form of a pharmaceutical composition comprising the aforementioned substance which is an active ingredient together with one or more pharmacologically acceptable pharmaceutical additives.
  • a ratio of the active ingredient to the pharmaceutical additives is 1 weight % to 90 weight %.
  • compositions of the present invention may be administered as pharmaceutical compositions for oral administration, for example, granules, subtilized granules, powders, hard capsules, soft capsules, syrup, emulsion, suspension, or solution, or may be administered as pharmaceutical compositions for parenteral administration, for example, injections for intravenous administration, intramuscular administration, or subcutaneous administration, drip infusions, suppositories, percutaneous absorbent, transmucosal absorption preparations, nasal drops, ear drops, instillation, and inhalants. Preparations made as pharmaceutical compositions in a form of powder may be dissolved when necessary and used as injections or drip infusions.
  • solid or liquid pharmaceutical additives may be used.
  • Pharmaceutical additives may either be organic or inorganic.
  • an excipient is added to the active ingredient, and further binders, disintegrator, lubricant, colorant, corrigent are added, if necessary, to manufacture preparations in the forms of tablets, coating tablets, granules, powders, capsules and the like by ordinary procedures.
  • the excipient include lactose, sucrose, saccharose, glucose, corn starch, starch, talc, sorbit, crystal cellulose, dextrin, kaolin, calcium carbonate, and silicon dioxide.
  • binder examples include, for example, polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, gum Arabic, tragacanth, gelatine, shellac, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, calcium citrate, dextrin, and pectin.
  • lubricant examples include, for example, magnesium stearate, talc, polyethylene glycol, silica, and hydrogenated vegetable oil.
  • the coloring agent any material can be used which are approved to be added to ordinary pharmaceuticals.
  • corrigent cocoa powder, menthol, aromatic acid, peppermint oil, d-borneol, cinnamon powder and the like can be used. These tables and granules may be applied with sugarcoating, gelatin coating, or an appropriate coating, if necessary. Preservatives, antioxidant and the like may be added, if required.
  • liquid preparations for oral administration such as emulsions, syrups, suspensions, and solutions
  • ordinary used inactive diluents for example, water or vegetable oil may be used.
  • adjuvants such as wetting agents, suspending aids, sweating agents, flavoring agents, coloring agents or preservatives may be blended.
  • the preparation may be filled in capsules made of a absorbable substance such as gelatin.
  • solvents or suspending agents used for the preparations of parenteral administration such as injections or suppositories include, for example, water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, and lecithin.
  • base materials used for preparation of suppositories include, for example, cacao butter, emulsified cacao butter, lauric fat, and witepsol. Methods for preparation of the aforementioned preparations are not limited, and any method ordinarily used in the art may be used.
  • carriers such as, for example, diluents including water, ethanol, macrogol, propylene glycol, citric acid, acetic acid, phosphoric acid, lactic acid, sodium lactate, sulfuric acid and sodium hydroxide, pH modifiers and buffer solutions including sodium citrate, sodium acetate and sodium phosphate, stabilizers such as sodium pyrosulfite, ethylenediaminetetraacetic acid, thioglycolic acid and thiolactate may be used.
  • diluents including water, ethanol, macrogol, propylene glycol, citric acid, acetic acid, phosphoric acid, lactic acid, sodium lactate, sulfuric acid and sodium hydroxide
  • pH modifiers and buffer solutions including sodium citrate, sodium acetate and sodium phosphate
  • stabilizers such as sodium pyrosulfite, ethylenediaminetetraacetic acid, thioglycolic acid and thiolactate
  • a sufficient amount of a salt, glucose, mannitol or glycerin may be blended in the preparation to manufacture an isotonic solution, and an ordinary solubilizer, a soothing agent, or a topical anesthetic may be used.
  • an ordinarily used base material, a stabilizer, a wetting agent, and a preservative may be blended, if necessary, and may be prepared by mixing the components by a common method.
  • the base material for example, white petrolatum, polyethylene, paraffin, glycerin, cellulose derivatives, polyethylene glycol, silicon, and bentonite may be used.
  • the preservative paraoxy methyl benzoate, paraoxy ethyl benzoate, paraoxy propyl benzoate and the like may be used.
  • the aforementioned ointment, cream gel, or paste and the like may be applied by a common method to an ordinary support.
  • the support fabric made of cotton, span rayon, and synthetic fibersor or nonwoven fabric, and a film or a foam sheet such as made of soft vinyl chloride, polyethylene, and polyurethane and the like may be preferably used.
  • a dose of the medicament of the present invention is not particularly limited.
  • a dose may generally be 0.01 to 5,000 mg per day for an adult as the weight of the compound of the present invention. It is preferred to increase or decrease the above dose appropriately depending on the age, pathological conditions, and symptoms of a patient.
  • the above dose may be administered once a day or 2 to 3 times a day as divided portions with appropriate intervals, or intermittent administration for every several days may be applied.
  • the dose When the medicament is used as an injection, the dose may be 0.001 to 100 mg per day for an adult as the weight of the compound of the present invention.
  • O-Acetylsalicyloyl chloride (0.20 g, 1.00 mmol) was dissolved in benzene (8 mL). Phenethylamine (0.12 g, 1.00 mmol) and pyridine (0.3 mL) were added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate.
  • organic bases such as pyridine, triethylamine or the like were used as the base.
  • reaction solvent solvents such as dichloromethane, tetrahydrofuran, benzene or the like were used alone or as a mixture.
  • inorganic bases such as sodium hydroxide, potassium carbonate or the like were used as the base.
  • reaction solvent solvents such as water, methanol, ethanol, tetrahydrofuran or the like were used alone or as a mixture.
  • Carbon tetrachloride (5 mL), iron powder (0.03 g) and bromine (25 ⁇ l, 0.48 mmol) were added to 2-hydroxy-N-(2-phenethyl)benzamide (79.6 mg, 0.33 mmol), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into aqueous sodium hydrogen sulfite and extracted with ethyl acetate.
  • WSC.HCl (96 mg, 0.5 mmol) was added to a solution of 5-bromosalicylic acid (109 mg, 0.5 mmol), 2-amino-5-(morpholino)carbonylindane (141 mg, 0.5 mmol) and triethylamine (70 ⁇ L, 0.5 mmol) in dichloromethane (5 mL), and the mixture was stirred at 40° C. for 1.5 hours.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • the solid was crystallized from n-hexane-ethyl acetate to give the title compound (445 mg, 63.1%) as a slight dark brown crystal.
  • This compound is a commercially available compound.
  • phosphorus trichloride was used as the acid halogenating agent.
  • reaction solvent solvents such as monochlorobenzene, toluene or the like were used.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • phosphorus oxychloride was used as the acid halogenating agent. Pyridine was used as the base.
  • reaction solvent solvents such as dichloromethane, tetrahydrofuran or the like were used alone or as a mixture.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • This compound is a commercially available compound.
  • This compound was obtained also by the following preparation method.
  • Iron powder (30 mg, 0.54 mmol) and bromine (0.02 mL, 0.39 mmol) were added to a solution of 2-acetoxy-N-[3,5-bis(trifluoromethyl)]benzamide (Compound No. 95; 100 mg, 0.25 mmol) in carbon tetrachloride (8 mL), and the mixture was stirred at 50° C. for 4 hours. After the reaction mixture was cooled to room temperature, it was poured into aqueous NaHSO 4 and extracted with ethyl acetate. The ethyl acetate layer was washed with water and brine, and dried over anhydrous sodium sulfate.
  • 2-acetoxy-N-[3,5-bis(trifluoromethyl)]benzamide Compound No. 95; 100 mg, 0.25 mmol
  • carbon tetrachloride 8 mL
  • Triethylamine (0.2 ml) was added to a mixture of 5-formylsalicylic acid (332 mg, 2 mmol). Cyanoacetic acid methyl ester (198 mg, 2 mmol) and acetic acid (6 mL), and the mixture was refluxed for 5 hours. After cooling, the reaction mixture was poured into water, and the separated crystal was filtered and recrystallized (n-hexane) to give the title compound (327.7 mg, 66.3%) as a light yellow solid.
  • N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52; 950 mg, 2 mmol) and trimethylsilylacetylene (246 mg, 2.5 mmol) were dissolved in triethylamine (2 mL) and N,N-dimethylformamide (4 mL). Tetrakis(triphenylphosphine)palladium (23 mg, 0.02 mmol) and cuprous iodide (4 mg, 0.02 mmol) were added under argon atmosphere, and the mixture was stirred at 40° C. for 2 hours.
  • N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52; 200 mg, 0.42 mmol) was dissolved in 1,2-dimethoxyethane (3 mL), Tetrakis(triphenylphosphine)palladium (16 mg, 0.0014 mmol) was added under argon atmosphere, and the mixture was stirred at room temperature for 5 minutes. Then dihydroxyphenylborane (57 mg, 0.47 mmol) and 1M sodium carbonate (1.3 mL) were added and the mixture was refluxed for 2 hours. After cooling to room temperature, the reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate.
  • N-[3,5-Bis(trifluoromethyl)phenyl]-5-iodo-2-methoxymethoxybenzamide (0.20 g, 0.39 mmol) was dissolved in N,N-dimethylformamide (8 ml). Tri-n-butyl(2-pyridyl)tin (0.13 ml, 0.41 mmol) and dichlorobis(triphenylphosphine)palladium (32.1 mg, 0.05 mmol) were added, and the mixture was stirred at 100° C. for 1.5 hours. After cooling, the reaction mixture was poured into water and extracted with ethyl acetate.
  • N-[3,5-Bis(trifluoromethyl)phenyl]-4-hydroxyisophthalamic acid methyl ester (Comound No. 81; 2.85 g, 7 mmol) was suspended in a mixed solvent of methanol (14 mL) and tetrahydrofuran (14 mL). 2N Aqueous sodium hydroxide (14 mL) was added, and the mixture was refluxed for 2 hours. After cooling, 2N hydrochloric acid (20 ml) was added to the reaction mixture and the separated solid was filtered, washed with water, dried to give the title compound (2.68 g, 97.4%) as a white crystal.
  • inorganic bases such as sodium hydroxide, potassium carbonate or the like were used as the base.
  • reaction solvent solvents such as water, methanol, ethanol, tetrahydrofuran or the like were used alone or as a mixture.
  • Example 16 Using 4-hydroxyisophthalic acid (182 mg, 1 mmol), 3,5-bis(trifluoromethyl)-aniline (687 mg, 3 mmol), phosphorus trichloride (87 ⁇ l; 1 mmol) and toluene (10 mL), the same operation as the Example 16 gave the title compound (151 mg, 25.0%) as a white crystal.
  • WSC.HCl (95 mg, 0.50 mmol) was added to a solution of 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid (242 mg, 0.50 mmol), dimethylamine hydrochloride (41 mg, 0.50 mmol) and triethylamine (51 mg, 0.50 mmol) in tetrahydrofuran (5 mL) under ice cooling, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate.
  • Methyl 2-methoxy-5-sulfamoylbenzoate (4.91 g, 20 mmol) was dissolved in methanol (30 mL). 2N Aqueous sodium hydroxide (30 mL, 60 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 2N hydrochloric acid, and the separated solid was filtered to give the title compound (4.55 g, 98.3%) as a white solid.

Abstract

A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:
Figure US20060122243A1-20060608-C00001
 wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

Description

    FIELD OF INVENTION
  • The present invention relates to pharmaceutical compositions effective for preventive and/or therapeutic treatment of allergic diseases such as pollinosis, bronchial asthma, atopic dermatitis, urticaria; endometriosis, and hysteromyoma.
    • BACKGROUND ART
  • Allergic diseases are understood to be caused by production of IgE by an antigen stimulation invaded in a body, and successive release of various chemical mediators such as inflammatory cytokine, histamine, leukotriene and the like by a degranulation from an activated mast cell stimulated by a complex of the antigen and IgE, thereby constriction of airway, accentuation of vascular permeability, inflammation of skin, bronchi and the like are induced. Accordingly, antiallergic agents are understood mainly as drugs inhibiting allergic reaction type I and successively-induced allergic inflammation, particularly as drugs inhibiting the production and release of the mediators from mast cells, or those as being antagonists against the aforementioned actions. At present, steroids, antihistaminic drugs, suppressants or inhibitors of the release of mediators and the like have been used as antiallergic agents. Although steroids are very effective drugs, they have a problem of side effects. Antihistaminic drugs are only for symptomatic therapies and fail to achieve radical therapy. Suppressants or inhibitors of the release of mediators are considered to have a high effectiveness. However, some of them lack immediate effectiveness or have central side effects. Accordingly, the antiallergic drugs currently available are not fully satisfactory as they are.
  • Patients with endometriosis are increasing in recent years, and currently, 10 to 14% of females are considered to be suffered from the disease. Endometriosis has been focused as a cause of sterility, as well as the disease lowers the quality of life of patients with severe pains during menstruation and coitus. For a treatment of the disease, a therapy by using a hormone drug has been currently applied as a pseudo menopausal therapy. However, the aforementioned therapy induces strong side effects, and it also has a risk of causing osteoporosis during a long-term administration. Therefore, at present, a drug or a method for treatment with safety and high efficacy is not available.
  • In recent years, it was found that mast cells exist apparently with high density in the lesion of endometriosis (American Journal of Reproductive Immunology (New York: 1998), (Denmark), Vol. 40, No. 4, p. 291-294), and that mast cells are activated to lead degranulation (Nikkei Medical, 2002, No. 415, p. 28; Fertility and Sterility, (USA), 2002, Vol. 78, No. 4, p. 782-786). Furthermore, a relation between endometriosis and allergy is strongly suggested, because interstitial hyperplasia, which is a major step of infiltration and lesion of mast cells, is significantly inhibited by the administration of a leukotriene antagonist having antiallergic action to an endometriosis model rat (Nikkei Medical, 2002, No. 415, p. 28; Fertility and Sterility, (USA), 2002, Vol. 78, No. 4, p. 782-786).
  • Therefore, an antiallergic drug, which strongly inhibits activation of mast cells and can be used as a therapeutic agent for radical treatment of allergic diseases, is usable as an effective therapeutic agent for endometriosis.
  • 45% of patients with endometriosis are suffered from hysteromyoma, which suggests a relation of hysteromyoma and allergy in the same manner as endometriosis. Accordingly, it is highly probable that an antiallergic agent, which can be used as a therapeutic agent for radical treatment of allergic diseases, is useful as a therapeutic agent for hysteromyoma.
  • N-phenylsalicylamide derivatives are disclosed as a plant growth inhibitor in the specification of U.S. Pat. No.4,358,443. As medicaments, said derivatives are disclosed as anti-inflammatory agents in the specification of European Patent No. 0,221,211, Japanese Patent Unexamined Publication (KOKAI) No. (Sho)62-99329, and the specification of U.S. Pat. No. 6,117,859. Furthermore, they are disclosed as NF-κ B inhibitors in the pamphlets of International Publication WO99/65499, International Publication WO02/49632, and International Publication WO02/076918, and as inhibitors against the production of cytokines in the pamphlet of International Publication WO02/051397.
    • DISCLOSURE OF THE INVENTION
  • An object of the present invention is to provide medicaments that enable radical preventive and/or therapeutic treatment of allergy by an inhibition of allergic reactions. To achieve the aforementioned object, the inventors of the present invention conducted various researches on the antiallergic actions of salicylamide derivatives which are generally believed to have low toxicity. As a result, they found that N-substituted salicylamide derivatives, particularly N-arylsalicylamide derivatives, specifically N-phenylsalicylamide derivatives wherein aniline moiety is substituted in both of 2- and 5-positions or in both of 3- and 5-positions, and N-thiazol-2-yl-salicylamide derivatives wherein thiazole ring is substituted in both of 4- and 5-positions have extremely superior activity in inhibitory action against the proliferation of mast cells, inhibitory action against the degranulation from mast cells by antigen and IgE stimulation, and inhibitory action against the production of IgE from activated B cells, and that radical preventive and/or therapeutic treatment of allergic diseases can be achieved. The inventors also conducted researches on hydroxyaryl derivatives which are analogous compounds thereof. The present invention was achieved on the basis of these findings.
  • The present invention thus provides:
    • (1) A medicament for preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:
      Figure US20060122243A1-20060608-C00002
    • wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted),
    • A represents hydrogen atom or acetyl group,
    • E represents an aryl group which may be substituted or a heteroaryl group which may be substituted,
    • ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
  • Examples of preferred medicaments provided by the present invention include:
    • (2) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein X is a group selected from the following connecting group α (said group may be substituted):
    • [Connecting group α] The groups of the following formulas:
      Figure US20060122243A1-20060608-C00003
    • wherein a bond at the left end binds to ring Z and a bond at the right end binds to E;
    • (3) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein X is a group represented by the following formula (said group may be substituted):
      Figure US20060122243A1-20060608-C00004
    • wherein a bond at the left end binds to ring Z and a bond at the right end binds to E;
    • (4) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein A is a hydrogen atom;
    • (5) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein ring Z is a C6 to C10 arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I), or a 5 to 13-membered heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I);
    • (6) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein ring Z is a ring selected from the following ring group β:
    • [Ring Group β] benzene ring, naphthalene ring, thiophene ring, pyridine ring, indole ring, quinoxaline ring, and carbazole ring
    • wherein said ring may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula(I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I);
    • (7) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein ring Z is a benzene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I);
    • (8) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein ring Z is a benzene ring which is substituted with halogen atom(s) in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I);
    • (9) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein ring Z is a naphthalene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I);
    • (10) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein E is a C6 to C10 aryl group which may be substituted or a 5 to 13-membered heteroaryl group which may be substituted;
    • (11) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein E is a phenyl group which may be substituted;
    • (12) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein E is 3,5-bis(trifluoromethyl)phenyl group;
    • (13) the aforementioned medicament which comprises as an active ingredient a substance selected from the group consisting of the compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein E is a 5-membered heteroaryl group which may be substituted.
  • From another aspect, the present invention provides use of each of the aforementioned substances for manufacture of the medicament according to the aforementioned (1) to (13).
  • The present invention further provides a method for preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma in a mammal including a human, which comprises the step of administering preventively and/or therapeutically effective amount of the aforementioned substances to a mammal including a human.
  • The present invention further provides:
    • (1) a compound represented by the general formula (I-1) or a salt thereof, or a hydrate thereof or a solvate thereof:
      Figure US20060122243A1-20060608-C00005
    • wherein Z1 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, and E1 represents a phenyl group which may be substituted.
  • Preferably, provided is:
    • (2) the compound or a salt thereof, or a hydrate thereof or a solvate thereof, wherein E1 is 2,5-bis(trifluoromethyl)phenyl group or 3,5-bis(trifluoromethyl)phenyl group, except that the following compounds are excluded:
    • N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide,
    • N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide,
    • N-[3,5-bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide,
    • N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide, and
    • N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-nitrobenzamide.
  • More preferably, provided is:
    • (3) the compound or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z1 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
  • Moreover, the present invention provides:
    • (1) a compound represented by the general formula (I-2) or a salt thereof, or a hydrate thereof or a solvate thereof:
      Figure US20060122243A1-20060608-C00006
    • wherein Z2 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, E2 represents a 2,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group or a 3,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group, provided that the following compounds are excluded:
    • 5-chloro-N-[5-chloro-3-(trifluoromethyl)phenyl]-2-hydroxybenzamide,
    • 5-fluoro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]benzamide,
    • 5-fluoro-2-hydroxy-N-[2-(6,6,6-trifluorohexyloxy)-5-(trifluoromethyl)phenyl]-benzamide,
    • 5-chloro-N-[2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide,
    • 5-chloro-2-hydroxy-N-[2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl]benzamide,
    • 5-chloro-N-[2-(4-chlorophenyl)sulfanyl-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide,
    • 5-chloro-2-hydroxy-N-[2-(1-naphthyloxy)-5-(trifluoromethyl)phenyl]benzamide, and
    • 5-chloro-2-hydroxy-N-[2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl]benzamide.
  • Preferably, provided is:
    • (2) the compound or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z2 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
  • Moreover, the present invention provides:
    • (1) a compound represented by the general formula (I-3) or a salt thereof, or a hydrate thereof or a solvate thereof:
      Figure US20060122243A1-20060608-C00007
    • wherein Z3 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, E3 represents a group represented by the following formula:
      Figure US20060122243A1-20060608-C00008
    • wherein one of R3e2 and R3e3 represents hydrogen atom and the other represents a hydrocarbon group which may be substituted or hydroxyl group which may be substituted, and
    • R3e5 represents a C2 to C6 hydrocarbon group which may be substituted.
  • Preferably, provided is:
    • (2) the compound according to claim 18 or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z3 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
  • The present invention also provides:
    • (1) a compound represented by the general formula (I-4) or a salt thereof, or a hydrate thereof or a solvate thereof:
      Figure US20060122243A1-20060608-C00009
    • wherein Z4 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, E4 represents a group represented by the following formula:
      Figure US20060122243A1-20060608-C00010
    • wherein R4e4 represents a hydrocarbon group which may be substituted, R4e5 represents a halogen atom, cyano group, an acyl group which may be substituted, or a heterocyclic group which may be substituted.
  • Preferably, provided is:
    • (2) the compound or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z4 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
    BRIEF EXPLANATION OF THE DRAWINGS
  • FIG. 1 shows inhibitory effect of the medicament of the present invention (compound No. 50) against immediate type allergy.
  • FIG. 2 shows inhibitory effect of the medicament of the present invention (compound No. 50) against dermatitis with an atopic dermatitis model.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • Reference to the disclosure of the pamphlet of International Publication WO02/49632 is useful for better understanding of the present invention. The entire disclosure of the aforementioned pamphlet of International Publication WO02/49632 is incorporated by reference in the disclosures of the present specification.
  • The terms used in the present specification have the following meanings.
  • As the halogen atom, any of fluorine atom, chlorine atom, bromine atom, or iodine atom may be used unless otherwise specifically referred to.
  • Examples of the hydrocarbon group include, for example, an aliphatic hydrocarbon group, an aryl group, an arylene group, an aralkyl group, a bridged cyclic hydrocarbon group, a spiro cyclic hydrocarbon group, and a terpene hydrocarbon.
  • Examples of the aliphatic hydrocarbon group include, for example, alkyl group, alkenyl group, alkynyl group, alkylene group, alkenylene group, alkylidene group and the like which are straight chain or branched chain monovalent or bivalent acyclic hydrocarbon groups; cycloalkyl group, cycloalkenyl group, cycloalkanedienyl group, cycloalkyl-alkyl group, cycloalkylene group, and cycloalkenylene group, which are saturated or unsaturated monovalent or bivalent alicyclic hydrocarbon groups.
  • Examples of the alkyl group include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, 1-methylbutyl, neopentyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1-ethylbutyl, 1-ethyl-1-methylpropyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, and n-pentadecyl, which are C1 to C15 straight chain or branched chain alkyl groups.
  • Examples of the alkenyl group include, for example, vinyl, prop-1-en-1-yl, allyl, isopropenyl, but-1-en-1-yl, but-2-en-1-yl, but-3-en-1-yl, 2-methylprop-2-en-1-yl, 1-methylprop-2-en-1-yl, pent-1-en-1-yl, pent-2-en-1-yl, pent-3-en-1-yl, pent-4-en-1-yl, 3-methylbut-2-en-1-yl, 3-methylbut-3-en-1-yl, hex-1-en-1-yl, hex-2-en-1-yl, hex-3-en-1-yl, hex-4-en-1-yl, hex-5-en-1-yl, 4-methylpent-3-en-1-yl, 4-methylpent-3-en-1-yl, hept-1-en-1-yl, hept-6-en-1-yl, oct-1-en-1-yl, oct-7-en-1-yl, non-1-en-1-yl, non-8-en-1-yl, dec-1-en-1-yl, dec-9-en-1-yl, undec-1-en-1-yl, undec-10-en-1-yl, dodec-1-en-1-yl, dodec-11-en-1-yl, tridec-1-en-1-yl, tridec-12-en-1-yl, tetradec-1-en-1-yl, tetradec-13-en-1-yl, pentadec-1-en-1-yl, and pentadec-14-en-1-yl, which are C2 to C15 straight chain or branched chain alkenyl groups.
  • Examples of the alkynyl group include, for example, ethynyl, prop-1-yn-1-yl, prop-2-yn-1-yl, but-1-yn-1-yl, but-3-yn-1-yl, 1-methylprop-2-yn-1-yl, pent-1-yn-1-yl, pent-4-yn-1-yl, hex-1-yn-1-yl, hex-5-yn-1-yl, hept-1-yn-1-yl, hept-6-yn-1-yl, oct-1-yn-1-yl, oct-7-yn-1-yl, non-1-yn-1-yl, non-8-yn-1-yl, dec-1-yn-1-yl, dec-9-yn-1-yl, undec-1-yn-1-yl, undec-10-yn-1-yl, dodec-1-yn-1-yl, dodec-11-yn-1-yl, tridec-1-yn-1-yl, tridec-12-yn-1-yl, tetradec-1-yn-1-yl, tetradec-13-yn-1-yl, pentadec-1-yn-1-yl, and pentadec-14-yn-1-yl, which are C2 to C15 straight chain or branched chain alkynyl groups.
  • Examples of the alkylene group include, for example, methylene, ethylene, ethane-1,1-diyl, propane-1,3-diyl, propane-1,2-diyl, propane-2,2-diyl, butane-1,4-diyl, pentane-1,5-diyl, hexane-1,6-diyl, and 1,1,4,4-tetramethylbutane-1,4-diyl group, which are C1 to C8 straight chain or branched chain alkylene groups.
  • Examples of the alkenylene group include, for example, ethene-1,2-diyl, propene-1,3-diyl, but-1-ene-1,4-diyl, but-2-ene-1,4-diyl, 2-methylpropene-1,3-diyl, pent-2-ene-1,5-diyl, and hex-3-ene-1,6-diyl, which are C1 to C6 straight chain or branched chain alkylene groups.
  • Examples of the alkylidene group include, for example, methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene, and hexylidene, which are C1 to C6 straight chain or branched chain alkylidene groups.
  • Examples of the cycloalkyl group include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, which are C3 to C8 cycloalkyl groups.
  • The aforementioned cycloalkyl group may be fused with benzene ring, naphthalene ring and the like, and examples include, for example, 1-indanyl, 2-indanyl, 1,2,3,4-tetrahydronaphthalen-1-yl, and 1,2,3,4-tetrahydronaphthalen-2-yl.
  • Examples of the cycloalkenyl group include, for example, 2-cyclopropen-1-yl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 1-cyclobuten-1-yl, and 1-cyclopenten-1-yl, which are C3 to C6 cycloalkenyl groups.
  • The aforementioned cycloalkenyl group may be fused with benzene ring, naphthalene ring and the like, and examples include, for example, 1-indanyl, 2-indanyl, 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 1-indenyl, and 2-indenyl.
  • Examples of the cycloalkanedienyl group include, for example, 2,4-cyclopentadien-1-yl, 2,4-cyclohexanedien-1-yl, and 2,5-cyclohexanedien-1-yl, which are C5 to C6 cycloalkanedienyl groups.
  • The aforementioned cycloalkanedienyl group may be fused with benzene ring, naphthalene ring and the like, and examples include, for example, 1-indenyl and 2-indenyl.
  • Examples of the cycloalkyl-alkyl group include the groups in which one hydrogen atom of the alkyl group is substituted with a cycloalkyl group, and include, for example, cyclopropylmethyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 3-cyclopropylpropyl, 4-cyclopropylbutyl, 5-cyclopropylpentyl, 6-cyclopropylhexyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylpropyl, cyclohexylbutyl, cycloheptylmethyl, cyclooctylmethyl, and 6-cyclooctylhexyl, which are C4 to C14 cycloalkyl-alkyl groups.
  • Examples of the cycloalkylene group include, for example, cyclopropane-1,1-diyl, cyclopropane-1,2-diyl, cyclobutane-1,1-diyl, cyclobutane-1,2-diyl, cyclobutane-1,3-diyl, cyclopentane-1,1-diyl, cyclopentane-1,2-diyl, cyclopentane-1,3-diyl, cyclohexane-1,1-diyl, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl, cyclohexane-1,4-diyl, cycloheptane-1,1-diyl, cycloheptane-1,2-diyl, cyclooctane-1,1-diyl, and cyclooctane-1,2-diyl, which are C3 to C8 cycloalkylene groups.
  • Examples of the cycloalkenylene group include, for example, 2-cyclopropene-1,1-diyl, 2-cyclobutene-1,1-diyl, 2-cyclopentene-1,1-diyl, 3-cyclopentene-1,1-diyl, 2-cyclohexene-1,1-diyl, 2-cyclohexene-1,2-diyl, 2-cyclohexene-1,4-diyl, 3-cyclohexene-1,1-diyl, 1-cyclobutene-1,2-diyl, 1-cyclopentene-1,2-diyl, and 1-cyclohexene-1,2-diyl, which are C3 to C6 cycloalkenylene groups.
  • Examples of the aryl group include a monocyclic or a fused polycyclic aromatic hydrocarbon group, and include, for example, phenyl, 1-naphthyl, 2-naphthyl, anthryl, phenanthryl, and acenaphthylenyl, which are C6 to C14 aryl groups.
  • The aforementioned aryl group may be fused with the aforementioned C3 to C8 cycloalkyl group, C3 to C6 cycloalkenyl group, C5 to C6 cycloalkanedienyl group or the like, and examples include, for example, 4-indanyl, 5-indanyl, 1,2,3,4-tetrahydronaphthalen-5-yl, 1,2,3,4-tetrahydronaphthalen-6-yl, 3-acenaphthenyl, 4-acenaphthenyl, inden-4-yl, inden-5-yl, inden-6-yl, inden-7-yl, 4-phenalenyl, 5-phenalenyl, 6-phenalenyl, 7-phenalenyl, 8-phenalenyl, and 9-phenalenyl.
  • Examples of the arylene group include, for example, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, naphthalene-1,2-diyl, naphthalene-1,3-diyl, naphthalene-1,4-diyl, naphthalene-1,5-diyl, naphthalene-1,6-diyl, naphthalene-1,7-diyl, naphthalene-1,8-diyl, naphthalene-2,3-diyl, naphthalene-2,4-diyl, naphthalene-2,5-diyl, naphthalene-2,6-diyl, naphthalene-2,7-diyl, naphthalene-2,8-diyl, and anthracene-1,4-diyl, which are C6 to C14 arylene groups.
  • Examples of the aralkyl group include the groups in which one hydrogen atom of the alkyl group is substituted with an aryl group, and include, for example, benzyl, 1-naphthylmethyl, 2-naphthylmethyl, anthracenylmethyl, phenanthrenylmethyl, acenaphthylenylmethyl, diphenylmethyl, 1-phenethyl, 2-phenethyl, 1-(1-naphthyl)ethyl, 1-(2-naphthyl)ethyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl, 3-phenylpropyl, 3-(1-naphthyl)propyl, 3-(2-naphthyl)propyl, 4-phenylbutyl, 4-(1-naphthyl)butyl, 4-(2-naphthyl)butyl, 5-phenylpentyl, 5-(1-naphthyl)pentyl, 5-(2-naphthyl)pentyl, 6-phenylhexyl, 6-(1-naphthyl)hexyl, and 6-(2-naphthyl)hexyl, which are C7 to C16 aralkyl groups.
  • Examples of the bridged cyclic hydrocarbon group include, for example, bicyclo[2.1.0]pentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]octyl, and adamantyl.
  • Examples of the spiro cyclic hydrocarbon group include, for example, spiro[3.4]octyl, and spiro[4.5]deca-1,6-dienyl.
  • Examples of the terpene hydrocarbon include, for example, geranyl, neryl, linalyl, phytyl, menthyl, and bornyl.
  • Examples of the halogenated alkyl group include the groups in which one hydrogen atom of the alkyl group is substituted with a halogen atom, and include, for example, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, iodomethyl, diiodomethyl, triiodomethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl, heptafluoropropyl, heptafluoroisopropyl, nonafluorobutyl, and perfluorohexyl, which are C1 to C6 straight chain or branched chain halogenated alkyl groups substituted with 1 to 13 halogen atoms.
  • Examples of the heterocyclic group include, for example, a monocyclic or a fused polycyclic hetero aryl group which comprises at least one atom of 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like as ring-constituting atoms (ring forming atoms), and a monocyclic or a fused polycyclic non-aromatic heterocyclic group which comprises at least one atom of 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like as ring-constituting atoms (ring forming atoms).
  • Examples of the monocyclic heteroaryl group include, for example, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, (1,2,3-oxadiazol)-4-yl, (1,2,3-oxadiazol)-5-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-5-yl, (1,2,5-oxadiazol)-3-yl, (1,2,5-oxadiazol)-4-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-5-yl, furazanyl, (1,2,3-thiadiazol)-4-yl, (1,2,3-thiadiazol)-5-yl, (1,2,4-thiadiazol)-3-yl, (1,2,4-thiadiazol)-5-yl, (1,2,5-thiadiazol)-3-yl, (1,2,5-thiadiazol)-4-yl, (1,3,4-thiadiazolyl)-2-yl, (1,3,4-thiadiazolyl)-5-yl, (1H-1,2,3-triazol)-1-yl, (1H-1,2,3-triazol)-4-yl, (1H-1,2,3-triazol)-5-yl, (2H-1,2,3-triazol)-2-yl, (2H-1,2,3-triazol)-4-yl, (1H-1,2,4-triazol)-1-yl, (1H-1,2,4-triazol)-3-yl, (1H-1,2,4-triazol)-5-yl, (4H-1,2,4-triazol)-3-yl, (4H-1,2,4-triazol)-4-yl, (1H-tetrazol)-1-yl, (1H-tetrazol)-5-yl, (2H-tetrazol)-2-yl, (2H-tetrazol)-5-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, (1,2,3-triazin)-4-yl, (1,2,3-triazin)-5-yl, (1,2,4-triazin)-3-yl, (1,2,4-triazin)-5-yl, (1,2,4-triazin)-6-yl, (1,3,5-triazin)-2-yl, 1-azepinyl, 2-azepinyl, 3-azepinyl, 4-azepinyl, (1,4-oxazepin)-2-yl, (1,4-oxazepin)-3-yl, (1,4-oxazepin)-5-yl, (1,4-oxazepin)-6-yl, (1,4-oxazepin)-7-yl, (1,4-thiazepin)-2-yl, (1,4-thiazepin)-3-yl, (1,4-thiazepin)-5-yl, (1,4-thiazepin)-6-yl, and (1,4-thiazepin)-7-yl, which are 5 to 7-membered monocyclic heteroaryl groups.
  • Examples of the fused polycyclic heteroaryl group include, for example, 2-benzofuranyl, 3-benzofuranyl, 4-benzofuranyl, 5-benzofuranyl, 6-benzofuranyl, 7-benzofuranyl, 1-isobenzofuranyl, 4-isobenzofuranyl, 5-isobenzofuranyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 4-benzo[b]thienyl, 5-benzo[b]thienyl, 6-benzo[b]thienyl, 7-benzo[b]thienyl, 1-benzo[c]thienyl, 4-benzo[c]thienyl, 5-benzo[c]thienyl, 1-indolyl, 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, (2H-isoindol)-1-yl, (2H-isoindol)-2-yl, (2H-isoindol)-4-yl, (2H-isoindol)-5-yl, (1H-indazol)-1-yl, (1H-indazol)-3-yl, (1H-indazol)-4-yl, (1H-indazol)-5-yl, (1H-indazol)-6-yl, (1H-indazol)-7-yl, (2H-indazol)-1-yl, (2H-indazol)-2-yl, (2H-indazol)-4-yl, (2H-indazol)-5-yl, 2-benzoxazolyl, 2-benzoxazolyl, 4-benzoxazolyl, 5-benzoxazolyl, 6-benzoxazolyl, 7-benzoxazolyl, (1,2-benzisoxazol)-3-yl, (1,2-benzisoxazol)-4-yl, (1,2-benzisoxazol)-5-yl, (1,2-benzisoxazol)-6-yl, (1,2-benzisoxazol)-7-yl, (2,1-benzisoxazol)-3-yl, (2,1-benzisoxazol)-4-yl, (2,1-benzisoxazol)-5-yl, (2,1-benzisoxazol)-6-yl, (2,1-benzisoxazol)-7-yl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl, (1,2-benzisothiazol)-3-yl, (1,2-benzisothiazol)-4-yl, (1,2-benzisothiazol)-5-yl, (1,2-benzisothiazol)-6-yl, (1,2-benzisothiazol)-7-yl, (2,1-benzisothiazol)-3-yl, (2,1-benzisothiazol)-4-yl, (2,1-benzisothiazol)-5-yl, (2,1-benzisothiazol)-6-yl, (2,1-benzisothiazol)-7-yl, (1,2,3-benzoxadiazol)-4-yl, (1,2,3-benzoxadiazol)-5-yl, (1,2,3-benzoxadiazol)-6-yl, (1,2,3-benzoxadiazol)-7-yl, (2,1,3-benzoxadiazol)-4-yl, (2,1,3-benzoxadiazol)-5-yl, (1,2,3-benzothiadiazol)-4-yl, (1,2,3-benzothiadiazol)-5-yl, (1,2,3-benzothiadiazol)-6-yl, (1,2,3-benzothiadiazol)-7-yl, (2,1,3-benzothiadiazol)-4-yl, (2,1,3-benzothiadiazol)-5-yl, (1H-benzotriazol)-1-yl, (1H-benzotriazol)-4-yl, (1H-benzotriazol)-5-yl, (1H-benzotriazol)-6-yl, (1H-benzotriazol)-7-yl, (2H-benzotriazol)-2-yl, (2H-benzotriazol)-4-yl, (2H-benzotriazol)-5-yl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl, 3-cinnolinyl, 4-cinnolinyl, 5-cinnolinyl, 6-cinnolinyl, 7-cinnolinyl, 8-cinnolinyl, 2-quinazolinyl, 4-quinazolinyl, 5-quinazolinyl, 6-quinazolinyl, 7-quinazolinyl, 8-quinazolinyl, 2-quinoxalinyl, 5-quinoxalinyl, 6-quinoxalinyl, 1-phthalazinyl, 5-phthalazinyl, 6-phthalazinyl, 2-naphthyridinyl, 3-naphthyridinyl, 4-naphthyridinyl, 2-purinyl, 6-purinyl, 7-purinyl, 8-purinyl, 2-pteridinyl, 4-pteridinyl, 6-pteridinyl, 7-pteridinyl, 1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl, 9-carbazolyl, 2-(α-carbolinyl), 3-(α-carbolinyl), 4-(α-carbolinyl), 5-(α-carbolinyl), 6-(α-carbolinyl), 7-(α-carbolinyl), 8-(α-carbolinyl), 9-(α-carbolinyl), 1-(β-carbolinyl), 3-(β-carbolinyl), 4-(β-carbolinyl), 5-(β-carbolinyl), 6-(β-carbolinyl), 7-(β-carbolinyl), 8-(β-carbolinyl), 9-(β-carbolinyl), 1-(γ-carbolinyl), 2-(γ-carbolinyl), 4-(γ-carbolinyl), 5-(γ-carbolinyl), 6-(γ-carbolinyl), 7-(γ-carbolinyl), 8-(γ-carbolinyl), 9-(γ-carbolinyl), 1-acridinyl, 2-acridinyl, 3-acridinyl, 4-acridinyl, 9-acridinyl, 1-phenoxazinyl, 2-phenoxazinyl, 3-phenoxazinyl, 4-phenoxazinyl, 10-phenoxazinyl, 1-phenothiazinyl, 2-phenothiazinyl, 3-phenothiazinyl, 4-phenothiazinyl, 10-phenothiazinyl, 1-phenazinyl, 2-phenazinyl, 1-phenanthridinyl, 2-phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl, 6-phenanthridinyl, 7-phenanthridinyl, 8-phenanthridinyl, 9-phenanthridinyl, 10-phenanthridinyl, 2-phenanthrolinyl, 3-phenanthrolinyl, 4-phenanthrolinyl, 5-phenanthrolinyl, 6-phenanthrolinyl, 7-phenanthrolinyl, 8-phenanthrolinyl, 9-phenanthrolinyl, 10-phenanthrolinyl, 1-thianthrenyl, 2-thianthrenyl, 1-indolizinyl, 2-indolizinyl, 3-indolizinyl, 5-indolizinyl, 6-indolizinyl, 7-indolizinyl, 8-indolizinyl, 1-phenoxathiinyl, 2-phenoxathiinyl, 3-phenoxathiinyl, 4-phenoxathiinyl, thieno[2,3-b]furyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridyl, imidazo[11,2-a]pyridyl, imidazo[1,5-a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrimidinyl, 1,2,4-triazolo[4,3-a]pyridyl, and 1,2,4-triazolo[4,3-a]pyridazinyl, which are 8 to 14-membered fused polycyclic heteroaryl groups.
  • Examples of the monocyclic non-aromatic heterocyclic group include, for example, 1-aziridinyl, 1-azetidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrofuryl, 3-tetrahydrofuryl, thiolanyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 1-(2-pyrrolinyl), 1-(2-imidazolinyl), 2-(2-imidazolinyl), 1-(2-pyrazolinyl), 3-(2-pyrazolinyl), piperidino, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-homopiperidinyl, 2-tetrahydropyranyl, morpholino, (thiomorpholin)-4-yl, 1-piperazinyl, and 1-homopiperazinyl, which are 3 to 7-membered saturated or unsaturated monocyclic non-aromatic heterocyclic groups.
  • Examples of the fused polycyclic non-aromatic heterocyclic group include, for example, 2-quinuclidinyl, 2-chromanyl, 3-chromanyl, 4-chromanyl, 5-chromanyl, 6-chromanyl, 7-chromanyl, 8-chromanyl, 1-isochromanyl, 3-isochromanyl, 4-isochromanyl, 5-isochromanyl, 6-isochromanyl, 7-isochromanyl, 8-isochromanyl, 2-thiochromanyl, 3-thiochromanyl, 4-thiochromanyl, 5-thiochromanyl, 6-thiochromanyl, 7-thiochromanyl, 8-thiochromanyl, 1-isothiochromanyl, 3-isothiochromanyl, 4-isothiochromanyl, 5-isothiochromanyl, 6-isothiochromanyl, 7-isothiochromanyl, 8-isothiochromanyl, 1-indolinyl, 2-indolinyl, 3-indolinyl, 4-indolinyl, 5-indolinyl, 6-indolinyl, 7-indolinyl, 1-isoindolinyl, 2-isoindolinyl, 4-isoindolinyl, 5-isoindolinyl, 2-(4H-chromenyl), 3-(4H-chromenyl), 4-(4H-chromenyl), 5-(4H-chromenyl), 6-(4H-chromenyl), 7-(4H-chromenyl), 8-(4H-chromenyl), 1-isochromenyl, 3-isochromenyl, 4-isochromenyl, 5-isochromenyl, 6-isochromenyl, 7-isochromenyl, 8-isochromenyl, 1-(1H-pyrrolidinyl), 2-(1H-pyrrolidinyl), 3-(1H-pyrrolidinyl), 5-(1H-pyrrolidinyl), 6-(1H-pyrrolidinyl), and 7-(1H-pyrrolidinyl), which are 8 to 10-membered saturated or unsaturated fused polycyclic non-aromatic heterocyclic groups.
  • Among the aforementioned heterocyclic groups, a monocyclic or a fused polycyclic hetero aryl groups which may have 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, in addition to the nitrogen atom that has the bond, as ring-constituting atoms (ring forming atoms), and a monocyclic or a fused polycyclic non-aromatic heterocyclic groups which may have 1 to 3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like, in addition to the nitrogen atom that has the bond, as ring-constituting atoms (ring forming atoms) are referred to as “cyclic amino group.” Examples include, for example, 1-pyrrolidinyl, 1-imidazolidinyl, 1-pyrazolidinyl, 1-oxazolidinyl, 1-thiazolidinyl, piperidino, morpholino, 1-piperazinyl, thiomorpholin-4-yl, 1-homopiperidinyl, 1-homopiperazinyl, 2-pyrolin-1-yl, 2-imidazolin-1-yl, 2-pyrazolin-1-yl, 1-indolinyl, 2-isoindolinyl, 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, 1-indolyl, 1-indazolyl, and 2-isoindolyl.
  • The aforementioned cycloalkyl group, cycloalkenyl group, cycloalkanedienyl group, aryl group, cycloalkylene group, cycloalkenylene group, arylene group, bridged cyclic hydrocarbon group, spiro cyclic hydrocarbon group, and heterocyclic group are generically referred to as “cyclic group.” Furthermore, among said cyclic groups, particularly, aryl group, arylene group, monocyclic heteroaryl group, and fused polycyclic heteroaryl group are generically referred to as “aromatic ring group.”
  • Examples of the hydrocarbon-oxy group include the groups in which a hydrogen atom of the hydroxy group is substituted with a hydrocarbon group, and examples of the hydrocarbon include similar groups to the aforementioned hydrocarbon groups. Examples of the hydrocarbon-oxy group include, for example, alkoxy group (alkyl-oxy group), alkenyl-oxy group, alkynyl-oxy group, cycloalkyl-oxy group, cycloalkyl-alkyl-oxy group and the like, which are aliphatic hydrocarbon-oxy groups; aryl-oxy group; aralkyl-oxy group; and alkylene-dioxy group.
  • Examples of the alkoxy (alkyl-oxy group) include, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, 2-methylbutoxy, 1-methylbutoxy, neopentyloxy, 1,2-dimethylpropoxy, 1-ethylpropoxy, n-hexyloxy, 4-methylpentyloxy, 3-methylpentyloxy, 2-methylpentyloxy, 1-methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethybutoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy, 2-ethylbutoxy, 1-ethylbutoxy, 1-ethyl-1-methylpropoxy, n-heptyloxy, n-octyloxy, n-nonyloxy, n-decyloxy, n-undecyloxy, n-dodecyloxy, n-tridecyloxy, n-tetradecyloxy, and n-pentadecyloxy, which are C1 to C15 straight chain or branched chain alkoxy groups.
  • Examples of the alkenyl-oxy group include, for example, vinyloxy, (prop-1-en-1-yl)oxy, allyloxy, isopropenyloxy, (but-1-en-1-yl)oxy, (but-2-en-1-yl)oxy, (but-3-en-1-yl)oxy, (2-methylprop-2-en-1-yl)oxy, (1-methylprop-2-en-1-yl)oxy, (pent-1-en-1-yl)oxy, (pent-2-en-1-yl)oxy, (pent-3-en-1-yl)oxy, (pent-4-en-1-yl)oxy, (3-methylbut-2-en-1-yl)oxy, (3-methylbut-3-en-1-yl)oxy, (hex-1-en-1-yl)oxy, (hex-2-en-1-yl)oxy, (hex-3-en-1-yl)oxy, (hex-4-en-1-yl)oxy, (hex-5-en-1-yl)oxy, (4-methylpent-3-en-1-yl)oxy, (4-methylpent-3-en-1-yl)oxy, (hept-1-en-1-yl)oxy, (hept-6-en-1-yl)oxy, (oct-1-en-1-yl)oxy, (oct-7-en-1-yl)oxy, (non-1-en-1-yl)oxy, (non-8-en-1-yl)oxy, (dec-1-en-1-yl)oxy, (dec-9-en-1-yl)oxy, (undec-1-en-1-yl)oxy, (undec-10-en-1-yl)oxy, (dodec-1-en-1-yl)oxy, (dodec-11-en-1-yl)oxy, (tridec-1-en-1-yl)oxy, (tridec-12-en-1-yl)oxy, (tetradec-1-en-1-yl)oxy, (tetradec-13-en-1-yl)oxy, (pentadec-1-en-1-yl)oxy, and (pentadec-14-en-1-yl)oxy, which are C2 to C15 straight chain or branched chain alkenyl-oxy groups.
  • Examples of the alkynyl-oxy group include, for example, ethynyloxy, (prop-1-yn-1-yl)oxy, (prop-2-yn-1-yl)oxy, (but-1-yn-1-yl)oxy, (but-3-yn-1-yl)oxy, (1-methylprop-2-yn-1-yl)oxy, (pent-1-yn-1-yl)oxy, (pent-4-yn-1-yl)oxy, (hex-1-yn-1-yl)oxy, (hex-5-yn-1-yl)oxy, (hept-1-yn-1-yl)oxy, (hept-6-yn-1-yl)oxy, (oct-1-yn-1-yl)oxy, (oct-7-yn-1-yl)oxy, (non-1-yn-1-yl)oxy, (non-8-yn-1-yl)oxy, (dec-1-yn-1-yl)oxy, (dec-9-yn-1-yl)oxy, (undec-1-yn-1-yl)oxy, (undec-10-yn-1-yl)oxy, (dodec-1-yn-1-yl)oxy, (dodec-11-yn-1-yl)oxy, (tridec-1-yn-1-yl)oxy, (tridec-12-yn-1-yl)oxy, (tetradec-1-yn-1-yl)oxy, (tetradec-13-yn-1-yl)oxy, (pentadec-1-yn-1-yl)oxy, and (pentadec-14-yn-1-yl)oxy, which are C2 to C15 straight chain or branched chain alkynyl-oxy groups.
  • Examples of the cycloalkyl-oxy group include, for example, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and cyclooctyloxy, which are C3 to C8 cycloalkyl-oxy groups.
  • Examples of the cycloalkyl-alkyl-oxy group include, for example, cyclopropylmethoxy, 1-cyclopropylethoxy, 2-cyclopropylethoxy, 3-cyclopropylpropoxy, 4-cyclopropylbutoxy, 5-cyclopropylpentyloxy, 6-cyclopropylhexyloxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-cyclohexylethoxy, 3-cyclohexylpropoxy, 4-cyclohexylbutoxy, cycloheptylmethoxy, cyclooctylmethoxy, and 6-cyclooctylhexyloxy, which are C4 to C14 cycloalkyl-alkyl-oxy groups.
  • Examples of the aryl-oxy group include, for example, phenoxy, 1-naphthyloxy, 2-naphthyloxy, anthryloxy, phenanthryloxy, and acenaphthylenyloxy, which are C6 to C14 aryl-oxy groups.
  • Examples of the aralkyl-oxy group include, for example, benzyloxy, 1-naphthylmethoxy, 2-naphthylmethoxy, anthracenylmethoxy, phenanthrenylmethoxy, acenaphthylenylmethoxy, diphenylmethoxy, 1-phenethyloxy, 2-phenethyloxy, 1-(1-naphthyl)ethoxy, 1-(2-naphthyl)ethoxy, 2-(1-naphthyl)ethoxy, 2-(2-naphthyl)ethoxy, 3-phenylpropoxy, 3-(1-naphthyl)propoxy, 3-(2-naphthyl)propoxy, 4-phenylbutoxy, 4-(1-naphthyl)butoxy, 4-(2-naphthyl)butoxy, 5-phenylpentyloxy, 5-(1-naphthyl)pentyloxy, 5-(2-naphthyl)pentyloxy, 6-phenylhexyloxy, 6-(1-naphthyl)hexyloxy, and 6-(2-naphthyl)hexyloxy, which are C7 to C16 aralkyl-oxy groups.
  • Examples of the alkylenedioxy group include, for example, methylenedioxy, ethylenedioxy, 1-methylmethylenedioxy, and 1,1-dimethylmethylenedioxy.
  • Examples of the halogenated alkoxy group (halogenated alkyl-oxy group) include the groups in which a hydrogen atom of the hydroxy group is substituted with a halogenated alkyl group, and include, for example, fluoromethoxy, difluoromethoxy, chloromethoxy, bromomethoxy, iodomethoxy, trifluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, 3,3,3-trifluoropropoxy, heptafluoropropoxy, heptafluoroisopropoxy, nonafluorobutoxy, and perfluorohexyloxy, which are C1 to C6 straight chain or branched chain halogenated alkoxy groups substituted with 1 to 13 halogen atoms.
  • Examples of the heterocyclic-oxy group include the groups in which a hydrogen atom of the hydroxy group is substituted with a heterocyclic group, and examples of the heterocyclic ring include similar groups to the aforementioned heterocyclic groups. Examples of the heterocyclic-oxy group include, for example, a monocyclic heteroaryl-oxy group, a fused polycyclic heteroaryl-oxy group, a monocyclic non-aromatic heterocyclic-oxy group, and a fused polycyclic non-aromatic heterocyclic-oxy group.
  • Examples of the monocyclic heteroaryl-oxy group include, for example, 3-thienyloxy, (isoxazol-3-yl)oxy, (thiazol-4-yl)oxy, 2-pyridyloxy, 3-pyridyloxy, 4-pyridyloxy, and (pyrimidin-4-yl)oxy.
  • Examples of the fused polycyclic heteroaryl-oxy group include, for example, 5-indolyloxy, (benzimidazol-2-yl)oxy, 2-quinolyloxy, 3-quinolyloxy, and 4-quinolyloxy.
  • Examples of the monocyclic non-aromatic heterocyclic-oxy group include, for example, 3-pyrrolidinyloxy, and 4-piperidinyloxy.
  • Examples of the fused polycyclic non-aromatic heterocyclic-oxy group include, for example, 3-indolynyloxy, and 4-chromanyloxy.
  • Examples of the hydrocarbon-sulfanyl group include the groups in which a hydrogen atom of the sulfanyl group is substituted with a hydrocarbon group, and examples of the hydrocarbon include similar groups to the aforementioned hydrocarbon groups. Examples of the hydrocarbon-sulfanyl groups include, for example, alkyl-sulfanyl group, alkenyl-sulfanyl group, alkynyl-sulfanyl group, cycloalkyl-sulfanyl group, cycloalkyl-alkyl-sulfanyl group and the like, which are aliphatic hydrocarbon-sulfanyl groups; aryl-sulfanyl group, and aralkyl-sulfanyl group.
  • Examples of the alkyl-sulfanyl group include, for example, methylsulfanyl, ethylsulfanyl, n-propylsulfanyl, isopropylsulfanyl, n-butylsulfanyl, isobutylsulfanyl, sec-butylsulfanyl, tert-butylsulfanyl, n-pentylsulfanyl, isopentylsulfanyl, (2-methylbutyl)sulfanyl, (1-methylbutyl)sulfanyl, neopentylsulfanyl, (1,2-dimethylpropyl)sulfanyl, (1-ethylpropyl)sulfanyl, n-hexylsulfanyl, (4-methylpentyl)sulfanyl, (3-methylpentyl)sulfanyl, (2-methylpentyl)sulfanyl, (1-methylpentyl)sulfanyl, (3,3-dimethylbutyl)sulfanyl, (2,2-dimethylbutyl)sulfanyl, (1,1-dimethylbutyl)sulfanyl, (1,2-dimethylbutyl)sulfanyl, (1,3-dimethylbutyl)sulfanyl, (2,3-dimethylbutyl)sulfanyl, (2-ethylbutyl)sulfanyl, (1-ethylbutyl)sulfanyl, (1-ethyl-1-methylpropyl)sulfanyl, n-heptylsulfanyl, n-octylsulfanyl, n-nonylsulfanyl, n-decylsulfanyl, n-undecylsulfanyl, n-dodecylsulfanyl, n-tridecylsulfanyl, n-tetradecylsulfanyl, and n-pentadecylsulfanyl, which are C1 to C15 straight chain or branched chain alkyl-sulfanyl groups.
  • Examples of the alkenyl-sulfanyl group include, for example, vinylsulfanyl, (prop-1-en-1-yl)sulfanyl, allylsulfanyl, isopropenylsulfanyl, (but-1-en-1-yl)sulfanyl, (but-2-en-1-yl)sulfanyl, (but-3-en-1-yl)sulfanyl, (2-methylprop-2-en-1-yl)sulfanyl, (1-methylprop-2-en-1-yl)sulfanyl, (pent-1-en-1-yl)sulfanyl, (pent-2-en-1-yl)sulfanyl, (pent-3-en-1-yl)sulfanyl, (pent-4-en-1-yl)sulfanyl, (3-methylbut-2-en-1-yl)sulfanyl, (3-methylbut-3-en-1-yl)sulfanyl, (hex-1-en-1-yl)sulfanyl, (hex-2-en-1-yl)sulfanyl, (hex-3-en-1-yl)sulfanyl, (hex-4-en-1-yl)sulfanyl, (hex-5-en-1-yl)sulfanyl, (4-methylpent-3-en-1-yl)sulfanyl, (4-methylpent-3-en-1-yl)sulfanyl, (hept-1-en-1-yl)sulfanyl, (hept-6-en-1-yl)sulfanyl, (oct-1-en-1-yl)sulfanyl, (oct-7-en-1-yl)sulfanyl, (non-1-en-1-yl)sulfanyl, (non-8-en-1-yl)sulfanyl, (dec-1-en-1-yl)sulfanyl, (dec-9-en-1-yl)sulfanyl, (undec-1-en-1-yl)sulfanyl, (undec-10-en-1-yl)sulfanyl, (dodec-1-en-1-yl)sulfanyl, (dodec-11-en-1-yl)sulfanyl, (tridec-1-en-1-yl)sulfanyl, (tridec-12-en-1-yl)sulfanyl, (tetradec-1-en-1-yl)sulfanyl, (tetradec-13-en-1-yl)sulfanyl, (pentadec-1-en-1-yl)sulfanyl, and (pentadec-14-en-1-yl)sulfanyl, which are C2 to C15 straight chain or branched chain alkenyl-sulfanyl groups.
  • Examples of the alkynyl-sulfanyl group include, for example, ethynylsulfanyl, (prop-1-yn-1-yl)sulfanyl, (prop-2-yn-1-yl)sulfanyl, (but-1-yn-1-yl)sulfanyl, (but-3-yn-1-yl)sulfanyl, (1-methylprop-2-yn-1-yl)sulfanyl, (pent-1-yn-1-yl)sulfanyl, (pent-4-yn-1-yl)sulfanyl, (hex-1-yn-1-yl)sulfanyl, (hex-5-yn-1-yl)sulfanyl, (hept-1-yn-1-yl)sulfanyl, (hept-6-yn-1-yl)sulfanyl, (oct-1-yn-1-yl)sulfanyl, (oct-7-yn-1-yl)sulfanyl, (non-1-yn-1-yl)sulfanyl, (non-8-yn-1-yl)sulfanyl, (dec-1-yn-1-yl)sulfanyl, (dec-9-yn-1-yl)sulfanyl, (undec-1-yn-1-yl)sulfanyl, (undec-10-yn-1-yl)sulfanyl, (dodec-1-yn-1-yl)sulfanyl, (dodec-11-yn-1-yl)sulfanyl, (tridec-1-yn-1-yl)sulfanyl, (tridec-12-yn-1-yl)sulfanyl, (tetradec-1-yn-1-yl)sulfanyl, (tetradec-13-yn-1-yl)sulfanyl, (pentadec-1-yn-1-yl)sulfanyl, and (pentadec-14-yn-1-yl)sulfanyl, which are C2 to C15 straight chain or branched chain alkynyl-sulfanyl groups.
  • Examples of the cycloalkyl-sulfanyl group include, for example, cyclopropylsulfanyl, cyclobutylsulfanyl, cyclopentylsulfanyl, cyclohexylsulfanyl, cycloheptylsulfanyl, and cyclooctylsulfanyl, which are C3 to C8 cycloalkyl-sulfanyl groups.
  • Examples of the cycloalkyl-alkyl-sulfanyl group include, for example, (cyclopropylmethyl)sulfanyl, (1-cyclopropylethyl)sulfanyl, (2-cyclopropylethyl)sulfanyl, (3-cyclopropylpropyl)sulfanyl, (4-cyclopropylbutyl)sulfanyl, (5-cyclopropylpentyl)sulfanyl, (6-cyclopropylhexyl)sulfanyl, (cyclobutylmethyl)sulfanyl, (cyclopentylmethyl)sulfanyl, (cyclobutylmethyl)sulfanyl, (cyclopentylmethyl)sulfanyl, (cyclohexylmethyl)sulfanyl, (2-cyclohexylethyl)sulfanyl, (3-cyclohexylpropyl)sulfanyl, (4-cyclohexylbutyl)sulfanyl, (cycloheptylmethyl)sulfanyl, (cyclooctylmethyl)sulfanyl, and (6-cyclooctylhexyl)sulfanyl, which are C4 to C14 cycloalkyl-alkyl-sulfanyl groups.
  • Examples of the aryl-sulfanyl group include, for example, phenylsulfanyl, 1-naphthylsulfanyl, 2-naphthylsulfanyl, anthrylsulfanyl, fenanthrylsulfanyl, and acenaphthylenylsulfanyl, which are C6 to C14 aryl-sulfanyl groups.
  • Examples of the aralkyl-sulfanyl group include, for example, benzylsulfanyl, (1-naphthylmethyl)sulfanyl, (2-naphthylmethyl)sulfanyl, (anthracenylmethyl)sulfanyl, (phenanthrenylmethyl)sulfanyl, (acenaphthylenylmethyl)sulfanyl, (diphenylmethyl)sulfanyl, (1-phenethyl)sulfanyl, (2-phenethyl)sulfanyl, (1-(1-naphthyl)ethyl)sulfanyl, (1-(2-naphthyl)ethyl)sulfanyl, (2-(1-naphthyl)ehyl)sulfanyl, (2-(2-naphthyl)ethyl)sulfanyl, (3-phenylpropyl)sulfanyl, (3-(1-naphthyl)propyl)sulfanyl, (3-(2-naphthyl)propyl)sulfanyl, (4-phenylbutyl)sulfanyl, (4-(1-naphthyl)butyl)sulfanyl, (4-(2-naphthyl)butyl)sulfanyl, (5-phenylpentyl)sulfanyl, (5-(1-naphthyl)pentyl)sulfanyl, (5-(2-naphthyl)pentyl)sulfanyl, (6-phenylhexyl)sulfanyl, (6-(1-naphthyl)hexyl)sulfanyl, and (6-(2-naphthyl)hexyl)sulfanyl, which are C7 to C16 aralkyl-sulfanyl groups.
  • Examples of the halogenated alkyl-sulfanyl group include the groups in which a hydrogen atom of the sulfanyl group is substituted with a halogenated alkyl group, and include, for example, (fluoromethyl)sulfanyl, (chloromethyl)sulfanyl, (bromomethyl)sulfanyl, (iodomethyl)sulfanyl, (difluoromethyl)sulfanyl, (trifluoromethyl)sulfanyl, (trichloromethyl)sulfanyl, (2,2,2-trifluoroethyl)sulfanyl, (pentafluoroethyl)sulfanyl, (3,3,3-trifluoropropyl)sulfanyl, (heptafluoropropyl)sulfanyl, (heptafluoroisopropyl)sulfanyl, (nonafluorobutyl)sulfanyl, and (perfluorohexyl)sulfanyl, which are C1 to C6 straight chain or branched chain halogenated alkyl-sulfanyl groups substituted with 1 to 13 halogen atoms.
  • Examples of the heterocyclic-sulfanyl group include the groups in which a hydrogen atom of the sulfanyl group is substituted with a heterocyclic group, and examples of the heterocyclic ring include similar groups to the aforementioned heterocyclic groups. Examples of the heterocyclic-sulfanyl group include, for example, a monocyclic heteroaryl-sulfanyl group, a fused polycyclic heteroaryl-sulfanyl group, a monocyclic non-aromatic heterocyclic-sulfanyl group, and a fused polycyclic non-aromatic heterocyclic-sulfanyl group.
  • Examples of the monocyclic heteroaryl-sulfanyl group include, for example, (imidazol-2-yl)sulfanyl, (1,2,4-triazol-2-yl)sulfanyl, (pyridin-2-yl)sulfanyl, (pyridin-4-yl)sulfanyl, and (pyrimidin-2-yl)sulfanyl.
  • Examples of the fused polycyclic heteroaryl-sulfanyl group include, for example, (benzimidazol-2-yl)sulfanyl, (quinolin-2-yl)sulfanyl, and (quinolin-4-yl)sulfanyl.
  • Examples of the monocyclic non-aromatic heterocyclic-sulfanyl groups include, for example, (3-pyrrolidinyl)sulfanyl, and (4-piperidinyl)sulfanyl.
  • Examples of the fused polycyclic non-aromatic heterocyclic-sulfanyl group include, for example, (3-indolinyl)sulfanyl, and (4-chromanyl)sulfanyl.
  • Examples of the acyl group include, for example, formyl group, glyoxyloyl group, thioformyl group, carbamoyl group, thiocarbamoyl group, sulfamoyl group, sulfinamoyl group, carboxy group, sulfo group, phosphono group, and groups represented by the following formulas:
    Figure US20060122243A1-20060608-C00011
    Figure US20060122243A1-20060608-C00012
    • wherein Ra1 and Rb1 may be the same or different and represent a hydrocarbon group or a heterocyclic group, or Ra1 and Rb1 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group.
  • In the definition of the aforementioned acyl group, among the groups represented by the formula (ω-1A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl group” whose examples include, for example, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, lauroyl, myristoryl, palmitoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, isocrotonoyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, 1-naphthoyl, 2-naphthoyl, and phenylacetyl, and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl group” whose examples include, for example, 2-thenoyl, 3-furoyl, nicotinoyl, and isonicotinoyl.
  • Among the groups represented by the formula (ω-2A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-oxy-carbonyl group” whose examples include, for example, methoxycarbonyl, ethoxycarbonyl, phenoxycarbonyl, and benzyloxycarbonyl, and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-oxy-carbonyl group” whose examples include, for example, 3-pyridyloxycarbonyl.
  • Among the groups represented by the formula (ω-3A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-carbonyl group” whose examples include, for example, pyruvoyl, and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl-carbonyl group.”
  • Among the groups represented by the formula (ω-4A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-oxy-carbonyl-carbonyl group” whose examples include, for example, methoxalyl and ethoxalyl groups, and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-oxy-carbonyl-carbonyl group.”
  • Among the groups represented by the formula (ω-5A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-sulfanyl-carbonyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-sulfanyl-carbonyl group.”
  • Among the groups represented by the formula (ω-6A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-thiocarbonyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-thiocarbonyl group.”
  • Among the groups represented by the formula (ω-7A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-oxy-thiocarbonyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-oxy-thiocarbonyl group.”
  • Among the groups represented by the formula (ω-8A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-sulfanyl-thiocarbonyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as
    • “heterocyclic ring-sulfanyl-thiocarbonyl group.”
  • Among the groups represented by the formula (ω-9A), those groups in which Ra1 is a hydrocarbon group are referred to as referred to as “N-hydrocarbon-carbamoyl group” whose examples include, for example, N-methylcarbamoyl group, and those groups in which Ra1 is a heterocyclic group are referred to as “N-heterocyclic ring-carbamoyl group.”
  • Among the groups represented by the formula (ω-10A), those groups in which both Ra1 and Rb1 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-carbamoyl group” whose examples include, for example, N,N-dimethylcarbamoyl group, those groups in which both Ra1 and Rb1 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-carbamoyl group,” those groups in which Ra1 is a hydrocarbon group and Rb1 is a heterocyclic group are referred to as p0 “N-hydrocarbon-N-heterocyclic ring-substituted carbamoyl group,” and those groups in which Ra1 and Rb1 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-carbonyl group” whose examples include, for example, morpholino-carbonyl.
  • Among the groups represented by the formula (ω-11A), those groups in which Ra1 is a hydrocarbon group are referred to as “N-hydrocarbon-thiocarbamoyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “N-heterocyclic ring-thiocarbamoyl group.”
  • Among the groups represented by the formula (ω-12A), those groups in which both Ra1 and Rb1 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-thiocarbamoyl group,” those groups in which both Ra1 and Rb1 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-thiocarbamoyl group,” those groups in which Ra1 is a hydrocarbon group and Rb1 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-thiocarbamoyl group,” and those groups in which Ra1 and Rb1 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-thiocarbonyl group.”
  • Among the groups represented by the formula (ω-13A), those groups in which Ra1 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfamoyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfamoyl group.”
  • Among the groups represented by the formula (ω-14A), those groups in which both Ra1 and Rb1 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-sulfamoyl group” whose examples include, for example, N,N-dimethylsulfamoyl group, those groups in which both Ra1 and Rb1 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfamoyl group,” those groups in which Ra1 is a hydrocarbon group and Rb1 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfamoyl group,” and those groups in which Ra1 and Rb1 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-sulfonyl group” whose examples include, for example 1-pyrrolylsulfonyl.
  • Among the groups represented by the formula (ω-15A), those groups in which Ra1 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfinamoyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfinamoyl group.”
  • Among the groups represented by the formula (ω-16A), those groups in which both Ra1 and Rb1 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-sulfinamoyl group,” those groups in which both Ra1 and Rb1 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfinamoyl group,” those groups in which Ra1 is a hydrocarbon group and Rb1 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfinamoyl group,” and those groups in which Ra1 and Rb1 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-sulfinyl group.”
  • Among the groups represented by the formula (ω-17A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfonyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-oxy-sulfonyl group.”
  • Among the groups represented by the formula (ω-18A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfinyl group,” and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-oxy-sulfinyl group.”
  • Among the groups represented by the formula (ω-19A), those groups in which both Ra1 and Rb1 are hydrocarbon groups are referred to as
    • “O,O′-di(hydrocarbon)-phosphono group,” those groups in which both Ra1 and Rb1 are heterocyclic groups are referred to as “O,O′-di(heterocyclic ring)-phosphono group,” and those groups in which Ra1 is a hydrocarbon group and Rb1 is a heterocyclic group are referred to as “O-hydrocarbon-O′-heterocyclic ring-phosphono group.”
  • Among the groups represented by the formula (ω-20A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-sulfonyl group” whose examples include, for example, methanesulfonyl and benzenesulfonyl, and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-sulfonyl group.”
  • Among the groups represented by the formula (ω-21A), those groups in which Ra1 is a hydrocarbon group are referred to as “hydrocarbon-sulfinyl group” whose examples include, for example, methylsulfinyl and benzenesulfinyl, and those groups in which Ra1 is a heterocyclic group are referred to as “heterocyclic ring-sulfinyl group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas (ω-1A) through (ω-21A) include the similar groups to the aforementioned hydrocarbon group. Examples of the hydrocarbon-carbonyl group represented by the formula (ω-1A) include, for example, an alkyl-carbonyl group, an alkenyl-carbonyl group, an alkynyl-carbonyl group, a cycloalkyl-carbonyl group, a cycloalkenyl-carbonyl group, a cycloalkanedienyl-carbonyl group, a cycloalkyl-alkyl-carbonyl group, which are aliphatic hydrocarbon-carbonyl groups; an aryl-carbonyl group; an aralkyl-carbonyl group; a bridged cyclic hydrocarbon-carbonyl group; a spirocyclic hydrocarbon-carbonyl group; and a terpene family hydrocarbon-carbonyl group. In the following, groups represented by the formulas (ω-2A) through (ω-21A) are similar to those explained above.
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas (ω-1A) through (ω-21A) include similar groups to the aforementioned heterocyclic group. Examples of the heterocyclic ring-carbonyl group represented by the formula (ω-1A) include, for example, a monocyclic heteroaryl-carbonyl group, a fused polycyclic heteroaryl-carbonyl group, a monocyclic non-aromatic heterocyclic ring-carbonyl group, and a fused polycyclic non-aromatic heterocyclic ring-carbonyl group. In the following, groups represented by the formulas (ω-2A) through (ω-21A) are similar to those explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas (ω-10A) through (ω-16A) include similar groups to the aforementioned cyclic amino group.
  • In the present specification, when a certain functional group is defined as “which may be substituted,” the definition means that the functional group may sometimes have one or more substituents at chemically substitutable positions, unless otherwise specifically mentioned. Kind of substituents, number of substituents, and the position of substituents existing in the functional groups are not particularly limited, and when two or more substituents exist, they may be the same or different. Examples of the substituent existing in the functional group include, for example, halogen atoms, oxo group, thioxo group, nitro group, nitroso group, cyano group, isocyano group, cyanato group, thiocyanato group, isocyanato group, isothiocyanato group, hydroxy group, sulfanyl group, carboxy group, sulfanylcarbonyl group, oxalo group, methooxalo group, thiocarboxy group, dithiocarboxy group, carbamoyl group, thiocarbamoyl group, sulfo group, sulfamoyl group, sulfino group, sulfinamoyl group, sulfeno group, sulfenamoyl group, phosphono group, hydroxyphosphonyl group, hydrocarbon group, heterocyclic group, hydrocarbon-oxy group, heterocyclic ring-oxy group, hydrocarbon-sulfanyl group, heterocyclic ring-sulfanyl group, acyl group, amino group, hydrazino group, hydrazono group, diazenyl group, ureido group, thioureido group, guanidino group, carbamoimidoyl group (amidino group), azido group, imino group, hydroxyamino group, hydroxyimino group, aminooxy group, diazo group, semicarbazino group, semicarbazono group, allophanyl group, hydantoyl group, phosphano group, phosphoroso group, phospho group, boryl group, silyl group, stannyl group, selanyl group, oxido group and the like.
  • When two or more substituents exist according to the aforementioned definition of “which may be substituted,” said two or more substituents may combine to each other, together with atom(s) to which they bind, to form a ring. For these cyclic groups, as ring-constituting atoms (ring forming atoms), one to three kinds of one or more hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the like may be included, and one or more substituents may exist on the ring. The ring may be monocyclic or fused polycyclic, and aromatic or non-aromatic.
  • The above substituents according to the aforementioned definition of “which may be substituted” may further be substituted with the aforementioned substituents at the chemically substitutable positions on the substituent. Kind of substituents, number of substituents, and positions of substituents are not particularly limited, and when the substituents are substituted with two or more substituents, they may be the same or different. Examples of the substituent include, for example, a halogenated alkyl-carbonyl group whose examples include, for example, trifluoroacetyl, a halogenated alkyl-sulfonyl group whose examples include, for example, trifluoromethanesulfonyl, an acyl-oxy group, an acyl-sulfanyl group, an N-hydrocarbon-amino group, an N,N-di(hydrocarbon)-amino group, an N-heterocyclic ring-amino group, an N-hydrocarbon-N-heterocyclic ring-amino group, an acyl-amino group, and a di(acyl)-amino group. Moreover, substitution on the aforementioned substituents may be repeated multiple orders.
  • Examples of the acyl-oxy group include the groups in which hydrogen atom of hydroxy group is substituted with acyl group, and include, for example, formyloxy group, glyoxyloyloxy group, thioformyloxy group, carbamoloxy group, thiocarbamoyloxy group, sulfamoyloxy group, sulfinamoloxy group, carboxyoxy group, sulphooxy group, phosphonooxy group, and groups represented by the following formulas:
    Figure US20060122243A1-20060608-C00013
    Figure US20060122243A1-20060608-C00014
    • wherein Ra2 and Rb2 may be the same or different and represent a hydrocarbon group or a heterocyclic group, or Ra2 and Rb2 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group.
  • In the definition of the aforementioned acyl-oxy group, among the groups represented by the formula (ω-1B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-oxy group” whose examples include, for example, acetoxy and benzoyloxy, and those groups in which Ra2 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl-oxy group.”
  • Among the groups represented by the formula (ω-2B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-oxy-carbonyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as “heterocyclic ring-oxy-carbonyl-oxy group.”
  • Among the groups represented by the formula (ω-3B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-carbonyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as
    • “heterocyclic ring-carbonyl-carbonyl-oxy group.”
  • Among the groups represented by the formula (ω-4B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-oxy-carbonyl-carbonyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as
    • “heterocyclic ring-oxy-carbonyl-carbonyl-oxy group.”
  • Among the groups represented by the formula (ω-5B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-sulfanyl-carbonyl-oxy group,” and those groups where Ra2 is a heterocyclic group are referred to as
    • “heterocyclic ring-sulfanyl-carbonyl-oxy group.”
  • Among the groups represented by the formula (ω-6B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-thiocarbonyl-oxy group,” and those groups where Ra2 is a heterocyclic group are referred to as “heterocyclic ring-thiocarbonyl-oxy group.”
  • Among the groups represented by the formula (ω-7B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-oxy-thiocarbonyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as
    • “heterocyclic ring-oxy-thiocarbonyl-oxy group.”
  • Among the groups represented by the formula (ω-8B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-sulfanyl-thiocarbonyl-oxy group,” and those groups wherein Ra2 is a heterocyclic group are referred to as
    • “heterocyclic ring-sulfanyl-thiocarbonyl-oxy group.”
  • Among the groups represented by the formula (ω-9B), those groups in which Ra2 is a hydrocarbon group are referred to as “N-hydrocarbon-carbamoyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as “N-heterocyclic ring-carbamoyl-oxy group.”
  • Among the groups represented by the formula (ω-10B), those groups in which both Ra2 and Rb2 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-carbamoyl-oxy group,” those groups in which both Ra2 and Rb2 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-carbamoyl-oxy group,” those groups in which Ra2 is a hydrocarbon group and Rb2 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-carbamoyl-oxy group,” and those groups in which Ra2 and Rb2 combine to each other, together with the nitrogen atom to which they bind, to form a cyclicic amino group are referred to as
    • “cyclicamino-carbonyl-oxy group.”
  • Among the groups represented by the formula (ω-11B), those groups in which Ra2 is a hydrocarbon group are referred to as “N-hydrocarbon-thiocarbamoyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as
    • “N-heterocyclic ring-thiocarbamoyl-oxy group.”
  • Among the groups represented by the formula (ω-12B), those groups in which both Ra2 and Rb2 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-thiocarbamoyl-oxy group,” those groups in which both Ra2 and Rb2 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-thiocarbamoyl-oxy group,” those groups in which Ra2 is a hydrocarbon group and Rb2 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-thiocarbamoyl-oxy group,” and those groups in which Ra2 and Rb2 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclicamino-thiocarbonyl-oxy group.”
  • Among the groups represented by the formula (ω-13B), those groups in which Ra2 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfamoyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfamoyl-oxy group.”
  • Among the groups represented by the formula (ω-14B), those groups in which both Ra2 and Rb2 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-sulfamoyl-oxy group,” those groups in which both Ra2 and Rb2 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfamoyl-oxy group,” those groups in which Ra2 is a hydrocarbon group and Rb2 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfamoyl-oxy group,” and those groups in which Ra2 and Rb2 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-sulfonyl-oxy group.”
  • Among the groups represented by the formula (ω-15B), those groups in which Ra2 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfinamoyl-oxy group,” and those groups where Ra2 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfinamoyl-oxy group.”
  • Among the groups represented by the formula (ω-16B), those groups in which both Ra2 and Rb2 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-sulfinamoyl-oxy group,” those groups in which both Ra2 and Rb2 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfinamoyl-oxy group,” those groups in which Ra2 is a hydrocarbon group and Rb2 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfinamoyl-oxy group,” and those groups in which Ra2 and Rb2 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-sulfinyl-oxy group.”
  • Among the groups represented by the formula (ω-17B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfonyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as “heterocyclic ring-oxy-sulfonyl-oxy group.”
  • Among the groups represented by the formula (ω-18B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfinyl-oxy group,” those groups in which Ra2 is a heterocyclic group are referred to as “heterocyclic ring-oxy-sulfinyl-oxy group.”
  • Among the groups represented by the formula (ω-19B), those groups in which both Ra2 and Rb2 are hydrocarbon groups are referred to as
    • “O,O′-di(hydrocarbon)-phosphono-oxy group,” those groups in which both Ra2 and Rb2 are heterocyclic groups are referred to as “O,O′-di(heterocyclic ring)-phosphono-oxy group,” and those groups in which Ra2 is a hydrocarbon group and Rb2 is a heterocyclic group are referred to as “O-hydrocarbon substituted-O′-heterocyclic ring substituted phophono-oxy group.”
  • Among the groups represented by the formula (ω-20B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-sulfonyl-oxy group,” and those groups in which Ra2 is a heterocyclic group referred to as “heterocyclic ring-sulfonyl-oxy group.”
  • Among the groups represented by the formula (ω-21B), those groups in which Ra2 is a hydrocarbon group are referred to as “hydrocarbon-sulfinyl-oxy group,” and those groups in which Ra2 is a heterocyclic group are referred to as “heterocyclic ring-sulfinyl-oxy group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas (ω-1B) through (ω-21B) include the similar groups to the aforementioned hydrocarbon group. Examples of the hydrocarbon-carbonyl-oxy group represented by the formula (ω-1B) include, for example, an alkyl-carbonyl-oxy group, an alkenyl-carbonyl-oxy group, an alkynyl-carbonyl-oxy group, a cycloalkyl-carbonyl-oxy group, a cycloalkenyl-carbonyl-oxy group, a cycloalkanedienyl-carbonyl-oxy group, and a cycloalkyl-alkyl-carbonyl-oxy group, which are aliphatic hydrocarbon-carbonyl-oxy groups; an aryl-carbonyl-oxy group; an aralkyl-carbonyl-oxy group; a bridged cyclic hydrocarbon-carbonyl-oxy group; a spirocyclic hydrocarbon-carbonyl-oxy group; and a terpene family hydrocarbon-carbonyl-oxy group. In the following, groups represented by the formulas (ω-2B) through (ω-21B) are similar to those explained above.
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas (ω-1B) through (ω-21B) include similar groups to the aforementioned heterocyclic group. Examples of the heterocyclic ring-carbonyl group represented by the formula (ω-1B) include, for example, a monocyclic heteroaryl-carbonyl group, a fused polycyclic heteroaryl-carbonyl group, a monocyclic non-aromatic heterocyclic ring-carbonyl group, and a fused polycyclic non-aromatic heterocyclic ring-carbonyl group. In the following, groups represented by the formulas (ω-2B) through (ω-21B) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas (ω-10B) through (ω-16B) include similar groups to the aforementioned cyclic amino group.
  • The aforementioned acyl-oxy group, hydrocarbon-oxy group, and heterocyclic-oxy group are generically referred to as “substituted oxy group.” Moreover, these substituted oxy group and hydroxy group are generically referred to as “hydroxy group which may be substituted.”
  • Examples of the acyl-sulfanyl group include the groups in which hydrogen atom of sulfanyl group is substituted with acyl group, and include, for example, formylsulfanyl group, glyoxyloylsulfanyl group, thioformylsulfanyl group, carbamoyloxy group, thicarbamoyloxy group, sulfamoyloxy group, sulfinamoyloxy group, carboxyoxy group, sulphooxy group, phosphonooxy group, and groups represented by the following formulas:
    Figure US20060122243A1-20060608-C00015
    Figure US20060122243A1-20060608-C00016
    • wherein Ra3 and Rb3 may be the same or different and represent a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, or Ra3 and Rb3 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group which may be substituted.
  • In the definition of the aforementioned acyl-sulfanyl group, among the groups represented by the formula (ω-1C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-2C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-oxy-carbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “heterocyclic ring-oxy-carbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-3C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-carbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “heterocyclic ring-carbonyl-carbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-4C), those groups in which Ra3 is a hydrocarbon group are referred to as
    • “hydrocarbon-oxy-carbonyl-carbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as “heterocyclic ring-oxy-carbonyl-carbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-5C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-sulfanyl-carbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “heterocyclic ring-sulfanyl-carbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-6C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-thiocarbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “heterocyclic ring-thiocarbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-7C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-oxy-thiocarbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “heterocyclic ring-oxy-thiocarbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-8C), those groups in which Ra3 is a hydrocarbon group are referred to as
    • “hydrocarbon-sulfanyl-thiocarbonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as “heterocyclic ring-sulfanyl-thiocarbonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-9C), those groups in which Ra3 is a hydrocarbon group are referred to as “N-hydrocarbon-carbamoyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “N-heterocyclic ring-carbamoyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-10C), those groups in which both Ra3 and Rb3 are a hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-carbamoyl-sulfanyl group,” those groups in which both Ra3 and Rb3 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-carbamoyl-sulfanyl group,” those groups in which Ra3 is a hydrocarbon group and Rb3 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-carbamoyl-sulfanyl group,” and those groups in which Ra3 and Rb3 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclicamino-carbonyl-sulfamoyl group.”
  • Among the groups represented by the formula (ω-11C), those groups in which Ra3 is a hydrocarbon group are referred to as “N-hydrocarbon-thiocarbamoyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “N-heterocyclic ring-thiocarbamoyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-12C), those groups in which both Ra3 and Rb3 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-thiocarbamoyl-sulfanyl group,” those groups in which and Ra3 and Rb3 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-thiocarbamoyl-sulfanyl group,” those groups in which Ra3 is a hydrocarbon group and Rb3 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-thiocarbamoyl-sulfanyl group,” and those groups in which Ra3 and Rb3 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclicamino-thiocarbonyl-sulfamoyl group.”
  • Among the groups represented by the formula (ω-13C), those groups in which Ra3 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfamoyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “N-heterocyclic ring-sulfamoyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-14C), those groups in which both Ra3 and Rb3 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-sulfamoyl-sulfanyl group,” those groups in which both Ra3 and Rb3 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfamoyl-sulfinyl group,” those groups in which Ra3 is a hydrocarbon group and Rb3 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfamoyl-sulfanyl group,” and those groups in which Ra3 and Rb3 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclicamino-sulfonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-15C), those groups in which Ra3 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfinamoyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “N-heterocyclic ring-sulfinamoyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-16C), those groups in which both Ra3 and Rb3 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-sulfinamoyl-sulfanyl group,” those groups in which both Ra3 and Rb3 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfinamoyl-sulfanyl group,” those groups in which Ra3 is a hydrocarbon group and Rb3 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfinamoyl-sulfanyl group,” and those groups in which Ra3 and Rb3 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclicamino-sulfanyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-17C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “heterocyclic ring-oxy-sulfonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-18C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfinyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as
    • “heterocyclic ring-oxy-sulfinyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-19C), those groups in which both Ra3 and Rb3 are hydrocarbon groups are referred to as
    • “O,O′-di(hydrocarbon)-phosphono-sulfanyl group,” those groups in which both Ra3 and Rb3 are heterocyclic groups are referred to as “O,O′-di(heterocyclic ring)-phosphono-sulfanyl group,” and those groups in which Ra3 is a hydrocarbon group and Rb3 is a heterocyclic group are referred to as “O-hydrocarbon-O′-heterocyclic ring-phosphono-sulfanyl group.”
  • Among the groups represented by the formula (ω-20C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-sulfonyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as “heterocyclic ring-sulfonyl-sulfanyl group.”
  • Among the groups represented by the formula (ω-21C), those groups in which Ra3 is a hydrocarbon group are referred to as “hydrocarbon-sulfinyl-sulfanyl group,” and those groups in which Ra3 is a heterocyclic group are referred to as “heterocyclic ring-sulfinyl-sulfanyl group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas (ω-1C) through (ω-21C) include similar groups to the aforementioned hydrocarbon group. Examples of the hydrocarbon-carbonyl-sulfanyl group represented by the formula (ω-1C) include, for example, an alkyl-carbonyl-sulfanyl group, an alkenyl-carbonyl-sulfanyl group, an alkynyl-carbonyl-sulfanyl group, a cycloalkyl-carbonyl-sulfanyl group, a cycloalkenyl-carbonyl-sulfanyl group, a cycloalkanedienyl-carbonyl-sulfanyl group, a cycloalkyl-alkyl-carbonyl-sulfanyl group which are aliphatic hydrocarbon-carbonyl-sulfanyl groups; an aryl-carbonyl-sulfanyl group; an aralkyl-carbonyl-sulfanyl group; a bridged cyclic hydrocarbon-carbonyl-sulfanyl group; a spiro cyclic hydrocarbon-carbonyl-sulfanyl group; and a terpene family hydrocarbon-carbonyl-sulfanyl group. In the following, groups represented by the formulas (ω-2C) through (ω-21C) are similar to those explained above.
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas (ω-1C) through (ω-21C) include similar groups to the aforementioned heterocyclic group. Examples of the heterocyclic ring-carbonyl-sulfanyl group represented by the formula (ω-1C) include, for example, a monocyclic heteroaryl-carbonyl-sulfanyl group, a fused polycyclic heteroaryl-carbonyl-sulfanyl group, a monocyclic non-aromatic heterocyclic ring-carbonyl-sulfanyl group, and a fused polycyclic non-aromatic heterocyclic ring-carbonyl-sulfanyl group. In the following, groups represented by the formula (ω-2C) through (ω-21C) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas (ω-1C) through (ω-16C) include similar groups to the aforementioned cyclic amino group.
  • The aforementioned acyl-sulfanyl group, hydrocarbon-sulfanyl group, and heterocyclic-sulfanyl group are generically referred to as “substituted sulfanyl group.” Moreover, these substituted sulfanyl group and sulfanyl group are generically referred to as “sulfanyl group which may be substituted.”
  • Examples of the N-hydrocarbon-amino group include the groups in which one hydrogen atom of amino group is substituted with a hydrocarbon group, and include, for example, an N-alkyl-amino group, an N-alkenyl-amino group, an N-alkynyl-amino group, an N-cycloalkyl-amino group, an N-cycloalkyl-alkyl-amino group, an N-aryl-amino group, and an N-aralkyl-amino group.
  • Examples of the N-alkyl-amino group include, for example, methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, tert-butylamino, n-pentylamino, isopentylamino, (2-methylbutyl)amino, (1-methylbutyl)amino, neopentylamino, (1,2-dimethylpropyl)amino, (1-ethylpropyl)amino, n-hexylamino, (4-methylpentyl)amino, (3-methylpentyl)amino, (2-methylpentyl)amino, (1-methylpentyl)amino, (3,3-dimethylbutyl)amino, (2,2-dimethylbutyl)amino, (1,1-dimethylbutyl)amino, (1,2-dimethylbutyl)amino, (1,3-dimethylbutyl)amino, (2,3-dimethylbutyl)amino, (2-ethylbutyl)amino, (1-ethylbutyl)amino, (1-ethyl-1-methylpropyl)amino, n-heptylamino, n-octylamino, n-nonylamino, n-decylamino, n-undecylamino, n-dodecylamino, n-tridecylamino, n-tetradecylamino, and n-pentadecylamino, which are C1 to C15 straight chain or branched chain N-alkyl amino groups.
  • Examples of the N-alkenyl-amino group include, for example, vinyl amino, (prop-1-en-1-yl)amino, allylamino, isopropenylamino, (but-1-en-1-yl)amino, (but-2-en-1-yl)amino, (but-3-en-1-yl)amino, (2-methylprop-2-en-1-yl)amino, (1-methylprop-2-en-1-yl)amino, (pent-1-en-1-yl)amino, (pent-2-en-1-yl)amino, (pent-3-en-1-yl)amino, (pent-4-en-1-yl)amino, (3-methylbut-2-en-1-yl)amino, (3-methylbut-3-en-1-yl)amino, (hex-1-en-1-yl)amino, (hex-2-en-1-yl)amino, (hex-3-en-1-yl)amino, (hex-4-en-1-yl)amino, (hex-5-en-1-yl)amino, (4-methylpent-3-en-1-yl)amino, (4-methylpent-3-en-1-yl)amino, (hept-1-en-1-yl)amino, (hept-6-en-1-yl)amino, (oct-1-en-1-yl)amino, (oct-7-en-1-yl)amino, (non-1-en-1-yl)amino, (non-8-en-1-yl)amino, (dec-1-en-1-yl)amino, (dec-9-en-1-yl)amino, (undec-1-en-1-yl)amino, (undec-10-en-1-yl)amino, (dodec-1-en-1-yl)amino, (dodec-11-en-1-yl)amino, (tridec-1-en-1-yl)amino, (tridec-12-en-1-yl)amino, (tetradec-1-en-1-yl)amino, (tetradec-13-en-1-yl)amino, (pentadec-1-en-1-yl)amino, and (pentadec-14-en-1-yl)amino, which are C2 to C15 straight chain or branched chain N-alkenyl amino groups.
  • Examples of the N-alkynyl-amino group include, for example, ethynylamino, (prop-1-yn-1-yl)amino, (prop-2-yn-1-yl)amino, (but-1-yn-1-yl)amino, (but-3-yn-1-yl)amino, (1-methylprop-2-yn-1-yl)amino, (pent-1-yn-1-yl)amino, (pent-4-yn-1-yl)amino, (hex-1-yn-1-yl)amino, (hex-5-yn-1-yl)amino, (hept-1-yn-1-yl)amino, (hept-6-yn-1-yl)amino, (oct-1-yn-1-yl)amino, (oct-7-yn-1-yl)amino, (non-1-yn-1-yl)amino, (non-8-yn-1-yl)amino, (dec-1-yn-1-yl)amino, (dec-9-yn-1-yl)amino, (undec-1-yn-1-yl)amino, (undec-10-yn-1-yl)amino, (dodec-1-yn-1-yl)amino, (dodec-11-yn-1-yl)amino, (tridec-1-yn-1-yl)amino, (tridec-12-yn-1-yl)amino, (tetradec-1-yn-1-yl)amino, (tetradec-13-yn-1-yl)amino, (pentadec-1-yn-1-yl)amino, and (pentadec-14-yn-1-yl)amino, which are C2 to C15 straight chain or branched chain N-alkynyl-amino groups.
  • Examples of the N-cycloalkyl-amino group include, for example, cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, and cyclooctylamino, which are C3 to C8 N-cycloalkyl-amino groups.
  • Examples of the N-cycloalkyl-alkyl-amino group include, for example, (cyclopropylmethyl)amino, (1-cyclopropylethyl)amino, (2-cyclopropylethyl)amino, (3-cyclopropylpropyl)amino, (4-cyclopropylbutyl)amino, (5-cyclopropylpentyl)amino, (6-cyclopropylhexyl)amino, (cyclobutylmethyl)amino, (cyclopentylmethyl)amino, (cyclobutylmethyl)amino, (cyclopentylmethyl)amino, (cyclohexylmethyl)amino, (2-cyclohexylethyl)amino, (3-cyclohexylpropyl)amino, (4-cyclohexylbutyl)amino, (cycloheptylmethyl)amino, (cyclooctylmethyl)amino, and (6-cyclooctylhexyl)amino, which are C4 to C14 N-cycloalkyl-alkyl-amino groups.
  • Examples of the N-aryl-amino group include, for example, phenylamino, 1-naphthylamino, 2-naphtylamino, anthrylamino, phenanthrylamino, and acenaphthylenylamino, which are C6 to C14 N-mono-arylamino groups.
  • Examples of the N-aralkyl-amino group include, for example, benzylamino, (1-naphthylmethyl)amino, (2-naphthylmethyl)amino, (anthracenylmethyl)amino, (phenanthrenylmethyl)amino, (acenaphthylenylmethyl)amino, (diphenylmethyl)amino, (1-phenethyl)amino, (2-phenethyl)amino, (1-(1-naphthyl)ethyl)amino, (1-(2-naphthyl)ethyl)amino, (2-(1-naphthyl)ethyl)amino, (2-(2-naphthyl)ethyl)amino, (3-phenylpropyl)amino, (3-(1-naphthyl)propyl)amino, (3-(2-naphthyl)propyl)amino, (4-phenylbutyl)amino, (4-(1-naphthyl)butyl)amino, (4-(2-naphthyl)butyl)amino, (5-phenylpentyl)amino, (5-(1-naphthyl)pentyl)amino, (5-(2-naphthyl)pentyl)amino, (6-phenylhexyl)amino, (6-(1-naphthyl)hexyl)amino, and (6-(2-naphthyl)hexyl)amino, which are C7 to C16 N-aralkyl-amino groups.
  • Examples of the N,N-di(hydrocarbon)-amino group include the groups in which two hydrogen atoms of amino group are substituted with hydrocarbon groups, and include, for example, N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino, N,N-di-n-propylamino, N,N-diisopropylamino, N-allyl-N-methylamino, N-(prop-2-yn-1-yl)-N-methylamino, N,N-dicyclohexylamino, N-cyclohexyl-N-methylamino, N-cyclohexylmethylamino-N-methylamino, N,N-diphenylamino, N-methyl-N-phenylamino, N,N-dibenzylamino, and N-benzyl-N-methylamino.
  • Examples of the N-heterocyclic ring-amino group include the groups in which one hydrogen atom of amino group is substituted with a heterocyclic group, and include, for example, (3-pyrrolizinyl)amino, (4-piperidinyl)amino, (2-tetrahydropyranyl)amino, (3-indolinyl)amino, (4-chromanyl)amino, (3-thienyl)amino, (3-pyridyl)amino, (3-quinolyl)amino, and (5-indolyl)amino.
  • Examples of the N-hydrocarbon-N-heterocyclic ring-amino group include the groups in which two hydrogen atoms of amino group are substituted with hydrocarbon group and heterocyclic group respectively, and include, for example, N-methyl-N-(4-piperidinyl)amino, N-(4-chromanyl)-N-methylamino, N-methyl-N-(3-thienyl)amino, N-methyl-N-(3-pyridyl)amino, N-methyl-N-(3-quinolyl)amino.
  • Examples of the acyl-amino group include the groups in which one hydrogen atom of the amino group is substituted with an acyl group, and include, for example, formylamino group, glyoxyloylamino group, thioformylamino group, carbamoylamino group, thiocarbamoylamino group, sulfamoylamino group, sulfinamoylamino group, carboxyamino group, sulphoamino group, phosphonoamino group, and groups represented by the following formulas:
    Figure US20060122243A1-20060608-C00017
    Figure US20060122243A1-20060608-C00018
    • wherein Ra4 and Rb4 may be the same or different and represent a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, or Ra4 and Rb4 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group which may be substituted.
  • In the definition of the aforementioned acyl-amino group, among the groups represented by the formula (ω-1D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-carbonyl-amino group.”
  • Among the groups represented by the formula (ω-2D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-oxy-carbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-oxy-carbonyl-amino group.”
  • Among the groups represented by the formula (ω-3D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-carbonyl-carbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as
    • “heterocyclic ring-carbonyl-carbonyl-amino group.”
  • Among the groups represented by the formula (ω-4D), those groups in which Ra4 is a hydrocarbon group are referred to as
    • “hydrocarbon-oxy-carbonyl-carbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-oxy-carbonyl-carbonyl-amino group.”
  • Among the groups represented by the formula (ω-5D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-sulfanyl-carbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as
    • “heterocyclic ring-sulfanyl-carbonyl-amino group.”
  • Among the groups represented by the formula (ω-6D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-thiocarbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-thiocarbonyl-amino group.”
  • Among the groups represented by the formula (ω-7D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-oxy-thiocarbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as
    • “heterocyclic ring-oxy-thiocarbonyl-amino group.”
  • Among the groups represented by the formula (ω-8D), those groups in which Ra4 is a hydrocarbon group are referred to as
    • “hydrocarbon-sulfanyl-thiocarbonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-sulfanyl-thiocarbonyl-amino group.”
  • Among the groups represented by the formula (ω-9D), those groups in which Ra4 is a hydrocarbon group are referred to as “N-hydrocarbon-carbamoyl group,” and those groups in which Ra4 is a heterocyclic group are referred to as “N-heterocyclic ring-carbamoyl-amino group.”
  • Among the groups represented by the formula (ω-10D), those groups in which both Ra4 and Rb4 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-carbamoyl-amino group,” those groups in which both Ra4 and Rb4 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-carbamoyl-amino group,” those groups in which Ra4 is a hydrocarbon group and Rb4 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-carbamoyl-amino group,” and those groups in which Ra4 and Rb4 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-carbonyl-amino group.”
  • Among the groups represented by the formula (ω-11D), those groups in which Ra4 is a hydrocarbon group are referred to as “N-hydrocarbon-thiocarbamoyl-amino group,” and those groups in which Ra4 is a heterocyclic ring group are referred to as
    • “N-heterocyclic-thiocarbamoyl-amino group.”
  • Among the groups represented by the formula (ω-12D), those groups in which both Ra4 and Rb4 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-thiocarbamoyl-amino group,” those groups in which both Ra4 and Rb4 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-thiocarbamoyl-amino group,” those groups in which Ra4 is a hydrocarbon group and Rb4 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-thiocarbamoyl-amino group,” and those groups in which Ra4 and Rb4 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-thiocarbonyl-amino group.”
  • Among the groups represented by the formula (ω-13D), those groups in which Ra4 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfamoyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “N-heterocyclic ring-sulfamoyl-amino group.”
  • Among the groups represented by the formula (ω-14D), those groups in which both Ra4 and Rb4 are hydrocarbon groups are referred to as
    • “di(hydrocarbon)-sulfamoyl-amino group,” those groups in which both Ra4 and Rb4 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfamoyl-amino group,” those groups in which Ra4 is a hydrocarbon group and Rb4 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfamoyl-amino group,” and those groups in which Ra4 and Rb4 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-sulfonyl-amino group.”
  • Among the groups represented by the formula (ω-15D), those groups in which Ra4 is a hydrocarbon group are referred to as “N-hydrocarbon-sulfinamoyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as
    • “N-heterocyclic ring-sulfinamoyl-amino group.”
  • Among the groups represented by the formula (ω-16D), those groups in which both Ra4 and Rb4 are hydrocarbon groups are referred to as
    • “N,N-di(hydrocarbon)-sulfinamoyl-amino group,” those groups in which both Ra4 and Rb4 are heterocyclic groups are referred to as “N,N-di(heterocyclic ring)-sulfinamoyl-amino group,” groups in which Ra4 is a hydrocarbon group and Rb4 is a heterocyclic group are referred to as “N-hydrocarbon-N-heterocyclic ring-sulfinamoyl-amino group,” and those groups in which Ra4 and Rb4 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “cyclic amino-sulfinyl-amino group.”
  • Among the groups represented by the formula (ω-17D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-oxy-sulfoyl-amino group.”
  • Among the groups represented by the formula (ω-18D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-oxy-sulfinyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-oxy-sulfinyl-amino group.”
  • Among the groups represented by the formula (ω-19D), those groups in which both Ra4 and Rb4 are hydrocarbon groups are referred to as
    • “O,O′-di(hydrocarbon)-phosphono-amino group,” those groups in which both Ra4 and Rb4 are heterocyclic groups are referred to as “O,O′-di(heterocyclic ring)-phosphono-amino group,” and those groups in which Ra4 is a hydrocarbon group and Rb4 is a heterocyclic group are referred to as “O-hydrocarbon-O′-heterocyclic ring-phosphono-amino group.”
  • Among the groups represented by the formula (ω-20D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-sulfonyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-sulfonyl-amino group.”
  • Among the groups represented by the formula (ω-21D), those groups in which Ra4 is a hydrocarbon group are referred to as “hydrocarbon-sulfinyl-amino group,” and those groups in which Ra4 is a heterocyclic group are referred to as “heterocyclic ring-sulfinyl-amino group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas (ω-1D) through (ω-21D) include the similar groups to the aforementioned hydrocarbon group. Examples of the hydrocarbon-carbonyl-amino groups represented by the formula (ω-1D) include, for example, an alkyl-carbonyl-amino group, an alkenyl-carbonyl-amino group, an alkynyl-carbonyl-amino group, a cycloalkyl-carbonyl-amino group, a cycloalkenyl-carbonyl-amino group, a cycloalkanedienyl-carbonyl-amino group, a cycloalkyl-alkyl-carbonyl-amino group which are aliphatic hydrocarbon-carbonyl-amino groups; an aryl-carbonyl-amino group; an aralkyl-carbonyl-amino group; a bridged cyclic hydrocarbon-carbonyl-amino group; a spiro cyclic hydrocarbon-carbonyl-amino group; and a terpene family hydrocarbon-carbonyl-amino group. In the following, groups represented by the formulas (ω-2D) through (ω-21D) are similar to those explained above.
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas (ω-1D) through (ω-21D) include similar groups to the aforementioned heterocyclic group. Examples of the heterocyclic ring-carbonyl-amino group represented by the formula (ω-1D) include, for example, a monocyclic heteroaryl-carbonyl-amino group, a fused polycyclic heteroaryl-carbonyl-amino group, a monocyclic non-aromatic heterocyclic-carbonyl-amino group, and a fused polycyclic non-aromatic heterocyclic-carbonyl-amino group. In the following, groups represented by the formulas (ω-2D) through (ω-21D) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas (ω-10D) through (ω-16D) include similar groups to the aforementioned cyclic amino group.
  • Examples of the di(acyl)-amino group include the groups in which two hydrogen atoms of amino group are substituted with acyl groups in the definitions of the aforementioned substituents according to “which may be substituted.” Examples include, for example, di(formyl)-amino group, di(glyoxyloyl)-amino group, di(thioformyl)-amino group, di(carbamoyl)-amino group, di(thiocarbamoyl)-amino group, di(sulfamoyl)-amino group, di(sulfinamoyl)-amino group, di(carboxy)-amino group, di(sulfo)-amino group, di(phosphono)-amino group, and groups represented by the following formulas:
    Figure US20060122243A1-20060608-C00019
    Figure US20060122243A1-20060608-C00020
    • wherein Ra5 and Rb5 may be the same or different and represent hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, or Ra5 and Rb5 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group which may be substituted.
  • In the definition of aforementioned di(acyl)-amino group, among the groups represented by the formula (ω-1E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(hydrocarbon-carbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(heterocyclic ring-carbonyl)-amino group.
  • Among the groups represented by the formula (ω-2E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(hydrocarbon-oxy-carbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(heterocyclic ring-oxy-carbonyl)-amino group.”
  • Among the groups represented by the formula (ω-3E), those groups in which Ra5 is a hydrocarbon group are referred to as
    • “bis(hydrocarbon-carbonyl-carbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(heterocyclic ring-carbonyl-carbonyl)-amino group.
  • Among the groups represented by the formula (ω-4E), those groups in which Ra5 is a hydrocarbon group are referred to as
    • “bis(hydrocarbon-oxy-carbonyl-carbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(heterocyclic ring-oxy-carbonyl-carbonyl)-amino group.”
  • Among the groups represented by the formula (ω-5E), those groups in which Ra5 is a hydrocarbon group are referred to as
    • “bis(hydrocarbon-sulfanyl-carbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(heterocyclic ring-sulfanyl-carbonyl)-amino group.”
  • Among the groups represented by the formula (ω-6E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(hydrocarbon-thiocarbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(heterocyclic ring-thiocarbonyl)-amino group.”
  • Among the groups represented by the formula (ω-7E), those groups in which Ra5 is a hydrocarbon group are referred to as
    • “bis(hydrocarbon-oxy-thiocarbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(heterocyclic ring-oxy-thiocarbonyl)-amino group.
  • Among the groups represented by the formula (ω-8E), those groups in which Ra5 is a hydrocarbon group are referred to as
    • “bis(hydrocarbon-sulfanyl-thiocarbonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(heterocyclic ring-sulfanyl-thiocarbonyl)-amino group.”
  • Among the groups represented by the formula (ω-9E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(N-hydrocarbon-carbamoyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(N-heterocyclic ring-carbamoyl)-amino group.”
  • Among the groups represented by the formula (ω-10E), those groups in which both Ra5 and Rb5 are hydrocarbon groups are referred to as
    • “bis[N,N-di(hydrocarbon)-carbamoyl]-amino group,” those groups in which both Ra5 and Rb5 are heterocyclic groups are referred to as “bis[N,N-di(heterocyclic ring)-carbamoyl]-amino group,” groups in which Ra5 is a hydrocarbon group and Rb5 is a heterocyclic group are referred to as “bis(N-hydrocarbon-N-heterocyclic ring-carbamoyl)-amino group,” and those groups in which Ra5 and Rb5 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino groups are referred to as “bis(cyclic amino-carbonyl)amino group.”
  • Among the groups represented by the formula (ω-11E), those groups in which Ra5 is a hydrocarbon group are referred to as
    • “bis(N-hydrocarbon-thiocarbamoyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as “bis(N-heterocyclic ring-thiocarbamoyl)-amino group.”
  • Among the groups represented by the formula (ω-12E), those groups in which both Ra5 and Rb5 are hydrocarbon groups are referred to as
    • “bis[N,N-di(hydrocarbon)-thiocarbamoyl]-amino group,” those groups in which both Ra5 and Rb5 are heterocyclic groups are referred to as “bis[N,N-di(heterocyclic ring)-thiocarbamoyl]-amino group,” those groups in which Ra5 is a hydrocarbon group and Rb5 is a heterocyclic group are referred to as “bis(N-hydrocarbon-N-heterocyclic ring-thiocarbamoyl)-amino group,” and those groups in which Ra5 and Rb5 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “bis(cyclic amino-thiocarbonyl)-amino group.”
  • Among the groups represented by the formula (ω-13E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(N-hydrocarbon-sulfamoyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(N-heterocyclic ring-sulfamoyl)-amino group.”
  • Among the groups represented by the formula (ω-14E), those groups in which both Ra5 and Rb5 are hydrocarbon groups are referred to as
    • “bis[N,N-di(hydrocarbon)-sulfamoyl]-amino group,” those groups in which both Ra5 and Rb5 are heterocyclic groups are referred to as “bis[N,N-di(heterocyclic ring)-sulfamoyl]-amino group,” those groups in which Ra5 is a hydrocarbon group and Rb5 is a heterocyclic group are referred to as “bis(N-hydrocarbon-N-heterocyclic ring-sulfamoyl)-amino group,” and those groups in which Ra5 and Rb5 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “bis(cyclic amino-sulfonyl)amino group.”
  • Among the groups represented by the formula (ω-15E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(N-hydrocarbon-sulfinamoyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(N-heterocyclic ring-sulfinamoyl)-amino group.”
  • Among the groups represented by the formula (ω-16E), those groups in which Ra5 and Rb5 are hydrocarbon groups are referred to as
    • “bis[N,N-di(hydrocarbon)-sulfinamoyl]-amino group,” those groups in which Ra5 and Rb5 are heterocyclic groups are referred to as “bis[N,N-di(heterocyclic ring)-sulfinamoyl]-amino group,” those groups in which Ra5 is a hydrocarbon group and Rb5 is a heterocyclic group are referred to as “bis(N-hydrocarbon-N-heterocyclic ring-sulfinamoyl)-amino group,” and those groups in which Ra5 and Rb5 combine to each other, together with the nitrogen atom to which they bind, to form a cyclic amino group are referred to as “bis(cyclic amino-sulfinyl)amino group.”
  • Among the groups represented by the formula (ω-17E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(hydrocarbon-oxy-sulfonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(heterocyclic ring-oxy-sulfonyl)-amino group.”
  • Among the groups represented by the formula (ω-18E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(hydrocarbon-oxy-sulfinyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(heterocyclic ring-oxy-sulfinyl)-amino group.”
  • Among the groups represented by the formula (ω-19E), those groups in which both Ra5 and Rb5 are hydrocarbon groups are referred to as
    • “bis[O,O′-di(hydrocarbon)-phosphono]-amino group,” those groups in which both Ra5 and Rb5 are heterocyclic groups are referred to as “bis[O,O′-di(heterocyclic ring)-phosphono]-amino group,” and those groups in which Ra5 is a hydrocarbon group and Rb5 is a heterocyclic group are referred to as “bis(O-hydrocarbon-O′-heterocyclic ring-phosphono)-amino group.”
  • Among the groups represented by the formula (ω-20E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(hydrocarbon-sulfonyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(heterocyclic ring-sulfonyl)-amino group.”
  • Among the groups represented by the formula (ω-21E), those groups in which Ra5 is a hydrocarbon group are referred to as “bis(hydrocarbon-sulfinyl)-amino group,” and those groups in which Ra5 is a heterocyclic group are referred to as
    • “bis(heterocyclic ring-sulfinyl)-amino group.”
  • Examples of the hydrocarbon in the groups represented by the aforementioned formulas (ω-1E) through (ω-21E) include the similar groups to the aforementioned hydrocarbon group. Examples of the bis(hydrocarbon-carbonyl)-amino groups represented by the formula (ω-1E) include, for example, a bis(alkyl-carbonyl)-amino group, a bis(alkenyl-carbonyl)-amino group, a bis(alkynyl-carbonyl)-amino group, a bis(cycloalkyl-carbonyl)-amino group, a bis(cycloalkenyl-carbonyl)-amino group, a bis(cycloalkanedienyl-carbonyl)-amino group, a bis(cycloalkyl-alkyl-carbonyl)-amino group which are bis(aliphatic hydrocarbon-carbonyl)-amino groups; a bis(aryl-carbonyl)-amino group; a bis(aralkyl-carbonyl)-amino group; a bis(bridged cyclic hydrocarbon-carbonyl)-amino group; a bis(spiro cyclic hydrocarbon-carbonyl)-amino group; and a bis(terpene family hydrocarbon-carbonyl)-amino group. In the following, groups represented by the formulas (ω-2E) through (ω-21E) are similar to those explained above.
  • Examples of the heterocyclic ring in the groups represented by the aforementioned formulas (ω-1E) through (ω-21E) include similar groups to the aforementioned heterocyclic group. Examples of the bis(heterocyclic ring-carbonyl)-amino group represented by the formula (ω-1E) include, for example, a bis(monocyclic heteroaryl-carbonyl)-amino group, a bis(fused polycyclic heteroaryl-carbonyl)-amino group, a bis(monocyclic non-aromatic heterocyclic-carbonyl)-amino group, and a bis(fused polycyclic non-aromatic heterocyclic-carbonyl)-amino group. In the following, groups represented by the formulas (ω-2E) through (ω-21E) are similar to those groups explained above.
  • Examples of the cyclic amino in the groups represented by the aforementioned formulas (ω-10E) through (ω-16E) include similar groups to the aforementioned cyclic amino group.
  • The aforementioned acyl-amino group and di(acyl)-amino group are generically referred to as “acyl substituted amino group.” Furthermore, the aforementioned N-hydrocarbon-amino group, N,N-di(hydrocarbon)-amino group, N-heterocyclic-amino group, N-hydrocarbon-N-heterocyclic-amino group, cyclic amino group, acyl-amino group, and di(acyl)-amino group are generically referred to as
    • “substituted amino group.”
  • In the following, compounds represented by the aforementioned general formula (I) are explained in details.
  • “Connecting group whose number of atoms of main chain is 2 to 5” in the definition of X means connecting groups wherein 2 to 5 atoms in a main chain link together between rings Z and E. The aforementioned “number of atoms of the main chain” is counted so as to minimize the number of connecting atoms existing between the rings Z and E, regardless of the presence or absence of hetero atom(s). For example, the number of atoms of 1,2-cyclopentylene is counted as 2, the number of atoms of 1,3-cyclopentylene is counted as 3, the number of atoms of 1,4-phenylene is counted as 4, and the number of atoms of 2,6-pyridine-diyl is counted as 3.
  • The aforementioned “connecting group whose number of atoms of main chain is 2 to 5” is formed by one functional group selected from the following group of divalent group ζ-1, or formed by combining 2 to 4 functional groups of 1 to 4 kinds selected from the following divalent group ζ-2.
    • [Divalent Group ζ-1] the Following Formulas:
      Figure US20060122243A1-20060608-C00021
    • [Divalent Group ζ-2] the Following Formulas:
      Figure US20060122243A1-20060608-C00022
    • When 2 or more divalent groups combine, each group may be the same or different.
  • The aforementioned “connecting group wherein the number of atoms of the main chain is 2 to 5,” is preferably a group selected from the following “connecting group α.”
    • [Connecting Group α] the Following Formulas:
      Figure US20060122243A1-20060608-C00023
    • wherein a bond at the left end binds to ring Z and a bond at the right end binds to E.
  • The group represented by the following formula is most preferred:
    Figure US20060122243A1-20060608-C00024
    • wherein the bond at the left end binds to ring Z and the bond at the right end binds to E.
  • Examples of the substituent, according to “connecting group which may be substituted” in the definition of “a connecting group whose number of atoms of the main chain is 2 to 5,” include similar groups to the substituents in the definition of the aforementioned “which may be substituted.” A C1 to C6 alkyl group is preferred, and a methyl group is more preferred. The substituent may combine with a substituent of the ring E or Z, together with atoms to which they bind, to form a cyclic group which may be substituted. Examples include the compounds represented by the general formula (I) being those represented by the following formulas:
    Figure US20060122243A1-20060608-C00025
  • In the aforementioned general formula (I), examples of A include hydrogen atom or acetyl group, and hydrogen atom is preferred.
  • Examples of the “arene” in “an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the definition of ring Z include a monocyclic or fused heterocyclic aromatic hydrocarbon, and include, for example, benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, and acenaphylene ring. C6 to C10 arenes such as benzene ring, naphthalene ring and the like are preferred, benzene ring and naphthalene ring are more preferred, and benzene ring is most preferred.
  • Examples of the substituent in the definition of “an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z include similar groups to the substituent explained for the definition “which may be substituted.” The position of substituents existing on the arene is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • When “an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z is “a benzene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above,” “a benzene ring which has one to three substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” is preferred, and “a benzene ring which has one substituent in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” is more preferred. Preferred examples of said substituents include groups selected from the following Substituent Group γ-1z. Halogen atom and tert-butyl group [(1,1-dimethyl)ethyl group] are more preferred, and halogen atom is most preferred.
    • [Substituent Group γ-1z] halogen atom, nitro group, cyano group, hydroxy group, methoxy group, methyl group, isopropyl group, tert-butyl group, 1,1,3,3-tetramethylbutyl group, 2-phenylethen-1-yl group, 2,2-dicyanoethen-1-yl group, 2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl group, ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group, trifluoromethyl group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group, 4-fluorophenyl group, 2,4-difluorophenyl group, 2-phenethyl group, 1-hydroxyethyl group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino]ethyl group, 2-thienyl group [thiophen-2-yl group], 3-thienyl group [thiophen-3-yl group], 1-pyrrolyl group [pyrrol-1-yl group], 2-methylthiazol-4-yl group, imidazo[1,2-a]pyridin-2-yl group, 2-pyridyl group [pyridin-2-yl group], acetyl group, isobutyryl group, piperidinocarbonyl group, 4-benzylpiperidinocarbonyl group, (pyrrol-1-yl)sulfonyl group, carboxy group, methoxycarbonyl group, N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl group, N,N-dimethylcarbamoyl group, sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfamoyl group, N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino group, 3-phenylureido group, (3-phenyl)thioureido group, (4-nitrophenyl)diazenyl group, and {[4-(pyridin-2-yl)sulfamoyl]phenyl}diazenyl group
  • When “an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z is “a benzene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above,” it is most preferable that one substituent exists and locates on the position of Rz when the following partial formula (Iz-1) in the general formula containing ring Z
    Figure US20060122243A1-20060608-C00026
    • is represented by the following formula (Iz-2).
      Figure US20060122243A1-20060608-C00027
    • At this time, said substituents can be defined as Rz. Preferred examples of Rz include a group selected from the following Substituent Group γ-2z. Halogen atom and tert-butyl group are more preferred, and halogen atom is most preferred.
    • [Substituent Group γ-2z] halogen atom, nitro group, cyano group, methoxy group, methyl group, isopropyl group, tert-butyl group, 1,1,3,3-tetramethylbutyl group, 2-phenylethen-1-yl group, 2,2-dicyanoethen-1-yl group, 2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl group, ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group, trifluoromethyl group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group, 4-fluorophenyl group, 2,4-difluorophenyl group, 2-phenethyl group, 1-hydroxyethyl group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino]ethyl group, 2-thienyl group, 3-thienyl group, 1-pyrrolyl group, 2-methylthiazol-4-yl group, imidazo[1,2-a]pyridin-2-yl group, 2-pyridyl group, acetyl group, isobutyryl group, piperidinocarbonyl group, 4-benzylpiperidinocarbonyl group, (pyrrol-1-yl)sulfonyl group, carboxy group, methoxycarbonyl group, N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl group, N,N-dimethylcarbamoyl group, sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfamoyl group, N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino group, 3-phenylureido group, (3-phenyl)thioureido group, (4-nitrophenyl)diazenyl group, and {[4-(pyridin-2-yl)sulfamoyl]phenyl}diazenyl group
  • When “an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z is “a naphthalene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above,” naphthalene ring is preferred.
  • Examples of the “hetero arene” in “a hetero arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z include a monocyclic or a fused polycyclic aromatic heterocyclic rings containing at least one of 1 to 3 kinds of heteroatoms selected from oxygen atom, sulfur atom and nitrogen atom and the like as ring-constituting atoms (ring forming atoms), and include, for example, furan ring, thiophene ring, pyrrole ring, oxazole ring, isoxazole ring, thiazole ring, isothiazole ring, imidazole ring, pyrazole ring, 1,2,3-oxadiazole ring, 1,2,3-thiadiazole ring, 1,2,3-triazole ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, 1,2,3-triazine ring, 1,2,4-triazine ring, 1H-azepine ring, 1,4-oxepine ring, 1,4-thiazepine ring, benzofuran ring, isobenzofuran ring, benzo[b]thiophene ring, benzo[c]thiophene ring, indole ring, 2H-isoindole ring, 1H-indazole ring, 2H-indazole ring, benzoxazole ring, 1,2-benzisoxazole ring, 2,1-benzisoxazole ring, benzothiazole ring, 1,2-benzisothiazole ring, 2,1-benzisothiazole ring, 1,2,3-benzoxadiazol ring, 2,1,3-benzoxadiazol ring, 1,2,3-benzothiadiazole ring, 2,1,3-benzothiadiazole ring, 1H-benzotriazole ring, 2H-benzotriazole ring, quinoline ring, isoquinoline ring, cinnoline ring, quinazoline ring, quinoxaline ring, phthalazine ring, naphthyridine ring, 1H-1,5-benzodiazepine ring, carbazole ring, α-carboline ring, β-carboline ring, γ-carboline ring, acridine ring, phenoxazine ring, phenothiazine ring, phenazine ring, phenanthridine ring, phenanthroline ring, thianthrene ring, indolizine ring, and phenoxathiine ring, which are 5 to 14-membered monocyclic or fused polycyclic aromatic heterocyclic rings. 5 to 13-membered monocyclic or fused polycyclic aromatic heterocyclic rings are preferred, and thiophene ring, pyridine ring, indole ring, quinoxaline ring, and carbazole ring are more preferred.
  • Examples of the substituent in the definition of “a hetero arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z include similar groups to the substituent explained for the aforementioned definition “which may be substituted.” The position of substituents existing on the hetero arene is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • Halogen atoms are preferred as the substituent in the definition of “a hetero arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above” in the aforementioned definition of ring Z.
  • Examples of the aryl group of “an aryl group which may be substituted” in the definition of E include similar groups to the aryl group in the definition of the aforementioned “hydrocarbon group,” and C6 to C10 aryl groups such as phenyl group, 1-naphthyl group, 2-naphthyl group and the like are preferred, and phenyl group is most preferred.
  • Examples of the substituent in the definition of “an aryl group which may be substituted” in the definition of E include similar groups to the substituent explained for the definition “which may be substituted.” The position of substituents existing on the aryl group is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a phenyl group which may be substituted,” “a mono-substituted phenyl group,” “a di-substituted phenyl group,” and “a phenyl group which has three or more substituents” are preferred, and “a di-substituted phenyl group” is more preferred.
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a di-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group δ-1e.
    • [Substituent Group δ-1e] 3,5-bis(trifluoromethyl)phenyl group, 3,4-propylenedioxyphenyl group, 3,5-dichlorophenyl group, 2,4-dihydroxyphenyl group, 2,5-dimethoxyphenyl group, 2-chloro-5-(trifluoromethyl)phenyl group, 3,5-bis[(1,1-dimethyl)ethyl]phenyl group, 2,5-bis(trifluoromethyl)phenyl group, 4-chloro-2-(trifluoromethyl)phenyl group, 2-fluoro-3-(trifluoromethyl)phenyl group, 4-fluoro-3-(trifluoromethyl)phenyl group, 4-chloro-3-(trifluoromethyl)phenyl group, 3-fluoro-5-(trifluoromethyl)phenyl group, 3-bromo-5-(trifluoromethyl)phenyl group, 2-fluoro-5-(trifluoromethyl)phenyl group, 4-nitro-3-(trifluoromethyl)phenyl group, 2-nitro-5-(trifluoromethyl)phenyl group, 4-cyano-3-(trifluoromethyl)phenyl group, 2-methyl-3-(trifluoromethyl)phenyl group, 4-methyl-3-(trifluoromethyl)phenyl group, 2-methyl-5-(trifluoromethyl)phenyl group, 4-methoxy-3-(trifluoromethyl)phenyl group, 3-methoxy-5-(trifluoromethyl)phenyl group, 2-methoxy-5-(trifluoromethyl)phenyl group, 2-methylsulfanyl-5-(trifluoromethyl)phenyl group, 2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl group, 2-morpholino-5-(trifluoromethyl)phenyl group, 2-chloro-4-(trifluoromethyl)phenyl group, 2,5-dichlorophenyl group, 3,4-dichlorophenyl group, 3,5-difluorophenyl group, 3,5-dinitrophenyl group, 2,5-bis[(1,1-dimethyl)ethyl]phenyl group, 5-[(1,1-dimethyl)ethyl]-2-methoxyphenyl group, 3,5-dimethylphenyl group, 4-methoxybiphenyl-3-yl group, 3,5-dimethoxyphenyl group, 3,5-bis(methoxycarbonyl)phenyl group, 2-bromo-5-(trifluoromethyl)phenyl group, 3-methoxycarbonyl-5-(trifluoromethyl)phenyl group, 3-carboxy-5-(trifluoromethyl)phenyl group, 2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group, 2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl group, 2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group, 2-piperidino-5-(trifluoromethyl)phenyl group, 2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group, 3,5-dicarboxyphenyl group, 5-isopropyl-2-methylphenyl group, 2,5-diethoxyphenyl group, 2,5-dimethylphenyl group, 5-chloro-2-cyano group, 5-diethylsulfamoyl-2-methoxyphenyl group, 2-chloro-5-nitrophenyl group, 2-methoxy-5-(phenylcarbamoyl)phenyl group, 5-acetylamino-2-methoxyphenyl group, 5-methoxy-2-methylphenyl group, 2,5-dibutoxyphenyl group, 2,5-diisopentyloxy group, 5-carbamoyl-2-methoxyphenyl group, 5-[(1,1-dimethyl)propyl]-2-phenoxyphenyl group, 2-hexyloxy-5-methanesulfonyl group, 5-(2,2-dimethylpropionyl)-2-methylphenyl group, 5-methoxy-2-(1-pyrrolyl)phenyl group, 5-chloro-2-(p-toluenesulfonyl)phenyl group, 2-chloro-5-(p-toluenesulfonyl)phenyl group, 2-fluoro-5-methanesulfonyl group, 2-methoxy-5-phenoxy group, 4-methylbiphenyl-3-yl group, 2-methoxy-5-(1-methyl-1-phenylethyl)phenyl group, 5-morpholino-2-nitrophenyl group, 5-fluoro-2-(1-imidazolyl)phenyl group, 2-butyl-5-nitrophenyl group, 5-[(1,1-dimethyl)]propyl-2-hydroxyphenyl group, 2-methoxy-5-methylphenyl group, 2,5-difluorophenyl group, 4-isopropyl-2-(trifluoromethyl)phenyl group, 2-nitro-4-(trifluoromethyl)phenyl group, 4-bromo-3-(trifluoromethyl)phenyl group, 4-bromo-2-(trifluoromethyl)phenyl group, 2-bromo-4-(trifluoromethyl)phenyl group, 4-fluoro-2-(trifluoromethyl)phenyl group, 4-isopropoxy-2-(trifluoromethyl)phenyl group, 4-cyano-2-(trifluoromethyl)phenyl group, 2,6-diisopropylphenyl group, 2,6-dimethylphenyl group, 3,4-dimethylphenyl group, 2,4-dichlorophenyl group, 2,3-dimethylphenyl group, indan-5-yl group, 2,4-dimethylphenyl group, 2,6-dichlorophenyl group, 4-bromo-2-(trifluoromethoxy)phenyl group, 3,4-ethylenedioxyphenyl group, 3-chloro-4-cyanophenyl group, 3-chloro-4-(trifluoromethoxy)phenyl group, 2-chloro-4-cyanophenyl group, 2,3-dichlorophenyl group, 4-isopropyl-3-methylphenyl group, 4-[(1,1-dimethyl)propyl]-2-hydroxyphenyl group, 3-chloro-2-cyanophenyl group, 2-cyano-4-methylphenyl group, 2,2-difluoro-1,3-benzodioxol-4-yl group, 2,2,3,3-tetrafluoro-1,4-benzodioxen-5-yl group, 3-chloro-4-(trifluoromethylsulfanyl)phenyl group, 2-nitro-4-(trifluoromethoxy)phenyl group, 2,2-difluoro-1,3-benzodioxol-5-yl group, 2-methyl-4-(trifluoromethoxy)phenyl group, 4-bromo-2-fluorophenyl group, 2,4-bis(methanesulfonyl)phenyl group, 2,2,3,3-tetrafluoro-1,4-benzodioxen-6-yl group, 2-benzoyl-4-chlorophenyl group, 2-bromo-4-fluorophenyl group, 3,4-dimethoxyphenyl group, 3,4-difluorophenyl group, 3-chloro-4-methoxyphenyl group, 2-chloro-4-nitrophenyl group, 2,4-difluorophenyl group, 2-benzoyl-5-methylphenyl group, 2-bromo-4-(trifluoromethoxy)phenyl group, 3,4-dihexyloxyphenyl group, 2,4-bis(trifluoromethyl)phenyl group, 4-cyano-2-(trifluoromethoxy)phenyl group, 2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group, and 2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a di-substituted phenyl group,” “a 2,5-di-substituted phenyl group,” and “a 3,5-di-substituted phenyl group” are preferred.
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a 2,5-di-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group δ-2e.
    • [Substituent Group δ-2e] 2,5-dimethoxyphenyl group, 2-chloro-5-(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl group, 2-fluoro-5-(trifluoromethyl)phenyl group, 2-nitro-5-(trifluoromethyl)phenyl group, 2-methyl-5-(trifluoromethyl)phenyl group, 2-methoxy-5-(trifluoromethyl)phenyl group, 2-methylsulfanyl-5-(trifluoromethyl)phenyl group, 2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl group, 2-morpholino-5-(trifluoromethyl)phenyl group, 2,5-dichlorophenyl group, 2,5-bis[( 1,1-dimethyl)ethyl]phenyl group, 5-[(1,1-dimethyl)ethyl]-2-methoxyphenyl group, 4-methoxybiphenyl-3-yl group, 2-bromo-5-(trifluoromethyl)phenyl group, 2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group, 2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl group, 2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group, 2-piperidino-5-(trifluoromethyl)phenyl group, 2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group, 5-isopropyl-2-methylphenyl group, 2,5-diethoxyphenyl group, 2,5-dimethylphenyl group, 5-chloro-2-cyano group, 5-diethylsulfamoyl-2-methoxyphenyl group, 2-chloro-5-nitrophenyl group, 2-methoxy-5-(phenylcarbamoyl)phenyl group, 5-acetylamino-2-methoxyphenyl group, 5-methoxy-2-methylphenyl group, 2,5-dibutoxyphenyl group, 2,5-diisopentyloxy group, 5-carbamoyl-2-methoxyphenyl group, 5-[(1,1-dimethyl)propyl]-2-phenoxyphenyl group, 2-hexyloxy-5-methanesulfonyl group, 5-(2,2-dimethylpropionyl)-2-methylphenyl group, 5-methoxy-2-(1-pyrrolyl)phenyl group, 5-chloro-2-(p-toluenesulfonyl)phenyl group, 2-chloro-5-(p-toluenesulfonyl)phenyl group, 2-fluoro-5-methanesulfonyl group, 2-methoxy-5-phenoxy group, 2-methoxy-5-(1-methyl-1-phenylethyl)phenyl group, 5-morpholino-2-nitrophenyl group, 5-fluoro-2-(1-imidazolyl)phenyl group, 2-butyl-5-nitrophenyl group, 5-[(1,1-dimethyl)propyl]-2-hydroxyphenyl group, 2-methoxy-5-methylphenyl group, 2,5-difluorophenyl group, 2-benzoyl-5-methylphenyl group, 2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group, and 2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a 2,5-di-substituted phenyl group,” “a 2,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group” is more preferred, a group selected from the following Substituent Group δ-3e is further preferred, and 2,5-bis(trifluoromethyl)phenyl group is most preferred.
    • [Substituent Group δ-3e] 2-chloro-5-(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl group, 2-fluoro-5-(trifluoromethyl)phenyl group, 2-nitro-5-(trifluoromethyl)phenyl group, 2-methyl-5-(trifluoromethyl)phenyl group, 2-methoxy-5-(trifluoromethyl)phenyl group, 2-methylsulfanyl-5-(trifluoromethyl)phenyl group, 2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl group, 2-morpholino-5-(trifluoromethyl)phenyl group, 2-bromo-5-(trifluoromethyl)phenyl group, 2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group, 2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl group, 2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group, 2-piperidino-5-(trifluoromethyl)phenyl group, 2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group, and 2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a 3,5-di-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group δ-4e.
    • [Substituent Group δ-4e] 3,5-bis(trifluoromethyl)phenyl group, 3,5-dichlorophenyl group, 3,5-bis[(1,1-dimethyl)ethyl]phenyl group, 3-fluoro-5-(trifluoromethyl)phenyl group, 3-bromo-5-(trifluoromethyl)phenyl group, 3-methoxy-5-(trifluoromethyl)phenyl group, 3,5-difluorophenyl group, 3,5-dinitrophenyl group, 3,5-dimethylphenyl group, 3,5-dimethoxyphenyl group, 3,5-bis(methoxycarbonyl)phenyl group, 3-methoxycarbonyl-5-(trifluoromethyl)phenyl group, 3-carboxy-5-(trifluoromethyl)phenyl group, and 3,5-dicarboxyphenyl group
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a 3,5-di-substituted phenyl group,” “a 3,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group” is more preferred, a group selected from the following Substituent Group δ-5e is further preferred, and 3,5-bis(trifluoromethyl)phenyl group is most preferred.
    • [Substituent Group δ-5e] 3,5-bis(trifluoromethyl)phenyl group, 3-fluoro-5-(trifluoromethyl)phenyl group, 3-bromo-5-(trifluoromethyl)phenyl group, 3-methoxy-5-(trifluoromethyl)phenyl group, 3-methoxycarbonyl-5-(trifluoromethyl)phenyl group, and 3-carboxy-5-(trifluoromethyl)phenyl group
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a mono-substituted phenyl group,” preferred examples of the group include groups represented by the following Substituent Group δ-6e.
    • [Substituent Group δ-6e] 4-methoxyphenyl group, 4-chlorophenyl group, 2-methoxyphenyl group, 2-(trifluoromethyl)phenyl group, 3-(trifluoromethyl)phenyl group, 4-(trifluoromethyl)phenyl group, 3-chlorophenyl group, biphenyl-3-yl group, 3-acetylphenyl group, 3-(acetylamino)phenyl group, 3-carbamoylphenyl group, 3-methylcarbomoylphenyl group, 4-methylphenyl group, 3-(trifluoromethoxy)phenyl group, 2-benzylphenyl group, 4-(trifluoromethoxy)phenyl group, 4-[(1,1-dimethyl)ethyl]phenyl group, 3-isopropoxyphenyl group, 4-isopropoxyphenyl group, 4-hexylphenyl group, 3-methylphenyl group, 4-cyclohexylphenyl group, 4-benzylphenyl group, 2-chlorophenyl group, 2-methylphenyl group, 4-butylphenyl group, 4-benzyloxyphenyl group, 3-benzylphenyl group, 4-hexyloxyphenyl group, 3-isopropylphenyl group, 4-cyanophenyl group, 3-cyanophenyl group, 4-(ethoxycarbonylmethyl)phenyl group, 3-(trifluoromethylsulfanyl)phenyl group, 4-(trifluoromethylsulfanyl)phenyl group, 4-(trifluoromethanesulfonyl)phenyl group, 3-ethynylphenyl group, 4-(1-methylpropyl)phenyl group, 3-benzoylphenyl group, 3-methoxyphenyl group, 4-(acetylamino)phenyl group, 4-sulfamoylphenyl group, 4-difluoromethoxy)phenyl group, 3-methylsulfanylphenyl group, 4-methanesulfonylphenyl group, 3-(butylsulfamoyl)phenyl group, 3-benzyloxyphenyl group, 4-(p-toluenesulfonylamino)phenyl group, 4-morpholinophenyl group, 3-[(1,1-dimethyl)ethyl]phenyl group, 3-(5-methylfuran-2-yl)phenyl group, 3-sulfamoylphenyl group, 3-(trifluoromethanesulfonyl)phenyl group, 3-hexyloxyphenyl group, 4-acetylphenyl group, biphenyl-2-yl group, biphenyl-4-yl group, 3-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]phenyl group, 3-[5-[(1,1-dimethyl)ethyl]-3-(trifluoromethyl)pyrazol-1-yl)phenyl group, 4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl group, 3-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl group, and 4-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]phenyl group
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a phenyl group which has three or more substituents,” preferred examples of the group include groups represented by the following Substituent Group δ-7e.
    • [Substituent Group δ-7e] 3,5-bis(trifluoromethyl)-2-bromophenyl group, 3,4,5-trichlorophenyl group, 3,5-dichloro-4-hydroxyphenyl group, pentafluorophenyl group, 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl group, 3,5-bis(trifluoromethyl)-2-methylphenyl group, 2,6-dichloro-4-(trifluoromethyl)phenyl group, 2,4-dimethoxy-5-(trifluoromethyl)phenyl group, 2,4-difluoro-5-(trifluoromethyl)phenyl group, 4-chloro-2-(4-chlorobenzenesulfonyl)-5-(trifluoromethyl)phenyl group, 5-chloro-2-nitro-4-(trifluoromethyl)phenyl group, 2,3-difluoro-4-(trifluoromethyl)phenyl group, 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl group, 2,4,6-trimethylphenyl group, 2-cyano-4,5-dimethoxyphenyl group, 2,4-dichloro-5-isopropoxyphenyl group, 2,3,5-trifluorophenyl group, 2,4,5-trichlorophenyl group, and 5-ethoxy-4-fluoro-2-nitrophenyl group
  • When “an aryl group which may be substituted” in the aforementioned definition of E is “a naphthyl group which may be substituted,” preferred examples of the group include 1-naphthyl group, 4-methoxynaphthalen-2-yl group, and 4-hydroxy-3-methylnaphthalen-1-yl group.
  • Examples of the “heteroaryl group” in “a heteroaryl group which may be substituted” in the definition of E include similar groups to the “monocyclic heteroaryl group” and “fused polycyclic heteroaryl group” in the definition of the aforementioned “heterocyclic group.” A 5 to 13-membered heteroaryl group is preferred, and preferred examples of the group include thienyl group, pyrazolyl group, oxazolyl group, 1,3,4-thiadiazolyl group, pyridyl group, pyrimidinyl group, indolyl group, quinolyl group, carbazolyl group, thiazolyl group, and pyrazinyl group.
  • A 5-membered heteroaryl group is more preferred as the “heteroaryl group” in “a heteroaryl group which may be substituted” in the definition of E. Thienyl group, pyrazolyl group, oxazolyl group, 1,3,4-thiadiazolyl group, and thiazolyl group are further preferred, and thiazolyl group is most preferred.
  • Examples of the substituent in the definition of “a heteroaryl group which may be substituted” in the aforementioned definition of E include similar groups to the substituent explained for the definition “which may be substituted.” The position of substituents existing on the heteroaryl group is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • When “a heteroaryl group which may be substituted” in the aforementioned definition of E is “a thiazolyl group which may be substituted,” “a thiazol-2-yl group which may be substituted.” “A mono-substituted thiazol-2-yl group” and “a di-substituted thiazol-2-yl group” are more preferred, and “a di-substituted thiazol-2-yl group” is further preferred.
  • When “a heteroaryl group which may be substituted” in the aforementioned definition of E is “a di-substituted thiazol-2-yl group,” a group selected from the following Substituent Group δ-8e is preferred, and 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group is most preferred.
    • [Substituent Group δ-8e] 5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-bromo-4-(trifluoromethyl)thiazol-2-yl group, 5-cyano-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-methylthiazol-2-yl group, 4,5-dimethylthiazol-2-yl group, 5-methyl-4-phenylthiazol-2-yl group, 5-(4-fluorophenyl)-4-methylthiazol-2-yl group, 4-methyl-5-[3-(trifluoromethyl)phenyl]thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-ethylthiazol-2-yl group, 4-ethyl-5-phenylthiazol-2-yl group, 4-isopropyl-5-phenylthiazol-2-yl group, 4-butyl-5-phenylthiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(ethoxycarbonyl)thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazol-2-yl group, 5-carboxymethyl-4-phenylthiazol-2-yl group, 4,5-diphenylthiazol-2-yl group, 4-benzyl-5-phenylthiazol-2-yl group, 5-phenyl-4-(trifluoromethyl)thiazol-2-yl group, 5-acetyl-4-phenylthiazol-2-yl group, 5-benzoyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(pentafluorophenyl)thiazol-2-yl group, 5-methylcarbamoyl-4-phenylthiazol-2-yl group, 5-ethylcarbamoyl-4-phenylthiazol-2-yl group, 5-isopropylcarbamoyl-4-phenylthiazol-2-yl group, 5-(2-phenylethyl)carbamoyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(trifluoromethyl)thiazol-2-yl group, 5-carboxy-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-(ethoxycarbonyl)methyl-4-phenylthiazol-2-yl group, 5-carboxy-4-phenylthiazol-2-yl group, and 5-propylcarbamoyl-4-phenylthiazol-2-yl group.
  • When “a heteroaryl group which may be substituted” in the aforementioned definition of E is “a mono-substituted thiazol-2-yl group,” preferred examples of the group include groups represented by the following Substituent Group δ-9e.
    • [Substituent Group δ-9e] 4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 4-phenylthiazol-2-yl group, 4-[3,5-bis(trifluoromethyl)phenyl]thiazol-2-yl group, 4-(2,4-dichlorophenyl)thiazol-2-yl group, 4-(3,4-dichlorophenyl)thiazol-2-yl group, 4-[4-(trifluoromethyl)phenyl]thiazol-2-yl group, 4-(2,5-difluorophenyl)thiazol-2-yl group, 4-(4-methoxyphenyl)thiazol-2-yl group, 4-[3-(trifluoromethyl)phenyl]thiazol-2-yl group, and 4-(pentafluorophenyl)thiazol-2-yl group
  • The compounds represented by the aforementioned general formula (I-1) are explained in details.
  • Examples of the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z1 include similar groups to the substituent explained for the definition “which may be substituted.”
  • “2-Hydroxyphenyl group which is substituted in the 5-position” is preferred as the “2-hydroxyphenyl group which may be substituted in the 5-position” in the definition of Z1.
  • Preferred examples of the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position ” in the definition of Z1 include a group selected from the following Substituent Group γ1-1z. A halogen atom and tert-butyl group are more preferred, and a halogen atom is most preferred.
    • [Substituent Group γ1-1z] a halogen atom, nitro group, cyano group, methoxy group, methyl group, isopropyl group, tert-butyl group, 1,1,3,3-tetramethylbutyl group, 2-phenylethen-1-yl group, 2,2-dicyanoethen-1-yl group, 2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl group, ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group, trifluoromethyl group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group, 4-fluorophenyl group, 2,4-difluorophenyl group, 2-phenethyl group, 1-hydroxyethyl group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino]ethyl group, 2-thienyl group, 3-thienyl group, 1-pyrrolyl group, 2-methylthiazol-4-yl group, imidazo[1,2-a]pyridin-2-yl group, 2-pyridyl group, acetyl group, isobutyryl group, piperidinocarbonyl group, 4-benzylpiperidinocarbonyl group, (pyrrol-1-yl)sulfonyl group, carboxy group, methoxycarbonyl group, N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl group, N,N-dimethylcarbamoyl group, sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfamoyl group, N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino group, 3-phenylureido group, (3-phenyl)thioureido group, (4-nitrophenyl)diazenyl group, and {[4-(pyridin-2-yl)sulfamoyl]phenyl} diazenyl group
  • “2-Acetoxyphenyl group which is substituted in the 5-position” is preferred as the “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z1.
  • A halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z1.
  • The definition “which may be substituted” in the definition of “a phenyl group which may be substituted” in the definition of E1 has the same meaning as “which may be substituted.”
  • Examples of the substituent in the definition of “a phenyl group which may be substituted” in the definition of E1 include similar groups to the substituents explained for the definition “which may be substituted.” A position of a substituent existing on the phenyl group is not particularly limited, and when two or more substituents exist, they may be the same or different.
  • Preferred examples of “a phenyl group which may be substituted” in the definition of E1 include 3,5-bis(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl group, a phenyl group which has three or more substituents wherein at least one of said substituents is trifluoromethyl group, and a di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, (provided that a 2,5-di-substituted phenyl group and a 3,5-di-substituted phenyl group are excluded as said di-substituted phenyl group.) 3,5-Bis(trifluoromethyl)phenyl group and 2,5-bis(trifluoromethyl)phenyl group are more preferred.
  • When “a phenyl group which may be substituted” in the definition of E1 is “a phenyl group which has three or more substituents wherein at least one of said substituents is trifluoromethyl group,” preferred examples of the group include groups represented by the following Substituent Group δ1-1e.
    • [Substituent Group δ1-1e] 3,5-bis(trifluoromethyl)-2-bromophenyl group, 3,5-bis(trifluoromethyl)-2-methylphenyl group, 2,6-dichloro-4-(trifluoromethyl)phenyl group, 2,4-dimethoxy-5-(trifluoromethyl)phenyl group, 2,4-difluoro-5-(trifluoromethyl)phenyl group, 4-chloro-2-(4-chlorobenzenesulfonyl)-5-(trifluoromethyl)phenyl group, 5-chloro-2-nitro-4-(trifluoromethyl)phenyl group, 2,3-difluoro-4-(trifluoromethyl)phenyl group, and 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl group
  • When “a phenyl group which may be substituted” in the definition of E1 is “a di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, (provided that a 2,5-di-substituted phenyl group and a 3,5-di-substituted phenyl group are excluded from said di-substituted phenyl group)” preferred examples of the group include groups represented by the following Substituent Group δ1-2e.
    • [Substituent Group δ1-2e] 4-chloro-2-(trifluoromethyl)phenyl group, 2-fluoro-3-(trifluoromethyl)phenyl group, 4-fluoro-3-(trifluoromethyl)phenyl group, 4-chloro-3-(trifluoromethyl)phenyl group, 4-nitro-3-(trifluoromethyl)phenyl group, 4-cyano-3-(trifluoromethyl)phenyl group, 2-methyl-3-(trifluoromethyl)phenyl group, 4-methyl-3-(trifluoromethyl)phenyl group, 4-methoxy-3-(trifluoromethyl)phenyl group, 2-chloro-4-(trifluoromethyl)phenyl group, 4-isopropyl-2-(trifluoromethyl)phenyl group, 2-nitro-4-(trifluoromethyl)phenyl group, 4-bromo-3-(trifluoromethyl)phenyl group, 4-bromo-2-(trifluoromethyl)phenyl group, 2-bromo-4-(trifluoromethyl)phenyl group, 4-fluoro-2-(trifluoromethyl)phenyl group, 4-isopropoxy-2-(trifluoromethyl)phenyl group, 4-cyano-2-(trifluoromethyl)phenyl group, and 2,4-bis(trifluoromethyl)phenyl group
  • Compounds represented by the aforementioned general formula (I-2) are explained in details.
  • Examples of the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z2 include similar groups to the substituent explained for the definition “which may be substituted.”
  • “2-Hydroxyphenyl group which is substituted in the 5-position” is preferred as the “2-hydroxyphenyl group which may be substituted in the 5-position” in the definition of Z2.
  • A halogen atom, nitro group, methyl group, and methoxy group are preferred as the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position” in the definition of Z2, and a halogen atom is most preferred.
  • “2-Acetoxyphenyl group which is substituted in the 5-position” is preferred as the “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z2.
  • A halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z2.
  • Examples of the substituent in the definition of “a 2,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” and “a 3,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” in the definition of E2 include similar groups to the substituent explained for the definition “which may be substituted.”
  • A group selected from the following Substituent Group δ2-1e is preferred as “a 2,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” in the definition of E2.
    • [Substituent Group δ2-1e] 2-chloro-5-(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl group, 2-fluoro-5-(trifluoromethyl)phenyl group, 2-nitro-5-(trifluoromethyl)phenyl group, 2-methyl-5-(trifluoromethyl)phenyl group, 2-methoxy-5-(trifluoromethyl)phenyl group, 2-methylsulfanyl-5-(trifluoromethyl)phenyl group, 2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl group, 2-morpholino-5-(trifluoromethyl)phenyl group, 2-bromo-5-(trifluoromethyl)phenyl group, 2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group, 2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl group, 2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group, 2-piperidino-5-(trifluoromethyl)phenyl group, 2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group, and 2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group
  • A group selected from the following Substituent Group δ2-2e is preferred as “a 3,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group” in the definition of E2.
    • [Substituent Group δ2-2e] 3,5-bis(trifluoromethyl)phenyl group, 3-fluoro-5-(trifluoromethyl)phenyl group, 3-bromo-5-(trifluoromethyl)phenyl group, 3-methoxy-5-(trifluoromethyl)phenyl group, 3-methoxycarbonyl-5-(trifluoromethyl)phenyl group, and 3-carboxy-5-(trifluoromethyl)phenyl group
  • Compounds represented by the aforementioned general formula (I-3) are explained in details.
  • Examples of the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z3 include similar groups to the substituent explained for the definition “which may be substituted.”
  • “2-Hydroxyphenyl group which is substituted in the 5-position” is preferred as the “2-hydroxyphenyl group which may be substituted in the 5-position” in the definition of Z3.
  • A halogen atom, nitro group, methyl group and methoxy group are preferred as the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position” in the definition of Z3, and a halogen atom is most preferred.
  • “2-Acetoxyphenyl group which is substituted in the 5-position” is preferred as the “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z3.
  • A halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z3.
  • Examples of the substituent in the definition of “a hydrocarbon group which may be substituted” in the definition of R3e2 and R3e3 and “a C2 to C6 hydrocarbon group which may be substituted” in the definition of R3e5 include similar groups to the substituent explained for the definition “which may be substituted.”
  • Examples of the “hydrocarbon group” in the definition of “a hydrocarbon group which may be substituted” in the definition of R3e2 and R3e3 and “a C2 to C6 hydrocarbon group which may be substituted” in the definition of R3e5 include similar groups to the “hydrocarbon group” in the aforementioned definition.
  • Examples of the “hydroxy group which may be substituted” in the definition of R3e2 and R3e3 include similar groups to the “hydroxy group which may be substituted” explained for the definition “which may be substituted.”
  • As E3, 3,5-bis[(1,1-dimethyl)ethyl]phenyl group, 2,5-bis[(1,1-dimethyl)ethyl]phenyl group, 5-[(1,1-dimethyl)ethyl]-2-methoxyphenyl group, 4-methoxybiphenyl-3-yl group, 5-[(1,1-dimethyl)propyl]-2-phenoxyphenyl group, 4-methylbiphenyl-3-yl group and 5-[(1,1-dimethyl)propyl]-2-hydroxyphenyl group are preferred, and 3,5-bis[(1,1-dimethyl)ethyl]phenyl group is more preferred.
  • Compounds represented by the aforementioned general formula (I-4) are explained in details.
  • Examples of the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z4 include similar groups to the substituent explained for the definition “which may be substituted.”
  • “2-Hydroxyphenyl group which is substituted in the 5-position” is preferred as the “2-hydroxyphenyl group which may be substituted in the 5-position” in the definition of Z4.
  • A halogen atom, phenyl group, 4-fluorophenyl group, 2,4-difluorophenyl group, 4-(trifluoromethyl)phenyl group, 1-pyrrolyl group and 2-thienyl group are preferred as the substituent in the definition of “2-hydroxyphenyl group which may be substituted in the 5-position” and “2-hydroxyphenyl group which is substituted in the 5-position” in the definition of Z4, and a halogen atom is most preferred.
  • “2-Acetoxyphenyl group which is substituted in the 5-position” is preferred as the “2-acetoxyphenyl group which may be substituted in the 5-position” in the definition of Z4.
  • A halogen atom is preferred as the substituent in the definition of “2-acetoxyphenyl group which may be substituted in the 5-position” and “2-acetoxyphenyl group which is substituted in the 5-position” in the definition of Z4.
  • Examples of the substituent in the definition of “a hydrocarbon group which may be substituted” in the definition of R4e4, and “an acyl group which may be substituted” and “a heterocyclic group which may be substituted” in the definition of R4e5 include similar groups to the substituent explained for the definition “which may be substituted.”
  • Examples of the “hydrocarbon group” in the definition of “a hydrocarbon group which may be substituted” in the definition of R4e4 include similar groups to the “hydrocarbon group” in the aforementioned definition.
  • Examples of the “acyl group” in the definition of “an acyl group which may be substituted” in the definition of R4e5 include similar groups to the “acyl group” in the aforementioned definition.
  • Examples of the “heterocyclic group” in the definition of “a heterocyclic group which may be substituted” in the definition of R4e5 include similar groups to the “heterocyclic group” in the aforementioned definition.
  • A group selected from the following Substituent Group δ4-1e is preferred as E4, and 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group is most preferred.
    • [Substituent Group δ-1e] 5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-bromo-4-(trifluoromethyl)thiazol-2-yl group, 5-cyano-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-methylthiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(ethoxycarbonyl)thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazol-2-yl group, 5-carboxymethyl-4-phenylthiazol-2-yl group, 5-acetyl-4-phenylthiazol-2-yl group, 5-benzoyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(pentafluorophenyl)thiazol-2-yl group, 5-methylcarbamoyl-4-phenylthiazol-2-yl group, 5-ethylcarbamoyl-4-phenylthiazol-2-yl group, 5-isopropylcarbamoyl-4-phenylthiazol-2-yl group, 5-(2-phenylethyl)carbamoyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(trifluoromethyl)thiazol-2-yl group, 5-carboxy-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-carboxy-4-phenylthiazol-2-yl group, and 5-propylcarbamoyl-4-phenylthiazol-2-yl group.
  • Among the compound represented by the general formulas (I), (I-1), (1-2), (I-3) and (I-4), preferred compounds are those other than “substituted benzoic acid derivatives represented by the following general formula (X-1) and/or compounds represented by the following Compound Group φ-1.”
    Figure US20060122243A1-20060608-C00028
    • wherein R1001 represents the following general formula (X-2):
      Figure US20060122243A1-20060608-C00029
    • or the following general formula (X-3):
      Figure US20060122243A1-20060608-C00030
    • wherein each of R1003, R1004 and R1005 independently represents hydrogen atom, an alkyl group having from 1 to 6 carbons or an alkoxy group having from 1 to 6 carbons, each of R1009 and R1010 independently represents hydrogen atom, an alkyl group having from 1 to 6 carbons, or an acyl group having from 2 to 11 carbons;
    • R1002 represents hydrogen atom, a lower alkyl group having from 1 to 6 carbons, which may be substituted, an aryl group having from 6 to 12 carbons, which may be substituted, a heteroaryl group having from 4 to 11 carbons, which may be substituted, an aralkyl group having from 7 to 14 carbons, which may be substituted, a heteroarylalkyl group having from 5 to 13 carbons, which may be substituted, or an acyl group having from 2 to 11 carbons;
    • X1001 represents carboxy group which may be esterified or amidated.
      Figure US20060122243A1-20060608-C00031
  • Each compound defined by the aforementioned general formulas (I-1), (I-2), (I-3), and (I-4), or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof is novel. Uses of the compound according to the aforementioned chemical substance invention are not particularly limited.
  • The compounds represented by the aforementioned general formulas (I), (I-1), (I-2), (I-3) and (1-4) may form salts. Examples of pharmacologically acceptable salts include, when acidic groups exist, metal salts such as lithium salt, sodium salt, potassium salt, magnesium salt, calcium salts, or ammonium salts such as ammonium salt, methylammonium salt, dimethylammonium salt, trimethylammonium salt, dicyclohexylammonium salt, and when basic groups exist, mineral acid salts such as hydrochloride, oxalate, hydrosulfate, nitrate, phosphate, or organic acid salts such as methane sulfonate, benzene sulfonate, para-toluene sulfonate, acetate, propionate, tartrate, fumarate, maleate, malate, oxalate, succinate, citrate, benzoate, mandelate, cinnamate, lactate. Salts may sometimes be formed with amino acids such as glycine. As active ingredients of the medicament of the present invention, pharmacologically acceptable salts may also be suitably used.
  • The compounds or salts thereof represented by the aforementioned general formulas (I), (I-1), (I-2), (1-3) and (1-4) may exist as hydrates or solvates. As active ingredients of the medicament of the present invention, any of the aforementioned substances may be used. Furthermore, the compounds represented by the aforementioned general formulas (I), (I-1), (I-2), (I-3) and (I-4) may sometimes have one or more asymmetric carbons, and may exist as steric isomers such as optically active substance and diastereomer. As active ingredients of the medicament of the present invention, pure forms of stereoisomers, arbitrary mixture of enantiomers or diastereomers, and racemates may be used.
  • Furthermore, when the compounds represented by the general formulas (I), (I-1), (I-2), (1-3) and (I-4) has, for example, 2-hydroxypyridine form, the compounds may exist as 2-pyridone form which is a tautomer. As active ingredients of the medicament of the present invention, pure forms of tautomers or a mixture thereof may be used. When the compounds represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) have olefinic double bonds, the configuration may be in either E or Z, and as active ingredients of the medicament of the present invention, geometrical isomer in either of the configurations or a mixture thereof may be used.
  • Examples of the compounds included in the general formulas (I), (I-1), (I-2), (I-3) and (I-4) as active ingredients of the medicaments of the present invention are shown below. However, the active ingredients of the medicaments of the present invention are not limited to the compound set out below.
  • The abbreviations used in the following tables have the following meanings.
  • Me: methyl group, Et: ethyl group.
    Figure US20060122243A1-20060608-C00032
         Compound Number
    Figure US20060122243A1-20060608-C00033
         		      X       E
    1
    Figure US20060122243A1-20060608-C00034
    Figure US20060122243A1-20060608-C00035
    Figure US20060122243A1-20060608-C00036
    2
    Figure US20060122243A1-20060608-C00037
    Figure US20060122243A1-20060608-C00038
    Figure US20060122243A1-20060608-C00039
    3
    Figure US20060122243A1-20060608-C00040
    Figure US20060122243A1-20060608-C00041
    4
    Figure US20060122243A1-20060608-C00042
    Figure US20060122243A1-20060608-C00043
    Figure US20060122243A1-20060608-C00044
    5
    Figure US20060122243A1-20060608-C00045
    Figure US20060122243A1-20060608-C00046
    Figure US20060122243A1-20060608-C00047
    6
    Figure US20060122243A1-20060608-C00048
    Figure US20060122243A1-20060608-C00049
    Figure US20060122243A1-20060608-C00050
    7
    Figure US20060122243A1-20060608-C00051
    Figure US20060122243A1-20060608-C00052
    Figure US20060122243A1-20060608-C00053
    8
    Figure US20060122243A1-20060608-C00054
    Figure US20060122243A1-20060608-C00055
    Figure US20060122243A1-20060608-C00056
    9
    Figure US20060122243A1-20060608-C00057
    Figure US20060122243A1-20060608-C00058
    Figure US20060122243A1-20060608-C00059
    10
    Figure US20060122243A1-20060608-C00060
    Figure US20060122243A1-20060608-C00061
    Figure US20060122243A1-20060608-C00062
    11
    Figure US20060122243A1-20060608-C00063
    Figure US20060122243A1-20060608-C00064
    Figure US20060122243A1-20060608-C00065
    12
    Figure US20060122243A1-20060608-C00066
    Figure US20060122243A1-20060608-C00067
    Figure US20060122243A1-20060608-C00068
    13
    Figure US20060122243A1-20060608-C00069
    Figure US20060122243A1-20060608-C00070
    Figure US20060122243A1-20060608-C00071
    14
    Figure US20060122243A1-20060608-C00072
    Figure US20060122243A1-20060608-C00073
    Figure US20060122243A1-20060608-C00074
    15
    Figure US20060122243A1-20060608-C00075
    Figure US20060122243A1-20060608-C00076
    Figure US20060122243A1-20060608-C00077
    16
    Figure US20060122243A1-20060608-C00078
    Figure US20060122243A1-20060608-C00079
    Figure US20060122243A1-20060608-C00080
    17
    Figure US20060122243A1-20060608-C00081
    Figure US20060122243A1-20060608-C00082
    Figure US20060122243A1-20060608-C00083
          Compound Number
    Figure US20060122243A1-20060608-C00084
         		      E
    18
    Figure US20060122243A1-20060608-C00085
    Figure US20060122243A1-20060608-C00086
    19
    Figure US20060122243A1-20060608-C00087
    Figure US20060122243A1-20060608-C00088
    20
    Figure US20060122243A1-20060608-C00089
    Figure US20060122243A1-20060608-C00090
    21
    Figure US20060122243A1-20060608-C00091
    Figure US20060122243A1-20060608-C00092
    22
    Figure US20060122243A1-20060608-C00093
    Figure US20060122243A1-20060608-C00094
    23
    Figure US20060122243A1-20060608-C00095
    Figure US20060122243A1-20060608-C00096
    24
    Figure US20060122243A1-20060608-C00097
    Figure US20060122243A1-20060608-C00098
    25
    Figure US20060122243A1-20060608-C00099
    Figure US20060122243A1-20060608-C00100
    26
    Figure US20060122243A1-20060608-C00101
    Figure US20060122243A1-20060608-C00102
    27
    Figure US20060122243A1-20060608-C00103
    Figure US20060122243A1-20060608-C00104
    28
    Figure US20060122243A1-20060608-C00105
    Figure US20060122243A1-20060608-C00106
    29
    Figure US20060122243A1-20060608-C00107
    Figure US20060122243A1-20060608-C00108
    30
    Figure US20060122243A1-20060608-C00109
    Figure US20060122243A1-20060608-C00110
    31
    Figure US20060122243A1-20060608-C00111
    Figure US20060122243A1-20060608-C00112
    32
    Figure US20060122243A1-20060608-C00113
    Figure US20060122243A1-20060608-C00114
    33
    Figure US20060122243A1-20060608-C00115
    Figure US20060122243A1-20060608-C00116
    34
    Figure US20060122243A1-20060608-C00117
    Figure US20060122243A1-20060608-C00118
    35
    Figure US20060122243A1-20060608-C00119
    Figure US20060122243A1-20060608-C00120
    36
    Figure US20060122243A1-20060608-C00121
    Figure US20060122243A1-20060608-C00122
    37
    Figure US20060122243A1-20060608-C00123
    Figure US20060122243A1-20060608-C00124
    38
    Figure US20060122243A1-20060608-C00125
    Figure US20060122243A1-20060608-C00126
    39
    Figure US20060122243A1-20060608-C00127
    Figure US20060122243A1-20060608-C00128
    40
    Figure US20060122243A1-20060608-C00129
    Figure US20060122243A1-20060608-C00130
    41
    Figure US20060122243A1-20060608-C00131
    Figure US20060122243A1-20060608-C00132
    42
    Figure US20060122243A1-20060608-C00133
    Figure US20060122243A1-20060608-C00134
    43
    Figure US20060122243A1-20060608-C00135
    Figure US20060122243A1-20060608-C00136
    44
    Figure US20060122243A1-20060608-C00137
    Figure US20060122243A1-20060608-C00138
    45
    Figure US20060122243A1-20060608-C00139
    Figure US20060122243A1-20060608-C00140
    46
    Figure US20060122243A1-20060608-C00141
    Figure US20060122243A1-20060608-C00142
    47
    Figure US20060122243A1-20060608-C00143
    Figure US20060122243A1-20060608-C00144
    48
    Figure US20060122243A1-20060608-C00145
    Figure US20060122243A1-20060608-C00146
    49
    Figure US20060122243A1-20060608-C00147
    Figure US20060122243A1-20060608-C00148
    50
    Figure US20060122243A1-20060608-C00149
    Figure US20060122243A1-20060608-C00150
    51
    Figure US20060122243A1-20060608-C00151
    Figure US20060122243A1-20060608-C00152
    52
    Figure US20060122243A1-20060608-C00153
    Figure US20060122243A1-20060608-C00154
    53
    Figure US20060122243A1-20060608-C00155
    Figure US20060122243A1-20060608-C00156
    54
    Figure US20060122243A1-20060608-C00157
    Figure US20060122243A1-20060608-C00158
    55
    Figure US20060122243A1-20060608-C00159
    Figure US20060122243A1-20060608-C00160
    56
    Figure US20060122243A1-20060608-C00161
    Figure US20060122243A1-20060608-C00162
    57
    Figure US20060122243A1-20060608-C00163
    Figure US20060122243A1-20060608-C00164
    58
    Figure US20060122243A1-20060608-C00165
    Figure US20060122243A1-20060608-C00166
    59
    Figure US20060122243A1-20060608-C00167
    Figure US20060122243A1-20060608-C00168
    60
    Figure US20060122243A1-20060608-C00169
    Figure US20060122243A1-20060608-C00170
    61
    Figure US20060122243A1-20060608-C00171
    Figure US20060122243A1-20060608-C00172
    62
    Figure US20060122243A1-20060608-C00173
    Figure US20060122243A1-20060608-C00174
    63
    Figure US20060122243A1-20060608-C00175
    Figure US20060122243A1-20060608-C00176
    64
    Figure US20060122243A1-20060608-C00177
    Figure US20060122243A1-20060608-C00178
    65
    Figure US20060122243A1-20060608-C00179
    Figure US20060122243A1-20060608-C00180
    66
    Figure US20060122243A1-20060608-C00181
    Figure US20060122243A1-20060608-C00182
    67
    Figure US20060122243A1-20060608-C00183
    Figure US20060122243A1-20060608-C00184
    68
    Figure US20060122243A1-20060608-C00185
    Figure US20060122243A1-20060608-C00186
    69
    Figure US20060122243A1-20060608-C00187
    Figure US20060122243A1-20060608-C00188
    70
    Figure US20060122243A1-20060608-C00189
    Figure US20060122243A1-20060608-C00190
    71
    Figure US20060122243A1-20060608-C00191
    Figure US20060122243A1-20060608-C00192
    72
    Figure US20060122243A1-20060608-C00193
    Figure US20060122243A1-20060608-C00194
    73
    Figure US20060122243A1-20060608-C00195
    Figure US20060122243A1-20060608-C00196
    74
    Figure US20060122243A1-20060608-C00197
    Figure US20060122243A1-20060608-C00198
    75
    Figure US20060122243A1-20060608-C00199
    Figure US20060122243A1-20060608-C00200
    76
    Figure US20060122243A1-20060608-C00201
    Figure US20060122243A1-20060608-C00202
    77
    Figure US20060122243A1-20060608-C00203
    Figure US20060122243A1-20060608-C00204
    78
    Figure US20060122243A1-20060608-C00205
    Figure US20060122243A1-20060608-C00206
    79
    Figure US20060122243A1-20060608-C00207
    Figure US20060122243A1-20060608-C00208
    80
    Figure US20060122243A1-20060608-C00209
    Figure US20060122243A1-20060608-C00210
    81
    Figure US20060122243A1-20060608-C00211
    Figure US20060122243A1-20060608-C00212
    82
    Figure US20060122243A1-20060608-C00213
    Figure US20060122243A1-20060608-C00214
    83
    Figure US20060122243A1-20060608-C00215
    Figure US20060122243A1-20060608-C00216
    84
    Figure US20060122243A1-20060608-C00217
    Figure US20060122243A1-20060608-C00218
    85
    Figure US20060122243A1-20060608-C00219
    Figure US20060122243A1-20060608-C00220
    86
    Figure US20060122243A1-20060608-C00221
    Figure US20060122243A1-20060608-C00222
    87
    Figure US20060122243A1-20060608-C00223
    Figure US20060122243A1-20060608-C00224
    88
    Figure US20060122243A1-20060608-C00225
    Figure US20060122243A1-20060608-C00226
    89
    Figure US20060122243A1-20060608-C00227
    Figure US20060122243A1-20060608-C00228
    90
    Figure US20060122243A1-20060608-C00229
    Figure US20060122243A1-20060608-C00230
    91
    Figure US20060122243A1-20060608-C00231
    Figure US20060122243A1-20060608-C00232
    92
    Figure US20060122243A1-20060608-C00233
    Figure US20060122243A1-20060608-C00234
    93
    Figure US20060122243A1-20060608-C00235
    Figure US20060122243A1-20060608-C00236
    94
    Figure US20060122243A1-20060608-C00237
    Figure US20060122243A1-20060608-C00238
    95
    Figure US20060122243A1-20060608-C00239
    Figure US20060122243A1-20060608-C00240
    96
    Figure US20060122243A1-20060608-C00241
    Figure US20060122243A1-20060608-C00242
    97
    Figure US20060122243A1-20060608-C00243
    Figure US20060122243A1-20060608-C00244
    98
    Figure US20060122243A1-20060608-C00245
    Figure US20060122243A1-20060608-C00246
    99
    Figure US20060122243A1-20060608-C00247
    Figure US20060122243A1-20060608-C00248
    100
    Figure US20060122243A1-20060608-C00249
    Figure US20060122243A1-20060608-C00250
    101
    Figure US20060122243A1-20060608-C00251
    Figure US20060122243A1-20060608-C00252
    102
    Figure US20060122243A1-20060608-C00253
    Figure US20060122243A1-20060608-C00254
    103
    Figure US20060122243A1-20060608-C00255
    Figure US20060122243A1-20060608-C00256
    104
    Figure US20060122243A1-20060608-C00257
    Figure US20060122243A1-20060608-C00258
    105
    Figure US20060122243A1-20060608-C00259
    Figure US20060122243A1-20060608-C00260
    106
    Figure US20060122243A1-20060608-C00261
    Figure US20060122243A1-20060608-C00262
    107
    Figure US20060122243A1-20060608-C00263
    Figure US20060122243A1-20060608-C00264
    108
    Figure US20060122243A1-20060608-C00265
    Figure US20060122243A1-20060608-C00266
    109
    Figure US20060122243A1-20060608-C00267
    Figure US20060122243A1-20060608-C00268
    110
    Figure US20060122243A1-20060608-C00269
    Figure US20060122243A1-20060608-C00270
    111
    Figure US20060122243A1-20060608-C00271
    Figure US20060122243A1-20060608-C00272
    112
    Figure US20060122243A1-20060608-C00273
    Figure US20060122243A1-20060608-C00274
    113
    Figure US20060122243A1-20060608-C00275
    Figure US20060122243A1-20060608-C00276
    114
    Figure US20060122243A1-20060608-C00277
    Figure US20060122243A1-20060608-C00278
    115
    Figure US20060122243A1-20060608-C00279
    Figure US20060122243A1-20060608-C00280
    116
    Figure US20060122243A1-20060608-C00281
    Figure US20060122243A1-20060608-C00282
    117
    Figure US20060122243A1-20060608-C00283
    Figure US20060122243A1-20060608-C00284
    118
    Figure US20060122243A1-20060608-C00285
    Figure US20060122243A1-20060608-C00286
    119
    Figure US20060122243A1-20060608-C00287
    Figure US20060122243A1-20060608-C00288
    120
    Figure US20060122243A1-20060608-C00289
    Figure US20060122243A1-20060608-C00290
    121
    Figure US20060122243A1-20060608-C00291
    Figure US20060122243A1-20060608-C00292
    122
    Figure US20060122243A1-20060608-C00293
    Figure US20060122243A1-20060608-C00294
    123
    Figure US20060122243A1-20060608-C00295
    Figure US20060122243A1-20060608-C00296
    124
    Figure US20060122243A1-20060608-C00297
    Figure US20060122243A1-20060608-C00298
    125
    Figure US20060122243A1-20060608-C00299
    Figure US20060122243A1-20060608-C00300
    126
    Figure US20060122243A1-20060608-C00301
    Figure US20060122243A1-20060608-C00302
    127
    Figure US20060122243A1-20060608-C00303
    Figure US20060122243A1-20060608-C00304
    128
    Figure US20060122243A1-20060608-C00305
    Figure US20060122243A1-20060608-C00306
    129
    Figure US20060122243A1-20060608-C00307
    Figure US20060122243A1-20060608-C00308
    130
    Figure US20060122243A1-20060608-C00309
    Figure US20060122243A1-20060608-C00310
    131
    Figure US20060122243A1-20060608-C00311
    Figure US20060122243A1-20060608-C00312
    132
    Figure US20060122243A1-20060608-C00313
    Figure US20060122243A1-20060608-C00314
    133
    Figure US20060122243A1-20060608-C00315
    Figure US20060122243A1-20060608-C00316
    134
    Figure US20060122243A1-20060608-C00317
    Figure US20060122243A1-20060608-C00318
    135
    Figure US20060122243A1-20060608-C00319
    Figure US20060122243A1-20060608-C00320
    136
    Figure US20060122243A1-20060608-C00321
    Figure US20060122243A1-20060608-C00322
    137
    Figure US20060122243A1-20060608-C00323
    Figure US20060122243A1-20060608-C00324
    138
    Figure US20060122243A1-20060608-C00325
    Figure US20060122243A1-20060608-C00326
    139
    Figure US20060122243A1-20060608-C00327
    Figure US20060122243A1-20060608-C00328
    140
    Figure US20060122243A1-20060608-C00329
    Figure US20060122243A1-20060608-C00330
    141
    Figure US20060122243A1-20060608-C00331
    Figure US20060122243A1-20060608-C00332
    142
    Figure US20060122243A1-20060608-C00333
    Figure US20060122243A1-20060608-C00334
    143
    Figure US20060122243A1-20060608-C00335
    Figure US20060122243A1-20060608-C00336
    144
    Figure US20060122243A1-20060608-C00337
    Figure US20060122243A1-20060608-C00338
    145
    Figure US20060122243A1-20060608-C00339
    Figure US20060122243A1-20060608-C00340
    146
    Figure US20060122243A1-20060608-C00341
    Figure US20060122243A1-20060608-C00342
    147
    Figure US20060122243A1-20060608-C00343
    Figure US20060122243A1-20060608-C00344
    148
    Figure US20060122243A1-20060608-C00345
    Figure US20060122243A1-20060608-C00346
    149
    Figure US20060122243A1-20060608-C00347
    Figure US20060122243A1-20060608-C00348
    150
    Figure US20060122243A1-20060608-C00349
    Figure US20060122243A1-20060608-C00350
    151
    Figure US20060122243A1-20060608-C00351
    Figure US20060122243A1-20060608-C00352
    152
    Figure US20060122243A1-20060608-C00353
    Figure US20060122243A1-20060608-C00354
    153
    Figure US20060122243A1-20060608-C00355
    Figure US20060122243A1-20060608-C00356
    154
    Figure US20060122243A1-20060608-C00357
    Figure US20060122243A1-20060608-C00358
    155
    Figure US20060122243A1-20060608-C00359
    Figure US20060122243A1-20060608-C00360
    156
    Figure US20060122243A1-20060608-C00361
    Figure US20060122243A1-20060608-C00362
    157
    Figure US20060122243A1-20060608-C00363
    Figure US20060122243A1-20060608-C00364
    158
    Figure US20060122243A1-20060608-C00365
    Figure US20060122243A1-20060608-C00366
    159
    Figure US20060122243A1-20060608-C00367
    Figure US20060122243A1-20060608-C00368
    160
    Figure US20060122243A1-20060608-C00369
    Figure US20060122243A1-20060608-C00370
    161
    Figure US20060122243A1-20060608-C00371
    Figure US20060122243A1-20060608-C00372
    162
    Figure US20060122243A1-20060608-C00373
    Figure US20060122243A1-20060608-C00374
    163
    Figure US20060122243A1-20060608-C00375
    Figure US20060122243A1-20060608-C00376
    164
    Figure US20060122243A1-20060608-C00377
    Figure US20060122243A1-20060608-C00378
    165
    Figure US20060122243A1-20060608-C00379
    Figure US20060122243A1-20060608-C00380
    166
    Figure US20060122243A1-20060608-C00381
    Figure US20060122243A1-20060608-C00382
    167
    Figure US20060122243A1-20060608-C00383
    Figure US20060122243A1-20060608-C00384
    168
    Figure US20060122243A1-20060608-C00385
    Figure US20060122243A1-20060608-C00386
    169
    Figure US20060122243A1-20060608-C00387
    Figure US20060122243A1-20060608-C00388
    170
    Figure US20060122243A1-20060608-C00389
    Figure US20060122243A1-20060608-C00390
    171
    Figure US20060122243A1-20060608-C00391
    Figure US20060122243A1-20060608-C00392
    172
    Figure US20060122243A1-20060608-C00393
    Figure US20060122243A1-20060608-C00394
    173
    Figure US20060122243A1-20060608-C00395
    Figure US20060122243A1-20060608-C00396
    174
    Figure US20060122243A1-20060608-C00397
    Figure US20060122243A1-20060608-C00398
    175
    Figure US20060122243A1-20060608-C00399
    Figure US20060122243A1-20060608-C00400
    176
    Figure US20060122243A1-20060608-C00401
    Figure US20060122243A1-20060608-C00402
    177
    Figure US20060122243A1-20060608-C00403
    Figure US20060122243A1-20060608-C00404
    178
    Figure US20060122243A1-20060608-C00405
    Figure US20060122243A1-20060608-C00406
    179
    Figure US20060122243A1-20060608-C00407
    Figure US20060122243A1-20060608-C00408
    180
    Figure US20060122243A1-20060608-C00409
    Figure US20060122243A1-20060608-C00410
    181
    Figure US20060122243A1-20060608-C00411
    Figure US20060122243A1-20060608-C00412
    182
    Figure US20060122243A1-20060608-C00413
    Figure US20060122243A1-20060608-C00414
    183
    Figure US20060122243A1-20060608-C00415
    Figure US20060122243A1-20060608-C00416
    184
    Figure US20060122243A1-20060608-C00417
    Figure US20060122243A1-20060608-C00418
    185
    Figure US20060122243A1-20060608-C00419
    Figure US20060122243A1-20060608-C00420
    186
    Figure US20060122243A1-20060608-C00421
    Figure US20060122243A1-20060608-C00422
    187
    Figure US20060122243A1-20060608-C00423
    Figure US20060122243A1-20060608-C00424
    188
    Figure US20060122243A1-20060608-C00425
    Figure US20060122243A1-20060608-C00426
    189
    Figure US20060122243A1-20060608-C00427
    Figure US20060122243A1-20060608-C00428
    190
    Figure US20060122243A1-20060608-C00429
    Figure US20060122243A1-20060608-C00430
    191
    Figure US20060122243A1-20060608-C00431
    Figure US20060122243A1-20060608-C00432
    192
    Figure US20060122243A1-20060608-C00433
    Figure US20060122243A1-20060608-C00434
    193
    Figure US20060122243A1-20060608-C00435
    Figure US20060122243A1-20060608-C00436
    194
    Figure US20060122243A1-20060608-C00437
    Figure US20060122243A1-20060608-C00438
    195
    Figure US20060122243A1-20060608-C00439
    Figure US20060122243A1-20060608-C00440
    196
    Figure US20060122243A1-20060608-C00441
    Figure US20060122243A1-20060608-C00442
    197
    Figure US20060122243A1-20060608-C00443
    Figure US20060122243A1-20060608-C00444
    198
    Figure US20060122243A1-20060608-C00445
    Figure US20060122243A1-20060608-C00446
    199
    Figure US20060122243A1-20060608-C00447
    Figure US20060122243A1-20060608-C00448
    200
    Figure US20060122243A1-20060608-C00449
    Figure US20060122243A1-20060608-C00450
    201
    Figure US20060122243A1-20060608-C00451
    Figure US20060122243A1-20060608-C00452
    202
    Figure US20060122243A1-20060608-C00453
    Figure US20060122243A1-20060608-C00454
    203
    Figure US20060122243A1-20060608-C00455
    Figure US20060122243A1-20060608-C00456
    204
    Figure US20060122243A1-20060608-C00457
    Figure US20060122243A1-20060608-C00458
    205
    Figure US20060122243A1-20060608-C00459
    Figure US20060122243A1-20060608-C00460
    206
    Figure US20060122243A1-20060608-C00461
    Figure US20060122243A1-20060608-C00462
    207
    Figure US20060122243A1-20060608-C00463
    Figure US20060122243A1-20060608-C00464
    208
    Figure US20060122243A1-20060608-C00465
    Figure US20060122243A1-20060608-C00466
    209
    Figure US20060122243A1-20060608-C00467
    Figure US20060122243A1-20060608-C00468
    210
    Figure US20060122243A1-20060608-C00469
    Figure US20060122243A1-20060608-C00470
    211
    Figure US20060122243A1-20060608-C00471
    Figure US20060122243A1-20060608-C00472
    212
    Figure US20060122243A1-20060608-C00473
    Figure US20060122243A1-20060608-C00474
    213
    Figure US20060122243A1-20060608-C00475
    Figure US20060122243A1-20060608-C00476
    214
    Figure US20060122243A1-20060608-C00477
    Figure US20060122243A1-20060608-C00478
    215
    Figure US20060122243A1-20060608-C00479
    Figure US20060122243A1-20060608-C00480
    216
    Figure US20060122243A1-20060608-C00481
    Figure US20060122243A1-20060608-C00482
    217
    Figure US20060122243A1-20060608-C00483
    Figure US20060122243A1-20060608-C00484
    218
    Figure US20060122243A1-20060608-C00485
    Figure US20060122243A1-20060608-C00486
    219
    Figure US20060122243A1-20060608-C00487
    Figure US20060122243A1-20060608-C00488
    220
    Figure US20060122243A1-20060608-C00489
    Figure US20060122243A1-20060608-C00490
    221
    Figure US20060122243A1-20060608-C00491
    Figure US20060122243A1-20060608-C00492
    222
    Figure US20060122243A1-20060608-C00493
    Figure US20060122243A1-20060608-C00494
    223
    Figure US20060122243A1-20060608-C00495
    Figure US20060122243A1-20060608-C00496
    Figure US20060122243A1-20060608-C00497
         Compound Number
    Figure US20060122243A1-20060608-C00498
         		      X       E
    301
    Figure US20060122243A1-20060608-C00499
    Figure US20060122243A1-20060608-C00500
    Figure US20060122243A1-20060608-C00501
    302
    Figure US20060122243A1-20060608-C00502
    Figure US20060122243A1-20060608-C00503
    Figure US20060122243A1-20060608-C00504
    303
    Figure US20060122243A1-20060608-C00505
    Figure US20060122243A1-20060608-C00506
    Figure US20060122243A1-20060608-C00507
    304
    Figure US20060122243A1-20060608-C00508
    Figure US20060122243A1-20060608-C00509
    Figure US20060122243A1-20060608-C00510
    305
    Figure US20060122243A1-20060608-C00511
    Figure US20060122243A1-20060608-C00512
    Figure US20060122243A1-20060608-C00513
    306
    Figure US20060122243A1-20060608-C00514
    Figure US20060122243A1-20060608-C00515
    Figure US20060122243A1-20060608-C00516
    307
    Figure US20060122243A1-20060608-C00517
    Figure US20060122243A1-20060608-C00518
    Figure US20060122243A1-20060608-C00519
    308
    Figure US20060122243A1-20060608-C00520
    Figure US20060122243A1-20060608-C00521
    309
    Figure US20060122243A1-20060608-C00522
    Figure US20060122243A1-20060608-C00523
    Figure US20060122243A1-20060608-C00524
    310
    Figure US20060122243A1-20060608-C00525
    Figure US20060122243A1-20060608-C00526
    Figure US20060122243A1-20060608-C00527
    311
    Figure US20060122243A1-20060608-C00528
    Figure US20060122243A1-20060608-C00529
    312
    Figure US20060122243A1-20060608-C00530
    Figure US20060122243A1-20060608-C00531
    Figure US20060122243A1-20060608-C00532
    313
    Figure US20060122243A1-20060608-C00533
    Figure US20060122243A1-20060608-C00534
    Figure US20060122243A1-20060608-C00535
    314
    Figure US20060122243A1-20060608-C00536
    Figure US20060122243A1-20060608-C00537
    Figure US20060122243A1-20060608-C00538
    315
    Figure US20060122243A1-20060608-C00539
    Figure US20060122243A1-20060608-C00540
    Figure US20060122243A1-20060608-C00541
    316
    Figure US20060122243A1-20060608-C00542
    Figure US20060122243A1-20060608-C00543
    Figure US20060122243A1-20060608-C00544
    317
    Figure US20060122243A1-20060608-C00545
    Figure US20060122243A1-20060608-C00546
    Figure US20060122243A1-20060608-C00547
    318
    Figure US20060122243A1-20060608-C00548
    Figure US20060122243A1-20060608-C00549
    Figure US20060122243A1-20060608-C00550
    319
    Figure US20060122243A1-20060608-C00551
    Figure US20060122243A1-20060608-C00552
    Figure US20060122243A1-20060608-C00553
    320
    Figure US20060122243A1-20060608-C00554
    Figure US20060122243A1-20060608-C00555
    321
    Figure US20060122243A1-20060608-C00556
    Figure US20060122243A1-20060608-C00557
    Figure US20060122243A1-20060608-C00558
    Figure US20060122243A1-20060608-C00559
          Compound Number
    Figure US20060122243A1-20060608-C00560
         		      E
    322
    Figure US20060122243A1-20060608-C00561
    Figure US20060122243A1-20060608-C00562
    323
    Figure US20060122243A1-20060608-C00563
    Figure US20060122243A1-20060608-C00564
    324
    Figure US20060122243A1-20060608-C00565
    Figure US20060122243A1-20060608-C00566
    325
    Figure US20060122243A1-20060608-C00567
    Figure US20060122243A1-20060608-C00568
    326
    Figure US20060122243A1-20060608-C00569
    Figure US20060122243A1-20060608-C00570
    327
    Figure US20060122243A1-20060608-C00571
    Figure US20060122243A1-20060608-C00572
    328
    Figure US20060122243A1-20060608-C00573
    Figure US20060122243A1-20060608-C00574
    329
    Figure US20060122243A1-20060608-C00575
    Figure US20060122243A1-20060608-C00576
    330
    Figure US20060122243A1-20060608-C00577
    Figure US20060122243A1-20060608-C00578
    331
    Figure US20060122243A1-20060608-C00579
    Figure US20060122243A1-20060608-C00580
    332
    Figure US20060122243A1-20060608-C00581
    Figure US20060122243A1-20060608-C00582
    333
    Figure US20060122243A1-20060608-C00583
    Figure US20060122243A1-20060608-C00584
    334
    Figure US20060122243A1-20060608-C00585
    Figure US20060122243A1-20060608-C00586
    335
    Figure US20060122243A1-20060608-C00587
    Figure US20060122243A1-20060608-C00588
    336
    Figure US20060122243A1-20060608-C00589
    Figure US20060122243A1-20060608-C00590
    337
    Figure US20060122243A1-20060608-C00591
    Figure US20060122243A1-20060608-C00592
    338
    Figure US20060122243A1-20060608-C00593
    Figure US20060122243A1-20060608-C00594
    339
    Figure US20060122243A1-20060608-C00595
    Figure US20060122243A1-20060608-C00596
    340
    Figure US20060122243A1-20060608-C00597
    Figure US20060122243A1-20060608-C00598
    341
    Figure US20060122243A1-20060608-C00599
    Figure US20060122243A1-20060608-C00600
    342
    Figure US20060122243A1-20060608-C00601
    Figure US20060122243A1-20060608-C00602
    343
    Figure US20060122243A1-20060608-C00603
    Figure US20060122243A1-20060608-C00604
    344
    Figure US20060122243A1-20060608-C00605
    Figure US20060122243A1-20060608-C00606
    345
    Figure US20060122243A1-20060608-C00607
    Figure US20060122243A1-20060608-C00608
    346
    Figure US20060122243A1-20060608-C00609
    Figure US20060122243A1-20060608-C00610
    347
    Figure US20060122243A1-20060608-C00611
    Figure US20060122243A1-20060608-C00612
    348
    Figure US20060122243A1-20060608-C00613
    Figure US20060122243A1-20060608-C00614
    349
    Figure US20060122243A1-20060608-C00615
    Figure US20060122243A1-20060608-C00616
    350
    Figure US20060122243A1-20060608-C00617
    Figure US20060122243A1-20060608-C00618
    351
    Figure US20060122243A1-20060608-C00619
    Figure US20060122243A1-20060608-C00620
    352
    Figure US20060122243A1-20060608-C00621
    Figure US20060122243A1-20060608-C00622
    353
    Figure US20060122243A1-20060608-C00623
    Figure US20060122243A1-20060608-C00624
    354
    Figure US20060122243A1-20060608-C00625
    Figure US20060122243A1-20060608-C00626
    355
    Figure US20060122243A1-20060608-C00627
    Figure US20060122243A1-20060608-C00628
    356
    Figure US20060122243A1-20060608-C00629
    Figure US20060122243A1-20060608-C00630
    357
    Figure US20060122243A1-20060608-C00631
    Figure US20060122243A1-20060608-C00632
    358
    Figure US20060122243A1-20060608-C00633
    Figure US20060122243A1-20060608-C00634
    359
    Figure US20060122243A1-20060608-C00635
    Figure US20060122243A1-20060608-C00636
    360
    Figure US20060122243A1-20060608-C00637
    Figure US20060122243A1-20060608-C00638
    361
    Figure US20060122243A1-20060608-C00639
    Figure US20060122243A1-20060608-C00640
    362
    Figure US20060122243A1-20060608-C00641
    Figure US20060122243A1-20060608-C00642
    363
    Figure US20060122243A1-20060608-C00643
    Figure US20060122243A1-20060608-C00644
    364
    Figure US20060122243A1-20060608-C00645
    Figure US20060122243A1-20060608-C00646
    365
    Figure US20060122243A1-20060608-C00647
    Figure US20060122243A1-20060608-C00648
    366
    Figure US20060122243A1-20060608-C00649
    Figure US20060122243A1-20060608-C00650
    367
    Figure US20060122243A1-20060608-C00651
    Figure US20060122243A1-20060608-C00652
    368
    Figure US20060122243A1-20060608-C00653
    Figure US20060122243A1-20060608-C00654
    369
    Figure US20060122243A1-20060608-C00655
    Figure US20060122243A1-20060608-C00656
    370
    Figure US20060122243A1-20060608-C00657
    Figure US20060122243A1-20060608-C00658
    371
    Figure US20060122243A1-20060608-C00659
    Figure US20060122243A1-20060608-C00660
    372
    Figure US20060122243A1-20060608-C00661
    Figure US20060122243A1-20060608-C00662
    373
    Figure US20060122243A1-20060608-C00663
    Figure US20060122243A1-20060608-C00664
    374
    Figure US20060122243A1-20060608-C00665
    Figure US20060122243A1-20060608-C00666
    375
    Figure US20060122243A1-20060608-C00667
    Figure US20060122243A1-20060608-C00668
    376
    Figure US20060122243A1-20060608-C00669
    Figure US20060122243A1-20060608-C00670
    377
    Figure US20060122243A1-20060608-C00671
    Figure US20060122243A1-20060608-C00672
    378
    Figure US20060122243A1-20060608-C00673
    Figure US20060122243A1-20060608-C00674
    379
    Figure US20060122243A1-20060608-C00675
    Figure US20060122243A1-20060608-C00676
    380
    Figure US20060122243A1-20060608-C00677
    Figure US20060122243A1-20060608-C00678
    381
    Figure US20060122243A1-20060608-C00679
    Figure US20060122243A1-20060608-C00680
    382
    Figure US20060122243A1-20060608-C00681
    Figure US20060122243A1-20060608-C00682
    383
    Figure US20060122243A1-20060608-C00683
    Figure US20060122243A1-20060608-C00684
    384
    Figure US20060122243A1-20060608-C00685
    Figure US20060122243A1-20060608-C00686
    385
    Figure US20060122243A1-20060608-C00687
    Figure US20060122243A1-20060608-C00688
    386
    Figure US20060122243A1-20060608-C00689
    Figure US20060122243A1-20060608-C00690
    387
    Figure US20060122243A1-20060608-C00691
    Figure US20060122243A1-20060608-C00692
    388
    Figure US20060122243A1-20060608-C00693
    Figure US20060122243A1-20060608-C00694
    389
    Figure US20060122243A1-20060608-C00695
    Figure US20060122243A1-20060608-C00696
    390
    Figure US20060122243A1-20060608-C00697
    Figure US20060122243A1-20060608-C00698
    391
    Figure US20060122243A1-20060608-C00699
    Figure US20060122243A1-20060608-C00700
    392
    Figure US20060122243A1-20060608-C00701
    Figure US20060122243A1-20060608-C00702
    393
    Figure US20060122243A1-20060608-C00703
    Figure US20060122243A1-20060608-C00704
    394
    Figure US20060122243A1-20060608-C00705
    Figure US20060122243A1-20060608-C00706
    395
    Figure US20060122243A1-20060608-C00707
    Figure US20060122243A1-20060608-C00708
    396
    Figure US20060122243A1-20060608-C00709
    Figure US20060122243A1-20060608-C00710
    397
    Figure US20060122243A1-20060608-C00711
    Figure US20060122243A1-20060608-C00712
    398
    Figure US20060122243A1-20060608-C00713
    Figure US20060122243A1-20060608-C00714
    399
    Figure US20060122243A1-20060608-C00715
    Figure US20060122243A1-20060608-C00716
    400
    Figure US20060122243A1-20060608-C00717
    Figure US20060122243A1-20060608-C00718
    401
    Figure US20060122243A1-20060608-C00719
    Figure US20060122243A1-20060608-C00720
    402
    Figure US20060122243A1-20060608-C00721
    Figure US20060122243A1-20060608-C00722
    403
    Figure US20060122243A1-20060608-C00723
    Figure US20060122243A1-20060608-C00724
    404
    Figure US20060122243A1-20060608-C00725
    Figure US20060122243A1-20060608-C00726
    405
    Figure US20060122243A1-20060608-C00727
    Figure US20060122243A1-20060608-C00728
    406
    Figure US20060122243A1-20060608-C00729
    Figure US20060122243A1-20060608-C00730
    407
    Figure US20060122243A1-20060608-C00731
    Figure US20060122243A1-20060608-C00732
    408
    Figure US20060122243A1-20060608-C00733
    Figure US20060122243A1-20060608-C00734
    409
    Figure US20060122243A1-20060608-C00735
    Figure US20060122243A1-20060608-C00736
    410
    Figure US20060122243A1-20060608-C00737
    Figure US20060122243A1-20060608-C00738
    411
    Figure US20060122243A1-20060608-C00739
    Figure US20060122243A1-20060608-C00740
    412
    Figure US20060122243A1-20060608-C00741
    Figure US20060122243A1-20060608-C00742
    413
    Figure US20060122243A1-20060608-C00743
    Figure US20060122243A1-20060608-C00744
    414
    Figure US20060122243A1-20060608-C00745
    Figure US20060122243A1-20060608-C00746
    415
    Figure US20060122243A1-20060608-C00747
    Figure US20060122243A1-20060608-C00748
    416
    Figure US20060122243A1-20060608-C00749
    Figure US20060122243A1-20060608-C00750
    417
    Figure US20060122243A1-20060608-C00751
    Figure US20060122243A1-20060608-C00752
    418
    Figure US20060122243A1-20060608-C00753
    Figure US20060122243A1-20060608-C00754
    419
    Figure US20060122243A1-20060608-C00755
    Figure US20060122243A1-20060608-C00756
    420
    Figure US20060122243A1-20060608-C00757
    Figure US20060122243A1-20060608-C00758
    421
    Figure US20060122243A1-20060608-C00759
    Figure US20060122243A1-20060608-C00760
    422
    Figure US20060122243A1-20060608-C00761
    Figure US20060122243A1-20060608-C00762
    423
    Figure US20060122243A1-20060608-C00763
    Figure US20060122243A1-20060608-C00764
    424
    Figure US20060122243A1-20060608-C00765
    Figure US20060122243A1-20060608-C00766
    425
    Figure US20060122243A1-20060608-C00767
    Figure US20060122243A1-20060608-C00768
    426
    Figure US20060122243A1-20060608-C00769
    Figure US20060122243A1-20060608-C00770
    427
    Figure US20060122243A1-20060608-C00771
    Figure US20060122243A1-20060608-C00772
    428
    Figure US20060122243A1-20060608-C00773
    Figure US20060122243A1-20060608-C00774
    429
    Figure US20060122243A1-20060608-C00775
    Figure US20060122243A1-20060608-C00776
    430
    Figure US20060122243A1-20060608-C00777
    Figure US20060122243A1-20060608-C00778
    431
    Figure US20060122243A1-20060608-C00779
    Figure US20060122243A1-20060608-C00780
    432
    Figure US20060122243A1-20060608-C00781
    Figure US20060122243A1-20060608-C00782
    434
    Figure US20060122243A1-20060608-C00783
    Figure US20060122243A1-20060608-C00784
    434
    Figure US20060122243A1-20060608-C00785
    Figure US20060122243A1-20060608-C00786
    435
    Figure US20060122243A1-20060608-C00787
    Figure US20060122243A1-20060608-C00788
    436
    Figure US20060122243A1-20060608-C00789
    Figure US20060122243A1-20060608-C00790
    437
    Figure US20060122243A1-20060608-C00791
    Figure US20060122243A1-20060608-C00792
    438
    Figure US20060122243A1-20060608-C00793
    Figure US20060122243A1-20060608-C00794
    439
    Figure US20060122243A1-20060608-C00795
    Figure US20060122243A1-20060608-C00796
    440
    Figure US20060122243A1-20060608-C00797
    Figure US20060122243A1-20060608-C00798
    441
    Figure US20060122243A1-20060608-C00799
    Figure US20060122243A1-20060608-C00800
    442
    Figure US20060122243A1-20060608-C00801
    Figure US20060122243A1-20060608-C00802
    443
    Figure US20060122243A1-20060608-C00803
    Figure US20060122243A1-20060608-C00804
    444
    Figure US20060122243A1-20060608-C00805
    Figure US20060122243A1-20060608-C00806
    445
    Figure US20060122243A1-20060608-C00807
    Figure US20060122243A1-20060608-C00808
    446
    Figure US20060122243A1-20060608-C00809
    Figure US20060122243A1-20060608-C00810
    447
    Figure US20060122243A1-20060608-C00811
    Figure US20060122243A1-20060608-C00812
    448
    Figure US20060122243A1-20060608-C00813
    Figure US20060122243A1-20060608-C00814
    449
    Figure US20060122243A1-20060608-C00815
    Figure US20060122243A1-20060608-C00816
    450
    Figure US20060122243A1-20060608-C00817
    Figure US20060122243A1-20060608-C00818
    451
    Figure US20060122243A1-20060608-C00819
    Figure US20060122243A1-20060608-C00820
    452
    Figure US20060122243A1-20060608-C00821
    Figure US20060122243A1-20060608-C00822
    453
    Figure US20060122243A1-20060608-C00823
    Figure US20060122243A1-20060608-C00824
    454
    Figure US20060122243A1-20060608-C00825
    Figure US20060122243A1-20060608-C00826
    455
    Figure US20060122243A1-20060608-C00827
    Figure US20060122243A1-20060608-C00828
    456
    Figure US20060122243A1-20060608-C00829
    Figure US20060122243A1-20060608-C00830
    457
    Figure US20060122243A1-20060608-C00831
    Figure US20060122243A1-20060608-C00832
    458
    Figure US20060122243A1-20060608-C00833
    Figure US20060122243A1-20060608-C00834
    459
    Figure US20060122243A1-20060608-C00835
    Figure US20060122243A1-20060608-C00836
    460
    Figure US20060122243A1-20060608-C00837
    Figure US20060122243A1-20060608-C00838
    461
    Figure US20060122243A1-20060608-C00839
    Figure US20060122243A1-20060608-C00840
    462
    Figure US20060122243A1-20060608-C00841
    Figure US20060122243A1-20060608-C00842
    463
    Figure US20060122243A1-20060608-C00843
    Figure US20060122243A1-20060608-C00844
    464
    Figure US20060122243A1-20060608-C00845
    Figure US20060122243A1-20060608-C00846
    465
    Figure US20060122243A1-20060608-C00847
    Figure US20060122243A1-20060608-C00848
    466
    Figure US20060122243A1-20060608-C00849
    Figure US20060122243A1-20060608-C00850
    467
    Figure US20060122243A1-20060608-C00851
    Figure US20060122243A1-20060608-C00852
    468
    Figure US20060122243A1-20060608-C00853
    Figure US20060122243A1-20060608-C00854
    469
    Figure US20060122243A1-20060608-C00855
    Figure US20060122243A1-20060608-C00856
    470
    Figure US20060122243A1-20060608-C00857
    Figure US20060122243A1-20060608-C00858
    471
    Figure US20060122243A1-20060608-C00859
    Figure US20060122243A1-20060608-C00860
    472
    Figure US20060122243A1-20060608-C00861
    Figure US20060122243A1-20060608-C00862
    473
    Figure US20060122243A1-20060608-C00863
    Figure US20060122243A1-20060608-C00864
    474
    Figure US20060122243A1-20060608-C00865
    Figure US20060122243A1-20060608-C00866
    475
    Figure US20060122243A1-20060608-C00867
    Figure US20060122243A1-20060608-C00868
    476
    Figure US20060122243A1-20060608-C00869
    Figure US20060122243A1-20060608-C00870
    477
    Figure US20060122243A1-20060608-C00871
    Figure US20060122243A1-20060608-C00872
    478
    Figure US20060122243A1-20060608-C00873
    Figure US20060122243A1-20060608-C00874
    479
    Figure US20060122243A1-20060608-C00875
    Figure US20060122243A1-20060608-C00876
    480
    Figure US20060122243A1-20060608-C00877
    Figure US20060122243A1-20060608-C00878
    481
    Figure US20060122243A1-20060608-C00879
    Figure US20060122243A1-20060608-C00880
    482
    Figure US20060122243A1-20060608-C00881
    Figure US20060122243A1-20060608-C00882
    483
    Figure US20060122243A1-20060608-C00883
    Figure US20060122243A1-20060608-C00884
    484
    Figure US20060122243A1-20060608-C00885
    Figure US20060122243A1-20060608-C00886
    485
    Figure US20060122243A1-20060608-C00887
    Figure US20060122243A1-20060608-C00888
    486
    Figure US20060122243A1-20060608-C00889
    Figure US20060122243A1-20060608-C00890
    487
    Figure US20060122243A1-20060608-C00891
    Figure US20060122243A1-20060608-C00892
    488
    Figure US20060122243A1-20060608-C00893
    Figure US20060122243A1-20060608-C00894
    489
    Figure US20060122243A1-20060608-C00895
    Figure US20060122243A1-20060608-C00896
    490
    Figure US20060122243A1-20060608-C00897
    Figure US20060122243A1-20060608-C00898
    491
    Figure US20060122243A1-20060608-C00899
    Figure US20060122243A1-20060608-C00900
    492
    Figure US20060122243A1-20060608-C00901
    Figure US20060122243A1-20060608-C00902
    493
    Figure US20060122243A1-20060608-C00903
    Figure US20060122243A1-20060608-C00904
    494
    Figure US20060122243A1-20060608-C00905
    Figure US20060122243A1-20060608-C00906
    495
    Figure US20060122243A1-20060608-C00907
    Figure US20060122243A1-20060608-C00908
    496
    Figure US20060122243A1-20060608-C00909
    Figure US20060122243A1-20060608-C00910
    497
    Figure US20060122243A1-20060608-C00911
    Figure US20060122243A1-20060608-C00912
    498
    Figure US20060122243A1-20060608-C00913
    Figure US20060122243A1-20060608-C00914
    499
    Figure US20060122243A1-20060608-C00915
    Figure US20060122243A1-20060608-C00916
    500
    Figure US20060122243A1-20060608-C00917
    Figure US20060122243A1-20060608-C00918
    501
    Figure US20060122243A1-20060608-C00919
    Figure US20060122243A1-20060608-C00920
    502
    Figure US20060122243A1-20060608-C00921
    Figure US20060122243A1-20060608-C00922
    503
    Figure US20060122243A1-20060608-C00923
    Figure US20060122243A1-20060608-C00924
    504
    Figure US20060122243A1-20060608-C00925
    Figure US20060122243A1-20060608-C00926
    505
    Figure US20060122243A1-20060608-C00927
    Figure US20060122243A1-20060608-C00928
    506
    Figure US20060122243A1-20060608-C00929
    Figure US20060122243A1-20060608-C00930
    507
    Figure US20060122243A1-20060608-C00931
    Figure US20060122243A1-20060608-C00932
    508
    Figure US20060122243A1-20060608-C00933
    Figure US20060122243A1-20060608-C00934
    509
    Figure US20060122243A1-20060608-C00935
    Figure US20060122243A1-20060608-C00936
    510
    Figure US20060122243A1-20060608-C00937
    Figure US20060122243A1-20060608-C00938
    511
    Figure US20060122243A1-20060608-C00939
    Figure US20060122243A1-20060608-C00940
    512
    Figure US20060122243A1-20060608-C00941
    Figure US20060122243A1-20060608-C00942
    513
    Figure US20060122243A1-20060608-C00943
    Figure US20060122243A1-20060608-C00944
    514
    Figure US20060122243A1-20060608-C00945
    Figure US20060122243A1-20060608-C00946
    515
    Figure US20060122243A1-20060608-C00947
    Figure US20060122243A1-20060608-C00948
    516
    Figure US20060122243A1-20060608-C00949
    Figure US20060122243A1-20060608-C00950
    517
    Figure US20060122243A1-20060608-C00951
    Figure US20060122243A1-20060608-C00952
    518
    Figure US20060122243A1-20060608-C00953
    Figure US20060122243A1-20060608-C00954
    519
    Figure US20060122243A1-20060608-C00955
    Figure US20060122243A1-20060608-C00956
    520
    Figure US20060122243A1-20060608-C00957
    Figure US20060122243A1-20060608-C00958
    521
    Figure US20060122243A1-20060608-C00959
    Figure US20060122243A1-20060608-C00960
    522
    Figure US20060122243A1-20060608-C00961
    Figure US20060122243A1-20060608-C00962
    523
    Figure US20060122243A1-20060608-C00963
    Figure US20060122243A1-20060608-C00964
    524
    Figure US20060122243A1-20060608-C00965
    Figure US20060122243A1-20060608-C00966
    525
    Figure US20060122243A1-20060608-C00967
    Figure US20060122243A1-20060608-C00968
    526
    Figure US20060122243A1-20060608-C00969
    Figure US20060122243A1-20060608-C00970
    527
    Figure US20060122243A1-20060608-C00971
    Figure US20060122243A1-20060608-C00972
    528
    Figure US20060122243A1-20060608-C00973
    Figure US20060122243A1-20060608-C00974
    529
    Figure US20060122243A1-20060608-C00975
    Figure US20060122243A1-20060608-C00976
    530
    Figure US20060122243A1-20060608-C00977
    Figure US20060122243A1-20060608-C00978
    531
    Figure US20060122243A1-20060608-C00979
    Figure US20060122243A1-20060608-C00980
    532
    Figure US20060122243A1-20060608-C00981
    Figure US20060122243A1-20060608-C00982
    533
    Figure US20060122243A1-20060608-C00983
    Figure US20060122243A1-20060608-C00984
    534
    Figure US20060122243A1-20060608-C00985
    Figure US20060122243A1-20060608-C00986
    535
    Figure US20060122243A1-20060608-C00987
    Figure US20060122243A1-20060608-C00988
    536
    Figure US20060122243A1-20060608-C00989
    Figure US20060122243A1-20060608-C00990
    537
    Figure US20060122243A1-20060608-C00991
    Figure US20060122243A1-20060608-C00992
    538
    Figure US20060122243A1-20060608-C00993
    Figure US20060122243A1-20060608-C00994
    539
    Figure US20060122243A1-20060608-C00995
    Figure US20060122243A1-20060608-C00996
    540
    Figure US20060122243A1-20060608-C00997
    Figure US20060122243A1-20060608-C00998
    541
    Figure US20060122243A1-20060608-C00999
    Figure US20060122243A1-20060608-C01000
    542
    Figure US20060122243A1-20060608-C01001
    Figure US20060122243A1-20060608-C01002
    543
    Figure US20060122243A1-20060608-C01003
    Figure US20060122243A1-20060608-C01004
    544
    Figure US20060122243A1-20060608-C01005
    Figure US20060122243A1-20060608-C01006
    545
    Figure US20060122243A1-20060608-C01007
    Figure US20060122243A1-20060608-C01008
    546
    Figure US20060122243A1-20060608-C01009
    Figure US20060122243A1-20060608-C01010
    547
    Figure US20060122243A1-20060608-C01011
    Figure US20060122243A1-20060608-C01012
    548
    Figure US20060122243A1-20060608-C01013
    Figure US20060122243A1-20060608-C01014
    549
    Figure US20060122243A1-20060608-C01015
    Figure US20060122243A1-20060608-C01016
    550
    Figure US20060122243A1-20060608-C01017
    Figure US20060122243A1-20060608-C01018
    551
    Figure US20060122243A1-20060608-C01019
    Figure US20060122243A1-20060608-C01020
    552
    Figure US20060122243A1-20060608-C01021
    Figure US20060122243A1-20060608-C01022
    Figure US20060122243A1-20060608-C01023
         Compound Number
    Figure US20060122243A1-20060608-C01024
         		      X       E
    553
    Figure US20060122243A1-20060608-C01025
    Figure US20060122243A1-20060608-C01026
    Figure US20060122243A1-20060608-C01027
    554
    Figure US20060122243A1-20060608-C01028
    Figure US20060122243A1-20060608-C01029
    Figure US20060122243A1-20060608-C01030
    555
    Figure US20060122243A1-20060608-C01031
    Figure US20060122243A1-20060608-C01032
    Figure US20060122243A1-20060608-C01033
  • Methods for preparation of the compounds represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) are not particularly limited. Reference to methods described in the pamphlet of International Publication WO02/49632 is useful.
  • The compounds represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) can be prepared, for example, by methods shown bellow.
  • <Method 1>
  • The compounds represented by the general formula (I), wherein X is —CONH— (the hydrogen atom on the nitrogen may be substituted) and the compounds represented by the general formulas (I-1), (I-2), (I-3) and (I-4) can be prepared, for example, by a method described in the reaction scheme 1.
    Figure US20060122243A1-20060608-C01034
    wherein each of A, ring Z, and E has the same meaning as that defined in the general formula (I), A101 represents a hydrogen atom or protecting groups of hydroxy group (preferably, an alkyl group such as methyl group and the like; an aralkyl group such as benzyl group and the like; an acetyl group, an alkoxyalkyl group such as methoxymethyl group and the like; a substituted silyl group such as trimethylsilyl group or the like), each of R and R101 represents a hydrogen atom, a C1 to C6 alkyl group or the like, E101 represents E or precursor of E in the definition of the general formula (I), G represents a hydroxy group, halogen atoms (preferably, a chlorine atom), a hydrocarbon-oxy group (preferably, an aryl-oxy group which may be substituted by halogen atom), an acyl-oxy group, an imido-oxy group or the like.
    (First Step)
  • The amide (3) can be prepared by dehydrocondensation of the carboxylic acid derivative (1) and the amine (2). This reaction is carried out at a reaction temperature of from 0° C. to 180° C., without solvent or in an aprotic solvent, in the presence of an acid halogenating agent or a dehydrocondensing agent, and in the presence or absence of a base.
  • As the halogenating agent, examples include, for example, thionyl chloride, thionyl bromide, sulfuryl chloride, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride or the like. When A101 is hydrogen atom, phosphorus trichloride is preferable, and when A101 is acetyl group or the like, phosphorus oxychloride is preferable. As the dehydrocondensing agent, examples include, for example, N,N′-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, diphenylphosphorylazide or the like. As the base, examples include inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic bases such as pyridine, triethylamine, N,N′-diethylaniline or the like. As the aprotic solvent, examples include dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 1,4-dioxane, benzene, toluene, monochlorobenzene, o-dichlorobenzene, N,N′-dimethylformamide, N-methylpyrrolidone or the like, when the reaction is carried out in the presence of the acid halogenating agent, particularly, toluene, monochlorobenzene, o-dichlorobenzene are preferable.
  • A target compound can also be prepared, for example, by a method or similar method described in Journal of Medicinal Chemistry, (USA), 1998, Vol. 41, No. 16, p. 2939-2945, in which the acid chloride is prepared and isolated beforehand from carboxylic acid, then the result is made to react with an amine having E101.
  • When G is hydroxy group, the reaction condition described in Archiv der Pharmazie, (Germany), 1998, Vol. 331, No. 1, p. 3-6 can be used as a preferred reaction condition.
  • Kinds of carboxylic acid derivative (1) and amine (2) are not particularly limited, and new compounds synthesized by referring to well-known preparation method described in the literature or commercially available reagents can be used for the aforementioned reaction.
  • (Second Step)
  • When the amide (3) has a protecting group and/or has a favorable substituent for functional group modification, for example, an amino group and a protected amino group or its precursor; a carboxy group and a protected carboxy group or its precursor; a hydroxy group and a protected hydroxy group or its precursor, the final target compound (4) can be prepared by a reaction for deprotection and/or functional group modification in this step. Various well-known methods can be used for the reaction. For the reaction of deprotection and functional group modification, for example, methods described in “Protective Groups in Organic Syntheses”, (USA), Theodra W. Green, Peter G. M. Wuts, Eds., Third edition, April in 1999, John Wiley & Sons, and “Handbook of Reagents for Organic Synthesis”, (USA), 4 Volumes, June in 1999, John Wiley & Sons can be used, and for the reaction of functional group modification, for example, methods described in “Palladium Reagents in Organic Syntheses”, (USA), Richard F. Heck, 1985, Academic Press, and “Palladium Reagents and Catalysts: Innovations in Organic Synthesis”, (USA), J. Tsuji, 1999, John Wiley & Sons, or the like can be used.
  • The aforementioned methods are applicable by appropriately combining raw materials even for the compounds wherein X is other connecting group, for example, —SO2NH—, —NHCO—, —NHSO2—, —CONHCH2—, —CONHCH2CH2—, —CONHCH2CONH—, —CONHNHCO—, —CONHNHCH2—, —COO—, —CONHNH—; wherein the hydrogen atom on said connecting group may be substituted.
  • In the general formula (I), when X is the formula: —CONHCH2— wherein the hydrogen atom on said connecting group may be substituted, the target compound can be prepared by using an amine represented by the formula: H2N—CH2-E101, wherein E101 has the same meaning as that defined above, instead of the amine (2).
  • In the general formula (I), when X is the formula: —CONHCH2CH2— wherein the hydrogen atom on said connecting group may be substituted, the target compound can be prepared by using an amine represented by the formula: H2N—CH2 CH2-E101, wherein E101 has the same meaning as that defined above, instead of the amine (2).
  • In the general formula (I), when X is the formula: —SO2NH—, the target compound can be prepared by using a sulfonyl chloride represented by the formula: A101-O-(ring Z)-SO2Cl, wherein each of A101 and ring Z has the same meaning as that defined above, instead of the carboxylic acid derivative (1).
  • In the general formula (I), when X is the formula: —NHCO—, the target compound can be prepared by using an amine represented by the formula: A101-O-(ring Z)-NH2, wherein each of A101 and ring Z has the same meaning as that defined above, and a carboxylic acid represented by the formula: E101-COOH, wherein -E101 has the same meaning as that defined above, or a carboxylic acid chloride represented by the formula: E101-COCl, wherein -E101 has the same meaning as that defined above.
  • In the general formula (I), when X is the formula: —NHSO2—, wherein said connecting group may be substituted, the target compound can be prepared by using an amine represented by the formula: HO-(ring Z)-NH2, wherein ring Z has the same meaning as that defined above, and a sulfonyl chloride represented by the formula: E101-SO2Cl, wherein E101 has the same meaning as that defined above.
  • In the general formula (I), when X is the formula: —CONHNHCO—, the target compound can be prepared by using a hydrazide represented by the formula: HO-(ring Z)-CONHNH2, wherein ring Z has the same meaning as that defined above, and a carboxylic acid chloride represented by the formula: E101-COCl, wherein -E101 has the same meaning as that defined above.
  • In the general formula (I), when X is the formula: —COO—, the target compound can be prepared by using a phenol derivative represented by the formula: HO-E101, wherein -E101 has the same meaning as that defined above, instead of the amine (2).
  • In the general formula (I), when X is the formula: —CONHNH—, the target compound can be prepared by using a hydrazine represented by the formula: H2N—NH-E101 , wherein E101 has the same meaning as that defined above, instead of the amine (2).
  • In the general formula (I), when X is the formula: —CONHCH2CONH—, the target compound can be prepared by using an amine represented by the formula: H2N—CH2CONH-E101, wherein E101 has the same meaning as that defined above, instead of the amine (2).
  • The amine represented by the formula: H2N—CH2CONH-E101, can be prepared, for example, by condensation of the amine (2) and a N-protected amino acid (for example, N-(tert-butoxycarbonyl)glycine), according to the aforementioned method 1, followed by a deprotection reaction.
  • In the general formula (I), when X is the following formula:
    Figure US20060122243A1-20060608-C01035
    wherein said connecting group may be substituted, the target compound can be prepared by using an amine represented by the following formula:
    Figure US20060122243A1-20060608-C01036
    wherein ring Z has the same meaning as that defined above, and a carboxylic acid represented by the formula: E101-COOH, wherein E101 has the same meaning as that defined above, or a carboxylic acid chloride represented by the formula: E101-COCl, wherein E101 has the same meaning as that defined above.
  • The amine represented by the following formula:
    Figure US20060122243A1-20060608-C01037
    can be prepared, for example, by a method described in the reaction scheme 1-2.
    Figure US20060122243A1-20060608-C01038
    wherein ring Z has the same meaning as that defined above.
  • The bromoacetophenone (20) can be prepared by bromination of the acetophenone (19).
  • This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in a solvent, in the presence of a brominating agent.
  • As the brominating agent, for example, phenyltrimethylammonium tribromide can preferably be used.
  • As the reaction solvent, any solvent can be used as long as it does not inhibit the reaction, for example, ethers such as tetrahydrofuran can be used.
  • The amine (21) can be prepared by reacting the bromoacetophenone (20) with thiourea.
  • This reaction is carried out at a reaction temperature of from 0° C. to 120° C. in a solvent.
  • As the reaction solvent, any solvent can be used as long as it does not inhibit the reaction, for example, alcohols such as ethanol can be used.
  • <Method 2>
  • The compounds represented by the general formula (I), wherein X is —CH2NH— can be prepared, for example, by a method described in the reaction scheme 2.
    Figure US20060122243A1-20060608-C01039
    wherein each of A, ring Z, and E has the same meaning as that defined in the general formula (I).
  • The imine derivative of the formula (7) can be prepared by dehydrocondensation of the aldehyde (5) and the amine (6). This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in a solvent, in the presence or absence of a dehydrating agent. As the dehydrating agent, examples include anhydrous magnesium sulfate, molecular sieves or the like. As the solvent, examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable.
  • The aforementioned methods are applicable by appropriately combining raw materials even for the compounds wherein X is other connecting group, for example, —CONHN═CH—, —CH═NNHCO—, —CHNNH—; wherein the hydrogen atom on said connecting group may be substituted.
  • In the general formula (I), when X is the formula: —CONHN═CH—, the target compound can be prepared by using a hydrazide represented by the formula: HO-(ring Z)-CONHNH2, wherein ring Z has the same meaning as that defined above, and an aldehyde represented by the formula: E-CHO, wherein E has the same meaning as that defined above.
  • In the general formula (I), when X is the formula: —CH═NNHCO—, the target compound can be prepared by using an aldehyde represented by the formula: HO-(ring Z)-CHO, wherein ring Z has the same meaning as that defined above, and a hydrazide represented by the formula: E-CONHNH2, wherein E has the same meaning as that defined above.
  • In the general formula (I), when X is the formula: —CH═NNH—, the target compound can be prepared by using an aldehyde represented by the formula: HO-(ring Z)-CHO, wherein ring Z has the same meaning as that defined above, and a hydrazine represented by the formula: E-NHNH2, wherein E has the same meaning as that defined above.
  • The target compound (8) can be prepared by reduction of the imine derivative (7). This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in a solvent, in the presence of a reducing agent. As the reducing agent, examples include sodium borohydride, lithium borohydride or the like. As the solvent, examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable. This reaction can also be carried out by a method of catalytic hydrogenation. As the catalyst, examples include palladium carbon, platinum carbon, palladium hydroxide, palladium black or the like. As solvent, examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable. The reaction is carried out at a reaction temperature of from 0° C. to 200° C., and the hydrogen pressure may be an ordinary pressure or a positive pressure.
  • <Method 3>
  • The compounds represented by the general formula (I), wherein X is —CH═CH— (the hydrogen atom on said connecting group may be substituted), can be prepared, for example, by methods described in the reaction scheme 3-1 or the reaction scheme 3-2.
    Figure US20060122243A1-20060608-C01040
    wherein each of ring Z and E has the same meaning as that defined in the general formula (I), W301 represents O,O′-di-hydrocarbon-phosphono group or triarylphosphonium group
  • The target compound (11) can be prepared by dehydrocondensation of the aldehyde (9-1) and the phosphorus compound (10-1). This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence of a base. As the base, examples include inorganic base such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic base such as pyridine, triethylamine, N,N-diethylaniline or the like. As the solvent, examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water or the like are preferable.
    Figure US20060122243A1-20060608-C01041
    wherein each of ring Z and E has the same meaning as that defined in the general formula (I), W302 represents halogen atoms (preferably, iodine atom and bromine atom), (trifluoromethanesulfonyl)oxy group and the like.
  • The target compound (11) can be prepared by reacting the halogenated compound (9-2) with the styrene compound (10-2) in the presence of a transition-metal complex catalyst. This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence or absence of a ligand and/or a base. As the transition-metal complex catalyst, examples include palladium catalyst such as palladium acetate and dichlorobis(triphenylphosphine)palladium. As the ligand, examples include phosphine ligand such as triphenylphosphine. As the base, examples include inorganic base such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate, or organic base such as pyridine, triethylamine, and N,N-diethylaniline. As the solvent, examples include inert solvents, and N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane or the like are preferable.
  • <Method 4>
  • The compounds represented by the general formula (I), wherein X is —COCH═CH— and —COCH2CH2— (the hydrogen atom on said connecting group may be substituted), can be prepared, for example, by a method described in the reaction scheme 4.
    Figure US20060122243A1-20060608-C01042
    wherein each of rings Z and E has the same meaning as that defined in the general formula (I).
  • The target compound enone (14) can be prepared by dehydrocondensation of the ketone (12) and the aldehyde (13). This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence of a base. As the base, examples include inorganic base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic base such as pyridine, triethylamine, N,N-diethylaniline or the like. Examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water or the like are preferable.
  • Next, the target compound (15) can be prepared by reduction of the enone (14). This reaction is carried out at a reaction temperature of from 0° C. to 100° C. in solvent, in the presence of a reducing agent. As the reducing agent, examples include sodium borohydride, lithium borohydride or the like. As the solvent, examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable. Moreover, this reaction is carried out by a method of catalytic hydrogenation also. As the catalyst, examples include palladium carbon, platinum carbon, palladium hydroxide, palladium black or the like. As solvent, examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol or the like are preferable. The reaction is carried out at a reaction temperature of from 0° C. to 200° C., and the hydrogen pressure is at normal pressure or applied pressure.
  • <Method 5>
  • The compounds represented by the general formula (I), wherein X is —NHCONH— (the hydrogen atom on said connecting group may be substituted), can be prepared, for example, by a method described in the reaction scheme 5.
    Figure US20060122243A1-20060608-C01043
    wherein each of ring Z and E has the same meaning as that defined in the general formula (I).
  • First, the target compound urea (18) can be prepared by reacting the amine (16) with the isocyanate (17). This reaction is carried out in a solvent at a reaction temperature of from 0° C. to the boiling point of the solvent, in the presence or absence of a base. As the base, examples include inorganic base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the like, or organic base such as pyridine, triethylamine, N,N-diethylaniline or the like. Examples include inert solvent, and tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water or the like are preferable.
  • <Method 6>
  • The compounds represented by the general formula (I), wherein X is the formula: —CONHNHCH2— (the hydrogen atom on said connecting group may be substituted), can be prepared, for example, by a method described in the reaction scheme 6.
    Figure US20060122243A1-20060608-C01044
    wherein each of ring Z and E has the same meaning as that defined above, and V represents a leaving group such as halogen atom.
  • The target compound hydrazide (24) can be prepared by reacting the hydrazide (22) with the benzyl derivative (23).
  • This reaction is carried out at a reaction temperature of from 0° C. to 180° C. in a solvent, in the presence or absence of a base.
  • As the base, for example, organic base such as pyridine, triethylamine or the like can preferably be used.
  • As the reaction solvent, any solvent can be used as long as it does not inhibit the reaction, for example, halogenated solvent such as dichloromethane; ethers such as tetrahydrofuran; and hydrocarbon solvent such as toluene can be used.
  • <Method 7>
  • The compounds represented by the general formula (I), wherein X is the formula:
    Figure US20060122243A1-20060608-C01045
    can be prepared, for example, by a method described in the reaction scheme 7.
    Figure US20060122243A1-20060608-C01046
    wherein each of ring Z and E has the same meaning as that defined above.
  • The target compound 5-(benzylidene)-3-benzylthiazolidin-2,4-dione derivative (26) can be prepared by reacting the aldehyde (9-1) with the 3-benzylthiazolidin-2,4-dione derivative (25).
  • This reaction is carried out at a reaction temperature of from 0° C. to 180° C. in a solvent, in the presence of a catalyst. As the catalyst, for example, a mixture of piperidine/acetic acid can preferably be used. As the reaction solvent, any solvent can be used as long as it does not inhibit the reaction, for example, hydrocarbon solvent such as toluene can be used.
  • The 3-benzylthiazolidine-2,4-dione derivative represented by the following formula:
    Figure US20060122243A1-20060608-C01047
    wherein E has the same meaning as that defined above, can be prepared, for example, by a method described in the reaction scheme 7-1.
    Figure US20060122243A1-20060608-C01048
    wherein each of E and V has the same meaning as that defined above.
  • The target compound 3-benzylthiazolidine-2,4-dione derivative (28) can be prepared by reacting thiazolidine-2,4-dione (30) with the benzyl derivative (23).
  • This reaction is carried out at a reaction temperature of from 0° C. to 180° C. in a solvent, in the presence of a base. As the base, for example, inorganic base such as sodium hydroxide, potassium carbonate or the like, or organic base such as pyridine, triethylamine or the like can preferably be used.
  • As the reaction solvent, any solvent can be used as long as it does not inhibit the reaction, for example, water; alcohols such as ethanol or the like; halogenated solvent such as dichloromethane or the like; ethers such as tetrahydrofuran or the like; or amides such as N,N-dimethylformamide or the like can be used.
  • The compounds represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) prepared by the aforementioned methods can be isolated and purified by methods widely known by those skilled in the art, for example, extraction, precipitation, fractional chromatography, fractional crystallization, suspension and washing, and recrystallization. Furthermore, each of the pharmaceutically acceptable salt of the compound of the present invention, the hydrate thereof and the solvate thereof can be prepared by methods widely known by those skilled in the art.
  • In the examples of the specification, preparation methods of typical compounds included in the general formulas (I), (I-1), (I-2), (I-3) and (I-4) are explained in details. Therefore, those skilled in the art can prepare any compound fall within the general formulas (I), (I-1), (I-2), (I-3) and (I-4) by referring to the explanations of the aforementioned general preparation methods and those of specific preparation methods of the examples, by choosing appropriate reaction raw materials, reaction reagents, and reaction conditions, and by adding appropriate modification and alteration of these methods, if necessary.
  • The compounds represented by the general formulas (I), (I-1), (I-2), (I-3), and (I-4) have antiallergic action, and accordingly, they are useful as active ingredients of the medicaments for the preventive and/or therapeutic treatment of allergic diseases. The aforementioned medicaments have inhibitory activity against the proliferation of mast cells, inhibitory activity against the production of IgE from activated B cells, and inhibitory activity against the degranulation from activated mast cells. Therefore, they can be suitably used as a suppressant against allergic reaction expression. More specifically, the medicaments of the present invention are useful for the preventive and/or therapeutic treatment of the following diseases wherein allergic reaction is believed to be involved, for example, allergic diseases such as contact dermatitis, atopic dermatitis, eczema, pruritus, pollinosis, asthma, bronchitis, urticaria, vasculitis, rhinitis, gastrointestinal symptoms, diarrhea, interstitial pneumonia, arthritis, ophthalmia, conjunctivitis, neuritis, otitis media, granulomatosis, encephalomyelitis, cystitis, laryngitis, peliosis, food allergy, insect allergy, drug allergy, metal allergy, anaphylactic shock and the like, and/or endometriosis and/or hysteromyoma.
  • Furthermore, in endometriosis, it is known that an adhesion of the uterus with its peripheral tissue frequently occurs due to an abnormal proliferation of endometrial tissue outside the uterus. It is known that this is caused by an inflammatory reaction by allergy and the like, and a phenomenon called as “remodeling” including fibrosis and hyperplasia of tissue as typical examples occurs (Frontiers in Bioscience, (USA), 2002, Vol. 7, the April 1 issue, p.e 91-115). As for the fibrosis of tissue, it is widely known that one of the causes is a production of a large amount of collagen, which is triggered by infiltration of effecter cells and activation of proliferation of fibroblast by inflammation. This remodeling phenomenon is considered to be occurred on the basis of a mechanism common in the remodeling of cardiac muscle after myocardial infarction, the remodeling of a vessel by arteriosclerosis, the remodeling of bronchus by bronchial asthma or the like, as well as in the adhesion of a tissue in endometriosis. Accordingly, an inhibitor against the proliferation or activation of a fibroblast is considered to be useful as a therapeutic drug not only for endometriosis but for diseases in which fibrosis or remodeling of a tissue is believed to be involved, for example, myocardial infarction, arteriosclerosis, asthma, nephritis, interstitial pneumonia, pulmonary fibrosis, hepatic cirrhosis and the like.
  • The compounds of the present invention was found to inhibit cell proliferation of HT-1080, which is a fibrosarcoma cell having properties similar to those of fibroblast and collagen productivity, under proliferative stimulation by PDGF (platelet-derived growth factor). Therefore, they are considered to be useful as a therapeutic drug and/or a preventive drug for diseases in which fibrosis or remodeling of tissue is involved.
  • As the active ingredient of the medicament on the present invention, one or more kinds of substances selected from the group consisting of the compound represented by the general formulas (I), (I-1), (I-2), (I-3) and (I-4) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof may be used. The aforementioned substance, per se, may be administered as the medicament of the present invention, however, preferably, the medicament of the present invention is provided in the form of a pharmaceutical composition comprising the aforementioned substance which is an active ingredient together with one or more pharmacologically acceptable pharmaceutical additives. In the aforementioned pharmaceutical compositions, a ratio of the active ingredient to the pharmaceutical additives is 1 weight % to 90 weight %.
  • The pharmaceutical compositions of the present invention may be administered as pharmaceutical compositions for oral administration, for example, granules, subtilized granules, powders, hard capsules, soft capsules, syrup, emulsion, suspension, or solution, or may be administered as pharmaceutical compositions for parenteral administration, for example, injections for intravenous administration, intramuscular administration, or subcutaneous administration, drip infusions, suppositories, percutaneous absorbent, transmucosal absorption preparations, nasal drops, ear drops, instillation, and inhalants. Preparations made as pharmaceutical compositions in a form of powder may be dissolved when necessary and used as injections or drip infusions.
  • For preparation of pharmaceutical compositions, solid or liquid pharmaceutical additives may be used. Pharmaceutical additives may either be organic or inorganic. When an oral solid preparation is prepared, an excipient is added to the active ingredient, and further binders, disintegrator, lubricant, colorant, corrigent are added, if necessary, to manufacture preparations in the forms of tablets, coating tablets, granules, powders, capsules and the like by ordinary procedures. Examples of the excipient include lactose, sucrose, saccharose, glucose, corn starch, starch, talc, sorbit, crystal cellulose, dextrin, kaolin, calcium carbonate, and silicon dioxide. Examples of the binder include, for example, polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, gum Arabic, tragacanth, gelatine, shellac, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, calcium citrate, dextrin, and pectin. Examples of the lubricant include, for example, magnesium stearate, talc, polyethylene glycol, silica, and hydrogenated vegetable oil. As the coloring agent, any material can be used which are approved to be added to ordinary pharmaceuticals. As the corrigent, cocoa powder, menthol, aromatic acid, peppermint oil, d-borneol, cinnamon powder and the like can be used. These tables and granules may be applied with sugarcoating, gelatin coating, or an appropriate coating, if necessary. Preservatives, antioxidant and the like may be added, if required.
  • For liquid preparations for oral administration such as emulsions, syrups, suspensions, and solutions, ordinary used inactive diluents, for example, water or vegetable oil may be used. For these preparations, besides inactive diluents, adjuvants such as wetting agents, suspending aids, sweating agents, flavoring agents, coloring agents or preservatives may be blended. After a liquid preparation is manufactured, the preparation may be filled in capsules made of a absorbable substance such as gelatin. Examples of solvents or suspending agents used for the preparations of parenteral administration such as injections or suppositories include, for example, water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, and lecithin. Examples of base materials used for preparation of suppositories include, for example, cacao butter, emulsified cacao butter, lauric fat, and witepsol. Methods for preparation of the aforementioned preparations are not limited, and any method ordinarily used in the art may be used.
  • When the composition are prepared in the form of injections, carriers such as, for example, diluents including water, ethanol, macrogol, propylene glycol, citric acid, acetic acid, phosphoric acid, lactic acid, sodium lactate, sulfuric acid and sodium hydroxide, pH modifiers and buffer solutions including sodium citrate, sodium acetate and sodium phosphate, stabilizers such as sodium pyrosulfite, ethylenediaminetetraacetic acid, thioglycolic acid and thiolactate may be used. For the preparation, a sufficient amount of a salt, glucose, mannitol or glycerin may be blended in the preparation to manufacture an isotonic solution, and an ordinary solubilizer, a soothing agent, or a topical anesthetic may be used.
  • When the preparation in the form of an ointment such as a paste, a cream, and a gel is manufactured, an ordinarily used base material, a stabilizer, a wetting agent, and a preservative may be blended, if necessary, and may be prepared by mixing the components by a common method. As the base material, for example, white petrolatum, polyethylene, paraffin, glycerin, cellulose derivatives, polyethylene glycol, silicon, and bentonite may be used. As the preservative, paraoxy methyl benzoate, paraoxy ethyl benzoate, paraoxy propyl benzoate and the like may be used. When the preparation in the form of a patch is manufactured, the aforementioned ointment, cream gel, or paste and the like may be applied by a common method to an ordinary support. As the support, fabric made of cotton, span rayon, and synthetic fibersor or nonwoven fabric, and a film or a foam sheet such as made of soft vinyl chloride, polyethylene, and polyurethane and the like may be preferably used.
  • A dose of the medicament of the present invention is not particularly limited. For oral administration, a dose may generally be 0.01 to 5,000 mg per day for an adult as the weight of the compound of the present invention. It is preferred to increase or decrease the above dose appropriately depending on the age, pathological conditions, and symptoms of a patient. The above dose may be administered once a day or 2 to 3 times a day as divided portions with appropriate intervals, or intermittent administration for every several days may be applied. When the medicament is used as an injection, the dose may be 0.001 to 100 mg per day for an adult as the weight of the compound of the present invention.
    • EXAMPLES
  • The present invention will be explained more specifically with reference to the following examples. However the scope of the present invention is not limited to the following examples. The compound number in the following examples correspond to those in the table shown above. And the commercially available compounds, which were purchased and used for the examinations, are contained in these examples. As for such compounds, the suppliers of the reagents and the catalog code numbers are shown.
    • Example 1 Preparation of the Compound of Compound No. 1
  • Under argon atmosphere, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (it is abbreviated as WSC.HCl hereafter.; 192 mg, 1 mmol) was added to a mixture of 5-bromosalicylic acid (217 mg, 1 mmol), 3,5-bis(trifluoromethyl)benzylamine (243 mg, 1 mmol), 4-dimethylaminopyridine (12 mg, 0.1 mmol) and tetrahydrofuran (10 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title compound (244.8 mg, 55.4%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 4.69(2H, d, J=5.7 Hz), 6.93(1H, d, J=8.7 Hz), 7.56(1H, dd, J=8.7, 2.4 Hz), 8.02(1H, d, J=2.4 Hz), 8.06(3H, s), 9.41(1H, t, J=5.7 Hz), 12.13(1H, s).
    • Example 2 Preparation of the Compound of Compound No. 2 (1) 2-Acetoxy-N-(2-phenethyl)benzamide
  • O-Acetylsalicyloyl chloride (0.20 g, 1.00 mmol) was dissolved in benzene (8 mL). Phenethylamine (0.12 g, 1.00 mmol) and pyridine (0.3 mL) were added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=2:1→1:1) to give the title compound (155.5 mg, 54.9%) as a white crystal.
  • 1H-NMR(CDCl3): δ 2.09(3H, s), 2.92(2H, t, J=6.8 Hz), 3.71(2H, q, J=6.8 Hz), 6.32(1H, brs),7.07(1H, dd, J=8.4, 1.2 Hz), 7.23-7.35(6H, m), 7.44(1H, ddd, J=8.0, 7.6, 1.6 Hz), 7.73(1H, dd, J=7.6, 1.6 Hz).
  • When the preparation method described in Example 2(1) is referred in the following examples, organic bases such as pyridine, triethylamine or the like were used as the base. As the reaction solvent, solvents such as dichloromethane, tetrahydrofuran, benzene or the like were used alone or as a mixture.
    • (2) 2-Hydroxy-N-(2-phenethyl)benzamide
  • Methanol (5 mL) and 2N sodium hydroxide (0.1 mL) were added to 2-acetoxy-N-(2-phenethyl)benzamide (155.5 mg), and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was crystallized (dichloromethane/hexane) to give the title compound (106.9 mg, 80.7%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.86(2H, t, J=7.6 Hz), 3.52(1H, q, J=7.6 Hz),6.84-6.88(2H, m), 7.18-7.31(5H, m), 7.37(1H, ddd, J=8.4, 7.2, 1.6 Hz), 7.80(1H, dd, J=8.4, 1.6 Hz), 8.84(1H, s), 12.51(1H, s).
  • When the method described in Example 2(2) is referred in the following examples, inorganic bases such as sodium hydroxide, potassium carbonate or the like were used as the base. As the reaction solvent, solvents such as water, methanol, ethanol, tetrahydrofuran or the like were used alone or as a mixture.
    • (3) 5-Bromo-2-hydroxy-N-(2-phenethyl)benzamide (Compound No. 2)
  • Carbon tetrachloride (5 mL), iron powder (0.03 g) and bromine (25 μl, 0.48 mmol) were added to 2-hydroxy-N-(2-phenethyl)benzamide (79.6 mg, 0.33 mmol), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into aqueous sodium hydrogen sulfite and extracted with ethyl acetate. After the organic layer was washed with brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the title compound (62 mg, 58.7%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 2.85(2H, t, J=7.6 Hz), 3.52(1H, q, J=7.6 Hz),6.87(1H, d, J=8.8 Hz), 7.18-7.31(5H, m), 7.52(1H, dd, J=8.8, 2.4 Hz), 8.01(1H, d, J=2.4 Hz), 8.90(1H, s), 12.51(1H, s).
    • Example 3 Preparation of the Compound of Compound No. 3
  • WSC.HCl (96 mg, 0.5 mmol) was added to a solution of 5-bromosalicylic acid (109 mg, 0.5 mmol), 2-amino-5-(morpholino)carbonylindane (141 mg, 0.5 mmol) and triethylamine (70 μL, 0.5 mmol) in dichloromethane (5 mL), and the mixture was stirred at 40° C. for 1.5 hours. After cooling, the reaction mixture was diluted with ethyl acetate, washed successively with 2N hydrochloric acid, water, and brine, dried over anhydrous magnesium sulfate, concentrated, and the residue was purified by column chromatography on silica gel(dichloromethane:methanol=19:1) to give the title compound (26 mg, 11.9%) as a white crystal.
  • 1H-NMR(CDCl3): δ 2.66(1H, dd, J=16.2, 7.2 Hz), 2.82(1H, dd, J=16.2, 7.2 Hz), 3.16-3.25(2H, m), 3.43-3.86(8H, m), 4.79-4.92(1H, m), 6.88(1H, d, J=8.7 Hz), 7.14-7.15(3H, m), 7.46(1H, dd, J=8.7, 2.4 Hz), 7.74(1H, d, J=7.8 Hz), 7.84(1H, d, J=2.4 Hz).
  • [2-Amino-5-(morpholino)carbonylindane: Refer to “Chemical and Pharmaceutical Bulletin”, 2000, Vol. 48, p. 131.]
    • Example 4 The Compound of Compound No. 4
  • This compound is a commercially available compound.
    • Supplier: Apin Chemicals.
    • Catalog code number: N 0100D.
    Example 5 The Compound of Compound No. 5
  • This compound is a commercially available compound.
    • Supplier: Specs.
    • Catalog code number: AI-233/31581024.
    Example 6 The Compound of Compound No. 6
  • This compound is a commercially available compound.
    • Supplier: Maybridge.
    • Catalog code number: RJC 00106.
    Example 7 The Compound of Compound No. 7
  • This compound is a commercially available compound.
    • Supplier: Maybridge.
    • Catalog code number: BTB 13230.
    Example 8 The Compound of Compound No. 8
  • This compound is a commercially available compound.
    • Supplier: Maybridge.
    • Catalog code number: BTB 114482.
    Example 9 Preparation of the Compound of Compound No. 9
  • 5-Chlorosalicylaldehyde (313 mg, 2 mmol) and 4-chlorobenzyltriphenylphosphonium chloride (847 mg, 2 mmol) were dissolved in N,N-dimethylfomamide (20 mL). Potassium carbonate (1.382 g, 10 mmol) dissolved in water (10 mL) was added, and the mixture was refluxed for 5 hours. After cooling, the reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (44.6 mg, 8.4%) as a light gray solid.
  • 1H-NMR(CDCl3): δ 5.04(1H, s), 6.74(1H, d, J=9.0 Hz), 7.05(1H, d, J=16.5 Hz), 7.10(1H, dd, J=8.4, 2.4 Hz), 7.26(1H, d, J=16.5 Hz), 7.33(2H, d, J=8.4 Hz), 7.45(2H, d, J=8.4 Hz), 7.49(1H, d, J=2.4 Hz).
    • Example 10 Preparation of the Compound of Compound No. 10 (1) 5-Bromo-N-(3,5-dichlorophenyl)-2-methoxybenzenesulfonamide
  • 5-Bromo-2-methoxybenzenesulfonyl chloride (857 mg, 3 mmol) was dissolved in dichloromethane (6 mL). A solution of 3,5-dichloroaniline (510 mg, 3.15 mmol) and pyridine (261 mg, 3.3 mmol) in dichloromethane (2 mL) was added dropwise under ice cooling and argon atmosphere, and the mixture was stirred at room temperature for 6 hours. After the reaction mixture was diluted with dichloromethane, washed successively with 2N hydrochloric acid, water, and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was crystallized from n-hexane-ethyl acetate to give 5-bromo-2-methoxy-N-(3,5-dichloro)benzenesulfonamide (900 mg, 73.0%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 4.03(3H, s), 6.92(1H, d, J=9.0 Hz), 7.01(2H, d, J=1.8 Hz), 7.07-7.08(1H, m), 7.24(1H, brs), 7.63(1H, dd, J=8.7, 2.4 Hz), 7.99(1H, d, J=2.4 Hz).
    • (2) 5-Bromo-N-(3,5-dichlorophenyl)-2-hydroxybenzenesulfonamide (Compound No. 10)
  • A mixture of the white crystal of 5-Bromo-N-(3,5-dichlorophenyl)-2-methoxybenzenesulfonamide (206 mg, 0.5 mmol), lithium iodide (134 mg, 1 mmol) and 2,4,6-collidine (5 mL) was refluxed for 30 minutes under argon atmosphere. After cooling to room temperature, the reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was crystallized from n-hexane-ethyl acetate to give the title compound (90 mg, 45.3%) as a white crystal.
  • mp 158-159° C.
  • 1H-NMR(DMSO-d6): δ 6.92(1H, d, J=8.7 Hz), 7.11(2H, d, J=2.1 Hz), 7.21-7.22(1H, m), 7.62(1H, dd, J=8.7, 2.7 Hz), 7.80(1H, d, J=2.4 Hz), 10.70(1H, br), 11.37(1H, br).
    • Example 11 Preparation of the Compound of Compound No. 11
  • 2-Aminophenol (120 mg, 1.1 mmol) was dissolved in dichloromethane (5 mL). A solution of 3,5-bis(trifluoromethyl)benzoyl chloride (300 mg, 1.1 mmol) in dichloromethane (3 mL) and pyridine (0.5 mL) was added dropwise under ice cooling and argon atmosphere, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was dissolved in ethanol (5 mL). 2N Sodium hydroxide (0.1 mL, 0.2 mmol) was added dropwise, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title compound (288 mg, 73.6%) as a light pink crystal.
  • mp 183° C. (dec.).
  • 1H-NMR(DMSO-d6): δ 6.83(1H, td, J=8.0, 1.2 Hz), 6.93(1H, dd, J=8.0, 1.2 Hz), 7.08(1H, td, J=8.0, 1.6 Hz), 7.50(1H, d, J=8.0 Hz), 8.35(2H, s), 9.61(1H, s), 10.15(1H, s).
    • Example 12 Preparation of the Compound of Compound No. 12
  • 2-Amino-4-chlorophenol (316 mg, 2.2 mmol) and triethylamine (243 mg, 2.4 mmol) were dissolved in dichloromethane (8 mL). A solution of 3,5-dichlorobenzoyl chloride (419 mg, 2 mmol) in dichloromethane (2 mL) was added dropwise under ice cooling and argon atmosphere, and the mixture was stirred at room temperature for 15 hours. After the reaction mixture was diluted with ethyl acetate, washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give a light brown solid. The solid was suspended and washed with n-hexane-ethyl acetate under heating at reflux to give the title compound (205 mg, 32.4%) as a white crystal.
  • mp 251-252° C.
  • 1H-NMR(DMSO-d6): δ 6.93(1H, d, J=9.0 Hz), 7.11(1H, dd, J=8.7, 2.7 Hz), 7.67(2H, d, J=2.7 Hz), 7.86-7.87(1H, m), 7.97(1H, d, J=1.8 Hz), 9.85(1H, s), 10.03(1H, s).
    • Example 13 Preparation of the Compound of Compound No. 13
  • 2-Amino-4-chlorophenol (287 mg, 2 mmol) and 3,5-dichlorobenzenesulfonyl chloride (540 mg, 2.2 mmol) were dissolved in dichloromethane (4 mL). Pyridine (1mL) was added dropwise under ice cooling and argon atmosphere, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1→1:1) to give a reddish brown solid. The solid was crystallized from n-hexane-ethyl acetate to give the title compound (445 mg, 63.1%) as a slight dark brown crystal.
  • mp 190-191° C.
  • 1H-NMR(DMSO-d6): δ 6.68(1H, d, J=9.0 Hz), 7.08(1H, dd, J=8.7, 2.7 Hz), 7.17(1H, d, J=2.4 Hz), 7.70(2H, d, J=1.8 Hz), 7.95-7.96(1H, m), 10.00(1H, s), 10.06(1H, s).
    • Example 14 Preparation of the Compound of Compound No. 14 (1) 4-Bromo-2-[(3,5-diphenylimino)methyl]phenyl
  • A mixture of 5-bromosalicylaldehyde (1.01 g, 5 mmol), 3,5-dichloroaniline (810 mg, 5 mmol) and ethanol (25 mL) was refluxed for 1 hour under argon atmosphere. After the reaction mixture was cooled to room temperature, the separated crystal was filtered to give the title compound (1.52 g, 88.2%) as an orange crystal.
  • mp 161-163° C.
  • 1H-NMR(CDCl3): δ 6.94(1H, d, J=9.0 Hz), 7.16(2H, d, J=1.8 Hz), 7.30-7.31(1H, m), 7.47-7.53(2H, m), 8.51(1H, s).
    • (2) N-[(5-Bromo-2-hydroxyphenyl)methyl]-3,5-dichloroaniline (Compound No. 14)
  • 4-Bromo-2-[(3,5-diphenylimino)methyl]phenol (1.04 g, 3 mmol) was dissolved in tetrahydrofuran (12 mL) and ethanol (6 mL). Sodium borohydride (113 mg, 3 mmol) was added under ice cooling and argon atmosphere, and the mixture was stirred at room temperature for 12 hours. Acetone (10 mL) was added to the reaction mixture. Water was added to the residue obtained by concentration under reduced pressure, and it was extracted with dichloromethane. After the dichloromethane layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give a light yellow viscous material. This was crystallized by n-hexane to give the title compound (971 mg, 93.3%) as a white crystal.
  • mp 125-126° C.
  • 1H-NMR(CDCl3): δ 4.31(2H, s), 6.64(2H, d, J=1.8 Hz), 6.74-6.77(1H, m), 6.84-6.85(1H, m), 7.30-7.34(2H, m).
    • Example 15 The Compound of Compound No. 15
  • This compound is a commercially available compound.
    • Supplier: Sigma-Aldrich.
    • Catalog code number: S3203-5.
    Example 16 Preparation of the Compound of Compound No. 16
  • A mixture of 5-chlorosalicylic acid (173 mg, 1 mmol), 3,5-bis(trifluoromethyl)-N-methylaniline (243 mg, 1 mmol), phosphorus trichloride (44 μl, 0.5 mmol) and monochlorobenzene (5 mL) was refluxed for 3 hours under argon atmosphere. After the reaction mixture was cooled to room temperature, n-hexane (50 mL) was added, and the separated crude crystal was filtered and dissolved in ethyl acetate (50 mL). After the ethyl acetate solution was washed successively with water and brine, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the title compound (75 mg, 18.9%) as a white crystal.
  • 1H-NMR(CDCl3): δ 3.57(3H, s), 6.59(1H, d, J=2.4 Hz), 6.94(1H, d, J=9.0 Hz), 7.21(1H, dd, J=9.0, 2.7 Hz), 7.58(2H, s), 7.80(1H, s), 10.00(1H, brs).
  • When the method described in Example 16 is referred in the following examples, phosphorus trichloride was used as the acid halogenating agent. As the reaction solvent, solvents such as monochlorobenzene, toluene or the like were used.
    • Example 17 Preparation of the Compound of Compound No. 17
  • Using 5-bromosalicylic acid and 7-trifluoromethyl-1,2,3,4-tetrahydroquinoline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 42.0%.
  • 1H-NMR(CDCl3): δ 2.08(2H, m), 2.92(2H, t, J=6.6 Hz), 3.95(2H, t, J=6.6 Hz), 6.91-6.94(2H, m), 7.14(1H, s), 7.32-7.35(2H, m), 7.40(1H, dd, J=8.7, 2.4 Hz), 10.06(1H, s).
    • Example 18 Preparation of the Compound of Compound No. 18
  • Using 2-hydroxynaphthalene-1-carboxylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 51.2%.
  • mp 246-248° C.
  • 1H-NMR(DMSO-d6): δ 7.26(1H, d, J=9.3 Hz), 7.31-7.37(2H, m), 7.44-7.50(1H, m), 7.65-7.68(1H, m), 7.85-7.90(4H, m), 10.23(1H, s), 10.74(1H, s).
    • Example 19 Preparation of the Compound of Compound No. 19
  • Using 3-hydroxynaphthalene-2-carboxylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.3%.
  • mp 254-255° C.
  • 1H-NMR(DMSO-d6): δ 7.34-7.39(3H, m), 7.49-7.54(1H, m), 7.76-7.79(1H, m), 7.89(2H, d, J=1.8 Hz), 7.92(1H, m), 8.39(1H, s), 10.75(1H, s), 11.01(1H, s).
    • Example 20 The Compound of Compound No. 20
  • This compound is a commercially available compound.
    • Supplier: Sigma-Aldrich.
    • Catalog code number: S01361-8.
    Example 21 Preparation of the Compound of Compound No. 21
  • Using 1-hydroxynaphthalene-2-carboxylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.5%.
  • 1H-NMR(DMSO-d6): δ 7.51(1H, d, J=9.0 Hz), 7.60(1H, td, J=7.8, 0.9 Hz), 7.70(1H, td, J=7.8, 0.9 Hz), 7.89(1H, s), 7.93(1H, d, J=8.4 Hz), 8.09(1H, d, J=9.0 Hz), 8.33(1H, d, J=8.7 Hz), 8.51(2H, s), 10.92(1H, s), 13.36(1H, s).
    • Example 22 The Compound of Compound No. 22
  • This compound is a commercially available compound.
    • Supplier: Sigma-Aldrich.
    • Catalog code number: S58026-0.
    Example 23 The Compound of Compound No. 23
  • This compound is a commercially available compound.
    • Supplier: Sigma-Aldrich.
    • Catalog code number: S63263-5.
    Example 24 Preparation of the Compound of Compound No. 24
  • 5-Chloro-2-hydroxynicotinic acid (174 mg, 1 mmol), 3,5-bis(trifluoromethyl)aniline (275 mg, 1.2 mmol) and pyridine (316 mg, 4 mmol) were dissolved in tetrahydrofuran (20 mL) and dichloromethane (10 mL). Phosphorus oxychloride (0.112 ml, 1.2 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into ethyl acetate (100 mL) and 0.2N hydrochloric acid (100 mL), filtered through celite after stirring for 30 minutes, and the water layer of the filtrate was extracted with ethyl acetate. After the combined ethyl acetate layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1→1:1) to give a light yellow solid. This was suspended and washed with ethanol under heating at reflux to give the title compound (183 mg, 47.6%) as a white crystal.
  • mp>270° C.
  • 1H-NMR(DMSO-d6): δ 7.83(1H, s), 8.15(1H, d, J=3.3 Hz), 8.36(1H, d, J=3.0 Hz), 8.40(2H, s), 12.43(1H, s).
  • When the preparation method described in Example 24 is referred in the following examples, phosphorus oxychloride was used as the acid halogenating agent. Pyridine was used as the base. As the reaction solvent, solvents such as dichloromethane, tetrahydrofuran or the like were used alone or as a mixture.
    • Example 25 Preparation of the Compound of Compound No. 25
  • Using 5-chloro-2-hydroxynicotinic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 42.9%.
  • 1H-NMR(DMSO-d6): δ 7.52(1H, dd, J=8.4, 2.1 Hz), 7.81(1H, d, J=8.4 Hz), 8.16(1H, s), 8.39(1H, d, J=2.7 Hz), 8.96(1H, d, J=2.1 Hz), 12.76(1H, s), 13.23(1H, s).
    • Example 26 Preparation of the Compound of Compound No. 26
  • Using 5-chloro-2-hydroxynicotinic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 59.1%.
  • 1H-NMR(DMSO-d6): δ 1.29(18H, s), 7.18(1H, t, J=1.8 Hz), 7.52(2H.d, J=1.8 Hz), 8.07(1H, d, J=2.4 Hz), 8.35(1H, d, J=3.3 Hz), 11.92(1H, s), 13.10(1H, s).
    • Example 27 Preparation of the Compound of Compound No. 27
  • Using 3-hydroxypyridine-2-carboxylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 45.0%.
  • 1H-NMR(CDCl3): δ 7.40(1H, dd, J=8.4, 1.8 Hz), 7.46(1H, dd, J=8.4, 4.2 Hz), 7.68(1H, s), 8.16(1H, dd, J=4.2, 1.2 Hz), 8.25(2H, s), 10.24(1H, s), 11.42(1H, s).
    • Example 28 Preparation of the Compound of Compound No. 28
  • Under argon atmosphere, 3,5-bis(trifluoromethyl)phenylisocyanate (255 mg, 1.0 mmol) was dissolved in tetrahydrofuran (5 mL). A solution of 6-chloro-oxindole (184 mg, 1.1 mmol) in tetrahydrofuran (5 ml) and triethylamine (0.3 mL) were added, and the mixture was stirred at room temperature for 4 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title compound (172.2 mg, 40.7%) as a pink solid.
  • 1H-NMR(DMSO-d6): δ 3.97(2H, s), 7.29(1H, dd, J=8.1, 2.1 Hz), 7.41(1H, d, J=8.1 Hz), 7.88(1H, s), 8.04(1H, d, J=2.1 Hz), 8.38(2H, s), 10.93(1H, s).
    • Example 29 Preparation of the Compound of Compound No. 29
  • Using 3-hydroxyquinoxaline-2-carboxylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 2.7%.
  • 1H-NMR(DMSO-d6): δ 7.40-7.45(2H, m), 7.69(1H, td, J=8.4, 1.5 Hz), 7.90-7.93(2H, m), 8.41(2H, s), 11.64(1H, s), 13.02(1H, s).
    • Example 30 The Compound of Compound No. 30
  • This compound is a commercially available compound.
    • Supplier: Sigma-Aldrich.
    • Catalog code number: S83846-2.
    Example 31 The Compound of Compound No. 31
  • This compound is a commercially available compound.
    • Supplier: Maybridge.
    • Catalog code number: RDR 01818.
    Example 32 Preparation of the Compound of Compound No. 32
  • Using 5-chlorosalicylic acid and 1-naphthylamine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.0%.
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=8.7 Hz), 7.51-7.61(4H, m), 7.85(1H, d, J=8.4 Hz), 7.96(1H, d, J=7.5 Hz), 7.99-8.05(2H, m), 8.13(1H, d, J=2.7 Hz), 10.88(1H, s), 12.31(1H, s).
    • Example 33 Preparation of the Compound of Compound No. 33
  • Using 5-chlorosalicylic acid and 4-methoxy-2-naphthylamine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 84.3%.
  • 1H-NMR(DMSO-d6): δ 3.99(3H, s), 7.05(1H, d, J=9.0 Hz), 7.30(1H, d, J=1.5 Hz), 7.39-7.45(1H, m), 7.48-7.54(2H, m), 7.83(1H, d, J=7.8 Hz), 8.00(1H, s), 8.02(1H, d, J=2.4 Hz), 8.09(1H, d, J=7.8 Hz), 10.54(1H, s), 11.88(1H, s).
    • Example 34 Preparation of the Compound of Compound No. 34 (1) 2-Acetoxy-5-chlorobenzoic acid
  • Concentrated sulfuric acid (0.08 mL) was added slowly to a mixture of 5-chlorosalicylic acid (13.35 g, 77 mmol) and acetic anhydride (20 mL). After the reaction mixture was solidified, it was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was washed with n-hexane under suspension to give the title compound (15.44 g, 93.0%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 2.25(3H, s), 7.27(1H, d, J=8.7 Hz), 7.72(1H, dd, J=8.7, 2.7 Hz), 7.89(1H, d, J=2.7 Hz), 13.47(1H, s).
    • (2) 2-Acetoxy-5-chloro-N-(1-methoxynaphthalen-3-yl)benzamide (Compound No. 34)
  • Using 2-acetoxy-5-chlorobenzoic acid and 4-methoxy-2-naphthylamine as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 39.9%, red solid.
  • 1H-NMR(DMSO-d6): δ 2.23(3H, s), 3.96(3H, s), 7.23(1H, d, J=1.2 Hz), 7.34(1H, d, J=8.7 Hz), 7.40(1H, dt, J=8.1, 1.2 Hz), 7.50(1H, dt, J=8.1, 1.5 Hz), 7.67(1H, dd, J=8.7, 2.7 Hz), 7.81(1H, d, J=8.7 Hz), 7.82(1H, d, J=3.0 Hz), 8.02(1H, s), 8.08(1H, d, J=8.7 Hz), 10.58(1H, s).
    • Example 35 Preparation of the Compound of Compound No. 35
  • Using 5-chlorosalicylic acid and 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 49.6%.
  • 1H-NMR(DMSO-d6): δ 1.32(3H, t, J=7.2 Hz), 1.74(4H, br), 2.63(2H, br), 2.75(2H, br), 4.30(2H, q, J=7.2 Hz), 7.05(1H, d, J=9.0 Hz), 7.50(1H, dd, J=8.7, 3.0 Hz), 7.92(1H, d, J=3.0 Hz), 12.23(1H, s), 13.07(1H, s).
    • Example 36 Preparation of the Compound of Compound No. 36
  • Using 5-bromosalicylic acid and 3-amino-5-phenylpyrazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 9.2%.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.8 Hz), 7.01(1H, s),7.35(1H, t, J=7.6 Hz), 7.46(2H, t, J=7.6 Hz), 7.58(1H, dd, J=8.8, 2.8 Hz), 7.74-7.76(2H, m), 8.19(1H, s), 10.86(1H, s), 12.09(1H, s), 13.00(1H, brs).
    • Example 37 Preparation of the Compound of Compound No. 37 (1) 2-Amino-4,5-diethyloxazole
  • Propioin (1.03 g, 8.87 mmol) was dissolved in ethanol (15 mL). Cyanamide (0.75 g, 17.7 mmol) and sodium ethoxide (1.21 g, 17.7 mmol) were added, and the mixture was stirred at room temperature for 3.5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(dichloromethane:methanol=9:1) to give the title compound (369.2 mg, 29.7%) as an yellow amorphous.
  • 1H-NMR(DMSO-d6): δ 1.04(3H, t, J=7.5 Hz), 1.06(3H, t, J=7.5 Hz), 2.20(2H, q, J=7.5 Hz), 2.43(2H, q, J=7.5 Hz), 6.15(2H, s).
    • (2) 2-Acetoxy-5-bromo-N-(4,5-diethyloxazol-2-yl)benzamide
  • Using 2-acetoxy-5-bromobenzoic acid and 2-amino-4,5-diethyloxazole as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 22.0%.
  • 1H-NMR(CDCl3): δ 1.22(3H, t, J=7.5 Hz), 1.23(3H, t, J=7.5 Hz), 2.38(3H, s), 2.48(2H, q, J=7.5 Hz), 2.57(2H, q, J=7.5 Hz), 6.96(1H, d, J=8.7 Hz), 7.58(1H, dd, J=8.7, 2.7 Hz), 8.32(1H, s), 11.40(1H, br).
  • [2-Acetoxy-5-bromosalicylic acid: It was obtained, using 5-bromosalicylic acid and acetic anhydride as the raw materials, by the same operation as the Example 34(1) with reference to “Europian Journal of Medicinal Chemistry”, 1996, Vol. 31, p. 861-874.]
    • (3) 5-Bromo-N-(4,5-diethyloxazol-2-yl)-2-hydroxybenzamide (Compound No. 37)
  • Using 2-acetoxy-5-bromo-N-(4,5-diethyloxazol-2-yl)benzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 70.2%.
  • 1H-NMR(CDCl3) δ :1.25(3H, t, J=7.5 Hz), 1.26(3H, t, J=7.5 Hz), 2.52(2H, q, J=7.5 Hz), 2.60(2H, q, J=7.5 Hz), 6.84(1H, d, J=8.7 Hz), 7.43(1H, dd, J=8.7, 3.0 Hz), 8.17(1H, d, J=3.0 Hz), 11.35(1H, br), 12.83(1H, br).
    • Example 38 Preparation of the Compound of Compound No. 38
  • Using 5-bromosalicylic acid and 2-amino-4,5-diphenyloxazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 32.6%.
  • mp 188-189° C.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.7 Hz), 7.40-7.49(6H, m), 7.53-7.56(2H, m), 7.59-7.63(3H, m), 8.01(1H, d, J=2.4 Hz), 11.80(2H, brs).
  • [2-Amino-4,5-diphenyloxazole: Refer to “Zhournal Organicheskoi Khimii: Russian Journal of Organic Chemistry”, (Russia), 1980, Vol. 16, p. 2185.]
    • Example 39 Preparation of the Compound of Compound No. 39 (1) 2-Amino-4,5-bis(furan-2-yl)oxazole
  • Furoin (0.50 g, 2.60 mmol) was dissolved in ethanol (15 mL). Cyanamide (218.8 mg, 5.20 mmol) and sodium ethoxide (530.8 mg, 7.80 mmol) were added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(hexane:ethyl acetate=1:1→1:2) to give the title compound (175.0 mg, 31.1%) as a dark brown crystal.
  • 1H-NMR(DMSO-d6): δ 6.59(1H, dd, J=3.3,2.1 Hz), 6.62(1H, dd, J=3.3, 2.1 Hz), 6.73(1H, dd, J=3.3, 0.6 Hz), 6.80(1H, dd, J=3.3, 0.9 Hz), 7.05(2H, s), 7.75-7.76(2H, m).
    • (2) 5-Bromo-N-[4,5-bis(furan-2-yl)oxazol-2-yl]-2-hydroxybenzamide (Compound No. 39)
  • Using 5-bromosalicylic acid and 2-amino-4,5-bis(furan-2-yl)oxazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 12.9%.
  • 1H-NMR(DMSO-d6): δ 6.65(1H, dd, J=3.6, 1.8 Hz), 6.68(1H, dd, J=3.6, 1.8 Hz), 6.75(1H, d, J=8, 7 Hz), 6.92(1H, dd, J=3.6, 0.9 Hz), 6.93(1H, d, J=3.3 Hz), 7.37(1H, dd, J=8.7, 2.7 Hz), 7.80(1H, dd, J=1.8, 0.9 Hz), 7.84(1H, dd, J=1.8, 0.9 Hz), 7.92(1H, d, J=3.0 Hz), 14.88(2H, br).
    • Example 40 Preparation of the Compound of Compound No. 40 (1) 2-Acetoxy-N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)benzamide
  • Using O-acetylsalicyloyl chloride and 2-amino-5-(trifluoromethyl)-1,3,4-thiadiazole as the raw materials, the same operation as the Example 2(1) gave the title compound.
  • Yield: 51.1%.
  • 1H-NMR(DMSO-d6): δ 2.23(3H, s), 7.32(1H, dd, J=8.0, 1.2 Hz),7.45(1H, td, J=7.6, 1.2 Hz), 7.69(1H, td, J=8.0, 2.0 Hz), 7.87(1H, dd, J=8.0, 2.0 Hz), 13.75(1H, brs).
    • (2) 2-Hydroxy-N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)benzamide (Compound No. 40)
  • Using 2-acetoxy-N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)benzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 92.9%.
  • 1H-NMR(DMSO-d6): δ 7.00(1H, td, J=8.0, 0.8 Hz),7.06(1H, d, J=8.4 Hz), 7.51(1H, ddd, J=8.4, 7.6, 2.0 Hz), 7.92(1H, dd, J=8.0, 1.6 Hz), 12.16(1H, br).
    • Example 41 Preparation of the Compound of Compound No. 41
  • Using 5-bromosalicylic acid and 2-amino-5-trifluoromethyl-1,3,4-thiadiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 80.2%.
  • 1H-NMR(DMSO-d6): δ 7.01(1H, d, J=9.0 Hz), 7.63(1H, dd, J=8.7, 2.7 Hz), 7.97(1H, d, J=2.4 Hz).
    • Example 42 Preparation of the Compound of Compound No. 42
  • Using 5-chlorosalicylic acid and 5-amino-2-chloropyridine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 12.2%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=9.0 Hz), 7.49(1H, dd, J=9.0, 3.0 Hz), 7.54(1H, d, J=8.4 Hz), 7.88(1H, d, J=2.7 Hz), 8.21(1H, dd, J=8.7, 2.7 Hz), 8.74(1H, d, J=2.7 Hz), 10.62(1H, s), 11.57(1H, s).
    • Example 43 Preparation of the Compound of Compound No. 43
  • Using 5-chlorosalicylic acid and 2-amino-6-chloro-4-methoxypyrimidine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 2.2%, white solid.
  • 1H-NMR(DMSO-d6): δ 3.86(3H, s), 6.85(1H, s), 7.01(1H, d, J=9.0 Hz), 7.47(1H, dd, J=9.0, 3.0 Hz), 7.81(1H, d, J=3.0 Hz), 11.08(1H, s), 11.65(1H, s).
    • Example 44 Preparation of the Compound of Compound No. 44
  • Using 2-acetoxy-5-chlorobenzoic acid and 5-aminoindole as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 13.3%.
  • 1H-NMR(DMSO-d6): δ 2.20(3H, s), 6.41(1H, t, J=2.1 Hz), 7.27-7.36(4H, m), 7.63(1H, dd, J=8.7, 2.7 Hz), 7.74(1H, d, J=2.7 Hz), 7.93(1H, s), 10.21(1H, s), 11.04(1H, s).
    • Example 45 The Compound of Compound No. 45
  • This compound is a commercially available compound.
    • Supplier: Peakdale.
    • Catalog code number: PFC-0448.
    Example 46 Preparation of the Compound of Compound No. 46
  • Using 5-chlorosalicylic acid and 3-aminoquinoline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 4.3%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.7 Hz), 7.51(1H, dd, J=9.0, 3.0 Hz), 7.61(1H, dt, J=7.8, 1.2 Hz), 7.70(1H, dt, J=7.8, 1.5 Hz), 7.98(2H, d, J=3.0 Hz), 8.01(1H, s), 8.82(1H, d, J=2.4 Hz), 10.80(1H, s), 11.74(1H, s).
    • Example 47 Preparation of the Compound of Compound No. 47
  • Using 5-chlorosalicylic acid and 3-amino-9-ethylcarbazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 64.6%.
  • 1H-NMR(DMSO-d6): δ 1.33(3H, t, J=7.0 Hz), 4.46(2H, q, J=7.0 Hz), 7.04(1H, d, J=9.0 Hz), 7.21(1H, t, J=7.3 Hz), 7.45-7.52(2H, m), 7.64-7.65(2H, m), 7.70(1H, d, J=8.4, 1.9 Hz), 8.11-8.15(2H, m), 8.49(1H, d, J=1.9 Hz), 10.55(1H, s), 12.22(1H, s).
    • Example 48 Preparation of the Compound of Compound No. 95
  • Using O-acetylsalicyloyl chloride and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 2(1) gave the title compound.
  • Yield: 84.2%.
  • 1H-NMR(DMSO-d6): δ 2.36(3H, s), 7.19(1H, dd, J=8.0, 1.2 Hz), 7.39(1H, td, J=7.6, 1.2 Hz), 7.57(1H, ddd, J=8.0, 7.6, 1.6 Hz), 7.65(1H, s), 7.83(1H, dd, J=8.0, 1.6 Hz), 8.11(2H, s), 8.31(1H, s).
    • Example 49 Preparation of the Compound of Compound No. 48
  • Using 2-acetoxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide (Compound No. 95) as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 45.1%.
  • 1H-NMR(DMSO-d6): δ 6.96-7.02(2H, m), 7.45(1H, ddd, J=8.0, 7.2, 1.6 Hz), 7.81(1H, s), 7.87(1H, dd, J=8.0, 1.6 Hz), 8.46(2H, s), 10.80(1H, s), 11.26(1H, s).
    • Example 50 Preparation of the Compound of Compound No. 49
  • Using 5-fluorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 58.7%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, ddd, J=9.0, 4.5, 1.2 Hz), 7.30-7.37(1H, m), 7.66(1H, ddd, J=9.0, 3.3, 1.2 Hz), 7.84(1H, s), 8.46(2H, s), 10.85(1H, s), 11.21(1H, brs).
    • Example 51 Preparation of the Compound of Compound No. 50
  • Using 5-chlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 85.5%.
  • 1H-NMR(DMSO-d6): δ 7.05(1H, d, J=8.7 Hz), 7.49(1H, dd, J=8.7, 2.7 Hz), 7.85(1H, s), 7.87(1H, d, J=2.7 Hz), 8.45(2H, s), 10.85(1H, s), 11.39(1H, s).
    • Example 52 Preparation of the Compound of Compound No. 51
  • Using 5-bromosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 88.5%.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.8 Hz), 7.59(1H, dd, J=8.8, 2.8 Hz), 7.83(1H, s), 7.98(1H, d, J=2.8 Hz), 8.43(2H, s), 10.82(1H, s), 11.37(1H, s).
  • This compound was obtained also by the following preparation method.
  • Iron powder (30 mg, 0.54 mmol) and bromine (0.02 mL, 0.39 mmol) were added to a solution of 2-acetoxy-N-[3,5-bis(trifluoromethyl)]benzamide (Compound No. 95; 100 mg, 0.25 mmol) in carbon tetrachloride (8 mL), and the mixture was stirred at 50° C. for 4 hours. After the reaction mixture was cooled to room temperature, it was poured into aqueous NaHSO4 and extracted with ethyl acetate. The ethyl acetate layer was washed with water and brine, and dried over anhydrous sodium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title compound (600 mg, 54.9%) as a white solid.
    • Example 53 Preparation of the Compound of Compound No. 52
  • Using 5-iodosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 62.2%.
  • 1H-NMR(DMSO-d6): δ 6.86(1H, d, J=8.4 Hz), 7.74(1H, dd, J=8.7, 2.4 Hz), 7.84(1H, s), 8.13(1H, d, J=2.1 Hz), 8.84(2H, s), 10.82(1H, s), 11.41(1H, s).
    • Example 54 Preparation of the Compound of Compound No. 53
  • Using 5-nitrosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 57.2%.
  • 1H-NMR(DMSO-d6):d 7.18(1H, d, J=9.0 Hz), 7.86(1H, s), 8.31(1H, dd, J=9.0, 3.0 Hz), 8.45(2H, s), 8.70(1H, d, J=3.0 Hz), 11.12(1H, s).
    • Example 55 Preparation of the Compound of Compound No. 54 (1) 2-Benzyloxy-5-formylbenzoic acid benzyl ester
  • A mixture of 5-formylsalicylic acid (4.98 g, 30 mmol), benzyl bromide (15.39 g, 90 mmol), potassium carbonate (16.59 g, 120 mmol), and methyl ethyl ketone (350 mL) was refluxed for 8 hours. After cooling, the solvent was evaporated under reduced pressure. 2N Hydrochloric acid was added to the residue, and the mixture was extracted with ethyl acetate. The layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1), suspended and washed with isopropyl ether under heating at reflux to give the title compound (5.98 g, 57.5%) as a white solid.
  • 1H-NMR(CDCl3):d 5.27(2H, s), 5.37(2H, s), 7.15(1H, d, J=9.0 Hz), 7.26-7.46(10H, m), 7.99(1H, dd, J=9.0, 2.4 Hz), 8.36(1H, d, J=2.4 Hz), 9.91(1H, s).
    • (2) 2-Benzyloxy-5-cyanobenzoic acid benzyl ester
  • A mixture of 2-benzyloxy-5-formylbenzoic acid benzyl ester (693 mg, 2 mmol), hydroxylamine hydrochloride (167 mg, 2.4 mmol), and N-methylpyrrolidone (3 mL) was stirred at 115 □ for 4 hours. After the reaction mixture was cooled, 2N hydrochloric acid (5 mL) and water (30 mL) were added and the mixture was extracted with ethyl acetate. The organic layer was washed with 2N aqueous sodium hydroxide, water, and brine, and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was suspended and washed with isopropyl ether under heating at reflux to give the title compound (527 mg, 76.7%) as a white solid.
  • 1H-NMR(CDCl3):d 5.23(2H, s), 5.35(2H, s), 7.08(1H, d, J=8.7 Hz), 7.33-7, 43(10H, m), 7.70(1H, dd, J=8.7, 2.4 Hz), 8.13(1H, d, J=2.4 Hz).
    • (3) 5-Cyanosalicylic acid
  • Ethanol (10 mL) and tetrahydrofuran (10 mL) were added to 2-benzyloxy-5-cyanobenzoic acid benzyl ester (446 mg, 1.3 mmol) and 5% palladium on carbon (45 mg), and the mixture was hydrogenated at room temperature for 2 hours. After the insoluble matter was filtered off, the solvent was evaporated under reduced pressure to give the title compound (212 mg, 100.0%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.7 Hz), 7.82(1H, dd, J=8.7, 2.4 Hz), 8.12(1H, d, J=2.1 Hz).
    • (4) N-[3,5-Bis(trifluoromethyl)phenyl]-5-cyano-2-hydroxybenzamide (Compound No. 54)
  • Using 5-cyanosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 16.6%.
  • 1H-NMR(DMSO-d6): δ 7.15(1H, d, J=8.7 Hz), 7.85(1H, s), 7.86(1H, dd, J=8.7, 2.1 Hz), 8.22(1H, d, J=2.4 Hz), 8.43(2H, s), 10.93(1H, s), 12.00(1H, brs).
    • Example 56 Preparation of the Compound of Compound No. 55
  • Using 5-methylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 54.9%.
  • 1H-NMR(DMSO-d6): δ 6.92(1H, d, J=8.7 Hz), 7.28(1H, dd, J=8.7, 1.8 Hz), 7.71(1H, d, J=1.8 Hz), 7.82(1H, s), 8.47(2H, s), 10.80(1H, s), 11.14(1H, s).
    • Example 57 Preparation of the Compound of Compound No. 56 (1) 5-[(1,1-Dimethyl)ethyl]salicylic acid
  • Sulfamic acid (1.76 g, 18.1 mmol) and sodium dihydrogenphosphate (7.33 g, 47 mmol) were added to a solution of 5-[(1,1-dimethyl)ethyl]-2-hydroxybenzaldehyde (2.15 g, 12.1 mmol) in 1,4-dioxane (100 mL) and water (40 mL). A solution of sodium chlorite (1.76 g, 15.5 mmol) in water (10 mL) was added to the mixture under ice cooling, and it was stirred for 1 hour. Then, sodium sulfite (1.80 g, 14.3 mmol) was added to the mixture, and it was stirred for 30 minutes. Concentrated hydrochloric acid was added to the reaction mixture, and pH was adjusted to 1. The residue obtained by evaporation of 1,4-dioxane under reduced pressure was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was washed with n-hexane under suspension to give the title compound (1.81 g, 77.4%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 1.26(9H, s), 6.90(1H, d, J=9.0 Hz), 7.58(1H, dd, J=8.7, 2.4 Hz), 7.75(1H, d, J=2.4 Hz), 11.07(1H, brs).
    • (2) N-[3,5-Bis(trifluoromethyl)phenyl]-5-[(1,1-dimethyl)ethyl]-2-hydroxybenzamide (Compound No. 56)
  • Using 5-[(1,1-dimethyl)ethyl]salicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 53.8%.
  • 1H-NMR(DMSO-d6): δ 1.30(9H, s), 6.96(1H, d, J=8.7 Hz), 7.50(1H, dd, J=8.7, 2.4 Hz), 7.82(1H, d, J=2.4 Hz), 7.83(1H, s), 8.46(2H, s), 10.80(1H, s)11.12(1H, s).
    • Example 58 Preparation of the Compound of Compound No. 78 (1) 5-Acetyl-2-benzyloxybenzoic acid methyl ester
  • A mixture of 5-acetylsalicylic acid methyl ester (13.59 g, 70 mmol), benzyl bromide (17.96 g, 105 mmol), potassium carbonate (19.35 g, 140 mmol) and methyl ethyl ketone (350 mL) was refluxed for 8 hours. After cooling, the solvent was evaporated under reduced pressure. 2N Hydrochloric acid was added to the residue, and it was extracted with ethyl acetate. After the ethyl acetate layer was washed with water and brine, dried over anhydrous magnesium sulfate and concentrated, the residue was recrystallized from isopropyl ether to give the title compound (14.20 g, 71.4%) as a white solid.
  • 1H-NMR(CDCl3): δ 2.58(3H, s), 3.93(3H, s), 5.27(2H, s), 7.07(1H, d, J=8.7 Hz), 7.26-7.43(3H, m), 7.47-7.50(2H, m), 8.07(1H, dd, J=8.7, 2.4 Hz), 8.44(1H, d, J=2.4 Hz).
    • (2) 5-Acetyl-2-benzyloxybenzoic acid
  • 5-Acetyl-2-benzyloxybenzoic acid methyl ester (5.69 g, 20 mmol) was dissolved in a mixed solvent of methanol (20 mL) and tetrahydrofuran (20 mL). 2N Sodium hydroxide (11 mL) was added dropwise, and the mixture was stirred for 8 hours. The solvent was evaporated under reduced pressure. 2N Hydrochloric acid was added to the residue, and it was extracted with dichloromethane. After the dichloromethane layer was washed with water and brine, dried over anhydrous magnesium sulfate and concentrated, the residue was washed with isopropyl ether to give the title compound (4.92 g, 91.0%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.55(3H, s), 5.32(2H, s), 7.30-7.43(4H, m), 7.49-7.52(2H, m), 8.09(1H, dd, J=9.0, 2.7 Hz), 8.22(1H, d, J=2.4 Hz).
    • (3) 5-Acetyl-2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide
  • Using 5-acetyl-2-benzyloxybenzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 63.1%.
  • 1H-NMR(DMSO-d6): δ 2.57(3H, s), 7.11(1H, d, J=8.7 Hz), 7.86(1H, s), 8.05(1H, dd, J=8.4, 2.1 Hz), 8.44(1H, d, J=2.1 Hz), 8.47(2H, s), 10.96(1H, s), 11.97(1H, brs).
    • (4) 5-Acetyl-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 78)
  • Ethanol (6 mL) and tetrahydrofuran (72 mL) were added to 5-acetyl-2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide (602 mg, 1.25 mmol) and 5% palladium on carbon (60 mg), and the mixture was hydrogenated at room temperature for 30 minutes. After the insoluble matter was filtered off, the solvent was evaporated under reduced pressure and the residue was recrystallized from n-hexane-ethyl acetate to give the title compound (230 mg, 47.0%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.59(3H, s), 5.35(2H, s), 7.32-7.36(3H, m), 7.43(1H, d, J=8.7 Hz), 7.52-7.55(2H, m), 7.82(1H, s), 8.16(1H, dd, J=8.7, 2.4 Hz), 8.25(1H, d, J=2.4 Hz), 8.31(2H, s), 10.89(1H, s).
    • Example 59 Preparation of the Compound of Compound No. 57
  • 5-Acetyl-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 78; 50.5 mg, 0.13 mmol) was suspended in ethanol (2 mL). Sodium borohydride (23.6 mg, 0.62 mmol) was added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was washed with isopropyl ether/n-hexane under suspension to give the title compound (39.7 mg, 78.3%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 1.34(3H, d, J=6.3 Hz), 4.71(1H, q, J=6.3 Hz), 5.18(1H, brs), 6.97(1H, d, J=8.4 Hz), 7.44(1H, dd, J=8.4, 2.1 Hz), 7.84(1H, s), 7.86(1H, d, J=2.1 Hz), 8.48(2H, s), 10.85(1H, s), 11.32(1H, s).
    • Example 60 Preparation of the Compound of Compound No. 58
  • 5-Acetyl-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 78; 100.0 mg, 0.26 mmol) was dissolved in ethanol (3 mL). Pyridine (45 μl, 0.56 mmol) and O-methylhydroxylamine hydrochloride (25.8 mg, 0.31 mmol) were added, and the mixture was refluxed for 1 hour. After cooling, the reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(hexane:ethyl acetate=4:1) to give the title compound (102.1 mg, 95.3%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 2.19(3H, s), 3.91(3H, s), 7.05(1H, d, J=8.7 Hz),7.77(1H, dd, J=8.7, 2.4 Hz), 7.85(1H, s), 8.09(1H, d, J=2.4 Hz), 8.47(2H, s), 10.87(1H, s), 11.48(1H, s).
    • Example 61 Preparation of the Compound of Compound No. 59
  • Using 5-acetyl-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 78) and O-benzylhydroxylamine hydrochloride as the raw materials, the same operation as the Example 60 gave the title compound.
  • Yield: 79.9%.
  • 1H-NMR(DMSO-d6): δ 2.24(3H, s), 5.20(2H, s), 7.04(1H, d, J=8.7 Hz), 7.29-7.47(5H, m), 7.76(1H, dd, J=8.7, 2.4 Hz), 7.85(1H, s), 8.07(1H, d, J=2.1 Hz), 8.46(2H, s), 10.87(1H, s), 11.47(1H, s).
    • Example 62 Preparation of the Compound of Compound No. 60 (1) 5-(2,2-Dicyanoethen-1-yl)-2-hydroxybenzoic acid
  • Malononitrile (132 mg, 2 mmol) was dissolved in ethanol (6 mL), and 5-formylsalicylic acid (332 mg, 2 mmol) was added. After cooling with ice bath, benzylamine (0.1 mL) was added and the mixture was stirred at room temperature for 2 hours. The separated yellow crystal was filtered and recrystallized (ethanol) to give the title compound (139.9 mg, 32.7%) as a light yellow solid.
  • 1H-NMR(DMSO-d6): δ 7.12(1H, d, J=8.7 Hz), 8.09(1H, dd, J=8.7, 2.4 Hz), 8.41(1H, s), 8.50(1H, d, J=2.4 Hz).
    • (2) N-[3,5-Bis(trifluoromethyl)phenyl]-5-(2,2-dicyanoethen-1-yl)-2-hydroxybenzamide (Compound No. 60)
  • Using 5-(2,2-dicyanoethen-1-yl)-2-hydroxybenzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 9.1%.
  • 1H-NMR(DMSO-d6): δ 7.13(1H, d, J=9.0 Hz), 7.83(1H, s), 8.04(1H, dd, J=9.0, 2.4 Hz), 8.36(1H, s), 8.38(1H, d, J=2.4 Hz), 8.43(2H, s), 11.43(1H, s).
    • Example 63 Preparation of the Compound of Compound No. 62 (1) 5-[(2-Cyano-2-methoxycarbonyl)ethen-1-yl]-2-hydroxybenzoic acid
  • Triethylamine (0.2 ml) was added to a mixture of 5-formylsalicylic acid (332 mg, 2 mmol). Cyanoacetic acid methyl ester (198 mg, 2 mmol) and acetic acid (6 mL), and the mixture was refluxed for 5 hours. After cooling, the reaction mixture was poured into water, and the separated crystal was filtered and recrystallized (n-hexane) to give the title compound (327.7 mg, 66.3%) as a light yellow solid.
  • 1H-NMR(DMSO-d6): δ 3.85(3H, s), 7.15(1H, d, J=8.7 Hz), 8.20(1H, dd, J=8.7, 2.4 Hz), 8.37(1H, s), 8.66(1H, d, J=2.4 Hz).
    • (2) 3-({N-[3,5-Bis(trifluoromethyl)phenyl]carbamoyl-4-hydroxyphenyl)-2-cyanoacrylic acid methyl ester (Compound No. 62)
  • Using 5-[(2-cyano-2-methoxycarbonyl)ethen-1-yl]-2-hydroxybenzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 66.3%.
  • 1H-NMR(DMSO-d6): δ 3.85(3H, s), 7.19(1H, d, J=9.0 Hz), 7.85(1H, s), 8.20(1H, dd, J=8.7, 2.1 Hz), 8.33(1H, s), 8.45(2H, s), 8.50(1H, d, J=2.1 Hz), 11.00(1H, s), 11.03(1H, s).
    • Example 64 Preparation of the Compound of Compound No. 61
  • 3-({N-[3,5-Bis(trifluoromethyl)phenyl]carbamoyl}-4-hydroxyphenyl)-2-cyanoacrylic acid methyl ester (Compound No. 62; 50 mg, 0.11 mmol) was dissolved in ethanol (5 mL). 2N Sodium hydroxide (0.11 ml, 0.22 mmol) was added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was recrystallized (ethyl acetate) to give the title compound (13.5 mg, 30.4%) as a light yellow solid.
  • 1H-NMR(DMSO-d6): δ 7.12(1H, d, J=8.4 Hz), 7.84(1H, s), 7.94(1H, dd, J=8.4, 2.1 Hz), 8.38(1H, d, J=2.1 Hz), 8.45(2H, s), 9.87(1H, s), 11.41(1H, s).
    • Example 65 Preparation of the Compound of Compound No. 63
  • A mixture of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52; 475 mg, 1 mmol), styrene (130 mg, 1.25 mmol), palladium acetate (4.5 mg, 0.02 mmol), tris(ortho-tolyl)phosphine (12.2 mg, 0.04 mmol), diisopropylamine (388 mg, 3 mmol) and N,N-dimethylformamide (2 mL) was refluxed for 8 hours. After cooling, water was added to the reaction mixture, and it was extracted with ethyl acetate. After the ethyl acetate layer was washed with water and brine, dried over anhydrous magnesium sulfate and concentrated, the residue was purified by column chromatography on silica gel(n-hexane:isopropyl ether=2:1→1:1) to give the title compound (173 mg, 38.3%) as a pale yellow solid.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.4 Hz), 7.20-7.29(3H, m), 7.38(2H, t, J=7.5 Hz), 7.59(2H, d, J=7.5 Hz), 7.72(1H, dd, J=8.4, 2.1 Hz), 7.86(1H, s), 8.07(1H, d, J=2.1 Hz), 8.49(2H, s), 10.89(1H, s), 11.33(1H, brs).
    • Example 66 Preparation of the Compound of Compound No. 66
  • N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52; 950 mg, 2 mmol) and trimethylsilylacetylene (246 mg, 2.5 mmol) were dissolved in triethylamine (2 mL) and N,N-dimethylformamide (4 mL). Tetrakis(triphenylphosphine)palladium (23 mg, 0.02 mmol) and cuprous iodide (4 mg, 0.02 mmol) were added under argon atmosphere, and the mixture was stirred at 40° C. for 2 hours. After cooling to room temperature, the reaction mixture was poured into ethyl acetate (100 mL) and 1N citric acid (100 mL), stirred, and filtered through celite. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=19:1) to give a light orange solid. This was crystallized by n-hexane to give the title compound (286 mg, 32.1%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 0.23(9H, s), 7.00(1H, d, J=8.7 Hz), 7.54(1H, dd, J=8.7, 2.4 Hz), 7.85(1H, s), 7.98(1H, d, J=2.1 Hz), 8.46(2H, s), 10.86(1H, s), 11.69(1H, s).
    • Example 67 Preparation of the Compound of Compound No. 64
  • N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-[(trimethylsilyl)ethynyl]-benzamide (Compound No. 66; 233 mg, 0.5 mmol) was dissolved in methanol (1 mL). 2N Sodium hydroxide (1 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was crystallized from ethanol-water to give the title compound (67 mg, 35.9%) as a light gray crystal.
  • 1H-NMR(DMSO-d6): δ 4.11(1H, s), 7.02(1H, d, J=8.4 Hz), 7.55(1H, dd, J=8.4, 2.1 Hz), 7.85(1H, s), 7.98(1H, d, J=2.1 Hz), 8.46(2H, s), 8.46(2H, s), 10.86(1H, s), 11.62(1H, s).
    • Example 68 Preparation of the Compound of Compound No. 65
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52) and phenylacetylene as the raw materials, the same operation as the Example 66 gave the title compound.
  • Yield: 40.8%.
  • 1H-NMR(DMSO-d6): δ 7.06(1H, d, J=8.4 Hz), 7.42-7.46(3H, m), 7.53-7.57(2H, m), 7.64(1H, dd, J=8.7, 2.1 Hz), 7.86(1H, s), 8.06(1H, d, J=2.1 Hz), 8.48(2H, s), 10.94(1H, s), 11.64(1H, brs).
    • Example 69 Preparation of the Compound of Compound No. 67
  • N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52; 200 mg, 0.42 mmol) was dissolved in 1,2-dimethoxyethane (3 mL), Tetrakis(triphenylphosphine)palladium (16 mg, 0.0014 mmol) was added under argon atmosphere, and the mixture was stirred at room temperature for 5 minutes. Then dihydroxyphenylborane (57 mg, 0.47 mmol) and 1M sodium carbonate (1.3 mL) were added and the mixture was refluxed for 2 hours. After cooling to room temperature, the reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=6:1→3:1) to give the title compound (109 mg, 61.1%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 7.12(1H, d, J=8.7 Hz), 7.33-7.38(1H, m), 7.48(2H, t, J=7.5 Hz), 7.67-7.70(2H, m), 7.79(1H, dd, J=8.4, 2.4 Hz), 7.87(1H, s), 8.17(1H, d, J=2.4 Hz), 8.49(2H, s), 10.92(1H, s), 11.41(1H, s).
    • Example 70 Preparation of the Compound of Compound No. 68
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-(phenylethynyl)benzamide (Compound No. 65) as the raw material, the same operation as the Example 58(4) gave the title compound.
  • Yield: 86.2%.
  • 1H-NMR(DMSO-d6): δ 2.88(4H, s), 6.93(1H, d, J=8.1 Hz), 7.15-7.34(6H, m), 7.76(1H, d, J=2.4 Hz), 7.84(1H, s), 8.47(2H, s), 10.79(1H, s), 11.15(1H, s).
    • Example 71 Preparation of the Compound of Compound No. 69
  • Using 2-hydroxy-5-(trifluoromethyl)benzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.7%.
  • 1H-NMR(CDCl3): δ 7.17(1H, d, J=9.0 Hz) 7.72-7.75(2H, m), 7.86(1H, s), 8.17(2H, s), 8.35(1H, s) 11.88(1H, s).
  • [2-Hydroxy-5-(trifluoromethyl)benzoic acid: Refer to “Chemical and Pharmaceutical Bulletin”, 1996, Vol. 44, p. 734.]
    • Example 72 Preparation of the Compound of Compound No. 70
  • Using 2-hydroxy-5-(pentafluoroethyl)benzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • 1H-NMR(CDCl3): δ 7.19(1H, d, J=9.0 Hz) 7.70(1H, dd, J=8.7, 2.1 Hz), 7.81(1H, d, J=2.1 Hz), 8.17(2H, s), 8.37(1H, s), 11.92(1H, s).
  • [2-Hydroxy-5-(pentafluoromethyl)benzoic acid: Refer to “Chemical and Pharmaceutical Bulletin”, 1996, Vol. 44, p. 734.]
    • Example 73 Preparation of the Compound of Compound No. 71
  • Using 2-hydroxy-5-(pyrrol-1-yl)benzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 57.8%.
  • 1H-NMR(DMSO-d6): δ 6.27(2H, dd, J=2.4, 1.8 Hz), 7.10(1H, d, J=9.0 Hz), 7.29(2H, dd, J=2.4, 1.8 Hz), 7.66(1H, dd, J=9.0, 2.7 Hz), 7.86(1H, s), 7.98(1H, d, J=2.4 Hz), 8.47(2H, s), 10.89(1H, s), 11.24(1H, s).
    • Example 74 Preparation of the Compound of Compound No. 72
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52) and 2-thiopheneboronic acid as the raw materials, the same operation as the Example 69 gave the title compound.
  • Yield: 44.4%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.4 Hz), 7.14(1H, dd, J=5.4, 3.6 Hz), 7.45(1H, dd, J=3.6, 1.2 Hz), 7.51(1H, dd, J=5.1, 0.9 Hz), 7.75(1H, dd, J=8.4, 2.4 Hz), 7.59(1H, s), 8.08(1H, d, J=2.4 Hz), 8.48(2H, s), 10.91(1H, s), 11.38(1H, s).
    • Example 75 Preparation of the Compound of Compound No. 73
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52) and 3-thiopheneboronic acid as the raw materials, the same operation as the Example 69 gave the title compound.
  • Yield: 38.7%.
  • 1H-NMR(DMSO-d6): δ 7.06(1H, d, J=8.7 Hz), 7.57(1H, dd, J=4.8, 1.5 Hz), 7.66(1H, dd, J=4.8, 3.0 Hz), 7.81-7.84(2H, m), 7.86(1H, s), 8.18(1H, d, J=2.1 Hz), 8.49(2H, s), 10.90(1H, s), 11.33(1H, s).
    • Example 76 Preparation of the Compound of Compound No. 74 (1) 2-Benzyloxy-5-(2-bromoacetyl)-N-[3,5-bis(trifluoromethyl)phenyl]benzamide
  • 5-Acetyl-2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide (compound of Example 58(3); 4.81 g, 10 mmol) was dissolved in tetrahydrofuran (30 ml). Phenyltrimethylammonium tribromide (3.75 g, 10 mmol) was added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with aqueous sodium hydrogen sulfite, water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=4:1), and recrystallized (ethyl acetate/n-hexane) to give the title compound (2.39 g, 42.7%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 4.91(2H, s), 5.36(2H, s), 7.32-7.35(3H, m), 7.47(1H, d, J=0.9 Hz), 7.52-7.56(2H, m), 7.82(1H, s), 8.21(1H, dd, J=8.7, 2.4 Hz), 8.29(1H, d, J=2.4 Hz), 8.31(2H, s), 10.91(1H, s).
    • (2) 2-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]-5-(2-methylthiazol-4-yl)benzamide
  • A mixture of 2-benzyloxy-5-(2-bromoacetyl)-N-[3,5-bis(trifluoromethyl)phenyl]benzamide (280 mg, 0.5 mmol), thioacetamide (41 mg, 0.55 mmol), sodium hydrogen carbonate (50 mg, 0.6 mmol) and ethanol (15 mL) was refluxed for 1 hour. The reaction mixture was poured into water, neutralized by sodium hydrogen carbonate, and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(hexane:ethyl acetate=4:1) to give the title compound (181 mg, 67.5%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.72(3H, s), 5.29(2H, s), 7.33-7.36(3H, m), 7.40(1H, d, J=9.0 Hz), 7.54-7.57(2H, m), 7.81(1H, s), 7.94(1H, s), 8.12(1H, dd, J=8.7, 2.1 Hz), 8.27(1H, d, J=2.1 Hz), 8.31(2H, s), 10.86(1H, s).
    • (3) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(2-methylthiazol-4-yl)benzamide (Compound No. 74)
  • 2-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]-5-(2-methylthiazol-4-yl)benzamide (160 mg, 0.3 mmol) and 10% Pd—C (240 mg) were dissolved in ethanol (10 ml) and stirred for 3.5 hours under hydrogen atmosphere. The reaction mixture was filtered and the filtrate was evaporated under reduced pressure to give the title compound (103.4 mg, 79.2%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.72(3H, s), 7.08(1H, d, J=8.7 Hz), 7.83(1H, s), 7.85(1H, s), 8.01(1H, dd, J=8.7, 2.4 Hz), 8.42(1H, d, J=2.1 Hz), 8.50(2H, s), 10.96(1H, s), 11.40(1H, s).
    • Example 77 Preparation of the Compound of Compound No. 75
  • A mixture of 2-benzyloxy-5-(2-bromoacetyl)-N-[3,5-bis(trifluoromethyl)-phenyl]benzamide (compound of Example 58(3); 280 mg, 0.5 mmol), 2-aminopyridine (51.8 mg, 0.55 mmol), sodium hydrogen carbonate (50 mg, 0.6 mmol) and ethanol (10 mL) was refluxed for 2 hours. After cooling, the reaction mixture was poured into aqueous sodium hydrogen carbonate and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=1:2) to give a white solid (130.3 mg, 45.9%). Then, a mixture of this solid (108 mg, 0.19 mmol), 10% Pd—C (11 mg), ethanol (8 mL) and ethyl acetate (8 mL) was stirred for 7 hours under hydrogen atmosphere. The reaction mixture was filtered and the residue obtained by evaporation of the filtrate under reduced pressur was purified by chromatography on silica gel(n-hexane:ethyl acetate=1:3) to give the title compound (18.3 mg, 20.2%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 6.90(1H, dt, J=6.6, 0.9 Hz), 7.10(1H, d, J=8.7 Hz), 7.25(1H, m), 7.57(1H, d, J=9.0 Hz), 7.86(1H, s), 8.04(1H, dd, J=8.7, 2.1 Hz), 8.35(1H, s), 8.48-8.56(4H, m), 11.00(1H, s), 11.41(1H, s).
    • Example 78 Preparation of the Compound of Compound No. 76 (1) N-[3,5-Bis(trifluoromethyl)phenyl]-5-iodo-2-methoxymethoxybenzamide
  • A mixture of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide (Compound No. 52; 4.75 g, 10 mmol), chloromethyl methyl ether (1.14 ml, 15 mmol), potassium carbonate (2.76 g, 20 mmol) and acetone (50 mL) was refluxed for 8 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:1), and recrystallized (n-hexane/ethyl acetate) to give the title compound (3.96 g, 76.3%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 3.38(3H, s), 5.28(2H, s), 7.12(1H, d, J=9.0 Hz), 7.81(1H, s), 7.82(1H, dd, J=8.7, 2.4 Hz), 7.88(1H, d, J=2.4 Hz), 8.40(2H, s), 10.87(1H, s).
    • (2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxymethoxy-5-(pyridin-2-yl)benzamide
  • N-[3,5-Bis(trifluoromethyl)phenyl]-5-iodo-2-methoxymethoxybenzamide (0.20 g, 0.39 mmol) was dissolved in N,N-dimethylformamide (8 ml). Tri-n-butyl(2-pyridyl)tin (0.13 ml, 0.41 mmol) and dichlorobis(triphenylphosphine)palladium (32.1 mg, 0.05 mmol) were added, and the mixture was stirred at 100° C. for 1.5 hours. After cooling, the reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=2:1→1:1) to give the title compound (37.9 mg, 20.8%) as a white powder.
  • 1H-NMR(CDCl3): δ 3.64(3H, s), 5.53(2H, s), 7.23-7.28(1H, m),7.36(1H, d, J=8.7 Hz), 7.65(1H, s), 7.77-7.84(2H, m), 8.20(2H, s), 8.31(1H, dd, J=8.7, 2.4 Hz), 8.68-8.70(1H, m), 8.83(1H, d, J=2.4 Hz), 10.12(1H, s).
    • (3) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(pyridin-2-yl)benzamide (Compound No. 76)
  • Methanol (3 ml) and concentrated hydrochloric acid (0.5 ml) were added to N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxymethoxy-5-(pyridin-2-yl)benzamide (37.9 mg, 0.08 mmol), and the mixture was refluxed for 2 hours. After cooling, the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the title compound (16.2 mg, 47.2%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 7.13(1H, d, J=8.4 Hz), 7.33(1H, ddd, J=7.5, 6.3, 1.2 Hz), 7.86-7.91(2H, m), 7.97(1H, d, J=7.8 Hz), 8.20(1H, dd, J=8.7, 2.1 Hz), 8.50(2H, s), 8.59(1H, d, J=2.4 Hz), 8.64-8.66(1H, m), 10.97(1H, s), 11.53(1H, s).
    • Example 79 Preparation of the Compound of Compound No. 77
  • Using 5-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 56.8%.
  • 1H-NMR(DMSO-d6): δ 3.77(3H, s), 6.97(1H, d, J=9.0 Hz), 7.10(1H, dd, J=9.0, 3.0 Hz), 7.43(1H, d, J=3.0 Hz), 7.84(1H, s), 8.47(2H, s), 10.84(1H, s), 10.91(1H, s).
    • Example 80 Preparation of the Compound of Compound No. 79 (1) 5-Acetyl-2-methoxybenzoic acid methyl ester
  • A mixture of 5-acetylsalicylic acid methyl ester (5.00 g, 25.7 mmol), sodium carbonate (7.10 g, 51.4 mmol) and N,N-dimethylformamide (25 mL) was cooled with ice bath. Methyl iodide (2.5 mL, 40.1 mmol) was added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into water, neutralized by hydrochloric acid, and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was washed under suspension(isopropyl ether/n-hexane) to give the title compound (5.17 g, 96.5%) as a white crystal.
  • 1H-NMR(CDCl3): δ 2.59(3H, s), 3.92(3H, s), 3.99(3H, s), 7.04(1H, d, J=8.7 Hz), 8.12(1H, dd, J=8.7, 2.4 Hz), 8.41(1H, d, J=2.4 Hz).
    • (2) 5-Isobutyryl-2-methoxybenzoic acid methyl ester
  • A mixture of 5-acetyl-2-methoxybenzoic acid methyl ester (0.50 g, 2.40 mmol), potassium tert-butoxide (0.81 g, 7.22 mmol) and tetrahydrofuran (10 mL) was cooled with ice bath. Methyl iodide (0.5 mL, 8.03 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, neutralized by hydrochloric acid, and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:1→2:1) to give the title compound (143.1 mg, 25.2%) as a light yellow oil.
  • 1H-NMR(CDCl3): δ 1.22(6H, d, J=6.9 Hz), 3.52(1H, m), 3.92(3H, s), 3.98(3H, s), 7.05(1H, d, J=8.7 Hz), 8.13(1H, dd, J=8.7, 2.4 Hz), 8.42(1H, d, J=2.4 Hz).
    • (3) 5-Isobutyryl-2-methoxybenzoic acid
  • 5-Isobutyryl-2-methoxybenzoic acid methyl ester (143.1 mg, 0.60 mmol) was dissolved in methanol (5 mL). 2N Aqueous sodium hydroxide (1 ml) was added, and the mixture was refluxed for 1 hour. After cooling, the reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give the title compound (134 mg, yield: quantitative) as a white crystal.
  • 1H-NMR(CDCl3): δ 1.22(6H, d, J=6.9 Hz), 3.59(1H, m), 4.15(3H, s), 7.16(1H, d, J=8.7 Hz), 8.24(1H, dd, J=8.7, 2.4 Hz), 8.73(1H, d, J=2.1 Hz).
    • (4) 5-Isobutyryl-N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxybenzamide
  • Using 5-isobutyryl-2-methoxybenzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 61.4%.
  • 1H-NMR(CDCl3): δ 1.23(6H, d, J=6.9 Hz), 3.64(1H, m), 4.20(3H, s), 7.18(1H, d, J=8.7 Hz), 7.65(1H, s), 8.19(2H, s), 8.22(1H, dd, J=8.7, 2.1 Hz), 8.88(1H, d, J=2.1 Hz), 9.98(1H, s).
    • (5) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-isobutyrylbenzamide (Compound No. 79)
  • A mixture of 5-isobutyryl-N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxybenzamide (143.4 mg, 0.33 mmol), 2,4,6-collidine (3 ml) and lithium iodide (53.1 mg, 0.40 mmol) was refluxed for 1 hour. After cooling, the reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:1) and crystallized (ethyl acetate/isopropyl ether) to give the title compound (90.3 mg, 65.3%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 1.12(6H, d, J=6.9 Hz), 3.66(1H, m), 7.12(1H, d, J=8.4 Hz), 7.85(1H, s), 8.07(1H, dd, J=8.4, 2.4 Hz), 8.45(1H, d, J=2.4 Hz), 8.47(2H, s), 10.93(1H, s), 11.95(1H, brs).
    • Example 81 Preparation of the Compound of Compound No. 81
  • Using 4-hydroxyisophthalic acid 1-methyl ester and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 91.5%.
  • 1H-NMR(DMSO-d6): δ 3.85(3H, s), 7.12(1H, d, J=8.4 Hz), 7.86(1H, s), 8.02(1H, dd, J=8.7, 2.4 Hz), 8.46-8.47(3H, m), 10.96(1H, s), 12.03(1H, brs).
  • [4-Hydroxyisophthalic acid 1-methyl ester: Refer to “Journal of the Chemical Society”, (England), 1956, p. 3099-3107.]
    • Example 82 Preparation of the Compound of Compound No. 80
  • N-[3,5-Bis(trifluoromethyl)phenyl]-4-hydroxyisophthalamic acid methyl ester (Comound No. 81; 2.85 g, 7 mmol) was suspended in a mixed solvent of methanol (14 mL) and tetrahydrofuran (14 mL). 2N Aqueous sodium hydroxide (14 mL) was added, and the mixture was refluxed for 2 hours. After cooling, 2N hydrochloric acid (20 ml) was added to the reaction mixture and the separated solid was filtered, washed with water, dried to give the title compound (2.68 g, 97.4%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 7.10(1H, d, J=8.7 Hz), 7.82(1H, s), 7.86(1H, s), 8.01(1H, dd, J=8.7, 2.4 Hz), 8.47(2H, s), 8.48(1H, d, J=2.4 Hz), 10.97(1H, s), 11.98(1H, brs).
  • When the method described in Example 82 is referred in the following examples, inorganic bases such as sodium hydroxide, potassium carbonate or the like were used as the base. As the reaction solvent, solvents such as water, methanol, ethanol, tetrahydrofuran or the like were used alone or as a mixture.
    • Example 83 Preparation of the Compound of Compound No. 82
  • Using 4-hydroxyisophthalic acid (182 mg, 1 mmol), 3,5-bis(trifluoromethyl)-aniline (687 mg, 3 mmol), phosphorus trichloride (87 μl; 1 mmol) and toluene (10 mL), the same operation as the Example 16 gave the title compound (151 mg, 25.0%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 7.18(1H, d, J=8.7 Hz), 7.82(1H, s), 7.86(1H, s), 8.11(1H, dd, J=8.7, 2.4 Hz), 8.50(2H, s), 8.54(2H, s), 8.56(1H, d, J=2.4 Hz), 10.79(1H, s), 10.99(1H, s), 11.84(1H, brs).
    • Example 84 Preparation of the Compound of Compound No. 83 (1) 4-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid methyl ester
  • Sodium hydride (60%; 1.04 g, 26 mmol) was washed with n-hexane, and suspended in N,N-dimethylformamide (100 mL). A solution of N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxyisophthalamic acid methyl ester (Compound No. 81; 8.15 g, 20 mmol) in N,N-dimethylformamide (100 mL) was added dropwise under cooling with ice bath. After the addition was finished, the mixture was stirred at room temperature for 1 hour. A solution of benzyl bromide (4.45 g, 26 mmol) in N,N-dimethylformamide (10 mL) was added, and the mixture was stirred at 60° C. for 3 hours. After cooling, the reaction mixture was poured into ice and water, and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was recrystallized (ethyl acetate/n-hexane) to give the title compound (5.38 g, 54.1%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 3.87(3H, s), 5.33(2H, s), 7.33-7.36(3H, m), 7.46(1H, d, J=8.7 Hz), 7.53-7.56(2H, m), 7.82(1H, s), 8.15(1H, dd, J=8.7, 2.1 Hz), 8.25(1H, d, J=2.1 Hz)8.28(2H, s), 10.87(1H, s).
    • (2) 4-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid
  • Using 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid methyl ester as the raw material, the same operation as the Example 82 gave the title compound.
  • Yield: 79.7%.
  • 1H-NMR(DMSO-d6): δ 5.32(2H, s), 7.32-7.34(3H, m), 7.43(1H, d, J=8.7 Hz), 7.52-7.56(2H, m), 7.81(1H, s), 8.12(1H, dd, J=8.7, 2.1 Hz), 8.22(1H, d, J=2.1 Hz), 8.28(2H, s), 10.85(1H, s), 13.81(1H, brs).
    • (3) 4-Benzyloxy-N3-[3,5-bis(trifluoromethyl)phenyl]—N1,N1-dimethylisophthalamide
  • WSC.HCl (95 mg, 0.50 mmol) was added to a solution of 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid (242 mg, 0.50 mmol), dimethylamine hydrochloride (41 mg, 0.50 mmol) and triethylamine (51 mg, 0.50 mmol) in tetrahydrofuran (5 mL) under ice cooling, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with diluted hydrochloric acid, water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by chromatography on silica gel(hexane:ethyl acetate=1:4) to give the title compound (165 mg, 64.9%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.99(6H, s)5.29(2H, s), 7.32-7.38(4H, m), 7.52-7.56(2H, m), 7.64(1H, dd, J=8.7, 2.1 Hz), 7.73(1H, d, J=2.1 Hz), 7.80(1H, s), 8.28(2H, s), 10.83(1H, s).
  • When the method described in Example 84(3) is referred in the following examples, organic bases such as pyridine, triethylamine or the like were used as the base. As the reaction solvent, solvents such as dichloromethane, tetrahydrofuran or the like were used alone or as a mixture.
    • (4) N3-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-N1,N1-dimethylisophthalamide (Compound No. 83)
  • A solution of 4-benzyloxy-N3-[3,5-bis(trifluoromethyl)phenyl]-N1,N1-dimethyl-isophthalamide (141 mg, 0.28 mmol) and 5% Pd—C (14 mg) in a mixed solvent of ethanol (5 ml) and ethyl acetate (5 ml) was stirred at room temperature for 1 hour under hydrogen atmosphere. The reaction mixture was filtered and the filtrate was evaporated under reduced pressure to give the title compound (106 mg, 91.2%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.98(6H, s), 7.02(1H, d, J=8.7 Hz), 7.52(1H, dd, J=8.7, 2.1 Hz), 7.84(1H, s), 7.95(1H, d, J=2.1 Hz), 8.46(2H, s), 11.10(1H, brs), 11.63(1H, brs).
    • Example 85 Preparation of the Compound of Compound No. 84 (1) 2-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]-5-(piperidine-1-carbonyl)-benzamide
  • Using 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid (compound of Example 84(2)) and piperidine as the raw materials, the same operation as the Example 84(3) gave the title compound.
  • Yield: 56.4%.
  • 1H-NMR(CDCl3): δ 1.53-1.70(6H, m), 3.44(2H, brs), 3.70(2H, brs), 5.26(2H, s), 7.24(1H, d, J=8.7 Hz), 7.26(1H, s), 7.52-7.58(5H, m), 7.66(2H, s), 7.74(1H, dd, J=8.7, 2.4 Hz), 8.37(1H, d, J=2.1 Hz), 10.27(1H, s).
    • (2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(piperidine-1-carbonyl)benzamide (Compound No. 84)
  • Using 2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]-5-(piperidine-1-carbonyl)benzamide as the raw material, the same operation as the Example 84(4) gave the title compound.
  • Yield: 96.3%, white solid.
  • 1H-NMR(DMSO-d6): δ 1.51(4H, brs), 1.60-1.65(2H, m), 3.47(4H, brs), 7.04(1H, d, J=8.4 Hz), 7.48(1H, dd, J=8.4, 2.1 Hz), 7.85(1H, s), 7.92(1H, d, J=2.1 Hz), 8.46(2H, s), 10.99(1H, s), 11.64(1H, brs).
    • Example 86 Preparation of the Compound of Compound No. 85 (1) 2-Benzyloxy-5-(4-benzylpiperidine-1-carbonyl)-N-[3,5-bis(trifluoromethyl)phenyl]-benzamide
  • Using 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid (compound of Example 84(2)) and 4-benzylpiperidine as the raw materials, the same operation as the Example 84(3) gave the title compound.
  • Yield: 76.7%.
  • 1H-NMR(CD3OD): δ 1.18-1.38(2H, m), 1.67(1H, brs), 1.74(1H, brs), 1.84-1.93(1H, m), 2.60(2H, d, J=7.2 Hz), 2.83(1H, brs), 3.10(1H, brs), 3.78(1H, brs), 4.59(1H, brs), 5.34(2H, s), 7.15-7.18(3H, m), 7.24-7.28(2H, m), 7.40-7.46(4H, m), 7.57-7.63(3H, m), 7.65(1H, dd, J=8.7, 2.4 Hz), 7.96(2H, s), 8.05(1H, d, J=2.1 Hz).
    • (2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(4-benzylpiperidine-1-carbonyl)-benzamide (Compound No. 85)
  • Using 2-benzyloxy-5-(4-benzylpiperidine-1-carbonyl)-N-[3,5-bis(trifluoromethyl)phenyl]-benzamide as the raw material, the same operation as the Example 84(4) gave the title compound.
  • Yield: 54.3%, white solid.
  • 1H-NMR(DMSO-d6): δ 1.08-1.22(2H, m), 1.59-1.62(2H, m), 1.77-1.80(1H, m), 2.50-2.55(2H, m), 2.87(2H, brs), 3.75(1H, br), 4.39(1H, br), 7.06(1H, d, J=8.4 Hz), 7.17-7.20(3H, m), 7.28(2H, t, J=7.2 Hz), 7.49(1H, dd, J=8.4, 2.1 Hz), 7.84(1H, s), 7.93(1H, d, J=2.1 Hz), 8.47(2H, s), 10.89(1H, s), 11.65(1H, s).
    • Example 87 Preparation of the Compound of Compound No. 86 (1) 2-Methoxy-5-sulfamoylbenzoic acid
  • Methyl 2-methoxy-5-sulfamoylbenzoate (4.91 g, 20 mmol) was dissolved in methanol (30 mL). 2N Aqueous sodium hydroxide (30 mL, 60 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 2N hydrochloric acid, and the separated solid was filtered to give the title compound (4.55 g, 98.3%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 3.89(3H, s), 7.30(1H, d, J=8.7 Hz), 7.32(2H, s), 7.92(1H, dd, J=8.7, 2.7 Hz), 8.09(1H, d, J=2.7 Hz), 13.03(1H, br).
    • (2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxy-5-sufamoylbenzamide
  • Using 2-methoxy-5-sulfamoylbenzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 24.2%.
  • 1H-NMR(DMSO-d6): δ 3.97(3H, s), 7.38(2H, s), 7.39(1H, d, J=8.7 Hz), 7.85(1H, s), 7.96(1H, dd, J=8.7, 2.4 Hz), 8.06(1H, d, J=2.4 Hz), 8.43(2H, s), 10.87(1H, s).
    • (3) N-[3,5-Bis(trifluoromethyl)phenyl)-5-dimethylsufamoyl-2-methoxybenzamide
  • A suspension of N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-5-sufamoylbenzamide (442 mg, 1.0 mmol), methyl iodide (710 mg, 5.0 mmol) and sodium carbonate (415 mg, 3.0 mmol) in acetonitrile (10 mL) was refluxed for 3 hours. After cooling to room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was recrystallized from a mixed solvent of n-hexane and ethyl acetate (2:1) to give the title compound (207 mg, 44.1%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.62(6H, s), 3.99(3H, s), 7.45(1H, d, J=9.0 Hz), 7.85(1H, s), 7.91(1H, dd, J=8.7, 2.4 Hz), 7.95(1H, d, J=2.4 Hz)8.43(2H, s), 10.90(1H, s).
    • (4) N-[3,5-Bis(trifluoromethyl)phenyl]-5-dimethylsufamoyl-2-hydroxybenzamide (Compound No. 86)
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-5-dimethylsufamoyl-2-methoxybenzamide as the raw material, the same operation as the Example 80(5) gave the title compound.
  • Yield: 45.5%.
  • 1H-NMR(DMSO-d6): δ 2.61(6H, s), 7.20(1H, d, J=8.7 Hz), 7.77(1H, dd, J=8.7, 2.1 Hz), 7.86(1H, s), 8.14(1H, d, J=2.1 Hz)8.45(2H, s), 11.16(1H, s), 12.15(1H, br).
    • Example 88 Preparation of the Compound of Compound No. 87 (1) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxy-5-(pyrrole-1-sulfonyl)benzamide
  • A mixture of N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-5-sulfamoyl-benzamide (compound of Example 87(2); 442 mg, 1 mmol), 2,5-dimethoxytetrahydrofuran (159 mg, 1.2 mmol) and acetic acid (5 mL) was refluxed for 2 hours. After cooling, the reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with water, saturated aqueous sodium hydrogen carbonate and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:2) to give the title compound (436.5 mg, 88.6%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 3.96(3H, s), 6.36(2H, dd, J=2.4, 2.1 Hz), 7.37(2H, dd, J=2.4, 2.1 Hz), 7.42(1H, d, J=9.0 Hz), 7.85(1H, s), 8.80(1H, dd, J=9.0, 2.4 Hz)8.18(1H, d, J=2.7 Hz), 8.38(2H, s), 10.92(1H, s).
    • (2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(pyrrole-1-sulfonyl)benzamide (Compound No. 87)
  • Using N-[3,5-bis(trifluoromethyl)phenyl)-2-methoxy-5-(pyrrole-1-sulfonyl)benzamide as the raw material, the same operation as the Example 80(5) gave the title compound.
  • Yield: 79.4%.
  • 1H-NMR(DMSO-d6): δ 6.36(2H, dd, J=2.4, 2.1 Hz), 7.18(1H, d, J=9.0 Hz), 7.34(2H, dd, J=2.4, 2.1 Hz), 7.86(1H, s), 7.99(1H, dd, J=9.0, 2.7 Hz)8.31(1H, d, J=2.7 Hz), 8.42(2H, s), 10.98(1H, s).
    • Example 89 Preparation of the Compound of Compound No. 88
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-nitrobenzamide (Compound No. 53) as the raw material, the same operation as the Example 84(4) gave the title compound.
  • Yield: 98.0%.
  • 1H-NMR(DMSO-d6): δ 4.79(2H, brs), 6.76(1H, d, J=2.1 Hz), 6.76(1H, s), 7.09(1H, dd, J=2.1, 1.2 Hz), 7.80(1H, s), 8.45(2H, s), 10.30(1H, br), 10.84(1H, s).
    • Example 90 Preparation of the Compound of Compound No. 89
  • Using 5-dimethylaminosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 28.8%.
  • 1H-NMR(DMSO-d6): δ 2.85(6H, s), 6.92(1H, d, J=9.0 Hz), 7.01(1H, dd, J=8.7, 3.0 Hz), 7.22(1H, d, J=3.0 Hz), 7.84(1H, s), 8.47(2H, s), 10.62(1H, s), 10.83(1H, s).
    • Example 91 Preparation of the Compound of Compound No. 90
  • Under argon atmosphere, a mixture of 5-amino-N-[3,5-bis(trifluoromethyl)-phenyl]-2-hydroxybenzamide (Compound No. 88; 364 mg, 1 mmol), pyridine (95 mg, 1.2 mmol) and tetrahydrofuran (10 mL) was cooled on ice. Benzoyl chloride (155 mg, 1.1 mmol) was added, and the mixture was stirred for 1 hour. The reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title compound (121 mg, 25.7%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.7 Hz), 7.51-7.62(3H, m), 7.81(1H, dd, J=8.7, 2.4 Hz), 7.83(1H, s), 7.98(2H, d, J=7.2 Hz), 8.22(1H, d, J=2.4 Hz), 8.49(2H, s), 10.27(1H, s), 10.89(1H, s), 11.07(1H, s).
    • Example 92 Preparation of the Compound of Compound No. 91
  • 5-Amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 88; 100.2 mg, 0.28 mmol) was dissolved in acetonitrile (4 ml). 4-Dimethylaminopyridine (3 mg) and phenylisocyanate (30 μl, 0.28 mmol) were added, and the mixture was stirred at 60° C. for 5 minutes. The reaction mixture was concentrated and the residue was purified by chromatography on silica gel(n-hexane:ethyl acetate=1:1) to give the title compound (54.8 mg, 41.2%) as a light brown solid.
  • 1H-NMR(DMSO-d6): δ 6.93-6.98(1H, m), 6.97(1H, d, J=9.3 Hz),7.27(2H, t, J=7.8 Hz), 7.34-7.46(2H, m), 7.50(1H, dd, J=9.0, 2.4 Hz), 7.83(1H, s), 7.88(1H, s), 8.47(2H, s), 8.56(1H, s), 8.63(1H, s), 10.87(1H, s), 10.89(1H, s).
    • Example 93 Preparation of the Compound of Compound No. 92
  • Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 88) and phenylisothiocyanate as the raw materials, the same operation as the Example 92 gave the title compound.
  • Yield: 66.3%.
  • 1H-NMR(DMSO-d6): δ 7.00(1H, d, J=8.4 Hz), 7.13(1H, tt, J=7.5, 1.2 Hz),7.34(2H, t, J=7.8 Hz), 7.45-7.51(3H, m), 7.84(1H, s), 7.87(1H, d, J=2.7 Hz), 8.47(2H, s), 9.65(1H, s), 9.74(1H, s), 10.84(1H, s), 11.32(1H, s).
    • Example 94 Preparation of the Compound of Compound No. 93
  • Using 5-[(4-nitrophenyl)diazenyl]salicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 11.3%.
  • 1H-NMR(DMSO-d6): δ 7.23(1H, d, J=9.0 Hz), 7.87(1H, s),8.06(2H, d, J=9.0 Hz), 8.10(1H, dd, J=9.0, 2.4 Hz), 8.44(2H, d, J=9.0 Hz), 8.50(2H, s), 8.53(1H, d, J=2.4 Hz), 11.13(1H, s), 12.14(1H, br).
    • Example 95 Preparation of the Compound of Compound No. 94
  • Using 5-({[(4-pyridin-2-yl)sulfamoyl]phenyl}diazenyl)salicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 7.9%.
  • 1H-NMR(DMSO-d6): δ 6.87(1H, t, J=6.0 Hz), 7.22(1H, d, J=8.7 Hz), 7.21-7.23(1H, m), 7.77(1H, t, J=8.4 Hz), 7.87(1H, s), 7.95-7.98(3H, m), 8.03-8.07(4H, m), 8.47(1H, d, J=2.4 Hz), 8.49(2H, s), 11.14(1H, s), 12.03(1H, br).
    • Example 96 Preparation of the Compound of Compound No. 96
  • N-[3,5-Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (Compound No. 50; 1.51 g, 3 mmol) and pyridine (285 mg, 3.6 mmol) were dissolved in tetrahydrofuran (6 mL). Acetyl chloride (234 mg, 3.3 mmol) was added dropwise under ice cooling, and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure. 2 N hydrochloric acid was added to the residue, and it was extracted with ethyl acetate. After the ethyl acetate layer was washed with water and brine, dried over anhydrous magnesium sulfate and concentrated, the residue was recrystallized from n-hexane/ethyl acetate to give the title compound (1.06 g, 83.0%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 2.22(3H, s), 7.35(1H, d, J=9.0 Hz), 7.71(1H, dd, J=8.7, 2.7 Hz), 7.85(1H, s), 7.88(1H, d, J=2.7 Hz), 8.37(2H, s), 11.05(1H, brs).
  • When the method described in Example 96 is referred in the following examples, organic bases such as pyridine, triethylamine or the like were used as the base. As the reaction solvent, solvents such as dichloromethane, tetrahydrofuran, benzene or the like were used alone or as a mixture.
    • Example 97 Preparation of the Compound of Compound No. 97 (1) 4-Acetylamino-5-chloro-2-methoxybenzoic acid
  • Using 4-acetylamino-5-chloro-2-methoxybenzoic acid methyl ester as the raw material, the same operation as the Example 82 gave the title compound.
  • Yield: 88.0%.
  • 1H-NMR(DMSO-d6): δ 2.16(3H, s), 3.78(3H, s), 7.72(1H, s), 7.77(1H, s), 9.57(1H, s), 12.74(1H, s).
    • (2) 4-Acetylamino-N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-methoxybenzamide
  • Using 4-acetylamino-5-chloro-2-methoxybenzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 23.8%.
  • 1H-NMR(DMSO-d6): δ 2.17(3H, s), 3.89(3H, s), 7.77-7.82(3H, m), 8.45-8.49(2H, m), 9.66(1H, s), 10.68(1H, s).
    • (3) 4-Acetylamino-N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydoxybenzamide (Compound No. 97)
  • Using 4-acetylamino-N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-methoxybenzamide as the raw material, the same operation as the Example 80(5) gave the title compound.
  • Yield: 72.8%.
  • 1H-NMR(DMSO-d6): δ 2.17(3H, s), 7.75(1H, s), 7.82(1H, s), 7.95(1H, s), 8.44(2H, s), 9.45(1H, s), 11.16(1H, brs), 11.63(1H, brs).
    • Example 98 Preparation of the Compound of Compound No. 98
  • Using 4-chlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 55.8%.
  • 1H-NMR(DMSO-d6): δ 7.05-7.08(2H, m), 7.84-7.87(2H, m), 8.45(2H, s), 10.84(1H, s)11.64(1H, brs).
    • Example 99 Preparation of the Compound of Compound No. 99
  • Using 5-chlorosalicylic acid and 3,5-bis(trifluoromethyl)-2-bromoaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 14.5%.
  • 1H-NMR(DMSO-d6): δ 7.11(1H, d, J=9.0 Hz), 7.53(1H, dd, J=9.0, 2.7 Hz), 7.91(1H, d, J=1.8 Hz), 7.98(1H, d, J=2.7 Hz), 9.03(1H, d, J=1.8 Hz), 11.26(1H, brs).
    • Example 100 Preparation of the Compound of Compound No. 100
  • Using 5-chlorosalicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 3.6%.
  • 1H-NMR(CDCl3): δ 7.03(1H, d, J=8.7 Hz), 7.43-7.48(2H, m), 6.61(1H, d, J=8.1 Hz), 7.85(1H, d, J=8.4 Hz), 8.36(1H, br s), 8.60(1H, s), 11.31(1H, s).
    • Example 101 Preparation of the Compound of Compound No. 101
  • Using 5-bromosalicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 24.0%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.65(1H, dd, J=8.7, 2.7 Hz), 7.76(1H, d, J=8.4 Hz), 8.03(1H, d, J=8.1 Hz)8.11(1H, d, J=2.7 Hz), 8.74(1H, s), 11.02(1H, s), 12.34(1H, s).
    • Example 102 Preparation of the Compound of Compound No. 102
  • Using 5-methylsalicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 1.5%.
  • 1H-NMR(CDCl3): δ 2.36(3H, s), 6.97(1H, d, J=8.4 Hz), 7.23(1H, s), 7.32(1H, dd, J=8.4, 1.5 Hz), 7.57(1H, d, J=8.4 Hz), 7.83(1H, d, J=8.4 Hz), 8.46(1H, s), 8.69(1H, s), 11.19(1H, s).
    • Example 103 Preparation of the Compound of Compound No. 103
  • Using N-[2,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (Compound No. 100) and acetyl chloride as the raw materials, the same operation as the Example 96 gave the title compound.
  • Yield: 6.6%.
  • 1H-NMR(CDCl3): δ 2.35(3H, s), 7.17(1H, d, J=8.7 Hz),7.54(1H, dd, J=8.7, 2.4 Hz), 7.55(1H, d, J=8.1 Hz), 7.80(1H, d, J=8.1 Hz), 7.95(1H, d, J=2.4 Hz), 8.60(1H, s), 8.73(1H, s).
    • Example 104 Preparation of the Compound of Compound No. 104
  • Using 5-chlorosalicylic acid and 2-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 58.0%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.7 Hz), 7.42(1H, t, J=7.5 Hz), 7.52(1H, dd, J=8.7, 2.7 Hz), 7.74(1H, t, J=8.1 Hz), 7.77(1H, t, J=8.1 Hz), 7.99(1H, d, J=2.7 Hz), 8.18(1H, d, J=8.1 Hz), 10.76(1H, s), 12.22(1H, s).
    • Example 105 Preparation of the Compound of Compound No. 105
  • Using 5-chlorosalicylic acid and 4-chloro-2-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 21.5%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.7 Hz), 7.52(1H, dd, J=8.7, 2.7 Hz), 7.80-7.85(2H, m), 7.97(1H, d, J=2.7 Hz), 8.26(1H, d, J=8.4 Hz), 10.80(1H, s), 12.26(1H, s).
    • Example 106 Preparation of the Compound of Compound No. 106
  • Using 5-bromosalicylic acid and 3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 50.3%.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.7 Hz), 7.48-7.52(1H, m), 7.59(1H, dd, J=8.7, 2.7 Hz), 7.62(1H, t, J=8.1 Hz), 7.92-7.96(1H, m), 8.02(1H, d, J=2.4 Hz), 8.20(1H, s), 10.64(1H, s), 11.60(1H, s).
    • Example 107 Preparation of the Compound of Compound No. 107
  • Using 5-chlorosalicylic acid and 2-fluoro-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 71.7%, white solid.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=9.0 Hz), 7.46(1H, t, J=7.8 Hz), 7.52(1H, dd, J=9.0, 2.7 Hz), 7.58(1H, t, J=7.2 Hz), 7.96(1H, d, J=2.7 Hz), 8.49(1H, t, J=7.2 Hz), 10.82(1H, s), 12.13(1H, brs).
    • Example 108 Preparation of the Compound of Compound No. 108
  • Using 5-chlorosalicylic acid and 4-fluoro-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 72.1%, white solid.
  • 1H-NMR(DMSO-d6):7.03(1H, d, J=9.0 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.56(1H, d, J=9.9 Hz), 7.90(1H, d, J=2.7 Hz), 7.99-8.03(1H, m), 8.21(1H, dd, J=6.6, 2.4 Hz), 10.63(1H, s), 11.58(1H, s).
    • Example 109 Preparation of the Compound of Compound No. 109
  • Using 5-bromosalicylic acid and 4-chloro-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 37.4%.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.7 Hz), 7.59(1H, dd, J=8.7, 2.4 Hz), 7.73(1H, d, J=8.7 Hz), 7.98(1H, d, J=2.4 Hz), 8.00(1H, dd, J=8.7, 2.4 Hz), 8.31(1H, d, J=2.4 Hz), 10.68(1H, s), 11.52(1H, brs).
    • Example 110 Preparation of the Compound of Compound No. 110
  • Using 5-chlorosalicylic acid and 3-fluoro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 62.0%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.7 Hz), 7.42(1H, d, J=8.4 Hz), 7.48(1H, dd, J=9.0, 3.0 Hz), 7.85(1H, d, J=2.4 Hz), 7.94(1H, dd, J=11.4, 2.1 Hz), 7.99(1H, s), 10.73(1H, s), 11.46(1H, s).
    • Example 111 Preparation of the Compound of Compound No. 111
  • Using 5-bromosalicylic acid and 3-bromo-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.3%.
  • 1H-NMR(DMSO-d6): δ 6.99(1H, d, J=9.0 Hz), 7.60(1H, dd, J=9.0, 2.4 Hz), 7.72(1H, s), 7.97(1H, d, J=2.7 Hz), 8.16(1H, s), 8.28(1H, s), 10.69(1H, s), 11.45(1H, s).
    • Example 112 Preparation of the Compound of Compound No. 112
  • Using 5-chlorosalicylic acid and 2-fluoro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 77.9%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=9.0 Hz), 7.52(1H, dd, J=9.0, 2.7 Hz), 7.58-7.61(2H, m), 7.95(1H, d, J=2.7 Hz), 8.71(1H, d, J=7.5 Hz), 10.90(1H, s), 12.23(1H, s).
    • Example 113 Preparation of the Compound of Compound No. 113
  • Using 5-chlorosalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 49.1%.
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=9.0 Hz), 7.53(1H, dd, J=9.0, 3.0 Hz), 7.55(1H, dd, J=8.4, 2.7 Hz), 7.83(1H, d, J=8.4 Hz), 7.98(1H, d, J=3.0 Hz), 8.88(1H, d, J=2.7 Hz), 11.14(1H, s), 12.39(1H, s).
    • Example 114 Preparation of the Compound of Compound No. 114
  • Using 5-bromosalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 34.2%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.7 Hz), 7.56(1H, ddd, J=8.1, 2.4, 1.2 Hz), 7.64(1H, dd, J=8.7, 2.7 Hz), 7.83(1H, dd, J=8.1, 1.2 Hz), 8.11(1H, d, J=2.7 Hz), 8.87(1H, d, J=2.4 Hz), 11.12(1H, s), 12.42(1H, s).
    • Example 115 Preparation of the Compound of Compound No. 115
  • Using 5-chlorosalicylic acid and 4-nitro-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.8%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=9.0 Hz), 7.49(1H, dd, J=9.0, 2.7 Hz), 7.81(1H, d, J=2.7 Hz), 8.23-8.24(2H, m), 8.43(1H, d, J=1.2 Hz), 11.02(1H, S), 11.30(1H, br).
    • Example 116 Preparation of the Compound of Compound No. 116
  • Using 5-chlorosalicylic acid and 2-nitro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 8.1%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=9.0 Hz), 7.53(1H, dd, J=8.7, 2.7 Hz), 7.73(1H, dd, J=8.4, 1.8 Hz), 7.95(1H, d, J=3.0 Hz), 8.36(1H, d, J=8.7 Hz), 9.01(1H, d, J=1.8 Hz), 12.04(1H, s), 12.20(1H, s).
    • Example 117 Preparation of the Compound of Compound No. 117
  • Using 5-bromosalicylic acid and 4-cyano-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 49.7%.
  • 1H-NMR(DMSO-d6): δ 6.99(1H, d, J=8.7 Hz), 7.60(1H, dd, J=8.7, 2.4 Hz), 7.92(1H, d, J=2.7 Hz), 8.16(2H, s), 8.42(1H, s), 10.93(1H, s), 11.36(1H, s).
    • Example 118 Preparation of the Compound of Compound No. 118
  • Using 5-chlorosalicylic acid and 2-methyl-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 14.5%.
  • 1H-NMR(DMSO-d6): δ 2.36(3H, d, J=1.2 Hz), 7.05(1H, d, J=8.7 Hz), 7.46(1H, t, J=8.1 Hz), 7.50(1H, dd, J=8.7, 2.7 Hz), 7.60(1H, d, J=7.2 Hz), 7.99(1H, d, J=7.2 Hz), 8.00(1H, d, J=2.4 Hz), 10.43(1H, s), 12.08(1H, s).
    • Example 119 Preparation of the Compound of Compound No. 119
  • Using 5-chlorosalicylic acid and 4-methyl-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 80.2%.
  • 1H-NMR(DMSO-d6): δ 7.01(1H, d, J=8.7 Hz), 7.44(1H, d, J=8.4 Hz), 7.47(1H, dd, J=9.0, 2.7 Hz), 7.84(1H, dd, J=8.4, 2.1 Hz), 7.92(1H, d, J=2.7 Hz), 8.13(1H, d, J=2.1 Hz), 10.65(1H, s), 11.68(1H, br).
    • Example 120 Preparation of the Compound of Compound No. 120
  • Using 5-chlorosalicylic acid and 2-methyl-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.3%.
  • 1H-NMR(DMSO-d6): δ 2.39(3H, s), 7.07(1H, d, J=8.7 Hz), 7.44-7.54(3H, m), 7.99(1H, d, J=3.0 Hz), 8.43(1H, s), 10.52(1H, s), 12.17(1H, brs).
    • Example 121 Preparation of the Compound of Compound No. 121
  • Using 5-chlorosalicylic acid and 4-methoxy-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 79.1%.
  • 1H-NMR(DMSO-d6): δ 3.89(3H, s), 7.02(1H, d, J=9.0 Hz), 7.30(1H, d, J=9.0 Hz), 7.48(1H, dd, J=9.0, 3.0 Hz), 7.92(1H, dd, J=9.0, 2.4 Hz), 7.96(1H, d, J=2.7 Hz), 8.04(1H, d, J=2.4 Hz), 10.47(1H, s), 11.78(1H, s).
    • Example 122 Preparation of the Compound of Compound No. 122
  • Using 5-bromosalicylic acid and 3-methoxy-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 58.8%.
  • 1H-NMR(DMSO-d6): δ 3.85(3H, s), 6.98(1H, d, J=8.7 Hz), 7.03(1H, s), 7.57-7.61(2H, m), 7.77(1H, s), 8.00(1H, d, J=2.4 Hz), 10.57(1H, s), 11.56(1H, s).
    • Example 123 Preparation of the Compound of Compound No. 123
  • Using 5-bromosalicylic acid and 2-methoxy-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 71.3%.
  • 1H-NMR(DMSO-d6): δ 3.99(3H, s), 7.03(1H, d, J=9.0 Hz), 7.30(1H, d, J=8.7 Hz), 7.47-7.51(1H, m), 7.61(1H, dd, J=9.0, 2.4 Hz), 8.10(1H, d, J=2.4 Hz), 8.82(1H, d, J=2.1 Hz)11.03(1H, s), 12.19(1H, s).
    • Example 124 Preparation of the Compound of Compound No. 124
  • Using 5-chlorosalicylic acid and 2-methoxy-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 83.4%.
  • 1H-NMR(DMSO-d6): δ 4.00(3H, s), 7.08(1H, d, J=9.0 Hz), 7.30(1H, d, J=8.7 Hz), 7.47-7.52(2H, m), 7.97(1H, d, J=2.7 Hz), 8.83(1H, d, J=2.4 Hz), 11.05(1H, s), 12.17(1H, s).
    • Example 125 Preparation of the Compound of Compound No. 125
  • Using 5-chlorosalicylic acid and 2-methylsulfanyl-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 79.2%.
  • 1H-NMR(DMSO-d6): δ 2.57(3H, s), 7.07(1H, d, J=8.7 Hz), 7.52(1H, dd, J=8.7, 2.4 Hz), 7.55(1H, dd, J=8.4, 1.5 Hz), 7.63(1H, d, J=8.1 Hz), 8.00(1H, d, J=2.4 Hz), 8.48(1H, d, J=1.5 Hz), 10.79(1H, s), 12.26(1H, s).
    • Example 126 Preparation of the Compound of Compound No. 126
  • Using 5-bromosalicylic acid and 2-(1-pyrrolidinyl)-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.5%.
  • 1H-NMR(DMSO-d6): δ 1.86-1.91(4H, m), 3.20-3.26(4H, m), 6.99(1H, d, J=8.7 Hz), 7.07(1H, d, J=8.7 Hz), 7.43(1H, dd, J=8.7, 2.1 Hz), 7.62(1H, dd, J=8.7, 2.4 Hz), 7.94(1H, d, J=2.1 Hz), 8.17(1H, d, J=2.4 Hz), 10.54(1H, s), 12.21(1H, s).
    • Example 127 Preparation of the Compound of Compound No. 12
  • Using 5-bromosalicylic acid and 2-morpholino-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.9%.
  • 1H-NMR(DMSO-d6): δ 2.90(4H, dd, J=4.5, 4.2 Hz), 3.84(4H, dd, J=4.8, 4.2 Hz), 7.09(1H, d, J=8.4 Hz), 7.48(2H, s), 7.61(1H, dd, J=8.4, 2.7 Hz), 8.13(1H, d, J=2.7 Hz), 8.90(1H, s), 11.21(1H, s), 12.04(1H, s).
    • Example 128 Preparation of the Compound of Compound No. 128
  • Using 5-chlorosalicylic acid and 4-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 75.0%, white solid
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=9.0 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.74(2H, d, J=8.7 Hz), 7.90(1H, d, J=2.7 Hz), 7.95(2H, d, J=9.0 Hz), 10.65(1H, s), 11.59(1H, s).
    • Example 129 Preparation of the Compound of Compound No. 129
  • Using 5-bromosalicylic acid and 2-chloro-4-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 34.9%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.7 Hz), 7.64(1H, dd, J=8.7, 2.7 Hz), 7.79(1H, dd, J=9.0, 2.1 Hz), 7.99(1H, d, J=2.1 Hz), 8.11(1H, d, J=2.4 Hz), 8.73(1H, d, J=9.0 Hz), 11.15(1H, s), 12.42(1H, s).
    • Example 130 Preparation of the Compound of Compound No. 130
  • Using 5-chloro-N-[2-chloro-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 113) and acetyl chloride as the raw materials, the same operation as the Example 96 gave the title compound.
  • Yield: 34.0%.
  • 1H-NMR(CDCl3): δ 2.39(3H, s), 7.16(1H, d, J=8.7 Hz),7.37(1H, ddd, J=8.7, 2.4, 0.6 Hz), 7.51-7.56(2H, m), 7.97(1H, d, J=3.0 Hz), 8.85(1H, s), 8.94(1H, d, J=1.8 Hz).
    • Example 131 Preparation of the Compound of Compound No. 131
  • Using 5-nitrosalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 31.1%.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=9.3 Hz), 7.52(1H, dd, J=8.4, 2.1 Hz), 7.81(1H, d, J=8.4 Hz), 8.21(1H, dd, J=9.0, 3.3 Hz), 8.82(1H, d, J=3.0 Hz), 8.93(1H, d, J=2.4 Hz), 12.18(1H, s).
    • Example 132 Preparation of the Compound of Compound No. 132
  • Using 5-methylsalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 15.8%.
  • 1H-NMR(CDCl3): δ 2.36(3H, s), 6.95(1H, d, J=8.1 Hz), 7.26-7.31(2H, m), 7.37(1H, dd, J=8.4, 1.8 Hz), 7.56(1H, d, J=8.4 Hz), 8.65(1H, br s), 8.80(1H, d, J=1.8 Hz), 11.33(1H, br s).
    • Example 133 Preparation of the Compound of Compound No. 133
  • Using 5-methoxysalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 56.4%.
  • 1H-NMR(DMSO-d6): δ 3.77(3H, s), 6.91(1H, d, J=9.0 Hz), 7.07(1H, dd, J=8.7, 3.0 Hz), 7.20(1H, t, J=1.8 Hz), 7.52-7.54(3H, m), 10.33(1H, s), 11.44(1H, s).
    • Example 134 Preparation of the Compound of Compound No. 134
  • Using 5-methylsalicylic acid and 4-chloro-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 70.4%.
  • 1H-NMR(DMSO-d6): δ 2.29(3H, s), 6.91(1H, d, J=8.3 Hz), 7.27(1H, ddd, J=8.3, 2.2, 0.6 Hz), 7.71(1H, d, J=2.2 Hz), 7.72(1H, d, J=8.5 Hz), 8.02(1H, dd, J=8.5, 2.5 Hz), 8.33(1H, d, J=2.5 Hz), 10.64(1H, s), 11.25(1H, s).
    • Example 135 Preparation of the compound of Compound No. 135
  • Using 5-methylsalicylic acid and 4-methyl-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 63.7%.
  • 1H-NMR(DMSO-d6): δ 2.29(3H, s), 2.42(3H, s), 6.89(1H, d, J=8.4 Hz), 7.26(1H, ddd, J=8.4, 2.1, 0.6 Hz), 7.44(1H, d, J=8.1 Hz), 7.75(1H, d, J=2.1 Hz), 7.86(1H, dd, J=8.4, 1.8 Hz), 8.13(1H.d, J=2.1 Hz), 10.50(1H, s), 11.42(1H, s).
    • Example 136 Preparation of the Compound of Compound No. 136
  • Using 5-methylsalicylic acid and 2-methyl-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 14.2%, white solid.
  • 1H-NMR(DMSO-d6): δ 2.29(3H, s), 2.38(3H, s), 6.94(1H, d, J=8.4 Hz), 7.27(1H, ddd, J=8.4, 2.4, 0.6 Hz), 7.44(1H, dd, J=8.1, 1.5 Hz), 7.52(1H, d, J=7.8 Hz), 7.84(1H, d, J=2.4 Hz), 8.46(1H, d, J=1.5 Hz), 10.55(1H, s), 11.72(1H, s).
    • Example 137 Preparation of the Compound of Compound No. 137
  • Using 5-methylsalicylic acid and 4-methoxy-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.1%, slightly yellow solid.
  • 1H-NMR(DMSO-d6): δ 2.35(3H, s), 3.89(3H, s), 6.88(1H, d, J=8.4 Hz), 7.26(1H, dd, J=8.1, 1.8 Hz), 7.30(1H, d, J=8.4 Hz), 7.77(1H, d, J=2.1 Hz), 7.92(1H, dd, J=9.0, 2.7 Hz), 8.04(1H, d, J=2.7 Hz), 10.42(1H, s), 11.54(1H, s).
    • Example 138 Preparation of the Compound of Compound No. 138
  • Using 5-methylsalicylic acid and 2-methoxy-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 77.9%.
  • 1H-NMR(CDCl3): δ 2.35(3H, s), 4.02(3H, s), 6.93(1H, d, J=9.0 Hz), 6.98(1H, d, J=8.4 Hz), 7.25-7.28(2H, m), 7.36(1H, ddd, J=8.4, 2.1, 0.9 Hz), 8.65(1H, br s), 8.73(1H, d, J=2.1 Hz), 11.69(1H, s).
    • Example 139 Preparation of the Compound of Compound No. 139
  • Using 5-bromosalicylic acid and aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 68.8%.
  • mp 229-230° C.
  • 1H-NMR(DMSO-d6): δ 6.96(1H, d, J=9.0 Hz), 7.12-7.18(1H, m), 7.35-7.41(2H, m), 7.58(1H, dd, J=8.7, 2.7 Hz), 7.67-7.71(2H, m), 8.08(1H, d, J=2.7 Hz), 10.43(1H, s), 11.87(1H, s).
    • Example 140 Preparation of the Compound of Compound No. 140
  • Using 5-bromosalicylic acid and 3-chloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 63.1%.
  • mp 231-232° C.
  • 1H-NMR(DMSO-d6): δ 6.97(1H, d, J=8.7 Hz), 7.19-7.22(1H, m), 7.38-7.43(1H, m), 7.57-7.63(2H, m), 7.91-7.92(1H, m), 8.01(1H, d, J=2.7 Hz), 10.49(1H, s), 11.64(1H, s).
    • Example 141 The Compound of Compound No. 141
  • This compound is a commercially available compound.
    • Supplier: Tokyo Kasei.
    • Catalog code number: B0897.
    Example 142 Preparation of the Compound of Compound No. 142
  • Using 5-chlorosalicylic acid and 2,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 10.8%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=9.0 Hz), 7.24-7.28(1H, m), 7.50-7.54(1H, m), 7.61(1H, dd, J=9.0, 3.0 Hz), 7.97(1H, d, J=2.7 Hz), 8.58(1H, d, J=2.4 Hz), 11.02(1H, s), 12.35(1H, brs).
    • Example 143 Preparation of the Compound of Compound No. 143
  • Using 5-bromosalicylic acid and 3,4-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 58.2%.
  • mp 249-251° C.
  • 1H-NMR(DMSO-d6): δ 6.97(1H, d, J=8.7 Hz), 7.57-7.70(3H, m), 7.98(1H, d, J=2.7 Hz), 8.10(1H, d, J=2.4 Hz), 10.54(1H, s), 11.55(1H, s).
    • Example 144 Preparation of the Compound of Compound No. 144
  • Using 5-bromosalicylic acid and 3,5-difluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 36.3%.
  • mp 259-261° C.
  • 1H-NMR(DMSO-d6): δ 6.96-7.04(2H, m), 7.45-7.54(2H, m), 7.58(1H, dd, J=8.7, 2.7Hz), 7.94(1H, d, J=2.7 Hz), 10.60(1H, s) 11.48(1H, s).
    • Example 145 Preparation of the Compound of Compound No. 172
  • Using O-acetylsalicyloyl chloride and 3,5-dichloroaniline as the raw materials, the same operation as the Example 2(1) gave the title compound.
  • Yield: 73.5%.
  • mp 167-168° C.
  • 1H-NMR(CDCl3): δ 2.35(3H, s), 7.14-7.18(2H, m), 7.35-7.40(1H, m), 7.52-7.57(3H, m), 7.81(1H, dd, J=7.8, 1.8 Hz), 8.05(1H, brs).
    • Example 146 Preparation of the Compound of Compound No. 145
  • Using 2-acetoxy-N-(3,5-dichlorophenyl)benzamide (Compound No. 172) as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 60.3%.
  • mp 218-219° C.
  • 1H-NMR(DMSO-d6): δ 6.95-7.02(2H, m), 7.35-7.36(1H, m), 7.42-7.47(1H, m), 7.83-7.87(3H, m), 10.54(1H, s), 11.35(1H, s).
    • Example 147 Preparation of the Compound of Compound No. 146
  • Using 5-fluorosalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 33.3%.
  • mp 258-260° C.
  • 1H-NMR(DMSO-d6): δ 7.00-7.05(1H, m), 7.28-7.37(2H, m), 7.63(1H, dd, J=9.3, 3.3Hz), 7.84(2H, d, J=2.1 Hz), 10.56(1H, s), 11.23(1H, s).
    • Example 148 Preparation of the Compound of Compound No. 147
  • Using 5-chlorosalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 41.2%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=9.0 Hz), 7.36-7.37(1H, m), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.83-7.84(3H, m), 10.56(1H, s), 11.44(1H, s).
    • Example 149 Preparation of the Compound of Compound No. 148
  • Using 5-bromosalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 61.6%.
  • mp 243-244° C.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.7 Hz), 7.36-7.37(1H, m), 7.59(1H, dd, J=9.0, 2.4 Hz), 7.83(2H, d, J=1.8 Hz), 7.95(1H, d, J=2.4 Hz), 10.56(1H, s), 11.46(1H, s).
    • Example 150 Preparation of the Compound of Compound No. 149
  • Using 5-iodosalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.4%.
  • mp 244-245° C.
  • 1H-NMR(DMSO-d6): δ 6.84(1H, d, J=9.0 Hz), 7.35-7.37(1H, m), 7.72(1H, dd, J=9.0, 2.1 Hz), 7.83(2H, d, J=1.8 Hz), 8.09(1H, d, J=2.1 Hz), 10.55(1H, s), 11.45(1H, s).
    • Example 151 Preparation of the Compound of Compound No. 150
  • Using 3,5-dibromosalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.2%.
  • mp 181-182° C.
  • 1H-NMR(DMSO-d6): δ 7.42-7.43(1H, m), 7.80(2H, d, J=1.8 Hz), 8.03(1H, d, J=2.1 Hz), 8.17(1H, d, J=2.1 Hz), 10.82(1H, s).
    • Example 152 Preparation of the Compound of Compound No. 151
  • Using 4-chlorosalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 57.2%.
  • mp 255-256° C.
  • 1H-NMR(DMSO-d6): δ 7.03-7.06(2H, m), 7.34-7.36(1H, m), 7.82-7.85(3H,m), 10.51(1H, s), 11.70(1H, brs).
    • Example 153 Preparation of the Compound of Compound No. 152
  • Using 5-nitrosalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 83.1%.
  • mp 232-233° C.
  • 1H-NMR(DMSO-d6): δ 7.16(1H, d, J=9.6 Hz), 7.37-7.39(1H, m), 7.84(1H, d, J=2.1 Hz), 8.29(1H, dd, J=9.0, 3.0 Hz), 8.65(1H, d, J=3.0 Hz), 10.83(1H, s).
    • Example 154 Preparation of the Compound of Compound No. 153
  • Using 5-methylsalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 71.0%.
  • mp 216-217° C.
  • 1H-NMR(DMSO-d6): δ 2.28(3H, s), 6.90(1H, d, J=8.4 Hz), 7.26(1H, dd, J=8.7, 1.8 Hz), 7.34-7.36(1H, m), 7.67(1H, d, J=1.5 Hz), 7.85(2H, d, J=1.8 Hz), 10.52(1H, s), 11.15(1H, s).
    • Example 155 Preparation of the Compound of Compound No. 154
  • Using 5-methoxysalicylic acid and 3,5-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 29.8%.
  • mp 230-232° C.
  • 1H-NMR(DMSO-d6): δ 3.76(3H, s), 6.95(1H, d, J=8.7 Hz), 7.08(1H, dd, J=9.0, 3.0 Hz), 7.35-7.36(1H, m), 7.40(1H, d, J=3.0 Hz), 7.85(2H, d, J=1.5 Hz), 10.55(1H, s), 10.95(1H, s).
    • Example 156 Preparation of the Compound of Compound No. 155
  • Using 5-bromosalicylic acid and 3,4,5-trichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 78.6%.
  • mp 297-299° C.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=9.0 Hz), 7.58(1H, dd, J=8.4, 2.4 Hz), 7.95(1H, d, J=2.4 Hz), 8.03(1H, s), 10.58(1H, s), 11.49(1H, s).
    • Example 157 Preparation of the Compound of Compound No. 156
  • Using 5-bromosalicylic acid and 3,5-dichloro-4-hydroxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 22.5%.
  • 1H-NMR(DMSO-d6): δ 6.96(1H, d, J=8.7 Hz), 7.58(1H, dd, J=8.7, 2.4 Hz), 7.76(2H, s), 8.01(1H, d, J=2.4 Hz), 10.03(1H, s), 10.36(1H, s), 11.67(1H, brs).
    • Example 158 Preparation of the Compound of Compound No. 157
  • Using 5-chlorosalicylic acid and 2,3,4,5,6-pentafluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 58.6%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.7 Hz), 7.53(1H, dd, J=8.7, 2.7 Hz), 7.91(1H, d, J=2.7 Hz), 10.38(1H, brs), 11.74(1H, brs).
    • Example 159 Preparation of the Compound of Compound No. 158
  • Using 5-bromosalicylic acid and 3,5-dinitroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 32.2%.
  • mp 258-260° C.
  • 1H-NMR(DMSO-d6): δ 6.98-7.02(1H, m), 7.59-7.63(1H, m), 7.96-7.97(1H, m), 8.56-8.58(1H, m), 9.03-9.05(2H, m), 11.04(1H, s), 11.39(1H, brs).
    • Example 160 Preparation of the Compound of Compound No. 159
  • Using 5-chlorosalicylic acid and 2,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 75.7%.
  • 1H-NMR(DMSO-d6): δ 1.27(9H, s), 1.33(9H, s), 7.04(1H, d, J=9.0 Hz), 7.26(1H, dd, J=8.4, 2.1 Hz), 7.35-7.38(2H, m), 7.49(1H, dd, J=8.7, 2.7 Hz), 8.07(1H, d, J=2.4 Hz), 10.22(1H, s), 12.38(1H, br s).
    • Example 161 Preparation of the Compound of Compound No. 160
  • Using 5-chlorosalicylic acid and 5-[(1,1-dimethyl)ethyl]-2-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 89.5%.
  • 1H-NMR(DMSO-d6): δ 1.28(9H, s), 3.33(3H, s), 7.01(1H, d, J=8.7 Hz), 7.05(1H, d, J=9.0 Hz), 7.11(1H, dd, J=8.7, 2.4 Hz), 7.47(1H, dd, J=9.0, 3.0 Hz), 7.99(1H, d, J=3.0 Hz), 8.49(1H, d, J=2.4 Hz), 10.78(1H, s), 12.03(1H, s).
    • Example 162 Preparation of the Compound of Compound No. 161
  • Using 5-bromosalicylic acid and 3,5-dimethylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 58.1%.
  • mp 188-190° C.
  • 1H-NMR(DMSO-d6): δ 2.28(6H, s), 6.80(1H, s), 6.96(1H, d, J=8.7 Hz), 7.33(2H, s), 7.58(1H, dd, J=9.0, 2.4 Hz), 8.10(1H, d, J=2.4 Hz), 10.29(1H, s), 11.93(1H, brs).
    • Example 163 Preparation of the Compound of Compound No. 162
  • Using 5-chlorosalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 34.1%.
  • 1H-NMR(CDCl3): δ 1.26(18H, s), 6.99(1H, d, J=8.7 Hz), 7.29(1H, t, J=1.8 Hz), 7.39(1 dd, J=9.0, 2.4 Hz), 7.41(2H, d, J=1.5 Hz), 7.51(1H, d, J=2.1 Hz), 7.81(1H, br s), 12.01(1H, s).
    • Example 164 Preparation of the Compound of Compound No. 163
  • Using 5-bromosalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 45.2%.
  • 1H-NMR(DMSO-d6): δ 1.30(18H, s), 6.95(1H, d, J=8.7 Hz), 7.20(1H, t, J=1.5 Hz), 7.56(2H, d, J=1.5 Hz), 7.58(1H, dd, J=8.7, 2.4 Hz), 8.12(1H, d, J=2.7 Hz), 10.39(1H, s), 11.98(1H, s).
    • Example 165 Preparation of the Compound of Compound No. 164
  • Using 5-chlorosalicylic acid and 2-amino-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 77.5%.
  • 1H-NMR(DMSO-d6): δ 1.23(6H, s), 1.24(6H, s), 1.64(4H, s), 2.19(3H, s), 7.13(1H, d, J=9.0 Hz), 7.20(1H, s), 7.49(1H, dd, J=8.7, 2.7 Hz), 7.67(1H, s), 8.04(1H, d, J=2.7 Hz), 10.23(1H, s), 12.26(1H, s).
    • Example 166 Preparation of the Compound of Compound No. 165
  • Using 5-chlorosalicylic acid and 3-aminobiphenyl as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 75.6%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.7 Hz), 7.35-7.44(1H, m), 7.45-7.54(5H, m), 7.65-7.68(2H, m), 7.72(1H, dt, J=7.2, 2.1 Hz).7.99(1H, d, J=3.0 Hz), 8.03(1H, m), 10.50(1H, s), 11.83(1H, brs).
    • Example 167 Preparation of the Compound of Compound No. 166
  • Using 5-chlorosalicylic acid and 3-amino-4-methoxybiphenyl as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 37.0%.
  • 1H-NMR(DMSO-d6): δ 3.95(3H, s), 7.08(1H, d, J=8.7 Hz), 7.20(1H, d, J=8.4 Hz), 7.34(1H, t, J=7.2 Hz), 7.40-7.50(4H, m), 7.62(1H, d, J=8.7 Hz), 8.00(1H, d, J=3.0 Hz), 8.77(1H, d, J=2.1 Hz), 10.92(1H, s), 12.09(1H, s).
    • Example 168 Preparation of the Compound of Compound No. 167
  • Using 5-bromosalicylic acid and 2,5-dimethoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 39.7%.
  • 1H-NMR(DMSO-d6): δ 3.72(3H, s), 3.84(3H, s), 6.66(1H, ddd, J=9.0, 3.0, 0.6 Hz), 6.99-7.03(2H, m), 7.58(1H, ddd, J=9.0, 2.7, 0.6 Hz), 8.10(1H, dd, J=2.4, 0.6 Hz), 8.12(1H, d, J=3.0 Hz), 10.87(1H, s), 12.08(1H, s).
    • Example 169 Preparation of the Compound of Compound No. 168
  • Using 5-bromosalicylic acid and 3,5-dimethoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 40.3%.
  • mp 207-209° C.
  • 1H-NMR(DMSO-d6): δ 3.75(6H, s), 6.30-6.32(1H, m), 6.94-6.97(3H, m), 7.57(1H, dd, J=8.7, 2.4 Hz), 8.04(1H, d, J=2.4 Hz), 10.32(1H, s), 11.78(1H, s).
    • Example 170 Preparation of the Compound of Compound No. 169
  • Using 5-chlorosalicylic acid and 3-acetylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 80.0%.
  • 1H-NMR(DMSO-d6): δ 2.60(3H, s), 7.03(1H, d, J=9.0 Hz), 7.49(1H, dd, J=9.0, 3.0 Hz), 7.54(1H, t, J=8.1 Hz), 7.76(1H, dq, J=7.8, 0.9 Hz), 7.96-8.00(2H, m), 8.30(1H, t, J=1.8 Hz), 10.56(1H, s), 11.75(1H, s).
    • Example 171 Preparation of the Compound of Compound No. 170
  • Using 5-bromosalicylic acid and 5-aminoisophthalic acid dimethyl ester as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 74.1%.
  • mp 254-256° C.
  • 1H-NMR(DMSO-d6): δ 3.92(6H, s), 6.97(1H, d, J=9.0 Hz), 7.60(1H, dd, J=9.0, 2.4 Hz), 8.06(1H, d, J=2.4 Hz), 8.24-8.25(1H, m), 8.62(2H, m), 10.71(1H, s), 11.57(1H, s).
    • Example 172 The Compound of Compound No. 171
  • This compound is a commercially available compound.
    • Supplier: Maybridge.
    • Catalog code number: RDR 01434
    Example 173 Preparation of the Compound of Compound No. 173
  • Using 5-methylsalicylic acid and 2,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 61.1%.
  • 1H-NMR(DMSO-d6): δ 1.27(9H, s), 1.33(9H, s), 2.28(3H, s), 6.89(1H, d, J=8.1 Hz), 7.24(1H, d, J=2.1 Hz), 7.27(1H, d, J=2.1 Hz), 7.32(1H, d, J=2.4 Hz), 7.37(1H, d, J=8.4 Hz), 7.88(1H, d, J=1.5 Hz), 10.15(1H, s), 11.98(1H, br s).
    • Example 174 Preparation of the Compound of Compound No. 174
  • Using N-{3,5-bis[(1,1-dimethyl)ethyl]phenyl}-5-chloro-2-hydroxybenzamide (Compound No. 162) and acetyl chloride as the raw materials, the same operation as the Example 96 gave the title compound.
  • Yield: 66.1%.
  • 1H-NMR(CDCl3): δ 1.34(18H, s), 2.36(3H, s), 7.12(1H, d, J=8.4 Hz),7.25(1H, d, J=1.5 Hz), 7.44(2H, d, J=1.2 Hz), 7.47(1H, dd, J=8.7, 2.7 Hz), 7.87(1H, d, J=2.4 Hz), 7.98(1H, s).
    • Example 175 Preparation of the Compound of Compound No. 175
  • Using 5-nitrosalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 46.7%.
  • 1H-NMR(CDCl3): δ 1.37(18H, s), 7.13(1H, d, J=9.3 Hz), 7.32(1H, t, J=1.8 Hz), 7.46(2H, d, J=1.8 Hz), 8.07(1H, s), 8.33(1H, dd, J=9.3, 2.1 Hz), 8.59(1H, d, J=2.4 Hz), 13.14(1H, s).
    • Example 176 Preparation of the Compound of Compound No. 176
  • Using 5-methylsalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 16.3%.
  • 1H-NMR(CDCl3): δ 1.35(18H, s), 2.35(3H, s), 6.94(1H, d, H=8.4 Hz), 7.23-7.28(2H, m), 7.31(1H, s), 7.42(1H, d, J=1.8 Hz), 7.88(1H, s), 11.86(1H, s).
    • Example 177 Preparation of the Compound of Compound No. 177
  • Using 5-methoxysalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 12.7%.
  • 1H-NMR(DMSO-d6): δ 1.30(18H, s), 3.77(3H, s), 6.91(1H, d, J=9.0 Hz), 7.07(1H, dd, J=8.7, 3.0 Hz), 7.19-7.20(1H, m), 7.52-7.54(3H, m), 10.33(1H, s), 11.44(1H, s).
    • Example 178 Preparation of the Compound of Compound No. 178
  • Using 5-chloro-N-{5-[(1,1-dimethyl)ethyl]-2-methoxyphenyl}-2-hydroxybenzamide (Compound No. 160) and acetyl chloride as the raw materials, the same operation as the Example 96 gave the title compound.
  • Yield: 87.5%.
  • 1H-NMR(CDCl3): δ 1.35(9H, s), 2.37(3H, s), 3.91(3H, s), 6.86(1H, d, J=8.7 Hz),7.12(1H, dd, J=8.7, 2.4 Hz), 7.13(1H, d, J=9.0 Hz), 7.47(1H, dd, J=9.0, 2.4 Hz), 8.02(1H, d, J=2.7 Hz), 8.66(1H, d, J=2.4 Hz), 8.93(1H, s).
    • Example 179 Preparation of the Compound of Compound No. 179
  • Using 5-methylsalicylic acid and 5-[(1,1-dimethyl)ethyl]-2-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 84.7%.
  • 1H-NMR(CDCl3): δ 1.35(9H, s), 2.34(3H, s), 3.93(3H, s), 6.86(1H, d, J=8.7 Hz), 6.93(1H, d, J=8.4 Hz), 7.12(1H, dd, J=8.7, 2.4 Hz), 7.24(1H, dd, J=8.4, 1.8 Hz), 7.27(1H, br s), 8.48(1H, d, J=2.4 Hz), 8.61(1H, brs), 11.95(1H, s).
    • Example 180 Preparation of the Compound of Compound No. 179
  • Using 5-bromosalicylic acid and 2-aminothiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 12.0%.
  • mp 212° C. (dec.).
  • 1H-NMR(DMSO-d6): δ 6.94(1H, brd, J=8.0 Hz), 7.25(1H, brd, J=3.2 Hz), 7.56(2H, m), 8.05(1H, d, J=2.8 Hz).
    • Example 181 Preparation of the Compound of Compound No. 186 (1) 2-Amino-4-[(1,1-dimethyl)ethyl]thiazole
  • A mixture of 1-bromo-3,3-dimethyl-2-butanone (5.03 g, 28.1 mmol), thiourea (2.35 g, 30.9 mmol) and ethanol (30 mL) was refluxed for 1.5 hours. After cooling, the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=2:1→1:1) to give the title compound (3.99 g, 90.9%) as an yellowish white powder.
  • 1H-NMR(CDCl3): δ 1.26(9H, s), 4.96(2H, brs), 6.09(1H, s).
  • When the method described in Example 181(1) is referred in the following examples, solvents such as ethanol or the like were used as the reaction solvent.
    • (2) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]thiazol-2-yl}benzamide
  • Using 2-acetoxy-5-bromobenzoic acid and 2-amino-4-[(1,1-dimethyl)ethyl]thiazole as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 59.4%.
  • 1H-NMR(CDCl3): δ 1.31(9H, s), 2.44(3H, s), 6.60(1H, s), 7.13(1H, d, J=8.4 Hz), 7.68(1H, dd, J=8.7, 2.4 Hz), 8.17(1H, d, J=2.4 Hz), 9.72(1H, brs).
    • (3) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]thiazol-2-yl}-2-hydroxybenzamide (Compound No. 186)
  • 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]thiazol-2-yl}benzamide (100.1 mg, 0.25 mmol) was dissolved in tetrahydrofuran (3 mL). 2N Sodium hydroxide (0.2 ml) was added, and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was crystallized (isopropyl ether/n-hexane) to give the title compound (70.1 mg, 78.9%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 1.30(9H, s), 6.80(1H, brs), 6.95(1H, brs), 7.57(1H, brs), 8.06(1H, d, J=2.4 Hz), 11.82(1H, brs), 13.27(1H, brs).
    • Example 182 Preparation of the Compound of Compound No. 181 (1) 2-Acetoxy-5-bromo-N-{5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl}benzamide
  • 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]thiazol-2-yl}benzamide (compound of Example 181(2); 0.20 g, 0.50 mmol) was dissolved in acetonitrile (10 mL). N-Bromosuccinimide (97.9 mg, 0.55 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound as a crude product.
    • (2) 5-Bromo-N-{5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl}-2-hydroxybenzamide (Compound No. 181)
  • Using 2-acetoxy-5-bromo-N-{5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl}benzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 90.9% (2 steps).
  • 1H-NMR(DMSO-d6): δ 1.42(9H, s), 6.99(1H, d, J=8.7 Hz), 7.61(1H, dd, J=8.7, 2.7 Hz), 8.02(1H, d, J=2.4 Hz), 11.79(1H, brs), 12.00(1H, brs).
    • Example 183 Preparation of the Compound of Compound No. 182
  • Using 5-bromosalicylic acid and 2-amino-5-bromo-4-(trifluoromethyl)thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 22.4%.
  • mp 215° C. (dec.).
  • 1H-NMR(DMSO-d6): δ 7.00(1H, d, J=8.8 Hz), 7.61(1H, dd, J=8.8, 2.8 Hz), 7.97(1H, d, J=2.4 Hz).
  • [2-Amino-5-bromo-4-(trifluoromethyl)thiazole: Refer to “Journal of Heterocyclic Chemistry”, (USA), 1991, Vol. 28, p. 1017.]
    • Example 184 Preparation of the Compound of Compound No. 183 (1) α-Bromo-pivaloylacetonitrile
  • Pivaloylacetonitrile (1.00 g, 7.99 mmol) was dissolved in carbon tetrachloride (15 mL). N-Bromosuccinimide (1.42 g, 7.99 mmol) was added, and the mixture was refluxed for 15 minutes. After cooling, the insoluble matter was filtered off, and the residue obtained by evaporation of the filtrate under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title compound (1.43 g, 87.9%) as an yellowish brown oil.
  • 1H-NMR(CDCl3): δ 1.33(9H, s), 5.10(1H, s).
  • When the method described in Example 184(1) is referred in the following examples, N-bromosuccinimide was used as the brominating agent. As the reaction solvent, solvents such as carbon tetrachloride or the like were used.
    • (2) 2-Amino-5-cyano-4-[(1,1-dimethyl)ethyl]thiazole
  • Using α-bromo-pivaloylacetonitrile and thiourea as the raw materials, the same operation as the Example 181(1) gave the title compound.
  • Yield: 66.3%.
  • 1H-NMR(CDCl3): δ 1.41(9H, s), 5.32(2H, s).
    • (3) 5-Chloro-N-{5-cyano-4-[(1,1-dimethyl)ethyl]thiazol-2-yl}-2-hydroxybenzamide (Compound No. 183)
  • Using 5-chlorosalicylic acid and 2-amino-5-cyano-4-[(1,1-dimethyl)-ethyl]thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 63.4%.
  • 1H-NMR(DMSO-d6): δ 1.43(9H, s), 7.06(1H, d, J=8.7 Hz), 7.51(1H, dd, J=8.7, 3.0 Hz), 7.85(1H, d, J=2.7 Hz), 12.31(2H, br).
    • Example 185 Preparation of the Compound of Compound No. 184
  • Using 5-bromosalicylic acid and 2-amino-5-cyano-4-[(1,1-dimethyl)-ethyl]thiazole (compound of Example 184(2)) as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 61.3%.
  • 1H-NMR(DMSO-d6): δ 1.43(9H, s), 7.00(1H, d, J=8.7 Hz), 7.62(1H, dd, J=8.7, 2.7 Hz), 7.97(1H, d, J=2.7 Hz), 11.75(1H, br), 12.43(1H, br).
    • Example 186 Preparation of the Compound of Compound No. 185
  • Using 5-bromosalicylic acid and 2-amino-5-methylthiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 12.9%.
  • 1H-NMR(DMSO-d6): δ 2.33(3H, s), 6.91(1H, d, J=7.6 Hz), 7.26(1H, s), 7.54(1H, d, J=9.6 Hz), 8.03(1H, d, J=2.8 Hz).
    • Example 187 Preparation of the Compound of Compound No. 187
  • Using 5-bromosalicylic acid and 2-amino-4,5-dimethylthiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 14.4%.
  • 1H-NMR(DMSO-d6): δ 2.18(3H, s), 2.22(3H, s), 6.89(1H, d, J=8.8 Hz), 7.51(1H, d, J=6.8 Hz), 8.02(1H, d, J=2.8 Hz), 13.23(1H, brs).
    • Example 188 Preparation of the Compound of Compound No. 188
  • Using 5-bromosalicylic acid and 2-amino-5-methyl-4-phenylthiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 27.7%.
  • mp 243-244° C.
  • 1H-NMR(CD3OD): δ 2.47(3H, s), 6.92(1H, d, J=8.7 Hz), 7.36-7.41(1H, m), 7.44-7.50(2H, m), 7.53(1H, dd, J=9.0, 2.7 Hz), 7.57-7.61(2H, m), 8.16(1H, d, J=2.7 Hz).
  • [2-Amino-5-methyl-4-phenylthiazole: Refer to “Yakugaku Zasshi: Journal of The Pharmaceutical Society of Japan”, 1961, Vol. 81, p. 1456.]
    • Example 189 Preparation of the Compound of Compound No. 189
  • Using (4-fluorophenyl)acetone as the raw material, the same operation as the Examples 184(1)-(3) gave the title compound.
  • Yield: 28.8% (3 steps).
    • (1) α-Bromo-(4-fluorophenyl)acetone
  • 1H-NMR(CDCl3): δ 2.33(3H, s), 5.41(1H, s), 7.07(2H, t, J=8.7 Hz), 7.43(2H, dd, J=8.7, 5.1 Hz).
    • (2) 2-Amino-4-methyl-5-(4-fluorophenyl)thiazole
  • 1H-NMR(CDCl3): δ 2.27(3H, s), 4.88(2H, s), 7.07(2H, t, J=8.7 Hz), 7.32(2H, dd, J=8.7, 5.4 Hz).
    • (3) 5-Bromo-N-[4-methyl-5-(4-fluorophenyl)thiazol-2-yl]-2-hydroxybenzamide (Compound No. 189)
  • 1H-NMR(DMSO-d6): δ 2.36(3H, s), 6.95(1H, d, J=8.4 Hz), 7.33(2H, t, J=8.7 Hz), 7.52-7.59(3H, m), 8.06(1H, d, J=3.0 Hz), 12.01-13.65(2H, br).
    • Example 190 Preparation of the Compound of Compound No. 190
  • Using 3-(trifluoromethyl)phenylacetone as the raw material, the same operation as the Examples 184(1)-(3) gave the title compound.
  • Yield: 39.8% (3 steps).
    • (1) α-Bromo-3-(trifluoromethyl)phenylacetone
  • 1H-NMR(CDCl3): δ 2.38(3H, s), 5.43(1H, s), 7.52(1H, t, J=7.8 Hz), 7.61-7.66(2H, m), 7.69-7.70(1H, m).
    • (2) 2-Amino-4-methyl-5-[3-(trifluoromethyl)phenyl]thiazole
  • 1H-NMR(CDCl3): δ 2.32(3H, s), 4.95(2H, s), 7.46-7.56(3H, m), 7.59-7.61(1H, m).
    • (3) 5-Bromo-N-{4-methyl-5-[3-(trifluoromethyl)phenyl]thiazol-2-yl}-2-hydroxy-benzamide (Compound No. 190)
  • 1H-NMR(DMSO-d6): δ 2.40(3H, s), 6.97(1H, d, J=8.7 Hz), 7.59(1H, dd, J=8.7, 2.4 Hz), 7.71-7.84(4H, m), (2H, m), 8.06(1H, d, J=2.4 Hz), 12.09(1H, br), 12.91-13.63(1H, br).
    • Example 191 Preparation of the Compound of Compound No. 191
  • Using 2,2-dimethyl-3-hexanone as the raw material, the same operation as the Examples 184(1)-(3) gave the title compound.
  • Yield: 17.0% (3 steps).
    • (2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-ethylthiazole
  • 1H-NMR(CDCl3): δ 1.21(3H, t, J=7.5 Hz), 1.32(9H, s), 2.79(2H, q, J=7.5 Hz), 4.63(2H, brs).
    • (3) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-ethylthiazol-2-yl}-2-hydroxybenzamide (Compound No. 191)
  • 1H-NMR(CDCl3): δ 1.32(3H, t, J=7.5 Hz), 1.41(9H, s), 2.88(2H, q, J=7.5 Hz), 6.84(1H, d, J=9.0 Hz), 7.44(1H, dd, J=8.7, 2.4 Hz), 8.05(1H, d, J=2.7 Hz), 11.46(2H, br).
    • Example 192 Preparation of the Compound of Compound No. 192
  • Using 5-bromosalicylic acid and 2-amino-4-ethyl-5-phenylthiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 17.4%.
  • mp 224-225° C.
  • 1H-NMR(DMSO-d6): δ 1.24(3H, t, J=7.6 Hz), 2.70(2H, q, J=7.6 Hz), 6.95(1H, brd, J=7.6 Hz), 7.39-7.42(1H, m), 7.45-7.51(4H, m), 7.56(1H, brd, J=8.0 Hz), 8.06(1H, d, J=2.8 Hz), 11.98(1H, brs).
    • Example 193 Preparation of the Compound of Compound No. 193
  • Using benzyl isopropyl ketone as the raw material, the same operation as the Examples 184(1)-(3) gave the title compound.
  • Yield: 4.4% (3 steps).
    • (2) 2-Amino-4-isopropyl-5-phenylthiazole
  • 1H-NMR(CDCl3): δ 1.23(6H, d, J=6.6 Hz), 3.05(1H, m), 4.94(2H, s), 7.28-7.41(5H, m).
    • (3) 5-Bromo-N-(4-isopropyl-5-phenylthiazol-2-yl)-2-hydroxybenzamide (Compound No. 193)
  • 1H-NMR(DMSO-d6): δ 1.26(6H, d, J=6.0 Hz), 3.15(1H, m), 6.98(1H, brs), 7.43-7.53(5H, m), 7.59(1H, brs), 8.08(1H, d, J=2.7 Hz), 11.90(1H, brd), 13.33(1H, brd).
    • Example 194 Preparation of the Compound of Compound No. 194
  • Using 1-phenyl-2-hexanone as the raw material, the same operation as the Examples 184(1)-(3) gave the title compound.
  • Yield: 52.6% (3 steps).
    • (1) α-Bromo-1-phenyl-2-hexanone
  • 1H-NMR(CDCl3):δ 0.85(3H, t, J=7.2 Hz), 1.19-1.32(2H, m), 1, 50-1.60(2H, m), 2.59(2H, td, J=7.5, 3.9 Hz), 5.44(1H, s), 7.34-7.45(5H, m).
    • (2) 2-Amino-4-butyl-5-phenylthiazole
  • 1H-NMR(CDCl3): δ 0.89(3H, t, J=7.5 Hz), 1.28-1.41(2H, m), 1.61-1.71(2H, m), 2.56-2.61(2H, m), 4.87(2H, s), 7.25-7.40(5H, m).
    • (3) 5-Bromo-N-(4-butyl-5-phenylthiazol-2-yl)-2-hydroxybenzamide (Compound No. 194)
  • 1H-NMR(DMSO-d6): δ 0.85(3H, t, J=7.2 Hz), 1.23-1.35(2H, m), 1.59-1.69(2H, m), 2.70(2H, t, J=7.2 Hz), 6.96(1H, d, J=6.9 Hz), 7.39-7.59(6H, m), 8.07(1H, d, J=2.4 Hz), 11.93(1H, br), 13.18-13.59(1H, br).
    • Example 195 Preparation of the Compound of Compound No. 195 (1) 4-Bromo-2,2,6,6-tetramethyl-3,5-heptanedione[α-Bromo-dipivaloylmethane]
  • 2,2,6,6-Tetramethyl-3,5-heptanedione(dipivaloylmethane; 1.00 g, 5.42 mmol) was dissolved in carbon tetrachloride (10 mL). N-Bromosuccinimide (965.8 mg, 5.42 mmol) was added, and the mixture was refluxed for 2 hours. After cooling, the insoluble matter was filtered off, and the filtrate was evaporated under reduced pressure to give the title compound (1.42 g, quant.) as a white crystal.
  • 1H-NMR(CDCl3): δ 1.27(18H, s), 5.67(1H, s).
  • When the method described in Example 195(1) is referred in the following examples, N-bromosuccinimide was used as the brominating agent. As the reaction solvent, solvents such as carbon tetrachloride or the like were used.
    • (2) 2-Amino-4-[(1,1-dimethyl)ethyl)-5-[(2,2-dimethyl)propionyl]thiazole
  • A mixture of 4-bromo-2,2,6,6-tetramethyl-3,5-heptanedione(α-bromo-dipivaloylmethane; 1.42 g, 5.40 mmol), thiourea (451.8 mg, 5.94 mmol) and ethanol (15 mL) was refluxed for 2 hours. After cooling, the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was crystallized (dichloromethane/hexane) to give the title compound (1.23 g, 94.5%) as a white crystal.
  • 1H-NMR(CDCl3): δ 1.26(9H, s), 1.29(9H, s), 5.03(2H, s).
    • (3) 5-Chloro-N-{4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl}-2-hydroxybenzamide (Compound No. 195)
  • A mixture of 5-chlorosalicylic acid (143.6 mg, 0.83 mmol), 2-amino-4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazole (200.0 mg, 0.83 mmol), phophorus trichloride (40 μl, 0.46 mmol) and chlorobenzene (4 mL) was refluxed for 3 hours. The residue obtained by concentration of the reaction mixture under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (159.1 mg, 48.4%) as a white powder.
  • 1H-NMR(CDCl3): δ 1.33(9H, s), 1.35(9H, s), 6.99(1H, d, J=8.7 Hz), 7.43(1H, dd, J=9.0, 2.7 Hz), 7.70(1H, d, J=2.7 Hz), 10.52(2H, br).
  • When the method described in Example 195(3) is referred in the following examples, phophorus trichloride was used as the acid halogenating agent. As the reaction solvent, solvents such as monochlorobenzene, toluene or the like were used.
    • Example 196 Preparation of the Compound of Compound No. 196
  • Using 5-bromosalicylic acid and 2-amino-4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazole (compound of Example 195(2)) as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 23.8%.
  • 1H-NMR(CDCl3): δ 1.33(9H, s), 1.35(9H, s), 6.94(1H, d, J=8, 7 Hz), 7.55(1H, dd, J=8.7, 2.1 Hz), 7.85(1H, d, J=2.1 Hz), 10.51(2H, br).
    • Example 197 Preparation of the Compound of Compound No. 197
  • Using pivaloylacetic acid ethyl ester as the raw material, the same operation as the Examples 195(1)-(3) gave the title compound.
  • Yield: 45.7% (3 steps).
    • (1) α-Bromo-pivaloylacetic acid ethyl ester
  • 1H-NMR(CDCl3): δ 1.28(9H, s), 1.29(3H, t, J=7.2 Hz), 4.26(2H, q, J=7.2 Hz), 5.24(1H, s).
    • (2) 2-Amino-4-[(1,1-dimethyl)ethyl]thiazole-5-carboxylic acid ethyl ester
  • 1H-NMR(CDCl3): δ 1.32(3H, t, J=7.2 Hz), 1.43(9H, s), 4.24(2H, q, J=7.2 Hz), 5.18(2H, s).
    • (3) 2-(5-Bromo-2-hydroxybenzoyl)amino-4-[(1,1-dimethyl)ethyl]thiazole-5-carboxylic acid ethyl ester (Compound No. 197)
  • 1H-NMR(DMSO-d6): δ 1.30(3H, t, J=7.2 Hz), 1.44(9H, s), 4.27(2H, q, J=6.9 Hz), 7.00(1H, d, J=8.7 Hz), 7.63(1H, dd, J=8.7, 2.7 Hz), 8.02(1H, d, J=2.4 Hz), 11.80(1H, br), 12.12(1H, br).
    • Example 198 Preparation of the Compound of Compound No. 198 (1) 2-Amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole
  • 2-Amino-4-[(1,1-dimethyl)ethyl]thiazole (compound of Example 181(1); 0.87 g, 5.6 mmol) was dissolved in carbon tetrachloride (9 mL). N-Bromosuccinimide (1.00 g, 5.6 mmol) was added, and the mixture was stirred at room temperature for 1 hour. Hexane was added to the reaction mixture. The insoluble matter was filtered off, and the residue obtained by evaporation of the filtrate under reduced pressure was purified by chromatography on silica gel(hexane:ethyl acetate=2:1) to give the title compound (1.23 g, 93.7%) as an yellowish gray powder.
  • 1H-NMR(CDCl3): δ 1.39(9H, s), 4.81(2H, brs).
    • (2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-piperidinothiazole
  • A mixture of 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole (0.10 g, 0.42 mmol), piperidine (0.1 mL), potassium carbonate (0.20 g) and acetonitrile (4 mL) was refluxed for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the title compound (80.7 mg, 79.3%) as an yellow crystal.
  • 1H-NMR(CDCl3): δ 1.32(9H, s), 1.64(4H, t, J=5.7 Hz), 1.71-1.77(2H, m), 2.35(2H, brs), 2.99(2H, brs), 4.68(2H, s).
  • When the preparation method described in Example 198(2) is referred in the following examples, bases such as potassium carbonate or the like were used as the base. As the reaction solvent, solvents such as acetonitrile or the like were used.
    • (3) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl)-5-piperidinothiazol-2-yl}benzamide
  • Under argon atmosphere, phosphorus oxychloride (46 μl, 0.50 mmol) was added to a mixture of 2-acetoxy-5-bromobenzoic acid (90.3 mg, 0.35 mmol), 2-amino-4-[(1,1-dimethyl)ethyl]-5-piperidinothiazole (80.7 mg, 0.34 mmol), pyridine (0.1 mL) and tetrahydrofuran (3 mL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (84.3 mg) as a crude product.
  • When the preparation method described in Example 198(3) is referred in the following examples, phosphorus oxychloride was used as the acid halogenating agent. As the reaction base, pyridine was used. As the reaction solvent, solvents such as dichloromethane, tetrahydrofuran or the like were used.
    • (4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl}-2-hydroxybenzamide (Compound No. 198)
  • 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl}-benzamide (crude product, 84.3 mg) was dissolved in ethanol (3 mL). 2N Aqueous sodium hydroxide (0.1 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title compound (54.1 mg, 36.3%; 2 steps) as a white powder.
  • 1H-NMR(CDCl3): δ 1.41(9H, s), 1.56(2H, brs), 1.67-1.74(4H, m), 2.79(4H, brs), 6.85(1H, d, J=9.0 Hz), 7.45(1H, dd, J=9.0, 2.4 Hz), 8.06(1H, d, J=2.4 Hz), 11.70(2H, br).
  • When the preparation method described in Example 198(4) is referred in the following examples, inorganic bases such as sodium hydroxide, potassium carbonate or the like were used as the base. As the reaction solvent, solvents such as water, methanol, ethanol, tetrahydrofuran or the like were used alone or as a mixture.
    • Example 199 Preparation of the Compound of Compound No. 199
  • Using 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole (compound of Example 198(1)) and morpholine as the raw materials, the same operation as the Examples 198(2)-(4) gave the title compound.
  • Yield: 17.1%.
    • (2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-morpholinothiazole
  • 1H-NMR(CDCl3): δ 1.33(9H, s), 2.76(4H,brs), 3.79(4H, brs), 4.66(2H, s).
    • (3) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl}benzamide
  • The product was used for the next reaction as a crude product.
    • (4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl}-2-hydroxybenzamide (Compound No. 199)
  • 1H-NMR(CDCl3): δ 1.24(9H, s), 2.89(4H, dd, J=4.8, 4.2 Hz), 3.83(4H, dd, J=4.5, 4.2 Hz), 6.89(1H, d, J=9.0 Hz), 7.49(1H, dd, J=9.0, 2.4 Hz), 7.98(1H, d, J=2.1 Hz), 11.20(2H, br).
    • Example 200 Preparation of the Compound of Compound No. 200
  • Using 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole (compound of Example 198(1)) and 4-methylpiperazine as the raw materials, the same operation as the Examples 198(2)-(4) gave the title compound.
  • Yield: 6.9%.
    • (2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazole
  • 1H-NMR(DMSO-d6): δ 1.25(9H, s), 2.12(2H, brs), 2.19(3H, s), 2.57(2H, brs), 2.72(4H, brs), 6.51(2H, s).
    • (3) 2-Acetoxy-N-{4-[(1,1-dimethyl)ethyl)-5-(4-methylpiperazin-1-yl)thiazol-2-yl}-benzamide
  • The product was used for the next reaction as a crude product.
    • (4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazol-2-yl}-2-hydroxybenzamide (Compound No. 200)
  • 1H-NMR(CD3OD): δ 1.41(9H, s), 2.55(3H, s), 2.87(4H, brs), 3.03(4H, brs), 6.88(1H, d, J=8.7 Hz), 7.49(1H, dd, J=8.7, 2.7 Hz), 8.11(1H, d, J=2.7 Hz).
    • Example 201 Preparation of the Compound of Compound No. 201
  • Using 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole (compound of Example 198(1)) and 4-phenylpiperazine as the raw materials, the same operation as the Examples 198(2)-(4) gave the title compound.
  • Yield: 6.9%.
    • (2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazole
  • 1H-NMR(CDCl3): δ 1.34(9H, s), 2.80(2H, brs), 3.03(4H, brs), 3.55(2H, brs), 4.69(2H, s), 6.88(1H, tt, J=7.2, 1.2 Hz), 6.95(2H, dd, J=9.0, 1.2 Hz), 7.28(2H, dd, J=8.7, 7.2 Hz).
    • (3) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl}thiazol-2-yl)benzamide
  • The product was used for the next reaction as a crude product.
    • (4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazol-2-yl}-2-hydroxybenzamide (Compound No. 201)
  • 1H-NMR(DMSO-d6): δ 1.39(9H, s), 2.97(4H, s), 3.30(4H, s), 6.82(1H, t, J=7.5 Hz), 6.97(2H, brs), 6.99(2H, t, J=7.5 Hz), 7.58(1H, brs), 8.05(1H, d, J=2.4 Hz), 11.69(1H, brs), 11.82(1H, brs).
    • Example 202 Preparation of the Compound of Compound No. 202
  • Using 5-bromosalicylic acid and 2-amino-4-phenylthiazole as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 16.0%.
  • mp 239° C. (dec.).
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.4 Hz), 7.34(1H, t, J=7.6 Hz), 7.44(2H, t, J=7.6 Hz), 7.62(1H, dd, J=8.4, 2.8 Hz), 7.67(1H, s), 7.92(2H, d, J=7.2 Hz), 8.08(1H, d, J=2.8 Hz), 11.88(1H, brs), 12.05(1H, brs).
    • Example 203 Preparation of the Compound of Compound No. 203 (1) {2-[(5-Bromo-2-hydroxybenzoyl)amino]-4-phenylthiazol-5-yl}acetic acid methyl ester
  • Using 5-bromosalicylic acid and 2-amino-4-phenylthiazole-5-acetic acid methyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 32.1%.
  • mp 288.5-229.5° C.
  • 1H-NMR(DMSO-d6): δ 3.66(3H, s), 3.95(2H, s), 6.99(1H, d, J=8.0 Hz), 7.42(1H, d, J=6.0 Hz), 7.48(2H, brt, J=7.6 Hz), 7.56-7.61(3H, m), 8.07(1H, d, J=2.4 Hz), 11.85(1H, brs), 11.98(1H, brs).
    • (2) {2-[(5-Bromo-2-hydroxybenzoyl)amino]-4-phenylthiazol-5-yl}acetic acid (Compound No. 203)
  • {2-[(5-Bromo-2-hydroxybenzoyl)amino]-4-phenylthiazol-5-yl}acetic acid methyl ester (75 mg, 0.17 mmol) was dissolved in methanol (5 mL). 2N Sodium hydroxide (0.5 mL, 1 mmol) was added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was suspended and washed with n-hexane-ethyl acetate under heating at reflux to give the title compound (56 mg, 77.3%) as a light yellow white crystal.
  • mp 284-286° C.
  • 1H-NMR(DMSO-d6): δ 3.84(2H, s), 6.98(1H, d, J=8.8 Hz), 7.42(1H, d, J=6.8 Hz), 7.49(2H, t, J=7.6 Hz), 7.58-7.61(3H, m), 8.07(1H, d, J=2.8 Hz), 12.25(H, brs).
    • Example 204 Preparation of the Compound of Compound No. 204
  • Using 5-bromosalicylic acid and 2-amino-4,5-diphenylthiazole as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 25.9%.
  • mp 262-263° C.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.1 Hz), 7.34-7.47(10H, m), 7.63(1H, d, J=6.9 Hz), 8.08(1H, d, J=2.4 Hz), 11.88(1H, brs), 12.08(1H, brs).
  • [2-Amino-4,5-diphenylthiazole: Refer to “Nihon Kagaku Zasshi”, 1962, Vol. 83, p. 209.]
    • Example 205 Preparation of the Compound of Compound No. 205
  • Using 5-bromosalicylic acid and 2-amino-4-benzyl-5-phenylthiazole as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 28.1%.
  • mp 198-200° C.
  • 1H-NMR(DMSO-d6): δ 4.08(2H, s), 6.95(1H, d, J=8.8 Hz), 7.15-7.22(3H, m), 7.30(2H, t, J=7.6 Hz), 7.38-7.43(1H, m), 7.47(4H, d, J=4.4 Hz), 7.57(1H, brd, J=8.8 Hz), 8.05(1H, d, J=2.4 Hz), 11.98(1H, brs).
  • [2-Amino-4-benzyl-5-phenylthiazole: Refer to “Chemical and Pharmaceutical Bulletin”, 1962, Vol. 10, p. 376.]
    • Example 206 Preparation of the Compound of Compound No. 206
  • Using 5-bromosalicylic acid and 2-amino-5-phenyl-4-(trifluoromethyl)thiazole as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 33.2%.
  • mp 250° C. (dec.).
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.8 Hz), 7.51(5H, s), 7.63(1H, dd, J=8.8, 2.4 Hz), 8.02(1H, d, J=2.8 Hz), 12.38(1H, brs).
    • Example 207 Preparation of the Compound of Compound No. 207
  • Using 1-phenyl-1,3-butanedione as the raw material, the same operation as the Examples 195(1)-(3) gave the title compound.
  • Yield: 8.9% (3 steps).
    • (1) α-Bromo-1-phenyl-1,3-butanedione
  • 1H-NMR(CDCl3): δ 2.46(3H, s), 5.62(1H, s), 7.48-7.54(2H, m), 7.64(1H, tt, J=7.5, 2.1 Hz), 7.97-8.01(2H, m).
    • (2) 2-Amino-5-acetyl-4-phenylthiazole
  • 1H-NMR(DMSO-d6): δ 2.18(3H, s), 7.50-7.55(2H, m), 7.59-7.68(3H, m), 8.69(2H, brs).
    • (3) 5-Bromo-N-(5-acetyl-4-phenylthiazol-2-yl)-2-hydroxybenzamide (Compound No. 207)
  • 1H-NMR(DMSO-d6): δ 2.44(3H, s), 6.99(1H, d, J=9.0 Hz), 7.55-7.71(4H, m), 7.76-7.80(2H, m), 8.01(1H, d, J=2.4 Hz), 12.36(2H, br).
    • Example 208 Preparation of the Compound of Compound No. 208
  • Using 1,3-diphenyl-1,3-propanedione as the raw material, the same operation as the Examples 195(1)-(3) gave the title compound.
  • Yield: 49.7%.
    • (1) α-Bromo-1,3-diphenyl-1,3-propanedione
  • 1H-NMR(CDCl3): δ 6.55(1H, s), 7.45-7.50(4H, m), 7.61(2H, tt, J=7.2, 2.1 Hz), 7.98-8.01(4H, m).
    • (2) 2-Amino-5-benzoyl-4-phenylthiazole
  • 1H-NMR(DMSO-d6): δ 7.04-7.18(5H, m), 7.22-7.32(3H, m), 7.35-7.38(2H, m), 8.02(2H, s).
    • (3) 5-Bromo-N-(5-benzoyl-4-phenylthiazol-2-yl)-2-hydroxybenzamide (Compound No. 208)
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.17-7.30(5H, m), 7.39-7.47(3H, m), 7.57-7.60(2H, m), 7.64(1H, dd, J=8.7, 2.7 Hz), 8.05(1H, d, J=2.4 Hz), 11.82(1H, brs), 12.35(1H, brs).
    • Example 209 Preparation of the Compound of Compound No. 210
  • Using 5-chlorosalicylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 69.4%.
  • 1H-NMR(DMSO-d6): δ 1.22(3H, t, J=7.5 Hz), 4.21(2H, q, J=7.5 Hz), 7.07(1H, d, J=8.7 Hz), 7.43-7.47(3H, m), 7.53(1H, dd, J=8.7, 2.4 Hz), 7.70-7.74(2H, m), 7.92(1H, d, J=3.0 Hz), 11.88(1H, br), 12.29(1H, brs).
    • Example 210 Preparation of the Compound of Compound No. 209
  • Using 5-bromosalicylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 28.6%.
  • mp 197-199° C.
  • 1H-NMR(DMSO-d6): δ 1.21(3H, t, J=6.8 Hz), 4.20(2H, q, J=6.8 Hz), 7.01(1H, d, J=8.8 Hz), 7.43-7.48(3H, m), 7.63(1H, dd, J=8.8, 2.4 Hz), 7.70-7.72(2H, m), 8.04(1H, d, J=2.4 Hz), 12.33(1H, brs).
    • Example 211 Preparation of the Compound of Compound No. 211
  • Using pentafluorobenzoylacetic acid ethyl ester as the raw material, the same operation as the Examples 195(1)-(3) gave the title compound.
  • Yield: 40.0% (3 steps).
    • (1) α-Bromo-pentafluorobenzoylacetic acid ethyl ester
  • It was used for the next reaction as a crude product.
    • (2) 2-Amino-4-(pentafluorophenyl)thiazole-5-carboxylic acid ethyl ester
  • 1H-NMR(CDCl3): δ 1.23(3H, t, J=7.2 Hz), 4.21(2H, q, J=7.2 Hz), 5.41(2H, s).
    • (3) Ethyl 2-(5-bromo-2-hydroxybenzoyl)amino-4-(pentafluorophenyl)thiazole-5-carboxylate (Compound No. 211)
  • 1H-NMR(DMSO-d6): δ 1.20(3H, t, J=7.2 Hz), 2.51(2H, q, J=7.2 Hz), 7.02(1H, d, J=8.7 Hz), 7.64(1H, dd, J=8.7, 2.7 Hz), 7.90(1H, d, J=3.0 Hz), 11.92(1H, br), 12.58(1H, br).
    • Example 212 Preparation of the Compound of Compound No. 212 (1) 2-(5-Bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid
  • Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid ethyl ester (compound No. 209) as the raw material, the same operation as the Example 82 gave the title compound.
  • Yield: 67.0%.
  • 1H-NMR(DMSO-d6): δ 7.00(1H, d, J=8.8 Hz), 7.42-7.44(3H, m), 7.62(1H, dd, J=8.8, 2.4 Hz), 7.70-7.72(2H, m), 8.04(1H, d, J=2.4 Hz), 12.31(1H, brs), 12.99(1H, brs).
    • (2) [2-(5-Bromo-2-hydroxybenzoyl)amino-4-phenylthiazol-5-yl]-N-methylcarboxamide (Compound No. 212)
  • A mixure of 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid (0.20 g, 0.48 mmol), methylamine 40% methanol solution (0.2 ml), 1-hydroxybenzotriazole hydrate (96.7 mg, 0.72 mmol), WSC.HCl (137.2 mg, 0.72 mmol) and tetrahydrofuran (15 mL) was stirred at room temperature for 18 hours. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation under reduced pressure was purified by chromatography on silica gel(n-hexane:ethyl acetate=1:2), and crystallized (dichloromethane/n-hexane) to give the title compound (87.9 mg, 42.6%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 2.70(3H, d, J=4.5 Hz), 7.02(1H, d, J=9.0 Hz), 7.40-7.48(3H, m), 7.63(1H, dd, J=9.0, 2.4 Hz), 7.68-7.71(2H, m), 8.06(1H, d, J=2.4 Hz), 8.16(1H, t, J=4.5 Hz), 11.88(1H, br), 12.15(1H, brs).
  • When the method described in Example 212(2) is referred in the following examples, WSC.HCl and 1-hydroxybenzotriazole hydrate were used as the dehydrocondensating agent. As the reaction solvent, solvents such as tetrahydrofuran or the like were used.
    • Example 213 Preparation of the Compound of Compound No. 213
  • Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid (compound of Example 212(1)) and 70% aqueous ethylamine solution as the raw materials, the same operation as the Example 212(2) gave the title compound.
  • Yield: 62.5%.
  • 1H-NMR(DMSO-d6): δ 1.05(3H, t, J=6.9 Hz), 3.15-3.24(2H, m), 7.02(1H, d, J=8.7 Hz), 7.40-7.47(3H, m), 7.63(1H, dd, J=8.7, 3.0 Hz), 7.69-7.72(2H, m), 8.06(1H, d, J=2.4 Hz), 8.20(1H, t, J=5.4 Hz), 11.84(1H, br), 12.14(1H, brs).
    • Example 214 Preparation of the Compound of Compound No. 214
  • Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid (compound of Example 212(1)) and isopropylamine as the raw materials, the same operation as the Example 212(2) gave the title compound.
  • Yield: 23.9%.
  • 1H-NMR(DMSO-d6): δ 1.07(6H, d, J=6.3 Hz), 4.02(1H, m), 7.02(1H, d, J=9.0 Hz), 7.40-7.52(3H, m), 7.64(1H, dd, J=8.7, 2.7 Hz), 7.69-7.73(2H, m), 8.06(1H, d, J=2.7 Hz), 11.89(1H, br), 12.14(1H, brs).
    • Example 215 Preparation of the Compound of Compound No. 215
  • Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid (compound of Example 212(1)) and 2-phenethylamine as the raw materials, the same operation as the Example 212(2) gave the title compound.
  • Yield: 62.2%.
  • 1H-NMR(DMSO-d6): δ 2.78(2H, t, J=7.5 Hz), 3.43(2H, q, J=7.5 Hz), 7.02(1H, d, J=9.0 Hz), 7.19-7.24(3H, m), 7.27-7.33(2H, m), 7.39-7.41(3H, m), 7.61-7.65(3H, m), 8.06(1H, d, J=2.4 Hz), 8.25(1H, t, J=6.0 Hz), 11.85(1H, brs), 12.15(1H, brs).
    • Example 216 Preparation of the Compound of Compound No. 216
  • Using 5-bromosalicylic acid and 2-amino-4-(trifluoromethyl)thiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 88.7%.
  • 1H-NMR(DMSO-d6): δ 1.32(3H, t, J=7.2 Hz), 4.33(2H, q, J=7.2 Hz), 7.01(1H, d, J=8.7 Hz), 7.63(1H, dd, J=8.7, 2.7 Hz), 7.98(1H, d, J=2.4 Hz), 12.64(1H, br).
    • Example 217 Preparation of the Compound of Compound No. 217
  • Using 5-chloro-N-{4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl}-2-hydroxybenzamide (compound No. 195) and acetyl chloride as the raw materials, the same operation as the Example 96 gave the title compound.
  • Yield: 65.3%.
  • 1H-NMR(CDCl3): δ 1.32(9H, s), 1.33(9H,s),2.46(3H, s), 7.22(1H, d, J=8.4 Hz), 7.56(1H, dd, J=8.7, 2.4 Hz), 8.05(1H, d, J=2.7 Hz), 9.82(1H, brs).
    • Example 218 Preparation of the Compound of Compound No. 218
  • Using 4-hydroxybiphenyl-3-carboxylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 61.7%.
  • mp 207-208° C.
  • 1H-NMR(DMSO-d6): δ 1.23(3H, t, J=7.2 Hz), 4.22(2H, q, J=7.2 Hz), 7.16(1H, d, J=8.7 Hz), 7.36(1H, t, J=7.5 Hz), 7.45-7.50(5H, m), 7.69-7.76(4H, m), 7.85(1H, dd, J=8.7, 2.4 Hz), 8.31(1H, d, J=2.4 Hz), 11.73(1H, brs), 12.60(1H, brs).
  • [4-Hydroxybiphenyl-3-carboxylic acid: Refer to “Tetrahedron”, 1997, Vol. 53, p. 11437.]
    • Example 219 Preparation of the Compound of Compound No. 219
  • Using (4′-fluoro-4-hydroxybiphenyl)-3-carboxylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 62.7%.
  • mp 237-238° C.
  • 1H-NMR(DMSO-d6): δ 1.22(3H, t, J=7.2 Hz), 4.21(2H, q, J=7.2 Hz), 7.13(1H, d, J=8.4 Hz), 7.28(2H, t, J=8.8 Hz), 7.44-7.45(3H, m), 7.71-7.75(4H, m), 7.81(1H, dd, J=8.8, 2.4 Hz), 8.27(1H, d, J=2.4 Hz), 11.67(1H, brs), 12.58(1H, brs).
  • [(4′-Fluoro-4-hydroxybiphenyl)-3-carboxylic acid: Refer to “Tetrahedron”, 1997, Vol. 53, p. 11437.]
    • Example 220 Preparation of the Compound of Compound No. 220
  • Using (2′,4′-difluoro-4-hydroxybiphenyl)-3-carboxylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 45.6%.
  • mp 206-207° C.
  • 1H-NMR(DMSO-d6): δ 1.22(3H, t, J=7.2 Hz), 4.22(2H, q, J=7, 2 Hz), 7.17(1H, d, J=9.0 Hz), 7.21(1H, td, J=8.7, 2.4 Hz), 7.38(1H, ddd, J=11.7, 9.3, 2.4 Hz), 7.44-7.46(3H, m), 7.60-7.75(4H, m), 8.13-8.14(1H, m), 11.86(1H, brs), 12.46(1H, brs).
    • Example 221 Preparation of the Compound of Compound No. 221 (1) [4-Hydroxy-4′-(trifluoromethyl)biphenyl]-3-carboxylic acid
  • A mixture of 5-bromosalicylic acid (500 mg, 2.30 mmol), dihydroxy-4-(trifluoromethyl)phenylborane (488 mg, 2.57 mmol), palladium acetate (10 mg, 0.040 mmol) and 1M sodium carbonate (7 mL) was stirred at 80° C. for 1 hour. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. According to the fixed procedure, the obtained residue was methyl-esterified by trimethylsilyldiazomethane and methanol, and purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give a colourless liquid (563 mg). This liquid was dissolved in methanol (10 mL). 2N Sodium hydroxide (3 mL) was added, and the mixture was stirred at 60° C. for 1 hour. After the reaction mixture was cooled to room temperature, it was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and saturted brine, dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The obtained residue was suspended and washed with n-hexane-dichloromethane under heating at reflux to give the title compound (458 mg, 70.4%) as a white crystal.
  • mp 185° C. (dec).
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=8.8 Hz), 7.77(2H, d, J=8.0 Hz), 7.85(2H, d, J=8.0 Hz), 7.90(1H, dd, J=8.8, 2.0 Hz), 8.10(1H, d, J=2.4 Hz), 11.80(1H, brs).
    • (2) 2-{[4-Hydroxy-4′-(trifluoromethyl)biphenyl]-3-carbonyl}amino-4-phenylthiazole-5-carboxylic acid ethyl ester (Compound No. 221)
  • Using [4-hydroxy-4′-(trifluoromethyl)biphenyl]-3-carboxylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 41.7%.
  • mp 236-237° C.
  • 1H-NMR(DMSO-d6): δ 1.22(3H, t, J=7.2 Hz), 4.21(2H, q, J=7.2 Hz), 7.18(1H, d, J=8.8 Hz), 7.44-7.45(3H, m), 7.72-7.74(2H, m), 7.81(2H, d, J=8.4 Hz), 7.91(1H, dd, J=8.8, 2.4 Hz), 7.93(2H, d, J=8.4 Hz), 8.36(1H, d, J=2.4 Hz), 11.78(1H, brs), 12.62(1H, brs).
    • Example 222 Preparation of the Compound of Compound No. 222
  • Using 2-hydroxy-5-(1-pyrrolyl)benzoic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 55.0%.
  • 1H-NMR(DMSO-d6): δ 1.22(3H, t, J=7.2 Hz), 4.22(2H, q, J=7.2 Hz), 6.26(2H, t, J=2.1 Hz), 7.13(1H, d, J=8.7 Hz), 7.32(2H, t, J=2.1 Hz), 7.43-7.47(3H, m), 7.70-7.75(3H, m), 8.09(1H, d, J=2.7 Hz), 11.58(1H, brs), 12.55(1H, brs).
    • Example 223 Preparation of the Compound of Compound No. 223 (1) 2-Hydroxy-5-(2-thienyl)benzoic acid
  • 5-Bromosalicylic acid (500 mg, 2.30 mmol) was dissolved in 1,2-dimethoxyethane (5 mL). Tetrakis(triphenylphosphine)palladium (80 mg, 0.07 mmol) was added under argon atmosphere, and the mixture was stirred at room temperature for 10 minutes. Then dihydroxy-2-thienylborane (324 mg, 2.53 mmol) and 1M sodium carbonate (7 mL) were added, and the mixture was refluxed for 2 hours. After the reaction mixture was cooled to room temperature, it was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. According to the fixed procedure, the obtained residue was methyl-esterified by trimethylsilyldiazomethane and methanol, and purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give an yellow liquid (277 mg). This was dissolved in methanol (5 mL). 2N Sodium hydroxide (1.5 mL) was added, and the mixture was stirred at 60° C. for 1 hour. After the reaction mixture was cooled to room temperature, it was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous magnesium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was crystallized from n-hexane-dichloromethane to give the title compound (58 mg, 11.5%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 6.95(1H, d, J=8.8 Hz), 7.09(1H, dd, J=4.8, 3.6 Hz), 7.37(1H, dd, J=4.0, 1.2 Hz), 7.45(1H, dd, J=5.2, 1.2 Hz), 7.74(1H, dd, J=8.8, 2.8 Hz), 7.96(1H, d, J=2.8 Hz).
    • (2) 2-[2-Hydroxy-5-(2-thienyl)benzoyl]amino-4-phenylthiazole-5-carboxylic acid ethyl ester (Compound No. 223)
  • Using 2-hydroxy-5-(2-thienyl)benzoic acid and 2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound.
  • Yield: 58.2%.
  • mp 213-214° C.
  • 1H-NMR(DMSO-d6): δ 1.22(3H, t, J=7.2 Hz), 4.21(2H, q, J=7.2 Hz), 7.10(1H, d, J=9.2 Hz), 7.12(1H, dd, J=4.8, 3.6 Hz), 7.44-7.46(4H, m), 7.50(1H, dd, J=4.8, 1.2 Hz), 7.71-7.74(2H, m), 7.79(1H, dd, J=8.8, 2.4 Hz), 8.21(1H, d, J=2.4 Hz), 11.78(1H, brs), 12.44(1H, brs).
    • Example 301 Preparation of the Compound of Compound No. 301 (1) 5-Chloro-2-methoxy-β-phenylstyrene
  • Palladium acetate (21 mg, 7mol %) was added to a solution of 2-bromo-4-chloroanisole (300 mg, 1.4 mmol), styrene (211 mg, 2 mmol), triethylamine (13 μL, 0.1 mmol) and triphenylphosphine (50 mg, 1.9 mmol) in acetonitrile (6 mL), and the mixture was refluxed for 8 hours under argon atmosphere. After the reaction mixture was cooled to room temperature, the solvent was concentrated under reduced pressure and the obtained residue was diluted with ethyl acetate (15 mL). After the solution was washed successively with 2N hydrochloric acid, water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=10:1) to give the title compound (118 mg, 35.6%) as a white powder.
  • 1H-NMR(CDCl3):d 3.85(3H, s), 6.80(1H, d, J=8.8 Hz), 7.08(1H, d, J=16.8 Hz), 7.17(1H, dd, J=8.8, 2.5 Hz), 7.20-7.42(4H, m), 7.51-7.55(3H, m).
    • (2) 4-Chloro-2-styrylphenol (Compound No. 301)
  • Under argon atmosphere, 1 mol/L boron tribromide/dichloromethane solution (0.5 mL, 0.5 mmol) was added to a solution of 5-chloro-2-methoxy-β-phenylstyrene (80 mg, 0.3 mmol) in dichloromethane (2 mL) at room temperature, and the mixture was stirred for 12 hours. The reaction mixture was diluted with ethyl acetate (15 mL), and after it was washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (34.2 mg, 45.4%) as a white powder.
  • 1H-NMR(CDCl3):d 4.95(1H, brs), 6.74(1H, d, J=8.7 Hz), 7.09(1H, dd, =8.7, 2.4 Hz), 7.10(1H, d, J=16.2 Hz), 7.28-7.39(4H, m), 7.49-7.54(3H, m).
    • Example 302 Preparation of the Compound of Compound No. 302 (1) (S)-2-Amino-3-phenyl-N-[3,5-bis(trifluoromethyl)phenyl]propionamide
  • A mixture of 3,5-bis(trifluoromethyl)aniline (0.20 g, 0.87 mmol), N-(tert-butoxycarbonyl)-L-phenylalanine (254.8 mg, 0.96 mmol), phosphorus trichloride (40 μL, 0.46 mmol) and toluene (4 mL) was stirred at 80° C. for 1.5 hours under argon atmosphere. After the reaction mixture was cooled to room temperature, it was poured into aqueous sodium hydrogen carbonate and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was crystallized by isopropyl ether/n-hexane to give the title compound (333.7 mg, 92.9%) as an yellow white powder.
  • 1H-NMR(DMSO-d6): δ 3.13(1H, dd, J=13.8, 8.1 Hz), 3.29(1H, dd, J=13.8, 6.0 Hz), 4.37(1H, s), 7.25-7.38(5H, m), 7.86(1H, s), 8.30(2H, s), 8.48(3H, s), 11.95(1H, s).
  • When the method described in Example 302(1) is referred in the following examples, phosphorus trichloride was used as the acid halogenating agent. As the reaction solvent, solvents such as toluene, monochlorobenzene or the like were used.
    • (2) (S)-2-Acetoxy-5-chloro-N-(2-phenyl-1-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-ethyl)benzamide
  • WSC.HCl (184 mg, 0.96 mmol) was added to a solution of 2-acetoxy-5-chlorobenzoic acid (104 mg, 0.48 mmol), (S)-2-amino-3-phenyl-N-[3,5-bis(trifluoromethyl)phenyl]propionamide (0.20 g, 0.48 mmol) and 1-hydroxybenzotriazole (71.4 mg, 0.53 mmol) in N,N-dimethylformamide (4 mL), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1→2:1) to give the title compound (141.4 mg, 51.4%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 2.05(3H, s), 3.04(1H, dd, J=13.8, 9.9 Hz), 3.19(1H, dd.J=13.8, 4.8 Hz), 4.73-4.81(1H, m), 7.22-7.35(6H, m), 7.54(1H, d, J=2.4 Hz), 7.60(1H, dd, J=8.7, 2.4 Hz), 7.81(1H, s), 8.27(2H, s), 8.91(1H, d, J=7.8 Hz), 10.81(1H, s).
  • When the method described in Example 302(2) is referred in the following examples, WSC.HCl and 1-hydroxybenzotriazole hydrate were used as the dehydrocondensating agent. As the reaction solvent, solvents such as N,N-dimethylformamide or the like were used.
    • (3) (S)-5-Chloro-2-hydroxy-N-(2-phenyl-1-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-ethyl)benzamide (Compound No. 302)
  • 5N Aqueous sodium hydroxide (0.2 mL) was added to a solution of (S)-2-acetoxy-5-chloro-N-(2-phenyl-1-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-ethyl)benzamide (141.4 mg, 0.25 mmol) in a mixed solvent of methanol/tetrahydrofuran (2 mL+2 mL), and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was crystallized by ethyl acetate/isopropyl ether/n-hexane to give the title compound (74.4 mg, 56.8%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 3.13(1H, dd, J=13.8, 9.0 Hz), 3.26(1H, dd, J=14.1, 4.8 Hz), 4.85-4.92(1H, m), 6.95(1H, d, J=8.7 Hz), 7.19-7.23(1H, m), 7.26-7.31(4H, m), 7.45(1H, dd, J=8.7, 2.4 Hz), 7.81(1H, s), 7.97(1H, d, J=2.4 Hz), 8.26(2H, s), 9.12(1H, d, J=7.2 Hz), 10.89(1H, s), 12.01(1H, s).
  • When the method described in Example 302(3) is referred in the following examples, inorganic bases such as sodium hydroxide, potassium carbonate or the like were used as the base. As the reaction solvent, solvents such as water, methanol, ethanol, tetrahydrofuran or the like were used alone or as a mixture.
    • Example 303 Preparation of the Compound of Compound No. 303 (1) [1-({[3,5-Bis(trifluoromethyl)phenyl]amino}carbonyl)methyl]carbamic acid 1,1-dimethyl ester
  • Under argon atmosphere, N-(tert-butoxycarbonyl)glycine (183.5 mg, 1.05 mmol) and triethylamine (0.25 mL, 1.79 mmol) were added to a solution of 3,5-bis(trifluoromethyl)aniline (0.20 g, 0.87 mmol) in tetrahydrofuran (4 mL), and after cooling with ice bath, phosphorus oxychloride (96 μL, 1.05 mmol) was added and the mixture was stirred at room temperature for 5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1→3:2) to give the title compound (101.9 mg, 30.3%) as a white crystal.
  • 1H-NMR(CDCl3): δ 1.49(9H, s), 3.99(2H, d, J=6.0 Hz), 5.37(1H, t, J=6.0 Hz), 7.57(1H, s), 8.00(2H, s), 9.06(1H, brs).
    • (2) 2-Amino-N-[3,5-bis(trifluoromethyl)phenyl]acetamide hydrochloride
  • 4N Hydrochloric acid/ethyl acetate solution (1 mL) was added to [1-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)methyl]carbamic acid 1,1-dimethyl ester (101.9 mg, 0.26 mmol), and the mixture was stirred at room temperature for 1 hour. n-Hexane (15 mL) was added to the reaction mixture and the separated white solid was filtered to give the title compound (80.8 mg, 96.4%) as a white powder.
  • 1H-NMR(CD3OD): δ 3.89(2H, s), 7.71(1H, s), 8.22(2H, s).
    • (3) 2-Acetoxy-5-chloro-N-({[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-methyl)benzamide
  • WSC.HCl (95.9 mg, 0.5 mmol) was added to a solution of 2-acetoxy-5-chlorobenzoic acid (59.1 mg, 0.28 mmol), 2-amino-N-[3,5-bis(trifluoromethyl)phenyl]acetamide hydrochloride (80.8 mg, 0.25 mmol) and 1-hydroxybenzotriazole (37.2 mg, 0.28 mmol) in N,N-dimethylformamide (3 mL), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:2→1:1) to give the title compound (83.7 mg, 69.3%) as a white crystal.
  • 1H-NMR(CDCl3): δ 2.40(3H, s), 4.40(2H, d, J=5.4 Hz), 7.17(1H, d.J=8.4 Hz), 7.40(1H, t, J=5.4 Hz), 7.53(1H, dd, J=8.4, 2.4 Hz), 7.62(1H, s), 7.82(1H, d, J=2.4 Hz), 8.19(2H, s), 9.20(1H, s).
    • (4) 5-Chloro-2-hydroxy-N-({[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-methyl)benzamide (Compound No. 303)
  • 5N Aqueous sodium hydroxide (0.1 mL) was added to a solution of 2-acetoxy-5-chloro-N-({[3,5-bis(trifluoromethyl)phenyl]carbamoyl}methyl)benzamide (83.7 mg, 0.17 mmol) in methanol/tetrahydrofuran (2 mL+1 mL), and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) and washed with n-hexane under suspension to give the title compound (47.7 mg, 63.7%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 4.18(2H, d, J=5.4 Hz), 7.00(1H, d, J=9.0 Hz), 7.47(1H, dd, J=9.0, 2.7 Hz), 7.80(1H, s), 7.96(1H, d, J=2.7 Hz), 8.27(2H, s), 9.25(1H, t, J=5.4 Hz), 10.78(1H, s), 12.14(1H, s).
    • Example 304 Preparation of the Compound of Compound No. 304 (1) 5-Chlorosalicylhydrazide
  • A mixture of 5-chloro-2-hydroxybenzoic acid methyl ester (0.50 g, 2.7 mmol), hydrazine monohydrate (0.3 mL, 6.2 mmol) and ethanol (5 mL) was refluxed for 6 hours. After the reaction mixture was cooled to room temperature, n-hexane was added and the separated crystal was filtered to give the title compound (395.9 mg, 79.2%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 6.90(1H, d, J=8.7 Hz), 7.38(1H, dd, J=8.7, 2.7 Hz), 7.85(1H, d, J=8.7 Hz), 10.23(brs).
    • (2) 5-Chlorosalicylic acid [3,5-bis(trifluoromethyl)benzylidene]hydrazide (Compound No. 304)
  • A mixture of 5-chlorosalicylhydrazide (213.9 mg, 1.2 mmol), 3,5-bis(trifluoromethyl)benzaldehyde (190 μL, 1.2 mmol), concentrated sulfric acid (3 drops) and ethanol (5 mL) was refluxed for 30 minutes. 3,5-Bis(trifluoromethyl)benzaldehyde (100 μL, 0.61 mmol) was added and the mixture was refluxed for further 1 hour. After the reaction mixture was cooled to room temperature, it was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine, dried over sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1→2:1) and washed with n-hexane under suspension to give the title compound (362.6 mg, 76.8%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=9.0 Hz), 7.49(1H, dd, J=9.0, 2.7 Hz), 7.86(1H, d, J=3.0 Hz), 8.20(1H, s), 8.40(2H, s), 8.59(1H, s), 11.65(1H, s), 12.14(1H, s).
    • Example 305 Preparation of the compound of Compound No. 305 (1) (S)-2-Amino-4-methyl-N-[3,5-bis(trifluoromethyl)phenyl]pentanamide
  • Using N-(tert-butoxycarbonyl)-L-leucine and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 302(1) gave the title compound.
  • Yield: 25.2%.
  • 1H-NMR(CDCl3): δ 0.98(3H, d, J=6.3 Hz), 1.01(3H, d, J=6.3 Hz), 1.39-1.48(1H, 1.74-1.89(2H, m), 3.55(1H, dd, J=9.9, 3.6 Hz), 7.58(1H, s), 8.12(2H, s), 10.01(1H, s).
    • (2) (S)-5-Chloro-2-hydroxy-N-(3-methyl-1-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-butyl)benzamide (Compound No. 305)
  • Using 2-acetoxy-5-chlorobenzoic acid and (S)-2-amino-4-methyl-N-[3,5-bis-(trifluoromethyl)phenyl]pentanamide as the raw materials, the same operation as the Example 302(2)-(3) gave the title compound.
  • Yield: 24.8% (2 steps).
  • 1H-NMR(DMSO-d6): δ 0.95(3H, d, J=5.7Hz), 0.97(3H, d, J=6.0 Hz), 1.65-1.84(3H, 4.65-4.72(1H, m), 6.98(1H, d, J=9.0 Hz), 7.47(1H, dd, J=8.7, 2.4Hz), 7.79(1H, s), 8.06(1H, d, J=2.7 Hz), 8.32(2H, s), 9.03(1H, d, J=8.1 Hz), 10.85(1H, s), 12.20(1H, s).
    • Example 306 Preparation of the Compound of Compound No. 306
  • Using 5-chlorosalicylaldehyde and 3,5-bis(trifluoromethyl)benzhydrazide as the raw materials, the same operation as the Example 304(2) gave the title compound.
  • Yield: 24.7%.
  • 1H-NMR(DMSO-d6): δ 6.97(1H, d, J=8.7 Hz), 7.34(1H, dd, J=9.0, 2.7 Hz), 7.73(1H, d, J=2.4 Hz), 8.41(1H, s), 8.59(2H, s), 8.67(1H, s), 11.07(1H, s), 12.45(1H, s).
    • Example 307 Preparation of the Compound of Compound No. 307
  • Using 5-chlorosalicylic acid and 3,5-bis(trifluoromethyl)phenethylamine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 30.2%.
  • 1H-NMR(CDCl3): δ 3.10(2H, t, J=6.9 Hz), 3.71-3.77(2H, m), 6.34(1H, brs), 6.95(1H, d, J=8.7 Hz), 7.23(1H, d, J=2.7 Hz), 7.36(1H, dd, J=8.7, 2.4 Hz), 7.70(2H, s), 7.80(1H, s), 12.06(1H, s).
    • Example 308 Preparation of the Compound of Compound No. 308
  • A mixture of 3-hydroxyphthalic anhydride (100 mg, 0.6 mmol), 3,5-bis(trifluoromethyl)aniline (168 mg, 0.7 mmol) and acetic acid (5 mL) was refluxed for 6 hours under argon atmosphere. After the reaction mixture was cooled to room temperature, acetic acid was evaporated under reduced pressure and the obtained residue was dissolved in ethyl acetate (15 mL). After the ethyl acetate solution was washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (100 mg, 43.7%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 7.31(1H, d, J=8.1 Hz),7.42(1H, d, J=7.5 Hz), 7.72(1H, dd, J=8.1, 7.5 Hz), 8.21(1H, s), 8.24(2H, s), 11.28(1H, s).
    • Example 309 Preparation of the Compound of Compound No. 309
  • 3,5-Bis(trifluoromethyl)phenylisocyanate (180 μL, 1.04 mmol) was added to a solution of 2-amino-4-chlorophenol (143.6 mg, 1 mmol) in a mixed solvent of tetrahydrofuran/toluene (0.5 mL+4.5 mL), and the mixture was stirred at 100° C. for 1 hour. After the reaction mixture was cooled to room temperature, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=1:1) and crystallized by isopropyl ether/n-hexane to give the title compound (288.5 mg, 72.4%) as a light yellowish brown powder.
  • 1H-NMR(DMSO-d6): δ 6.84-6.91(2H, m),7.67(1H, s),8.06(2H, s), 8.14(1H, d, J=2.1 Hz), 8.45(1H, s), 10.10(1H, s), 10.44(1H, s).
    • Example 310 Preparation of the Compound of Compound No. 310 (1) 5-Chloro-2-methoxy-β-[3,5-bis(trifluoromethyl)phenyl]styrene.
  • A solution of sodium nitrite (57 mg, 0.8 mmol) in water (1 mL) was added to a solution of 2-amino-4-chloroanisole (131 mg, 0.8 mmol) in 48% hydrogen tetrafluoroborate (0.3 mL) under ice cooling and argon atmosphere. After the mixture was stirred at 0° C. for 1 hour, a solution of 3,5-bis(trifluoromethyl)styrene (100 mg, 0.4 mmol) in methanol (3 mL) was added and the mixture was stirred at 50° C. for 1 hour. After the reaction mixture was cooled to room temperature, the residue obtained by evaporation of the solvent under reduced pressure was diluted with ethyl acetate. After the solution was washed successively with 2N hydrochloric acid, water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the title compound (52.8 mg, 33.3%) as a white powder.
  • 1H-NMR(CDCl3): δ 3.85(3H, s), 6.80(1H, d, J=8.8 Hz), 7.08(1H, d, J=16.8 Hz), 7.17(1H, dd, J=8.8, 2.5 Hz), 7.20-7.42(4H, m), 7.51-7.55(3H, m).
    • (2) 4-Chloro-2-[3,5-bis(trifluoromethyl)styryl]phenol (Compound No. 310)
  • Using 5-chloro-2-methoxy-β-[3,5-bis(trifluoromethyl)phenyl]styrene as the raw material, the same operation as the Example 301(2) gave the title compound.
  • Yield: 18.1%.
  • 1H-NMR(CDCl3): δ 5.16(1H, brs), 6.76(1H, d, J=8.4 Hz), 7.15(1H, dd, J=8.4, 2.7 Hz), 7.19(1H, d, J=16.5 Hz), 7.45(1H, d, J=15.5 Hz), 7.53(1H, d, J=2.4 Hz), 7.76(1H, s), 7.93(2H, s).
    • Example 311 Preparation of the Compound of Compound No. 311
  • Using 5-chlorosalicylic acid and 2-aminoindane as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 45.3%.
  • 1H-NMR(DMSO-d6): δ 2.98(2H, dd, J=16.2, 5.7 Hz), 3.29(2H, dd, J=16.2, 7.5 Hz), 4.69-4.79(1H, m), 6.93(1H, d, J=8.7 Hz), 7.16-7.20(2H, m), 7.23-7.28(2H, m), 7.43(1H, dd, J=8.7, 2.4 Hz), 8.02(1H, d, J=2.4 Hz), 9.03(1H, d, J=6.9 Hz), 12.66(1H, s).
    • Example 312 Preparation of the Compound of Compound No. 312 (1) 4-Chloro-2-({[3,5-bis(trifluoromethyl)phenyl]imino}methyl)phenol
  • Using 5-chlorosalicylaldehyde and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 14(1) gave the title compound.
  • Yield: 76.6%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=9.0 Hz), 7.50(1H, dd, J=9.0, 2.7 Hz), 7.80(1H, d, J=2.7 Hz), 8.01(1H, s), 8.12(2H, s), 9.03(1H, s), 12.09(1H, brs).
    • (2) N-[(5-Chloro-2-hydroxyphenyl)methyl]-3,5-bis(trifluoromethyl)aniline (Compound No. 312)
  • Using 4-chloro-2-({[3,5-bis(trifluoromethyl)phenyl]imino}methyl)phenol as the raw material, the same operation as the Example 14(2) gave the title compound.
  • Yield: 78.1%.
  • 1H-NMR(CDCl3): δ 4.40(3H, s), 6.27(1H, s), 6.80(1H, d, J=8.4 Hz), 7.11(2H, s), 7.17-7.20(2H, m), 7.30(1H, s).
    • Example 313 Preparation of the Compound of Compound No. 313
  • WSC.HCl (138 mg, 0.7 mmol) was added to a solution of N-[(5-chloro-2-hydroxyphenyl)methyl]-3,5-bis(trifluoromethyl)aniline (Compound No. 312; 88.8 mg, 0.24 mmol) and acetic acid (43 mg, 0.7 mmol) in dichloromethane (2 mL) under argon atmosphere, and the mixture was stirred at room temperature for 12 hours. After the reaction mixture was diluted with ethyl acetate, washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (69 mg, 70.4%) as a white powder.
  • 1H-NMR(CDCl3): δ 1.92(3H, s),4.73(2H, s), 6.54(1H, d, J=2.4 Hz), 6.95(1H, d, J=8.4 Hz), 7.22(1H, dd, J=8.7, 2.4 Hz), 7.53(2H, s), 7.99(1H, s), 9.21(1H, s).
    • Example 314 Preparation of the Compound of Compound No. 314
  • 3,5-Bis(trifluoromethyl)benzoyl chloride (100 μL, 0.55 mmol) was added to a solution of 5-chlorosalicyl hydrazide (compound of Example 304(1); 0.1 g, 0.53 mmol) in pyridine (3 mL) and the mixture was stirred at room temperature for 6 hours. The reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was washed with ethyl acetate/isopropyl ether/n-hexane under suspension to give the title compound (169 mg, 74.7%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=9.0 Hz), 7.51(1H, dd, J=8.7, 2.4 Hz), 7.92(1H, d, J=2.4 Hz), 8.43(1H, s), 8.57(2H, s), 10.79(1H, s), 11.37(1H, s), 11.81(1H, s).
    • Example 315 Preparation of the Compound of Compound No. 315
  • A mixture of 5-chlorosalicylhydrazide (compound of Example 304(1); 0.10 g, 0.53 mmol), 3,5-bis(trifluoromethyl)benzyl bromide (120 μL, 0.65 mmol), triethylamine (0.2 mL, 1.43 mmol) and toluene (4 mL) was stirred at 100° C. for 2 hours. After the reaction mixture was cooled to room temperature, it was poured into diluted hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) and crystallized by n-hexane to give the title compound (45.6 mg, 20.9%) as a white powder.
  • 1H-NMR(CDCl3): δ 4.22(2H, d, J=4.8 Hz), 5.13(1H, q, J=4.8 Hz), 6.96(1H, d, J=8.7 Hz), 7.23(1H, d, J=2.4 Hz), 7.37(1H, dd, J=9.0, 2.4 Hz), 7.69(1H, d, J=4.8 Hz), 7.85(1H, s), 7.88(2H, s), 11.54(1H, s).
    • Example 316 Preparation of the Compound of Compound No. 316
  • A mixture of 5-chlorosalicylic acid (172.6 mg, 1 mmol), 3,5-bis(trifluoromethyl)phenol (152 μL, 1 mmol), phosphorus oxychloride (40 μL, 0.43 mmol) and xylene (3 mL) was stirred at 140° C. for 2 hours. After the reaction mixture was cooled to room temperature, it was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=10:1→5:1) to give the title compound (53.6 mg, 13.9%) as a white crystal.
  • 1H-NMR(CDCl3): δ 7.04(1H, d, J=9.0 Hz), 7.54(1H, dd, J=9.0, 2.7 Hz), 7.75(2H, s), 7.86(1H, s), 8.02(1H, d, J=2.7 Hz), 10.09(1H, s).
    • Example 317 Preparation of the Compound of Compound No. 317
  • WSC.HCl (30.9 mg, 0.2 mmol) was added to a solution of 5-chlorosalicylic acid (35 mg, 0.2 mmol) and 3,5-bis(trifluoromethyl)phenylhydrazine (50 mg, 0.2 mmol) in dichloromethane (2 mL) under argon atmosphere, and the mixture was stirred at room temperature for 1 hour. After the reaction mixture was diluted with ethyl acetate, washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (56.3 mg, 69.6%) as a white powder.
  • 1H-NMR(CDCl3): δ 6.61(1H, d, J=2.7 Hz), 6.99(1H, d, J=8.7 Hz), 7.28(2H, s), 7.41-7.45(2H, m), 7.62(1H, d, J=2.4 Hz), 8.53(1H, brs), 11.11(1H, s).
    • Example 318 Preparation of the Compound of Compound No. 318 (1) 2-Bromo-1-(5-chloro-2-hydroxyphenyl)ethanone
  • Phenyltrimethylammonium tribromide (0.44 g, 1.17 mmol) was added to a solution of 5′-chloro-2′-hydroxyacetophenone (0.20 g, 1.17 mmol) in tetrahydrofuran (6 mL) and the mixture was stirred at room temperature for 8 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the title compound (220.7 mg, 75.6%) as an yellow oil.
  • 1H-NMR(CDCl3): δ 4.41(2H, s), 7.00(1H, d, J=9.3 Hz), 7.47(1H, dd, J=8.7, 2.4 Hz), 7.71(1H, d, J=2.7 Hz), 11.63(1H, s).
    • (2) 2-(2-Aminothiazol-4-yl)-4-chlorophenol
  • A mixture of 2-bromo-1-(5-chloro-2-hydroxyphenyl)ethanone (156.9 mg, 0.63 mmol), thiourea (47.9 mg, 0.63 mmol) and ethanol (3 mL) was refluxed for 2 hours. After the reaction mixture was cooled to room temperature, it was poured into saturated sodium hydrogen carbonate solution and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the title compound (98.6 mg, 64.5%) as a light yellowish white powder.
  • 1H-NMR(DMSO-d6): δ 6.85(1H, d, J=8.7 Hz), 7.14(1H, dd, J=8.7, 3.0 Hz), 7.25(1H, s), 7.48(2H, s), 7.79(1H, d, J=3.0 Hz), 11.95(1H, s).
    • (3) N-[4-(5-Chloro-2-hydroxymethyl)thiazol-2-yl]-[3,5-bis(trifluoromethyl)phenyl]-benzamide (Compound No. 318)
  • Phosphorus trichloride (36 μL, 0.41 mmol) was added to a mixture of 2-(2-aminothiazol-4-yl)-4-chlorophenol (98.6 mg, 0.41 mmol), 3,5-bis(trifluoromethyl)benzoid acid (104.9 mg, 0.41 mmol), chlorobenzene (3 mL) and N-methyl-2-pyrrolidinone (3 mL), and the mixture was refluxed for 3 hours. After the reaction mixture was cooled to room temperature, it was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=4:1→2:1) and washed with isopropyl ether/n-hexane under suspension to give the title compound (19.6 mg, 10.3%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.4 Hz), 7.21(1H, dd, J=8.7, 2.7 Hz), 7.95(1H, s), 8.08(1H, d, J=2.7 Hz), 8.45(1H, s), 8.77(2H, s), 10.90(1H, s), 13.15(1H, s).
    • Example 319 Preparation of the Compound of Compound No. 319 (1) 3-[3,5-Bis(trifluoromethyl)benzyl]thiazolidine-2,4-dione
  • 5N Aqueous sodium hydroxide (0.5 mL) was added to a mixture of 2,4-thiazolidinedione (198.7 mg, 1.69 mmol), 3,5-bis(trifluoromethyl)benzyl bromide (0.50g, 1.63 mmol) and ethanol (5 mL), and the mixture was refluxed for 4 hours. After the reaction mixture was cooled to room temperature, it was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1→2:1) to give the title compound (405.6 mg, 72.5%) as a white crystal.
  • 1H-NMR(CDCl3): δ 4.01(2H, s), 4.87(2H, s), 7.84(1H, s), 7.86(2H, s).
    • (2) 5-(5-Chloro-2-hydroxybenzylidene)-3-[3,5-bis(trifluoromethyl)benzyl]thiazolidine-2,4-dione (Compound No. 319)
  • A mixture of 3-[3,5-bis(trifluoromethyl)benzyl]thiazolidine-2,4-dione (0.20 g, 0.58 mmol), piperidine (3 drops), acetic acid (3 drops) and toluene (5 mL) was stirred at room temperature for 10 minutes, then 5-chlorosalicylaldehyde (92.3 mg, 0.59 mmol) was added and the mixture was refluxed for 1 hour. After the reaction mixture was cooled to room temperature, it was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1→3:2) to give the title compound (173.2 mg, 62.0%) as a light yellow powder.
  • 1H-NMR(DMSO-d6): δ 5.03(2H, s), 7.00(1H, d, J=9.0 Hz), 7.33(1H, d, J=2.4 Hz), 7.38(1H, dd, J=8.7, 2.7 Hz), 8.03(1H, s), 8.05(2H, s), 8.07(1H, s), 10.95(1H, s).
    • Example 320 Preparation of the Compound of Compound No. 320
  • A mixture of 3-hydroxyphthalic anhydride (33.5 mg, 0.2 mmol), 3,5-bis(trifluoromethyl)benzyl amine (62 mg, 0.2 mmol) and chlorobenzene (5 mL) was refluxed for 3 hours under argon atmosphere. After the reaction mixture was cooled to room temperature, the solvent was evaporated under reduced pressure and the obtained residue was crystallized from n-hexane/ethyl acetate to give the title compound (68.5 mg, 85.2%) as a white crystal.
  • 1H-NMR(CDCl3): δ 4.90(2H, s), 7.19(1H, dd, J=8.4, 0.6 Hz), 7.41(1H, dd, J=7.2, 0.6 Hz), 7.61(1H, dd, J=8.4, 7.2 Hz), 7.75(1H, brs), 7.82(1H, brs), 7.86(2H, s).
    • Example 321 Preparation of the Compound of Compound No. 321
  • A mixture of 5-chlorosalicylaldehyde (150 mg, 1 mmol), 3,5-bis(trifluoromethyl)phenylhydrazine (200 mg, 0.9 mmol) and methanol (5 mL) was refluxed for 1 hour under argon atmosphere. After the reaction mixture was cooled to room temperature, methanol was evaporated under reduced pressure and the obtained residue was crystallized from n-hexane/ethyl acetate to give the title compound (224 mg, 66.6%) as a white powder.
  • 1H-NMR(CDCl3): δ 6.97(1H, d, J=8.7 Hz), 7.17(1H,d,J=2.4 Hz), 7.24(1H, dd, J=9.0, 2.7 Hz), 7.35(2H, s), 7.41(1H, s), 7.82(1H, s), 7.87(1H, s), 10.29(1H, s).
    • Example 322 Preparation of the Compound of Compound No. 322
  • Using 6-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 86.9%.
  • 1H-NMR(DMSO-d6): δ 6.36(2H,d,J=8.4 Hz), 7.13(1H,t,J=8.4 Hz),7.79(1H, s),8.38(2H, s),11.40(2H,brs),11.96(1H, brs).
    • Example 323 Preparation of the Compound of Compound No. 323
  • Using 4-methylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 42.9%.
  • 1H-NMR(DMSO-d6): δ 2.32(3H, s)6.82(1H, d, J=6.6 Hz)6.84(1H, s)7.83(1H, s)7.84(1H, d, J=8.5 Hz)8.47(2H, s)10.76(1H, s)11.44(1H, s).
    • Example 324 Preparation of the Compound of Compound No. 324
  • Using 5-bromo-4-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw material, the same operation as the Example 16 gave the title compound.
  • Yield: 82.4%.
  • 1H-NMR(CDCl3): δ 5.89(1H, s)6.70(1H, s)7.69(2H, s)7.95(1H, s)8.12(2H, s)11.62(1H, s).
    • Example 325 Preparation of the Compound of Compound No. 325
  • Using 4-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 29.9%.
  • 1H-NMR(DMSO-d6): δ 6.37(1H, d, J=2.5 Hz), 6.42(1H, dd, J=8.8, 2.5 Hz), 7.81(1H, s), 7.86(1H, d, J=8.5 Hz), 8.44(2H, s), 10.31(1H, s), 10.60(1H, s), 11.77(1H, s).
    • Example 326 Preparation of the Compound of Compound No. 326
  • Using 3,5-dichlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.8%.
  • 1H-NMR(DMSO-d6): δ 7.85(1H, d, J=2.5 Hz), 7.91(1H, s), 8.01(1H, d, J=2.5 Hz), 8.42(2H, s), 11.10(1H, s).
    • Example 327 Preparation of the Compound of Compound No. 327
  • Using 3-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 22.7%.
  • 1H-NMR(DMSO-d6): δ 6.81(1H, t, J=8.0 Hz), 7.01(1H, dd, J=8.0, 1.5 Hz), 7.35(1H, dd, J=8.0, 1.5 Hz), 7.84(1H, s), 8.46(2H, s), 9.56(1H, s), 10.79(1H, s), 10.90(1H, brs).
    • Example 328 Preparation of the Compound of Compound No. 328
  • Using 3-methylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 54.9%.
  • 1H-NMR(DMSO-d6): δ 2.22(3H, s), 6.94(1H, t, J=7.4 Hz), 7.42(1H, d, J=7.4 Hz), 7.84-7.85(2H, m), 8.47(2H, s), 10.87(1H, s), 11.87(1H, s).
    • Example 329 Preparation of the Compound of Compound No. 329
  • Using 3-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 34.6%.
  • 1H-NMR(DMSO-d6): δ 3.85(3H, s), 6.94(1H, t, J=8.0 Hz), 7.20(1H, dd, J=8.0, 1.4 Hz), 7.44(1H, dd, J=8.0, 1.4 Hz), 7.84(1H, s), 8.45(2H, s), 10.82(1H, s), 10.94(1H, brs).
    • Example 330 Preparation of the Compound of Compound No. 330
  • Using 5-[(1,1,3,3-tetramethyl)butyl]salicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 64.2%.
  • 1H-NMR(DMSO-d6): δ 0.70(9H, s), 1.35(6H, s), 1.72(2H, s), 6.95(1H, d, J=8.4 Hz), 7.50(1H, dd, J=8.0, 2.1 Hz), 7.83(1H, s), 7.84(1H, d, J=2.1 Hz), 8.46(1H, s), 10.77(1H, s), 11.20(1H, s).
    • Example 331 Preparation of the Compound of Compound No. 331
  • Using 3,5,6-trichlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 26.2%.
  • 1H-NMR(DMSO-d6): δ 7.88(1H, s), 7.93(1H, s), 8.33(2H, s), 10.88(1H, s), 11.36(1H, s).
    • Example 332 Preparation of the Compound of Compound No. 332
  • Using 3,5-bis[(1,1-dimethyl)ethyl]salicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.0%.
  • 1H-NMR(DMSO-d6): δ 1.34(9H, s), 1.40(9H, s), 7.49(1H, d, J=2.2 Hz), 7.82(1H, d, J=2.2 Hz), 7.91(1H, s), 8.40(2H, s), 10.82(1H, s), 12.44(1H, s).
    • Example 333 Preparation of the Compound of Compound No. 333
  • Using 6-fluorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 35.9%.
  • 1H-NMR(DMSO-d6): δ 6.73-6.82(2H, m), 7.32(1H, ddd, J=1.4, 8.5, 15.3 Hz), 7.83(1H, s), 8.39(2H, s), 10.50(1H, d, J=1.4 Hz), 11.11(1H, s).
    • Example 334 Preparation of the Compound of Compound No. 334
  • Using 3-chlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 61.3%.
  • 1H-NMR(DMSO-d6): δ 7.05(1H, dd, J=7.6, 8.0 Hz), 7.69(1H, dd, J=1.4, 13.3 Hz), 7.90(1H, s), 7.93(1H, dd, J=1.4, 8.0 Hz), 8.44(2H, s), 11.01(1H, s), 11.92(1H, br.s).
    • Example 335 Preparation of the Compound of Compound No. 335
  • Using 4-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 14.2%.
  • 1H-NMR(DMSO-d6): δ 3.81(3H, s), 6.54(1H, d, J=2.5 Hz), 6.61(1H, dd, J=2.5, 8.8 Hz), 7.83(1H, s), 7.95(1H, d, J=8.8 Hz), 8.45(2H, s), 10.69(1H, s), 11.89(1H, s).
    • Example 336 Preparation of the Compound of Compound No. 336
  • Using 6-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 63.1%.
  • 1H-NMR(DMSO-d6): δ 3.24(3H, s), 6.03(1H, d, J=8.0 Hz), 6.05(1H, d, J=8.5 Hz), 6.71(1H, dd, J=8.2, 8.5 Hz), 7.25(1H, s), 7.88(2H, s), 9.67(1H, s), 10.31(1H, s)
    • Example 337 Preparation of the Compound of Compound No. 337
  • Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 88) and methanesulfonyl chloride as the raw materials, the same operation as the Example 91 gave the title compound.
  • Yield: 22.6%.
  • 1H-NMR(DMSO-d6): δ 2.93(3H, s), 7.02(1H, d, J=8.4 Hz), 7.31(1H, dd, J=8.4, 2.7 Hz), 7.68(1H, d, J=2.7 Hz), 7.83(1H, s), 8.46(2H, s), 9.48(1H, s), 10.85(1H, s), 11.15(1H, s).
    • Example 338 Preparation of the Compound of Compound No. 338
  • Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 88) and benzenesulfonyl chloride as the raw materials, the same operation as the Example 91 gave the title compound.
  • Yield: 45.3%.
  • 1H-NMR(DMSO-d6): δ 6.89(1H, d, J=8.7 Hz), 7.10(1H, dd, J=8.7, 2.7 Hz), 7.51-7.64(4H, m), 7.68-7.71(2H, m), 7.81(1H, s), 8.42(2H, s), 10.03(1H, s), 10.87(1H, s), 11.13(1H, brs).
    • Example 339 Preparation of the Compound of Compound No. 339
  • Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide (Compound No. 88) and acetyl chloride as the raw materials, the same operation as the Example 91 gave the title compound.
  • Yield: 44.8%.
  • 1H-NMR(DMSO-d6): δ 2.02(3H, s), 6.97(1H, d, J=8.7 Hz), 7.61(1H, dd, J=8.7, 2.7 Hz), 7.82(1H, s), 7.99(1H, d, J=2.7 Hz), 8.46(2H, s), 9.90(1H, s), 10.85(1H, s), 10.94(1H, s).
    • Example 340 Preparation of the Compound of Compound No. 340
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-5-sulfamoyl-benzamide (compound of Example 87(2)) as the raw material, the same operation as the Example 80(5) gave the title compound.
  • Yield: 59.9%.
  • 1H-NMR(DMSO-d6): δ 7.17(1H, d, J=8.7 Hz), 7.31(2H, s), 7.85(1H, s), 7.86(1H, dd, J=8.4, 2.4 Hz), 8.26(1H, d, J=2.7 Hz), 8.47(2H, s), 10.95(1H, s), 11.90(1H, s).
    • Example 341 Preparation of the Compound of Compound No. 341
  • Using 3-hydroxynaphthalene-2-carboxylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 46.9%.
  • 1H-NMR(DMSO-d6): δ 7.36-7.41(2H, m), 7.50-7.55(1H, m), 7.79(1H, d, J=8.2 Hz), 7.85(1H, d, J=0.6 Hz), 7.96(1H, d, J=8.0 Hz), 8.51(2H, s), 10.98(1H, s), 11.05(1H, s).
    • Example 342 Preparation of the Compound of Compound No. 342
  • Using 2-hydroxynaphthalene-1-carboxylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 30.2%.
  • 1H-NMR(DMSO-d6): δ 7.27(1H, d, J=8.8 Hz), 7.32-7.38(1H, m), 7.45-7.50(1H, m), 7.72(1H, d, J=8.5 Hz), 7.82-7.93(3H, m), 8.50(1H, s), 10.28(1H, s), 11.07(1H, brs).
    • Example 343 Preparation of the Compound of Compound No. 343 (1) 4-Bromo-3-hydroxythiophene-2-carboxylic acid
  • A mixture of 4-bromothiophene-2-carboxylic acid methyl ester (500 mg, 2.1 mmol), sodium hydroxide (261 mg, 6.3 mmol) in a mixed solvent of methanol/water (2.5 mL+2.5 mL) was refluxed for 2 hours. After the reaction mixture was cooled to room temperature, 2N hydrochloric acid was added to adjust pH to 1, and it was diluted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure to give the title compound (326 mg, 69.4%) as a red brown powder.
  • 1H-NMR(CDCl3): δ 4.05(1H, brs), 7.40(1H, s).
    • (2) 4-Bromo-3-hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]thiophene-2-carboxamide (Compound No. 343)
  • Using 4-bromo-3-hydroxythiophene-2-carboxylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 82.4%.
  • 1H-NMR(CDCl3): δ 7.42(1H, s), 7.67(1H, brs), 7.78(1H, brs), 8.11(2H, s), 9.91(1H, brs).
    • Example 344 Preparation of the Compound of Compound No. 344
  • Using 3,5-bis(trifluoromethyl)phenylisocyanate and oxindole as the raw materials, the same operation as the Example 28 gave the title compound.
  • Yield: 44.8%.
  • 1H-NMR(DMSO-d6): δ 3.98(2H, s), 7.22(1H, td, J=7.8, 1.2 Hz), 7.33-7.40(2H, m), 7.87(1H, s), 8.02(1H, d, J=7.8 Hz), 8.38(2H, s), 11.00(1H, s).
    • Example 345 Preparation of the Compound of Compound No. 345
  • Using 3,5-bis(trifluoromethyl)phenylisocyanate and 5-chlorooxindole as the raw materials, the same operation as the Example 28 gave the title compound.
  • Yield: 31.1%.
  • 1H-NMR(DMSO-d6): δ 3.99(2H, s), 7.41(1H, dd, J=8.7, 2.4 Hz), 7.47(1H, d, J=2.1 Hz), 7.87(1H, s), 8.01(1H, d, J=8.4 Hz), 8.38(2H, s), 10.93(1H, s).
    • Example 346 Preparation of the Compound of Compound No. 346
  • Using 5-chlorosalicylic acid and 3-bromo-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 37.1%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=9.3 Hz), 7.48(1H, dd, J=8.7, 2.4 Hz), 7.72(1H, s), 7.84(1H, d, J=2.7 Hz), 8.16(1H, s), 8.28(1H, s), 10.69(1H, s), 11.42(1H, s).
    • Example 347 Preparation of the Compound of Compound No. 347
  • Using 5-chlorosalicylic acid and 3-methoxy-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 68.0%.
  • 1H-NMR(DMSO-d6): δ 3.85(3H, s), 7.02(1H, s), 7.03(1H, d, J=8.7 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.61(1H, s), 7.77(1H, s), 7.88(1H, d, J=2.7 Hz), 10.57(1H, s), 11.53(1H, s).
    • Example 348 Preparation of the Compound of Compound No. 348
  • Using 5-chlorosalicylic acid and 2-morpholino-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 64.8%.
  • 1H-NMR(DMSO-d6): δ 2.90(4H, m), 3.84(4H, m), 7.15(1H, d, J=9.0 Hz), 7.48(2H, s), 7.50(1H, dd, J=9.0, 2.7 Hz), 8.00(1H, d, J=2.7 Hz), 8.91(1H, s), 11.24(1H, s), 12.05(1H, s).
    • Example 349 Preparation of the Compound of Compound No. 349
  • Using 5-chlorosalicylic acid and 2-bromo-5-(trifluoromethyl)aniline as the raw material, the same operation as the Example 16 gave the title compound.
  • Yield: 59.2%.
  • 1H-NMR(DMSO-d6): δ 7.10(1H, d, J=8.7 Hz), 7.48(1H, dd, J=8.4, 2.1 Hz), 7.53(1H, dd, J=8.7, 3.0 Hz), 7.97-7.99(2H, m), 8.81(1H, d, J=2.1 Hz), 11.03(1H, s), 12.38(1H, s).
    • Example 350 Preparation of the Compound of Compound No. 350
  • Using 5-chlorosalicylic acid and 3-amino-5-(trifluoromethyl)benzoic acid methyl ester as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 67.0%.
  • 1H-NMR(DMSO-d6): δ 3.91(3H, s), 7.02(1H, d, J=9.3 Hz), 7.43(1H, dd, J=9.0, 2.4 Hz), 7.57(1H, d, J=2.4 Hz), 8.13(1H, s), 8.23(1H, s), 8.29(1H, s), 8.36(1H, s), 11.52(1H, s).
    • Example 351 Preparation of the Compound of Compound No. 351
  • 2N Aqueous sodium hydroxide (O.6 mL) was added to a mixture of 5-chloro-2-hydroxy-N-[3-methoxycarbonyl-5-(trifluoromethyl)phenyl]benzamide (Compound No. 350; 105 mg, 0.281 mmol) and methanol (2.5 mL), and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction mixture and it was washed with ethyl acetate. After the water layer was acidified by addition of diluted hydrochloric acid, it was extracted with ethyl acetate. After the ethyl acetate layer was washed successively with water and brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was crystallized by isopropyl ether to give the title compound (100 mg, 99.0%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=9.0 Hz), 7.49(1H, dd, J=8.7, 2.7 Hz), 7.91(1H, d, J=2.7 Hz), 7.93(1H, s), 8.43(1H, s), 8.59(1H, s), 10.78(1H, s), 11.48(1H, s).
    • Example 352 Preparation of the Compound of Compound No. 352
  • Using 5-chlorosalicylic acid and 2-(2-naphthyloxy)-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 89.6%.
  • 1H-NMR(CDCl3): δ 6.94(1H, d, J=9.6 Hz), 6.98(1H, d, J=9.2 Hz), 7.25-7.41(4H, m), 7.48-7.57(3H, m), 7.81(1H, d, J=6.9 Hz), 7.88(1H, d, J=6.9 Hz), 7.95(1H, d, J=8.9 Hz), 8.72(1H, s), 8.83(1H, d, J=2.0 Hz), 11.70(1H, s).
    • Example 353 Preparation of the Compound of Compound No. 353
  • Using 5-chlorosalicylic acid and 2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 4.7%.
  • 1H-NMR(CDCl3): δ 6.78(1H, d, J=8.9 Hz), 7.02(1H, d, J=8.6 Hz), 7.16(1H, d, J=8.6 Hz), 7.33-7.38(3H, m), 7.42(1H, dd, J=8.6, 2.6 Hz), 7.49(1H, d, J=2.6 Hz)7.58(1H, d, J=2.3 Hz), 8.66(1H, brs, ), 8.82(1H, d, J=2.0 Hz), 11.65(1H, s).
    • Example 354 Preparation of the Compound of Compound No. 354
  • Using 5-chlorosalicylic acid and 2-[(4-trifluoromethyl)piperidino]-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 60.5%.
  • 1H-NMR(CDCl3): δ 1.85-2.05(2H, m), 2.15(2H, d, J=10.9 Hz), 2.28(1H, m), 2.82(2H, t, J=11.0 Hz), 3.16(2H, d, J=12.2 Hz), 7.02(1H, d, J=8.9 Hz), 7.31(1H, d, J=8.3 Hz), 7.42(2H, m), 7.50(1H, d, J=2.6 Hz), 8.75(1H, s), 9.60(1H, s), 11.94(1H, s)
    • Example 355 Preparation of the Compound of Compound No. 355
  • Using 5-chlorosalicylic acid and 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 94.5%.
  • 1H-NMR(CDCl3): δ 4.58(2H, q, J=7.9 Hz), 6.99-7.05(2H, m), 7.41-7.50(3H, m), 8.63(1H, brs), 8.79(1H, d, J=2.0 Hz), 11.59(1H, s).
    • Example 356 Preparation of the Compound of Compound No. 356
  • Using 5-chlorosalicylic acid and 2-(2-methoxyphenoxy)-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 80.6%.
  • 1H-NMR(DMSO-d6): δ 3.74(3H, s), 6.70(1H, d, J=8.4 Hz), 7.02(1H, d, J=8.7 Hz), 7.07(1H, dd, J=1.5, 7.8 Hz), 7.24-7.39(4H, m), 7.49(1H, dd, J=3.0, 8.7 Hz), 8.00(1H, d, J=3.0 Hz), 8.92(1H, d, J=2.1 Hz), 11.36(1H, s), 12.18(1H, s).
    • Example 357 Preparation of the Compound of Compound No. 357
  • Using 5-chlorosalicylic acid and 2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 91.5%.
  • 1H-NMR(DMSO-d6): δ 2.34(6H, s), 7.03(1H, d, J=8.8 Hz), 7.05(1H, d, J=8.1 Hz), 7.11(2H, s), 7.43-7.47(1H, m), 7.48(1H, dd, J=2.9, 8.8 Hz), 7.97(1H, d, J=2.6 Hz), 8.94(1H, d, J=2.2 Hz), 11.25(1H, s), 12.12(1H, s).
    • Example 358 Preparation of the Compound of Compound No. 358
  • Using 5-chlorosalicylic acid and 2-piperidino-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.7%.
  • 1H-NMR(CDCl3): δ 1.68-1.72(2H, m), 1.80-1.88(4H, m), 2.89(4H, t, J=5.2 Hz), 7.01(1H, d, J=8.7 Hz), 7.31(1H, d, J=8.4 Hz), 7.39-7.43(2H, m), 7.55(1H, d, J=2.4 Hz), 8.73(1H, d, J=1.8 Hz), 9.71(1H, s), 12.05(1H, s)
    • Example 359 Preparation of the Compound of Compound No. 359
  • Using 5-chlorosalicylic acid and 2-(4-methylphenoxy)-5-(trifluoromethyl)-aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 67.3%.
  • 1H-NMR(DMSO-d6): δ 2.33(3H, s), 6.93(1H, d, J=8.8 Hz), 7.03(1H, dd, J=0.5, 8.8 Hz), 7.12(2H, d, J=8.2 Hz), 7.29(2H, d, J=8.5 Hz), 7.43(1H, dd, J=2.0, 8.6 Hz), 7.48(1H, ddd, J=0.8, 2.7, 8.8 Hz), 7.98(1H, dd, J=0.8, 2.7 Hz), 8.94(1H, d, J=2.2 Hz), 11.29(1H, s), 12.15(1H, s).
    • Example 360 Preparation of the Compound of Compound No. 360
  • Using 5-chlorosalicylic acid and 2-(4-chlorophenoxy)-5-(trifluoromethyl)-aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 74.5%.
  • 1H-NMR(DMSO-d6): δ 7.01(1H, d, J=8.8 Hz), 7.06(1H, d, J=8.5 Hz), 7.22(1H, d, J=8.5 Hz), 7.43-7.48(2H, m), 7.50(2H, d, J=8.2 Hz), 7.94(1H, dd, J=0.5, 2.7 Hz), 8.92(1H, d, J=2.2 Hz), 11.20(1H, s), 12.10(1H, s).
    • Example 361 Preparation of the Compound of Compound No. 361
  • Using 5-bromo-2-hydroxy-N-[3,5-bis(methoxycarbonyl)phenyl]benzamide (Compound No. 170) as the raw material, the same operation as the Example 351 gave the title compound.
  • Yield: 89.0%.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.7 Hz), 7.60(1H, dd, J=8.7, 2.4 Hz), 7.24(1H, dd, J=8.7, 2.7 Hz), 8.08(1H, d, J=2.7 Hz), 8.24(1H, t, J=1.5 Hz), 8.57(2H, d, J=1.2 Hz), 10.67(1H, s), 11.64(1H, s).
    • Example 362 Preparation of the Compound of Compound No. 362
  • Using 5-chlorosalicylic acid and 2-methyl-5-[(1-methyl)ethyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 19.1%.
  • 1H-NMR(CDCl3): δ 1.26(6H, d, J=6.9 Hz), 2.30(3H, s), 2.87-2.96(1H, m), 7.00(1H, d, J=8.7 Hz), 7.08(1H, dd, J=7.8, 1.8 Hz), 7.20(1H, d, J=7.8 Hz), 7.40(1H, dd, J=8.7, 2.4 Hz), 7.49(1H, d, J=2.7 Hz), 7.50(1H, s), 7.71(1H, s), 11.99(1H, s).
    • Example 363 Preparation of the Compound of Compound No. 363
  • Using 5-chlorosalicylic acid and 2,5-diethoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 59.2%.
  • 1H-NMR(DMSO-d6): δ 1.32(3H, t, J=6.9 Hz), 1.41(3H, t, J=6.9 Hz),3.97(2H, q, J=6.9 Hz), 4.06(2H, q, J=6.9 Hz), 6.61(1H, dd, J=9.0, 3.0 Hz), 6.98(1H, d, J=8.7 Hz), 7.10(1H, d, J=8.7 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.97(1H, d, J=2.7 Hz), 8.16(1H, d, J=3.0 Hz), 10.96(1H, s), 11.91(1H, s).
    • Example 364 Preparation of the Compound of Compound No. 364
  • Using 5-chlorosalicylic acid and 2,5-dimethylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 90.5%.
  • 1H-NMR(CDCl3): δ 2.28(3H, s), 2.35(3H, s), 6.99(1H, d, J=8.8 Hz), 7.02(1H, brs), 7.15(1H, d, J=7.7 Hz), 7.40(1H, dd, J=8.8, 2.5 Hz), 7.45(1H, brs), 7.49(1H, d, J=2.5 Hz)7.70(1H, br), 11.96(1H, brs).
    • Example 365 Preparation of the Compound of Compound No. 365
  • Using 5-chlorosalicylic acid and 5-chloro-2-cyanoaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 90.0%.
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=9.0 Hz), 7.53(1H, dd, J=8.7, 3.0 Hz), 7.82(1H, dd, J=8.7, 2.4 Hz), 7.95(1H, d, J=3.0 Hz), 8.07(1H, d, J=2.4 Hz), 8.36(1H, d, J=9.0 Hz), 11.11(1H, s), 12.36(1H, s).
    • Example 366 Preparation of the Compound of Compound No. 366
  • Using 5-chlorosalicylic acid and 5-(N,N-diethylsulfamoyl)-2-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.8%.
  • 1H-NMR(CDCl3): δ 1.17(6H, t, J=7.3 Hz), 3.29(4H, q, J=7.3 Hz), 4.05(3H, s), 7.00(2H, dd, J=2.3, 8.9 Hz), 7.41(1H, dd, J=2.3, 8.9 Hz), 7.48(1H, d, J=2.6 Hz), 7.65(1H, dd, J=2.3, 8.6 Hz), 8.56(1H, br.s), 8.84(1H, d, J=2.3 Hz), 11.82(1H, s).
    • Example 367 Preparation of the Compound of Compound No. 367
  • Using 5-chlorosalicylic acid and 2-chloro-5-nitroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.3%.
  • 1H-NMR(CD3OD): δ 6.98(1H, d, J=8.6 Hz), 7.43(1H, dd, J=2.6, 8.6 Hz), 7.74(1H, d, J=8.9 Hz), 7.99(1H, dd, J=3.0, 8.9 Hz), 8.08(1H, d, J=2.6 Hz), 9.51(1H, d, J=2.6 Hz).
    • Example 368 Preparation of the Compound of Compound No. 368
  • Using 5-chlorosalicylic acid and 5-(N-phenylcarbamoyl)-2-methoxyaniline as the raw material, the same operation as the Example 16 gave the title compound.
  • Yield: 40.3%.
  • 1H-NMR(DMSO-d6): δ 3.99(3H, s), 7.09(2H, dd, J=6.6, 6.9 Hz), 7.24(1H, d, J=8.6 Hz), 7.35(2H, dd, 6.9, 7.3 Hz), 7.49(1H, d, J=2.3, 8.9 Hz), 7.77(3H, d, J=8.6 Hz), 8.00(1H, s), 8.97(1H, s), 10.17(1H, s), 10.91(1H, s), 12.11(1H, s).
    • Example 369 Preparation of the Compound of Compound No. 369
  • Using 5-chlorosalicylic acid and 2,5-dimethoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.9%.
  • 1H-NMR(CDCl3): δ 3.82(3H, s), 3.93(3H, s), 6.66(1H, dd, J=3.0, 8.9 Hz), 6.86(1H, d, J=8.9 Hz), 6.98(1H, d, J=8.9 Hz), 7.39(1H, dd, J=2.6, 8.9 Hz), 7.47(1H, d, J=2.6 Hz), 8.08(1H, d, J=3.0 Hz), 8.60(1H, br.s), 12.03(1H, s).
    • Example 370 Preparation of the Compound of Compound No. 370
  • Using 5-chlorosalicylic acid and 5-acetylamino-2-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 16.9%.
  • 1H-NMR(DMSO-d6): δ 2.01(3H, s), 3.85(3H, s), 7.03(2H, t, J=9.6 Hz), 7.49(2H, dd, J=8.9, 9.2 Hz), 7.96(1H, s), 8.51(1H, s), 9.87(1H, s), 10.82(1H, s), 12.03(1H, d, J=4.0 Hz).
    • Example 371 Preparation of the Compound of Compound No. 371
  • Using 5-chlorosalicylic acid and 5-methoxy-2-methylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 100%.
  • 1H-NMR(CDCl3): δ 2.29(3H, s), 3.82(3H, s), 6.75(1H, dd, J=2.6, 8.2 Hz), 7.00(1H, d, J=8.9 Hz), 7.16(1H, d, J=8.6 Hz), 7.38(1H, d, 2.3 Hz), 7.41(1H, dd, J=2.3, 8.9 Hz), 7.48(1H, d, J=2.3 Hz), 7.70(1H, br.s), 11.92(1H, s).
    • Example 372 Preparation of the Compound of Compound No. 372
  • Using 5-chlorosalicylic acid and 2,5-dibutoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.9%.
  • 1H-NMR(CDCl3): δ 0.98(3H, t, J=7.2 Hz), 1.05(3H, t, J=7.2 Hz), 1.44-1.65(4H, m), 1.72-1.79(2H, m), 1.81-1.91(2H, m), 3.97(2H, t, J=6.3 Hz), 4.07(2H, t, J=6.3 Hz), 6.64(1H, dd, J=9.0, 3.0 Hz), 6.85(1H, d, J=9.3 Hz), 6.99(1H, d, J=9.0 Hz), 7.39(1H, dd, J=8.7, 2.4 Hz), 7.44(1H, d, J=2.7 Hz), 8.08(1H, d, J=3.0 Hz), 8.76(1H, s), 12.08(1H, s).
    • Example 373 Preparation of the Compound of Compound No. 373
  • Using 5-chlorosalicylic acid and 2,5-diisopentyloxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 59.7%.
  • 1H-NMR(CDCl3): δ 0.97(6H, d, J=6.6 Hz), 1.03(6H, d, 6.6 Hz), 1.64-1.98(6H, m), 3.99(2H, t, J=6.6 Hz), 4.09(2H, t, J=6.3 Hz), 6.63(1H, dd, J=8.7, 3.0 Hz), 6.85(1H, d, J=8.7 Hz), 6.98(1H, d, J=8.7 Hz), 7.38(1H, dd, J=9.0, 2.4 Hz), 7.43(1H, d, J=2.7 Hz), 8.09(1H, d, J=3.0 Hz), 8.75(1H, s), 12.08(1H, s).
    • Example 374 Preparation of the Compound of Compound No. 374
  • Using 5-chlorosalicylic acid and 5-carbamoyl-2-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 31.2%.
  • 1H-NMR(CD3OD): δ 4.86(3H, s), 6.93(1H, d, J=7.6 Hz), 7.18(1H, d, J=8.6 Hz), 7.35(1H, dd, J=3.0, 7.6 Hz), 7.47(1H, dd, J=2.0, 8.6 Hz), 8.00(1H, d, J=3.0 Hz), 8.80(1H, d, J=2.0 Hz).
    • Example 375 Preparation of the Compound of Compound No. 375
  • Using 5-chlorosalicylic acid and 5-[(1,1-dimethyl)propyl]-2-phenoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.2%.
  • 1H-NMR(CDCl3): δ 0.69(3H, t, J=7.6 Hz), 1.29(6H, s), 1.64(2H, q, J=7.6 Hz), 6.91(1H, dd, J=1.7, 7.6 Hz), 6.96(1H, d, J=8.9 Hz), 7.03(2H, d, J=8.9 Hz), 7.10(1H, dt, J=1.7, 7.6 Hz), 7.16(1H, dt, J=1.7, 7.6 Hz), 7.40-7.31(4H, m), 8.42(1H, dd, J=2.0, 7.9 Hz), 8.53(1H, br.s)11.94(1H, s).
    • Example 376 Preparation of the Compound of Compound No. 376
  • Using 5-chlorosalicylic acid and 2-hexyloxy-5-(methylsulfonyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 33.0%.
  • 1H-NMR(CDCl3): δ 0.92(3H, t, J=6.9 Hz), 1.40-1.59(6H, m), 1.90-2.01(2H, m), 3.09(3H, s), 4.22(2H, t, J=6.3 Hz), 7.01(1H, d, J=8.9 Hz), 7.06(1H, d, J=8.6 Hz), 7.40-7.43(2H, m), 7.73(1H, dd, J=8.6, 2.3 Hz), 8.74(1H, brs), 8.99(1H, d, J=2.3 Hz), 11.76(1H, s).
    • Example 377 Preparation of the Compound of Compound No. 377
  • Using 5-chlorosalicylic acid and 3′-amino-2,2,4′-trimethylpropiophenone as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 44.8%.
  • 1H-NMR(CDCl3): δ 1.38(9H, s),2.38(3H, s),7.01(1H, d, J=8.9 Hz), 7.31(1H, d, J=7.9 Hz), 7.42(1H, dd, J=8.9, 2.6 Hz), 7.53(1H, d, J=2.6 Hz), 7.57(1H, dd, J=7.9, 2.0 Hz), 7.83(1H, brs), 8.11(1H, d, J=2.0 Hz), 11.82(1H, s).
    • Example 378 Preparation of the Compound of Compound No. 378
  • Using 5-chlorosalicylic acid and 5-methoxy-2-(1-pyrrolyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 53.4%.
  • 1H-NMR(CDCl3): δ 2.46(3H, s), 6.51-6.52(2H, m), 6.82-6.85(3H, m), 6.93(1H, d, J=8.9 Hz), 7.06(1H, d, J=7.9 Hz), 7.30(1H, d, J=7.9 Hz), 7.32(1H, dd, J=2.3, 8.9 Hz), 7.61(1H, s), 8.29(1H, s), 11.86(1H, br.s).
    • Example 379 Preparation of the Compound of Compound No. 379
  • Using 5-chlorosalicylic acid and 5-chloro-2-tosylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 8.0%.
  • 1H-NMR(CDCl3): δ 2.38(3H, s), 7.02(1H, d, J=8.9 Hz), 7.25-7.31(3H, m), 7.46(1H, dd, J=2.6, 8.9 Hz), 7.68(2H, d, J=8.6 Hz), 7.74(1H, d, J=2.3 Hz), 7.96(1H, d, J=8.6 Hz), 8.56(1H, d, J=2.0 Hz), 10.75(1H, s), 11.70(1H, s).
    • Example 380 Preparation of the Compound of Compound No. 380
  • Using 5-chlorosalicylic acid and 2-chloro-5-tosylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 43.5%.
  • 1H-NMR(CDCl3): δ 2.38(3H, s), 7.02(1H, d, J=8.9 Hz), 7.27(1H, d, J=7.9 Hz), 7.29(1H, dd, J=2.0, 6.6 Hz), 7.46(1H, dd, J=2.3, 8.9 Hz), 7.68(2H, d, J=8.6 Hz), 7.73(2H, d, J=2.3 Hz), 7.97(1H, d, J=8.6 Hz), 8.56(1H, d, J=2.0 Hz), 10.73(1H, s), 11.71(1H, s).
    • Example 381 Preparation of the Compound of Compound No. 381
  • Using 5-chlorosalicylic acid and 2-fluoro-5-(methylsulfonyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 28.8%.
  • 1H-NMR(CDCl3): δ 3.12(3H, s), 7.03(1H, d, J=8.9 Hz), 7.38(1H, dd, J=8.6, 10.2 Hz), 7.45(1H, dd, J=2.3, 8.9 Hz), 7.53(1H, d, J=2.3 Hz), 7.80(1H, ddd, J=2.3, 4.6, 8.6 Hz), 8.25(1H, s), 8.98(1H, dd, J=2.3, 7.7 Hz), 11.33(1H, br.s).
    • Example 382 Preparation of the Compound of Compound No. 382
  • Using 5-chlorosalicylic acid and 2-methoxy-5-phenoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 77.0%.
  • 1H-NMR(CDCl3): δ 3.98(3H, s), 6.80(1H, d, J=8.8 Hz), 6.90(1H, d, J=8.8 Hz), 6.95-7.00(3H, m), 7.04-7.09(1H, m), 7.29-7.35(2H, m), 7.38(1H, dd, J=8.8, 2.6 Hz), 7.47(1H, d, J=2.6 Hz), 8.19(1H, d, J=2.9 Hz), 8.61(1H, brs), 11.92(1H, s).
    • Example 383 Preparation of the Compound of Compound No. 383
  • Using 5-chlorosalicylic acid and 3-amino-4-methylbiphenyl as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 47.7%.
  • 1H-NMR(DMSO-d6): δ 2.33(3H, s), 7.06(1H, d, J=8.7 Hz), 7.43-7.52(4H, m), 7.64-7.67(2H, m), 8.04(1H, d, J=2.7 Hz), 8.19(1H, d, J=1.5 Hz), 10.40(1H, s), 12.22(1H, s).
    • Example 384 Preparation of the Compound of Compound No. 384
  • Using 5-chlorosalicylic acid and 5-( a, a -dimethylbenzyl)-2-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 89.0%.
  • 1H-NMR(CDCl3): δ 1.72(6H, s), 3.93(3H, s), 6.83(1H, d, J=8.8 Hz), 6.93(1H, dd, J=2.6, 8.8 Hz), 6.96(1H, d, J=9.2 Hz), 7.15-7.20(1H, m), 7.25-7.28(4H, m), 7.36(1H, dd, J=2.6, 8.8 Hz), 7.46(1H, d, J=2.6 Hz), 8.35(1H, d, J=2.6 Hz), 8.51(1H, s), 12.04(1H, s).
    • Example 385 Preparation of the Compound of Compound No. 385
  • Using 5-chlorosalicylic acid and 5-morpholino-2-nitroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 4.1%.
  • 1H-NMR(DMSO-d6): δ 3.46-3.52(4H, m), 3.85-3.94(4H, m), 7.03(1H, d, J=8.8 Hz), 7.47(1H, dd, J=2.9, 8.8 Hz), 7.80(1H, dd, J=2.6, 8.8 Hz), 7.82(1H, d, J=2.6 Hz), 7.88(1H, d, J=8.8 Hz), 8.20(1H, d, J=2.2 Hz), 10.70(1H, s), 11.43(1H, s)
    • Example 386 Preparation of the Compound of Compound No. 386
  • Using 5-chlorosalicylic acid and 5-fluoro-2-(1-imidazolyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 33.8%.
  • 1H-NMR(DMSO-d6): δ 6.99(1H, d, J=8.8 Hz), 7.12-7.19(2H, m), 7.42-7.51(3H, m), 7.89(1H, d, J=2.8 Hz), 7.93(1H, d, J=1.1 Hz), 8.34(1H, dd, J=11.4, 2.8 Hz), 10.39(1H, s), 11.76(1H, brs).
    • Example 387 Preparation of the Compound of Compound No. 387
  • Using 5-chlorosalicylic acid and 2-butyl-5-nitroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 15.3%.
  • 1H-NMR(CDCl3): δ 0.99(3H, t, J=7.3 Hz), 1.39-1.51(2H, m), 1.59-1.73(2H, m), 2.71-2.79(2H, m), 7.03(1H, d, J=8.9 Hz), 7.41-7.49(3H, m), 7.92(1H, s), 8.07(1H, dd, J=2.3, 8.4 Hz), 8.75(1H, d, J=2.4 Hz), 11.51(1H, s).
    • Example 388 Preparation of the Compound of Compound No. 388
  • Using 5-chlorosalicylic acid and 5-[(1,1-dimethyl)propyl]-2-hydroxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 36.0%.
  • 1H-NMR(CDCl3): δ 0.70(3H, t, J=7.4 Hz), 1.28(6H, s), 1.63(2H, q, J=7.4 Hz), 6.97(1H, d, J=6.3 Hz), 7.00(1H, d, J=6.6 Hz), 7.08(1H, s), 7.14(1H, dd, J=2.5, 8.6 Hz), 7.36(1H, d, J=2.2 Hz), 7.42(1H, dd, J=2.5, 8.8 Hz), 7.57(1H, d, J=2.5 Hz), 8.28(1H, s), 11.44(1H, s).
    • Example 389 Preparation of the Compound of Compound No. 389
  • Using 5-chlorosalicylic acid and 2-methoxy-5-methylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 74.2%.
  • 1H-NMR(DMSO-d6): δ 2.27(3H, s), 3.85(3H, s), 6.90(1H, dd, J=9.0, 2.4 Hz), 6.98(1H, d, J=9.0 Hz), 7.05(1H, d, J=9.0 Hz), 7.47(1H, dd, J=9.0, 3.0 Hz), 7.97(1H, d, J=3.0 Hz), 8.24(1H, d, J=2.4 Hz), 10.79(1H, s), 12.03(1H, s).
    • Example 390 Preparation of the Compound of Compound No. 390
  • Using 5-chlorosalicylic acid and 2,5-difluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 81.5%.
  • 1H-NMR(DMSO-d6): δ 6.98-7.07(1H, m), 7.07(1H, d, J=9.0 Hz), 7.37-7.49(1H, m), 7.52(1H, dd, J=8.7, 3.0 Hz), 7.95(1H, d, J=2.7 Hz), 8.15-8.22(1H, m), 10.83(1H, s), 12.25(1H, s).
    • Example 391 Preparation of the Compound of Compound No. 391
  • Using 5-chlorosalicylic acid and 3,5-difluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 82.0%.
  • 1H-NMR(DMSO-d6): δ 7.00(1H, tt, J=9.3, 2.1), 7.03(1H, d, J=9.0 Hz), 7.47(1H, dd, J=7.5, 2.7 Hz), 7.49(1H, d, J=2.7 Hz), 7.51(1H, d, J=2.1 Hz), 7.82(1H, d, J=3.0 Hz), 10.63(1H, s), 11.43(1H, brs).
    • Example 392 Preparation of the Compound of Compound No. 392
  • Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-[(1,1-dimethyl)ethyl]thiazole-5-carboxylic acid ethyl ester (Compound No. 197) as the raw material, the same operation as the Example 82 gave the title compound.
  • Yield: 85.5%.
  • 1H-NMR(DMSO-d6): δ 1.44(9H, s), 7.00(1H, d, J=9.0 Hz), 7.62(1H, dd, J=9.0, 2.7 Hz), 8.02(1H, d, J=2.4 Hz), 11.83(1H, brs), 12.04(1H, brs), 12.98(1H, brs).
    • Example 393 Preparation of the Compound of Compound No. 393
  • Using 5-bromosalicylic acid and 2-amino-4-phenylthiazole-5-acetic acid methyl ester as the raw materials, the same operation as the Example 195(3) gave the title compound. (This compound is the compound of Example 203(1).)
  • Yield: 32.1%.
  • mp 288.5-229.5° C.
  • 1H-NMR(DMSO-d6): δ 3.66(3H, s), 3.95(2H, s), 6.99(1H, d, J=8.0 Hz), 7.42(1H, d, J=6.0 Hz), 7.48(2H, brt, J=7.6 Hz), 7.56-7.61(3H, m),8.07(1H, d, J=2.4 Hz), 11.85(1H, brs), 11.98(1H, brs).
    • Example 394 Preparation of the Compound of Compound No. 394
  • Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid ethyl ester (Compound No. 209) as the raw material, the same operation as the Example 82 gave the title compound. (This compound is the compound of Example 212(1).)
  • Yield: 67.0%.
  • 1H-NMR(DMSO-d6): δ 7.00(1H, d, J=8.8 Hz), 7.42-7.44(3H, m), 7.62(1H, dd, J=8.8, 2.4 Hz), 7.70-7.72(2H, m), 8.04(1H, d, J=2.4 Hz), 12.31(1H, brs), 12.99(1H, brs).
    • Example 395 Preparation of the Compound of Compound No. 395 (1) 2-Amino-4-[3,5-bis(trifluoromethyl)phenyl]thiazole
  • Phenyltrimethylammonium tribromide (753 mg, 2 mmol) was added to a solution of 3′,5′-bis(trifluoromethyl)acetophenone (0.51 g, 2.0 mmol) in tetrahydrofuran (5 mL) and the mixture was stirred at room temperature for 5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine, dried over anhydrous sodium sulfate, ethanol (5 mL) and thiourea (152 mg, 2 mmol) were added to the residue obtained by evaporation of the solvent under reduced pressure, and the mixture was refluxed for 30 minutes. After the reaction mixture was cooled to room temperature, it was poured into saturated aqueous sodium hydrogen carbonate and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine and dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) and washed with n-hexane under suspension to give the title compound (520.1 mg, 83.3%) as a light yellow white crystal.
  • 1H-NMR(CDCl3): δ 5.03(2H, s), 6.93(1H, s), 7.77(1H, s), 8.23(2H, s).
    • (2) 5-Chloro-2-hydroxy-N-{4-[3,5-bis(trifluoromethyl)phenyl]thiazol-2-yl}benzamide (Compound No. 395)
  • A mixture of 5-chlorosalicylic acid (172.6 mg, 1 mmol), 2-amino-4-[3,5-bis(trifluoromethyl)phenyl]thiazole(312.2 mg, 1 mmol), phosphorus trichloride (44 μL, 0.5 mmol) and monochlorobenzene (5 mL) was refluxed for 4 hours. After the reaction mixture was cooled to room temperature, it was poured into water and extracted with ethyl acetate. After the ethyl acetate layer was washed with brine, dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1→2:1) to give the title compound (109.8 mg, 23.5%) as a pale yellow white powder.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.7 Hz), 7.53(1H, dd, J=9.0, 3.0 Hz), 7.94(1H, d, J=3.0 Hz), 8.07(1H, s), 8.29(1H, s), 8.60(2H, s), 11.77(1H, s), 12.23(1H, s).
    • Example 396 Preparation of the Compound of Compound No. 396
  • Using 5-chlorosalicylic acid and 3-aminopyridine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 23.2%.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=9.3 Hz), 7.42(1H, ddd, J=9.0, 4.8, 0.6 Hz), 7.47(1H, dd, J=8.7, 5.7 Hz), 7.92(1H, d, J=2.7 Hz), 8.15(1H, ddd, J=8.4, 2.4, 1.5 Hz), 8.35(1H, dd, J=7.8, 1.5 Hz), 8.86(1H, d, J=2.4 Hz), 10.70(1H, s).
    • Example 397 Preparation of the Compound of Compound No. 397
  • Using 5-chlorosalicylic acid and 2-amino-6-bromopyridine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 12.3%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.7 Hz), 7.42(1H, d, J=7.8 Hz), 7.51(1H, dd, J=8.7, 2.7 Hz), 7.82(1H, t, J=7.5 Hz), 7.94(1H, d, J=3.0 Hz), 8.24(1H, d, J=7.8 Hz), 10.95(1H, s), 11.97(1H, s).
    • Example 398 Preparation of the Compound of Compound No. 398 (1) 2-Acetoxy-5-chloro-N-(pyridazin-2-yl)benzamide
  • Using 2-acetoxy-5-chlorobenzoic acid and 2-aminopyridazine as the raw materials, the same operation as the Example 198(3) gave the title compound.
  • Yield: 19.7%.
  • 1H-NMR(CDCl3): δ 2.42(3H, s), 7.19(1H, d, J=8.7 Hz), 7.54(1H, dd, J=8.7, 2.7 Hz), 8.01(1H, d, J=2.4 Hz), 8.28(1H, dd, J=2.4, 1.8 Hz), 8.42(1H, d, J=2.4 Hz), 9.09(1H, s), 9.66(1H, d, J=1.8 Hz).
    • (2) 5-Chloro-2-hydroxy-N-(pyridazin-2-yl)benzamide (Compound No. 398)
  • Using 2-acetoxy-5-chloro-N-(pyridazin-2-yl)benzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 72.6%.
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=9.0 Hz), 7.52(1H, dd, J=8.7, 2.7 Hz), 7.96(1H, d, J=2.7 Hz), 8.44-8.47(2H, m), 9.49(1H, s), 10.99(1H, s), 12.04(1H, s).
    • Example 399 Preparation of the Compound of Compound No. 399
  • Using 5-bromosalicylic acid and 2-amino-5-bromopyrimidine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 10.3%.
  • 1H-NMR(DMSO-d6): δ 6.98(1H, d, J=8.8 Hz), 7.59(1H, dd, J=8.8, 2.4 Hz), 8.00(1H, d, J=2.8 Hz), 8.86(2H, s), 11.09(1H, s), 11.79(1H, s).
    • Example 400 Preparation of the Compound of Compound No. 400
  • Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid (Compound No. 394) and propylamine as the raw materials, the same operation as the Example 212(2) gave the title compound.
  • Yield: 23.1%.
  • 1H-NMR(DMSO-d6): δ 0.82(3H, t, J=7.5 Hz), 1.39-1.51(2H, m), 3.13(2H, q, J=6.6 Hz), 7.02(1H, d, J=9.0 Hz), 7.40-7.48(3H, m), 7.63(1H, dd, J=8.7, 2.7 Hz), 7.68-7.72(2H, m), 8.06(1H, d, J=2.7 Hz), 8.18(1H, t, J=5.7 Hz), 11.87(1H, brs), 12.14(1H, brs).
    • Example 401 Preparation of the Compound of Compound No. 401
  • Using 5-chlorosalicylic acid and 2-methyl-3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 15.0%.
  • 1H-NMR(DMSO-d6): δ 2.49(3H, s), 7.07(1H, d, J=8.7 Hz), 7.52(1H, dd, J=8.7, 2.8 Hz), 7.84(1H, s), 7.97(1H, d, J=2.8 Hz), 8.60(1H, s), 10.69(1H, brs), 12.07(1H, brs).
    • Example 402 Preparation of the Compound of Compound No. 402
  • Using 5-chlorosalicylic acid and 4-chloro-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 66.5%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.73(1H, d, J=8.7 Hz), 7.86(1H, d, J=2.4 Hz), 8.00(1H, dd, J=8.7, 2.4 Hz), 8.32(1H, d, J=2.4 Hz), 10.69(1H, s), 11.49(1H, s).
    • Example 403 Preparation of the Compound of Compound No. 403
  • Using 5-chlorosalicylic acid and 4-isopropyl-2-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 33.4%.
  • 1H-NMR(DMSO-d6): δ 1.24(6H, d, J=6.6 Hz), 2.97-3.06(1H, m), 7.06(1H, d, J=8.7 Hz), 7.51(1H, dd, J=8.7, 2.7 Hz), 7.61(1H, s), 7.62(1H, d, J=7.5 Hz), 7.98(1H, d, J=2.7 Hz), 8.03(1H, d, J=8.1 Hz), 10.67(1H, s), 12.21(1H, s).
    • Example 404 Preparation of the Compound of Compound No. 404
  • Using 5-chlorosalicylic acid and 3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 68.5%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.6 Hz), 7.46-7.51(2H, m), 7.62(1H, t, J=7.9 Hz), 7.90(1H, d, J=3.0 Hz), 7.94(1H, d, J=9.2 Hz), 8.21(1H, s), 10.64(1H, s), 11.58(1H, brs).
    • Example 405 Preparation of the Compound of Compound No. 405
  • Using 5-chlorosalicylic acid and 2-nitro-4-(trifluoromethyl)aniline as the raw materials the same operation as the Example 16 gave the title compound.
  • Yield: 18.7%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=9.0 Hz), 7.54(1H, dd, J=8.7, 2.7 Hz), 7.94(1H, d, J=2.7 Hz), 8.17(1H, dd, J=9.0, 2.4 Hz), 8.46(1H, d, J=1.8 Hz), 8.88(1H, d, J=9.0 Hz), 12.19(1H, s), 12.25(1H, s).
    • Example 406 Preparation of the Compound of Compound No. 406
  • Using 5-chlorosalicylic acid and 2,6-dichloro-4-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 22.1%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.7 Hz), 7.55(1H, dd, J=8.7, 2.7 Hz), 7.99(1H, d, J=2.4 Hz), 8.10(2H, s), 10.62(1H, s), 11.88(1H, s).
    • Example 407 Preparation of the Compound of Compound No. 407
  • Using 5-chlorosalicylic acid and 4-cyano-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 55.8%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.7 Hz), 7.49(1H, dd, J=8.7, 2.7 Hz), 7.80(1H, d, J=2.7 Hz), 8.17(2H, s), 8.43(1H, s), 10.94(1H, s), 11.34(1H, s).
    • Example 408 Preparation of the Compound of Compound No. 408
  • Using 5-chlorosalicylic acid and 4-bromo-3-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 81.2%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.48(1H, dd, J=9.0, 2.7 Hz), 7.85-7.94(3H, m), 8.31(1H, d, J=1.8 Hz), 10.67(1H, s), 11.48(1H, s).
    • Example 409 Preparation of the Compound of Compound No. 409
  • Using 5-chlorosalicylic acid and 4-bromo-2-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 41.8%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.7 Hz), 7.52(1H, dd, J=9.0, 2.7 Hz), 7.93-7.97(3H, m), 8.21(1H, d, J=9.3 Hz), 10.81(1H, s), 12.28(1H, s).
    • Example 410 Preparation of the Compound of Compound No. 410
  • Using 5-chlorosalicylic acid and 2-bromo-4-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 17.6%.
  • 1H-NMR(DMSO-d6): δ 7.10(1H, d, J=9.0 Hz), 7.53(1H, dd, J=8.7, 3.0 Hz), 7.82(1H, dd, J=9.0, 1.8 Hz), 7.98(1H, d, J=3.0 Hz), 8.11(1H, d, J=1.5 Hz), 8.67(1H, d, J=8.7 Hz), 11.05(1H, s), 12.40(1H, s).
    • Example 411 Preparation of the Compound of Compound No. 411
  • Using 5-chlorosalicylic acid and 4-fluoro-2-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 36.0%.
  • 1H-NMR(DMSO-d6): δ 7.06(1H, d, J=9.0 Hz), 7.52(1H, dd, J=8.7, 2.7 Hz), 7.63(1H, td, J=8.7, 3.3 Hz), 7.71(1H, dd, J=8.7, 3.0 Hz), 7.97(1H, d, J=2.7 Hz), 8.11(1H, dd, J=8.7, 5.1 Hz), 10.67(1H, s), 12.20(1H, s).
    • Example 412 Preparation of the Compound of Compound No. 412
  • Using 5-chlorosalicylic acid and 4-isopropyloxy-2-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 39.2%.
  • 1H-NMR(DMSO-d6): δ 1.29(6H, d, J=5.7 Hz), 4.67-4.79(1H, m), 7.04(1H, d, J=9.0 Hz), 7.22(1H, d, J=2.7 Hz), 7.30(1H, dd, J=8.7, 2.7 Hz), 7.51(1H, dd, J=8.7, 2.4 Hz), 7.86(1H, d, J=9.0 Hz), 7.99(1H, d, J=3.0 Hz), 10.50(1H, s), 12.18(1H, s).
    • Example 413 Preparation of the Compound of Compound No. 413
  • Using 5-chlorosalicylic acid and 2,4-dimethoxy-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 19.0%.
  • 1H-NMR(CDCl3): δ 3.93(3H, s),4.03(3H, s),6.70(1H, s), 6.98(1H, d, J=8.9 Hz),7.39(1H, dd, J=8.9, 2.6 Hz), 7.45(1H, d, J=2.6 Hz), 8.29(1H, brs, ), 8.54(1H, s), 11.92(1H, s).
    • Example 414 Preparation of the Compound of Compound No. 414
  • Using 5-chlorosalicylic acid and 2,4-difluoro-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 66.0%.
  • 1H-NMR(DMSO-d6): δ 7.06(1H, d, J=8.8 Hz), 7.51(1H, dd, J=8.8, 2.8 Hz), 7.82(1H, t, J=10.7 Hz), 7.94(1H, d, J=2.8 Hz), 8.64(1H, d, J=8.0 Hz), 10.78(1H, s), 12.37(1H, brs).
    • Example 415 Preparation of the Compound of Compound No. 415
  • Using 5-chlorosalicylic acid and 4-cyano-2-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 24.8%.
  • 1H-NMR(DMSO-d6): δ 7.06(1H, d, J=8.8 Hz), 7.52(1H, dd, J=2.8, 8.8 Hz), 7.94(1H, d, J=2.8 Hz), 8.17(1H, dd, J=1.8, 8.9 Hz), 8.31(1H, d, J=2.1 Hz), 8.63(1H, d, J=8.9 Hz), 11.16(1H, s), 12.45(1H, br.s).
    • Example 416 Preparation of the Compound of Compound No. 416
  • Using 5-chlorosalicylic acid and 4-chloro-2-(4-chlorobenzenesulfonyl)-5-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 8.5%.
  • 1H-NMR(CDCl3): δ 6.98(1H, d, J=8.9 Hz), 7.13(1H, d, J=2.6 Hz), 7.22(2H, d, J=8.6 Hz), 7.34(2H, d, J=8.6 Hz), 7.40(1H, dd, J=2.3, 8.9 Hz), 7.66(1H, s), 8.71(1H, s), 8.80(1H, s), 11.42(1H, s).
    • Example 417 Preparation of the Compound of Compound No. 417
  • Using 5-chlorosalicylic acid and 5-chloro-2-nitro-4-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 22.8%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.8 Hz), 7.55(1H, dd, J=8.8, 2.8 Hz), 7.93(1H, d, J=2.8 Hz), 8.52(1H, s), 9.13(1H, s), 12.38(1H, brs), 12.45(1H, s).
    • Example 418 Preparation of the Compound of Compound No. 418
  • Using 5-chlorosalicylic acid and 2,3-difluoro-4-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 21.8%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.8 Hz), 7.53(1H, dd, J=2.9, 8.8 Hz), 7.66(1H, dt, J=1.8, 7.7 Hz), 7.93(1H, d, J=2.6 Hz), 8.35(1H, t, J=7.7 Hz), 11.02(1H, d, J=1.5 Hz), 12.32(1H, s).
    • Example 419 Preparation of the Compound of Compound No. 419
  • Using 5-chlorosalicylic acid and 4,4′-diamino-2,2′-bis(trifluoromethyl)biphenyl as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 35.9%.
  • 1H-NMR(DMSO-d6): δ 7.05(2H, d, J=8.8 Hz), 7.39(2H, d, J=8.5 Hz), 7.49-7.51(2H, m), 7.91(2H, d, J=2.5 Hz), 7.99(2H, dd, J=2.0, 8.5 Hz), 8.31(2H, d, J=1.9 Hz), 10.71(2H, s), 11.54(2H, s).
    • Example 420 Preparation of the Compound of Compound No. 420
  • Using 5-chlorosalicylic acid and 2,3,5,6-tetrafluoro-4-(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 42.5%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.8 Hz), 7.53(1H, dd, J=2.9, 8.8 Hz), 7.89(1H, d, J=2.6 Hz), 10.65(1H, br.s), 11.76(1H, br.s).
    • Example 421 Preparation of the Compound of Compound No. 421
  • Using 5-chlorosalicylic acid and 3′-aminoacetanilide as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 22.4%.
  • 1H-NMR(DMSO-d6): δ 2.05(3H, s),7.01(1H, d, J=8.7 Hz),7.24-7.39(3H, m),7.47(1H, dd, J=9.0, 3.0 Hz), 7.97(1H, d, J=3.0 Hz), 8.03(1H, s), 10.01(1H, s), 10.41(1H, s), 11.87(1H, s).
    • Example 422 Preparation of the Compound of Compound No. 422 (1) 2-Acetoxy-5-chloro-N-(3-carbamoylphenyl)benzamide
  • Using 2-acetoxy-5-chlorobenzoic acid and 3-aminobenzamide as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 15.8%.
  • 1H-NMR(CDCl3): δ 2.33(3H, s), 5.89(1H, brs), 6.31(1H, brs), 7.14(1H, d, J=9.0 Hz), 7.42-7.49(2H, m), 7.55-7.58(1H, m), 7.80(1H, d, J=2.7 Hz), 7.93(1H, d, J=8.1 Hz), 8.07(1H, s), 8.71(1H, s).
    • (2) 5-Chloro-2-hydroxy-N-(3-carbamoylphenyl)benzamide (Compound No. 422)
  • Using 2-acetoxy-5-chloro-N-(3-carbamoylphenyl)benzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 76.0%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.40(1H, brs), 7.45(1H, t, J=7.5 Hz), 7.48(1H, dd, J=8.7, 2.4 Hz), 7.62-7.65(1H, m), 7.86-7.89(1H, m), 7.98-7.99(2H, m), 8.15(1H, t, J=1.8 Hz), 10.51(1H, s), 11.85(1H, s).
    • Example 423 Preparation of the Compound of Compound No. 423
  • Using 5-chlorosalicylic acid and 3-amino-N-methylbenzamide as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 19.3%.
  • 1H-NMR(DMSO-d6): δ 2.79(3H, d, J=4.5 Hz), 7.03(1H, d, J=9.0 Hz), 7.43-7.51(2H, m), 7.59(1H, dt, J=8.1, 1.5 Hz), 7.87(1H, ddd, J=8.1, 2.1, 0.9 Hz), 7.99(1H, d, J=2.4 Hz), 8.15(1H, t, J=1.8 Hz), 8.46(1H, d, J=4.2 Hz), 10.52(1H, s), 11.84(1H, s).
    • Example 424 Preparation of the Compound of Compound No. 424
  • Using 5-chlorosalicylic acid and 2,6-diisopropylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 52.5%.
  • 1H-NMR(DMSO-d6): δ 1.14(12H, s), 2.96-3.13(2H, m), 7.16(1H, d, J=8.7 Hz), 7.23(1H, d, J=7.5 Hz), 7.33(1H, dd, J=8.4, 6.6 Hz), 7.52(1H, dd, J=8.7, 2.4 Hz), 8.11(1H, d, J=2.4 Hz), 10.09(1H, s), 12.40(1H, s).
    • Example 425 Preparation of the Compound of Compound No. 425
  • Using 5-chlorosalicylic acid and 4-methylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 58.6%.
  • 1H-NMR(DMSO-d6): δ 2.29(3H, s), 7.01(1H, d, J=8.7 Hz), 7.18(1H, d, J=8.1 Hz), 7.47(1H, dd, J=8.7, 2.7 Hz), 7.58(1H, d, J=8.4 Hz), 7.98(1H, d, J=2.7 Hz), 10.35(1H, s), 11.94(1H, s).
    • Example 426 Preparation of the Compound of Compound No. 426
  • Using 5-chlorosalicylic acid and 2,6-dimethylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 59.6%.
  • 1H-NMR(DMSO-d6): δ 2.19(6H, s),7.01(1H, d, J=9.0 Hz), 7.15-7.16(2H, m), 7.50(1H, dd, J=9.0, 2.7 Hz), 8.07(1H, d, J=2.7 Hz), 10.03(1H, s), 10.10(1H, s), 12.29(1H, s).
    • Example 427 Preparation of the Compound of Compound No. 427
  • Using 5-chlorosalicylic acid and 3,4-dimethylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 68.3%.
  • 1H-NMR(DMSO-d6): δ 2.20(3H, s), 2.23(3H, s), 7.01(1H, d, J=9.0 Hz), 7.13(1H, d, J=8.4 Hz), 7.40-7.47(2H, m), 7.47(1H, dd, J=9.0, 2.7 Hz), 7.99(1H, d, J=2.7 Hz), 10.29(1H, s), 11.97(1H, brs).
    • Example 428 Preparation of the Compound of Compound No. 428
  • Using 5-chlorosalicylic acid and 2,4,6-trimethylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 61.0%.
  • 1H-NMR(DMSO-d6): δ 2.14(6H, s), 2.26(3H, s), 6.95(2H, s), 7.00(1H, d, J=9.3 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 8.09(1H, d, J=2.4 Hz), 10.03(1H, s), 12.37(1H, s).
    • Example 429 Preparation of the Compound of Compound No. 429
  • Using 5-chlorosalicylic acid and 3-(trifluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 41.4%.
  • 1H-NMR(CDCl3): δ 7.00(1H, d, J=9.0 Hz), 7.09(1H, d, J=7.5 Hz), 7.40-7.48(3H, m), 7.51(1H, d, J=2.4 Hz), 7.64(1H, s), 7.94(1H, s), 11.66(1H, s).
    • Example 430 Preparation of the Compound of Compound No. 430
  • Using 5-chlorosalicylic acid and 2-benzylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 93.3%.
  • 1H-NMR(CDCl3): δ 4.08(2H, s), 6.56(1H, d, J=2.5 Hz), 6.92(1H, d, J=8.8 Hz), 7.20-7.46(9H, m), 7.53(1H, brs), 7.85(1H, d, J=8.0 Hz), 12.01(1H, brs).
    • Example 431 Preparation of the Compound of Compound No. 431
  • Using 5-chlorosalicylic acid and 4-(trifluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 20.4%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=9.3 Hz), 7.39(2H, d, J=9.0 Hz), 7.48(1H, dd, J=9.0, 2.7 Hz), 7.83(2H, d, J=9.3 Hz), 7.92(1H, d, J=2.7 Hz), 10.54(1H, s), 11.78(1H, s).
    • Example 432 Preparation of the Compound of Compound No. 432
  • Using 5-chlorosalicylic acid and 2,4-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 60.0%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.7 Hz), 7.48-7.54(2H, m), 7.75(1H, d, J=2.1 Hz), 7.98(1H, d, J=2.7 Hz), 8.44(1H, d, J=8.7 Hz), 10.93(1H, s), 12.31(1H, s).
    • Example 433 Preparation of the Compound of Compound No. 433
  • Using 5-chlorosalicylic acid and 4-(tert-butyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 69.0%.
  • 1H-NMR(DMSO-d6): δ 1.29(9H, s), 7.01(1H, d, J=8.7 Hz), 7.39(2H, d, J=8.4 Hz), 7.47(1H, dd, J=8.7, 2.7 Hz), 7.61(2H, d, J=8.4 Hz), 7.99(1H, d, J=2.4 Hz), 10.37(1H, s), 11.96(1H, s).
    • Example 434 Preparation of the Compound of Compound No. 434
  • Using 5-chlorosalicylic acid and 2,3-dimethylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 79.5%.
  • 1H-NMR(DMSO-d6): δ 2.14(3H, s),2.29(3H, s), 7.03(1H, d, J=9.0 Hz), 7.06-7.15(2H, m), 7.46-7.51(2H, m), 8.05(1H, d, J=3.0 Hz), 10.32(1H, s), 12.28(1H, s).
    • Example 435 Preparation of the Compound of Compound No. 435
  • Using 5-chlorosalicylic acid and 5-aminoindane as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 80.7%.
  • 1H-NMR(DMSO-d6): δ 1.98-2.08(2H, m), 2.81-2.89(4H, m), 7.01(1H, d, J=8.8 Hz), 7.21(1H, d, J=8.0, Hz), 7.42(1H, dd, J=8.0, 1.9 Hz), 7.48(1H, dd, J=8.8, 2.8 Hz), 7.60(1H, s), 7.99(1H, d, J=2.8, Hz), 10.34(1H, s), 12.00(1H, brs).
    • Example 436 Preparation of the Compound of Compound No. 436
  • Using 5-chlorosalicylic acid and 2,4-dimethylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 37.1%.
  • 1H-NMR(DMSO-d6): δ 2.23(3H, s), 2.28(3H, s), 7.03(2H, d, J=8.7 Hz), 7.10(1H, s), 7.49(1H, dd, J=9.0, 2.7 Hz), 7.63(1H, d, J=8.1 Hz), 8.03(1H, d, J=2.4 Hz), 10.24(1H, s), 12.25(1H, s).
    • Example 437 Preparation of the Compound of Compound No. 437
  • Using 5-chlorosalicylic acid and 3-isopropyloxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 21.5%.
  • 1H-NMR(CDCl3): δ 1.36(6H, d, J=6.0 Hz), 4.52-4.64(1H, m), 6.75(1H, ddd, J=8.4, 2.4, 0.9 Hz), 6.99(1H, d, J=8.7 Hz), 7.03(1H, ddd, J=8.1, 2.1, 0.9 Hz), 7.25-7.31(3H, m), 7.39(1H, dd, J=8.7, 2.4 Hz), 7.49(1H, d, J=2.4 Hz), 7.81(1H, s).
    • Example 438 Preparation of the Compound of Compound No. 438
  • Using 5-chlorosalicylic acid and 2,6-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 10.3%.
  • 1H-NMR(DMSO-d6): δ 7.05(1H, d, J=8.7 Hz), 7.43(1H, dd, J=8.7, 7.8 Hz), 7.54(1H, dd, J=9.0, 2.7 Hz), 7.62(1H, d, J=8.1 Hz), 8.05(1H, d, J=2.4 Hz), 10.52(1H, s), 12.01(1H, s).
    • Example 439 Preparation of the Compound of Compound No. 439
  • Using 5-chlorosalicylic acid and 4-isopropyloxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 76.8%.
  • 1H-NMR(DMSO-d6): δ 1.26(6H, d, J=6.3 Hz), 4.52-4.64(1H, m), 6.93(2H, dt, J=9.0, 2.1 Hz), 7.46(1H, dd, J=9.0, 2.7 Hz), 7.58(2H, dt, J=9.0, 2.1 Hz), 7.99(1H, d, J=3.0 Hz), 10.36(1H, s), 11.83(1H, brs).
    • Example 440 Preparation of the Compound of Compound No. 440
  • Using 5-chlorosalicylic acid and 4-bromo-2-(trifluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 59.2%.
  • 1H-NMR(CDCl3): δ 7.01(1H, d, J=9.3 Hz), 7.42-7.52(4H, m), 8.23(1H, s), 8.31(1H, d, J=9.3 Hz), 11.35(1H, s).
    • Example 441 Preparation of the Compound of Compound No. 441
  • Using 5-chlorosalicylic acid and 4-butylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 77.6%
  • 1H-NMR(CDCl3): δ 0.89(3H, t, J=6.9 Hz), 1.27-1.36(6H, m), 1.56-1.64(2H, m), 2.61(2H, t, J=7.8 Hz), 6.99(1H, d, J=9.0 Hz), 7.21(2H, d, J=8.7 Hz), 7.39(1H, dd, J=9.0, 2.7 Hz), 7.44-7.49(3H, m), 7.80(1H, s), 11.96(1H, s).
    • Example 442 Preparation of the Compound of Compound No. 442
  • Using 5-chlorosalicylic acid and 3-methylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 88.3%.
  • 1H-NMR(CDCl3): δ 2.38(3H, s), 6.98(1H, d, J=8.8 Hz), 7.03(1H, d, J=7.4 Hz), 7.25-7.40(4H, m), 7.48(1H, d, J=2.2 Hz), 7.83(1H, brs), 11.92(1H, brs).
    • Example 443 Preparation of the Compound of Compound No. 443
  • Using 5-chlorosalicylic acid and 4-cyclohexylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 90.6%.
  • 1H-NMR(CDCl3): δ 1.15-1.47(5H, m), 1.56-1.87(5H, m), 2.40-2.53(2H, m), 7.01(1H, d, J=8.8 Hz), 7.21(2H, d, J=8.5 Hz), 7.47(1H, dd, J=8.8, 2.7 Hz), 7.60(2H, d, J=8.5H), 8.00(1H, d, J=2.7 Hz), 10.36(1H, s), 11.98(1H, brs).
    • Example 444 Preparation of the Compound of Compound No. 444
  • Using 5-chlorosalicylic acid and 4-benzylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 90.3%.
  • 1H-NMR(DMSO-d6): δ 3.93(2H, s),7.01(1H, d, J=9.0 Hz),7.16-7.32(7H, m), 7.57(1H, dd, J=9.0, 2.7 Hz), 7.61(2H, d, J=8.4 Hz), 7.96(1H, d, J=2.4 Hz), 10.37(1H, s).
    • Example 445 Preparation of the Compound of Compound No. 445
  • Using 5-chlorosalicylic acid and 2-amino-4,5-dimethoxybenzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 52.8%.
  • 1H-NMR(DMSO-d6): δ 3.81(3H, s), 3.86(3H, s), 7.08(1H, d, J=8.7 Hz), 7.40(1H, s), 7.52(1H, dd, J=8.7, 2.7 Hz), 7.89(1H, s), 7.99(1H, d, J=3.0 Hz), 10.93(1H, s), 12.31(1H, s).
    • Example 446 Preparation of the Compound of Compound No. 446
  • Using 5-chlorosalicylic acid and 6-amino-1,4-benzodioxane as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 79.7%.
  • 1H-NMR(DMSO-d6): δ 4.25(4H, s), 6.86(1H, d, J=8.8 Hz), 7.00(1H, d, J=8.8 Hz), 7.12(1H, dd, J=8.8, 2.5 Hz), 7.33(1H, d, J=2.5 Hz), 7.46(1H, dd, J=8.8, 2.5 Hz), 7.97(1H, d, J=2.5 Hz), 10.27(1H, s), 11.96(1H, s).
    • Example 447 Preparation of the Compound of Compound No. 447
  • Using 5-chlorosalicylic acid and 2,4-dichloro-5-(isopropyloxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 76.1%.
  • 1H-NMR(DMSO-d6): δ 1.35(6H, d, J=6.0 Hz), 4.58-4.66(1H, m), 7.07(1H, d, J=9.0 Hz), 7.51(1H, dd, J=8.7, 3.0 Hz), 7.68(1H, s), 7.98(1H, d, J=3.0 Hz), 8.35(1H, s), 10.94(1H, s), 12.34(1H, s).
    • Example 448 Preparation of the Compound of Compound No. 448
  • Using 5-chlorosalicylic acid and 4-amino-2-chlorobenzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 57.9%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=9.0 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.78(1H, d, J=2.7 Hz), 7.82(1H, dd, J=9.0, 2.1 Hz), 7.97(1H, d, J=8.7 Hz), 8.19(1H, d, J=2.1 Hz), 10.79(1H, s), 11.38(1H, s).
    • Example 449 Preparation of the Compound of Compound No. 449
  • Using 5-chlorosalicylic acid and 3-chloro-4-(trifluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 50.6%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.60(1H, dd, J=9.0, 1.5 Hz), 7.76(1H, dd, J=9.0, 2.4 Hz), 7.85(1H, d, J=3.0 Hz), 8.13(1H, d, J=2.4 Hz), 10.61(1H, s), 11.51(1H, s).
    • Example 450 Preparation of the Compound of Compound No. 450
  • Using 5-chlorosalicylic acid and 4-amino-3-methylbenzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 80.6%.
  • 1H-NMR(DMSO-d6): δ 2.36(3H, s), 7.06(1H, d, J=8.7 Hz), 7.49(1H, dd, J=8.7, 2.4 Hz), 7.71(1H, dd, J=8.4, 1.8 Hz), 7.77(1H, s), 7.95(1H, d, J=3.0 Hz), 8.40(1H, d, J=8.4 Hz), 10.76(1H, s), 12.31(1H, brs).
    • Example 451 Preparation of the Compound of Compound No. 451
  • Using 5-chlorosalicylic acid and 2,3-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 37.1%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=9.0 Hz), 7.40-7.48(2H, m), 7.52(1H, dd, J=9.0, 2.7 Hz), 7.98(1H, d, J=2.7 Hz), 8.40(1H, dd, J=7.2, 2.4 Hz), 11.00(1H, s), 12.32(1H, s).
    • Example 452 Preparation of the Compound of Compound No. 452
  • Using 5-chlorosalicylic acid and 2-chloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 67.3%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.7 Hz), 7.20(1H, td, J=8.1, 1.8 Hz), 7.40(1H, td, J=8.4, 1.8 Hz), 7.52(1H, dd, J=8.7, 2.7 Hz), 7.57(1H, dd, J=8.4, 1.8 Hz), 8.00(1H, d, J=2.7 Hz), 8.40(1H, dd, J=8.4, 1.8 Hz), 10.89(1H, s), 12.27(1H, s).
    • Example 453 Preparation of the Compound of Compound No. 453
  • Using 5-chlorosalicylic acid and 4-isopropyl-3-methylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 21.6%.
  • 1H-NMR(CDCl3): δ 1.23(6H, d, J=6.9 Hz), 2.36(3H, s), 3.12(1H, m), 6.89(1H, d, J=9.0 Hz), 7.15-7.40(5H, m), 7.48(1H, d, J=2.1 Hz), 7.83(1H, brs).
    • Example 454 Preparation of the Compound of Compound No. 454
  • Using 5-chlorosalicylic acid and 2-amino-5-[(1,1-dimethyl)propyl]phenol as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 24.9%.
  • 1H-NMR(CDCl3): δ 0.69(3H, t, J=7.5 Hz), 1.28(6H, s), 1.63(2H, q, J=7.5 Hz), 6.98(1H, d, J=8.7 Hz), 7.01(1H, d, J=9.0 Hz), 7.06(1H, s), 7.15(1H, dd, =8.4, 2.4 Hz), 7.35(1H, d, J=2.1 Hz), 7.42(1H, dd, J=8.7, 2.4 Hz), 7.56(1H, d, J=2.4 Hz), 8.26(1H, s), 11.44(1H, s).
    • Example 455 Preparation of the Compound of Compound No. 455
  • Using 5-chlorosalicylic acid and 2-methylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 64.7%.
  • 1H-NMR(DMSO-d6): δ 2.28(3H, s), 7.05(1H, d, J=8.7 Hz), 7.13(1H, td, J=7.5, 1.5 Hz), 7.22-7.30(2H, m), 7.50(1H, dd, J=9.0, 2.7 Hz), 7.83(1H, d, J=7.8 Hz), 8.03(1H, d, J=3.0 Hz), 10.32(1H, s), 12.22(1H, s).
    • Example 456 Preparation of the Compound of Compound No. 456
  • Using 5-chlorosalicylic acid and 4-butylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 82.1%.
  • 1H-NMR(DMSO-d6): δ 0.90(3H, t, J=7.2 Hz), 1.24-1.36(2H, m), 1.50-1.60(2H, m), 2.56(2H, t, J=7.2 Hz), 7.01(1H, d, J=8.7 Hz), 7.19(2H, d, J=8.7 Hz), 7.47(1H, dd, J=8.7, 2.4 Hz), 7.59(2H, d, J=8.4 Hz), 7.98(1H, d, J=2.7 Hz), 10.36(1H, s), 11.94(1H, s).
    • Example 457 Preparation of the Compound of Compound No. 457
  • Using 5-chlorosalicylic acid and 2-amino-6-chlorobenzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 12.7%.
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=8.7 Hz), 7.52(1H, d, J=8.1 Hz), 7.53(1H, dd, J=9.0, 3.0 Hz), 7.76(1H, t, J=8.7 Hz), 7.95(1H, d, J=3.0 Hz), 8.34(1H, d, J=8.4 Hz), 11.17(1H, s), 12.39(1H, s).
    • Example 458 Preparation of the Compound of Compound No. 458
  • Using 5-chlorosalicylic acid and 2-amino-5-methylbenzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 9.0%.
  • 1H-NMR(CDCl3): δ 2.48(3H, s), 7.01(1H, d, J=9.0 Hz), 7.10(1H, dd, J=8.0, 0.9 Hz), 7.44(1H, d, J=9.0, 2.4 Hz), 7.56(1H, d, J=8.1 Hz), 7.62(1H, d, J=2.4 Hz), 8.22(1H, s), 8.54(1H, brs), 11.25(1H, brs).
    • Example 459 Preparation of the Compound of Compound No. 459
  • Using 5-chlorosalicylic acid and 4-benzyloxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 26.8%.
  • 1H-NMR(DMSO-d6): δ 5.11(2H, s), 6.99-7.05(3H, m), 7.33-7.49(6H, m), 7.60(2H, d, J=9.0 Hz), 7.99(1H, d, J=2.7 Hz), 10.33(1H, s), 12.02(1H, s).
    • Example 460 Preparation of the Compound of Compound No. 460
  • Using 5-chlorosalicylic acid and 4-amino-2,2-difluorobenzo[1,3]dioxole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 66.9%.
  • 1H-NMR(DMSO-d6): δ 7.05(1H, d, J=8.8 Hz), 7.31-7.32(2H, m), 7.51(1H, dd, J=8.8, 2.8 Hz), 7.70(1H, dd, J=5.6, 3.8 Hz), 7.96(1H, d, J=2.8 Hz), 10.59(1H, s), 12.05(1H, brs).
    • Example 461 Preparation of the Compound of Compound No. 461
  • Using 5-chlorosalicylic acid and 5-amino-2,2,3,3-tetrafluoro-2,3-dihydrobenzo[1,4]dioxene as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 67.9%.
  • 1H-NMR(CDCl3): δ 6.99-7.03(2H, m), 7.21-7.27(2H, m), 7.45(1H, dd, J=8.9, 2.5 Hz), 7.52(1H, d, J=2.5 Hz), 8.13(1H, s), 11.44(1H, s).
    • Example 462 Preparation of the Compound of Compound No. 462
  • Using 5-chlorosalicylic acid and 3-chloro-4-(trifluoromethyl)sulfanylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 52.3%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.8 Hz), 7.47(1H, dd, J=2.9, 8.8 Hz), 7.80(1H, dd, J=2.6, 8.8 Hz), 7.82(1H, d, J=2.6 Hz), 7.88(1H, d, J=8.8 Hz), 8.20(1H, d, J=2.2 Hz), 10.70(1H, s), 11.43(1H, s).
    • Example 463 Preparation of the Compound of Compound No. 463
  • Using 5-chlorosalicylic acid and 2-nitro-4-(trifluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 68.4%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=8.8 Hz), 7.52(1H, dd, J=2.6, 8.8 Hz), 7.85-7.89(1H, m), 7.93(1H, d, J=2.6 Hz), 8.17(1H, d, J=2.9 Hz), 8.67(1H, d, J=9.5 Hz), 11.92(1H, s), 12.14(1H, s).
    • Example 464 Preparation of the Compound of Compound No. 464
  • Using 5-chlorosalicylic acid and 5-amino-2,2-difluorobenzo[1,3]dioxole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 75.8%.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.8 Hz), 7.42-7.43(2H, m), 7.48(1H, dd, J=8.8, 2.5 Hz), 7.90(1H, d, J=2.5 Hz), 10.54(1H, s), 11.69(1H, s).
    • Example 465 Preparation of the Compound of Compound No. 465
  • Using 5-chlorosalicylic acid and 3-benzylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 66.4%.
  • 1H-NMR(CDCl3): δ 3.99(2H, s), 6.97(1H, d, J=9.1 Hz), 7.06(1H, d, J=7.4 Hz), 7.18-7.48(8H, m), 7.37(1H, dd, J=9.1, 2.5 Hz), 7.45(1H, d, J=2.5 Hz), 7.80(1H, brs), 11.88(1H, s).
    • Example 466 Preparation of the Compound of Compound No. 466
  • Using 5-chlorosalicylic acid and 2-nitro-4-(trifluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 40.9%.
  • 1H-NMR(DMSO-d6): δ 2.33(3H, s), 7.05(1H, d, J=8.8 Hz), 7.25(1H, dd, J=1.8, 8.8 Hz), 7.33(1H, d, J=1.8 Hz), 7.49(1H, dd, J=2.9, 8.8 Hz), 7.97-8.00(2H, m), 10.37(1H, s), 12.15(1H, s).
    • Example 467 Preparation of the Compound of Compound No. 467
  • Using 5-chlorosalicylic acid and 2,3,5-trifluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 54.2%.
  • 1H-NMR(DMSO-d6): δ 7.06(1H, d, J=8.8 Hz), 7.28-7.37(1H, m), 7.51(1H, dd, J=2.6, 8.8 Hz), 7.92(1H, d, J=2.6 Hz), 7.98-8.04(1H, m), 10.93(1H, s), 12.27(1H, br.s)
    • Example 468 Preparation of the Compound of Compound No. 468
  • Using 5-chlorosalicylic acid and 4′-aminobenzo-15-crown-5 as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 45.1%.
  • 1H-NMR(CDCl3): δ 3.74-3.77(8H, m), 3.90-3.92(4H, m), 4.10-4.15(4H, m), 6.83(1H, d, J=8.5 Hz), 6.96-6.99(2H, m), 7.24(1H, d, J=2.5 Hz), 7.36(1H, dd, J=2.5, 8.8 Hz), 7.53(1H, s), 8.06(1H, br.s), 11.92(1H, s).
    • Example 469 Preparation of the Compound of Compound No. 469
  • Using 5-chlorosalicylic acid and 4-bromo-2-fluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 45.1%.
  • 1H-NMR(DMSO-d6): δ 7.05(1H, d, J=8.8 Hz), 7.43-7.53(2H, m), 7.64-7.71(1H, m), 7.94(1H, d, J=1.5 Hz), 8.20(1H, dd, J=8.4, 8.8 Hz), 10.70(1H, s), 12.16(1H, s).
    • Example 470 Preparation of the Compound of Compound No. 470
  • Using 5-chlorosalicylic acid and 2,4-bis(methanesulfonyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 7.2%.
  • 1H-NMR(CDCl3): δ 3.13(3H, s), 3.21(3H, s), 7.04(1H, d, J=8.9 Hz), 7.48(1H, dd, J=2.2, 8.9 Hz), 7.62(1H, d, J=2.2 Hz), 8.24(1H, dd, J=2.4, 9.0 Hz), 8.56(1H, d, J=2.4 Hz), 8.91(1H, d, J=8.9 Hz), 10.96(1H, s), 11.57(1H, s).
    • Example 471 Preparation of the Compound of Compound No. 471
  • A mixture of 5-chlorosalicylic acid (87 mg, 0.5 mmol), 2,2-bis(3-amino-4-methylphenyl)-1,1,1,3,3,3-hexafluoropropane (363 mg, 1 mmol), phosphorus trichloride (44 μL, 0.5 mmol) and toluene (4 mL) was refluxed for 4 hours. After the reaction mixture was cooled to room temperature, it was purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the white title compound (16 mg, 4.9%). (The compound of Compound No. 529 described in the following Example 529 was obtained as a by-product.)
  • 1H-NMR(DMSO-d6): δ 2.34(6H, s), 7.04(4H, d, J=8.8 Hz), 7.39(2H, d, J=8.4 Hz), 7.48(2H, dd, J=2.9, 8.8 Hz), 7.96(2H, d, J=2.9 Hz), 8.19(2H, s), 10.44(2H, s), 12.17(2H, s).
    • Example 472 Preparation of the Compound of Compound No. 472
  • Using 5-chlorosalicylic acid and 6-amino-2,2,3,3-tetrafluoro-2,3-dihydrobenzo-[1,4]dioxene as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 10.1%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.8 Hz), 7.48(1H, dd, J=9.0, 2.7 Hz), 7.50(1H, d, J=9.0 Hz), 7.59(1H, dd, J=8.8, 2.2 Hz), 7.86(1H, d, J=2.7 Hz), 7.92(1H, d, J=2.2 Hz), 10.59(1H, s), 11.55(1H, s).
    • Example 473 Preparation of the Compound of Compound No. 473
  • Using 5-chlorosalicylic acid and 2-amino-5-chlorobenzophenone as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 27.6%.
  • 1H-NMR(DMSO-d6): δ 6.96(1H, d, J=8.7 Hz), 7.43(1H, dd, J=8.7, 3.0 Hz), 7.49-7.56(3H, m), 7.64-7.75(5H, m), 8.21(1H, d, J=9.3 Hz), 11.21(1H, s), 11.83(1H, s).
    • Example 474 Preparation of the Compound of Compound No. 474
  • Using 5-chlorosalicylic acid and 2-bromo-4-fluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 77.1%.
  • 1H-NMR(DMSO-d6): δ 7.07(1H, d, J=9.0 Hz), 7.31-7.38(1H, m), 7.51(1H, dd, J=9.0, 3.0 Hz), 7.72(1H, d, J=8.1, 3.0 Hz), 8.00(1H, d, J=3.0 Hz), 8.23(1H, dd, J=9.3, 5.4 Hz), 10.70(1H, s), 12.24(1H, s).
    • Example 475 Preparation of the Compound of Compound No. 475
  • Using 5-chlorosalicylic acid and 4-hexyloxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 74.8%.
  • 1H-NMR(DMSO-d6): δ 0.88(3H, t, J=6.6 Hz), 1.28-1.46(6H, m), 2.49-2.52(2H, m), 3.95(2H, t, J=6.6 Hz), 6.91-6.96(2H, m), 7.00(1H, d, J=8.8 Hz), 7.46(1H, dd, J=8.8, 2.9 Hz), 7.55-7.61(2H, m), 8.00(1H, d, J=2.9 Hz), 10.31(1H, 9), 12.03(1H, s).
    • Example 476 Preparation of the Compound of Compound No. 476
  • Using 5-chlorosalicylic acid and 2,2-bis(3-aminophenyl)-1,1,1,3,3,3-hexafluoropropane as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 64.5%.
  • 1H-NMR(DMSO-d6): δ 6.99(2H, d, J=8.8 Hz), 7.11(2H, d, J=8.0 Hz), 7.45(2H, dd, J=8.8, 2.6 Hz), 7.50(2H, t, J=8.4 Hz), 7.86(2H, d, J=2, 6 Hz), 7.88-7.91(4H, m), 10.53(2H, s), 11.56(2H, s).
    • Example 477 Preparation of the Compound of Compound No. 477
  • Using 5-chlorosalicylic acid and 2,4,5-trichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 38.9%.
  • 1H-NMR(CDCl3): δ 7.02(1H, d, J=8.6 Hz),7.46(1H, d, J=8.6 Hz), 7.49(1H, s),7.57(1H, s), 8.41(1H, br.s), 8.63(1H, s), 11.42(1H, s).
    • Example 478 Preparation of the Compound of Compound No. 478
  • Using 5-chlorosalicylic acid and 3-isopropylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 55.3%.
  • 1H-NMR(DMSO-d6): δ 1.22(6H, d, 6.9 Hz), 2.76-2.94(1H, m), 7.01(1H, d, J=8.6 Hz), 7.04(1H, d, J=7.9 Hz), 7.29(1H, t, J=7.9 Hz), 7.47(1H, dd, J=8.6, 2.6 Hz), 7.54(1H, d, J=7.9 Hz), 7.57(1H, s), 7.98(1H, d, J=2.6 Hz), 10.37(1H, s), 11.90(1H, brs).
    • Example 479 Preparation of the Compound of Compound No. 479
  • Using 5-chlorosalicylic acid and 4-aminobenzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 45.6%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.6 Hz), 7.47(1H, dd, J=8.6, 2.6 Hz), 7.83(1H, d, J=2.6 Hz), 7.84(2H, d, J=8.9 Hz), 7.92(2H, d, J=8.9 Hz), 10.71(1H, s), 11.59(1H, brs).
    • Example 480 Preparation of the Compound of Compound No. 480
  • Using 5-chlorosalicylic acid and 3-aminobenzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 97.1%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.48(1H, dd, J=9.0, 2.7 Hz), 7.56-7.63(2H, m), 7.88(1H, d, J=2.7 Hz), 7.95-8.02(1H, m), 8.20-8.21(1H, m), 10.62(1H, s), 11.57(1H, s).
    • Example 481 Preparation of the Compound of Compound No. 481
  • Using 5-chlorosalicylic acid and 3,4-dimethoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.3%.
  • 1H-NMR(DMSO-d6): δ 3.75(3H, s), 3.76(3H, s), 6.95(1H, d, J=8.7 Hz), 7.01(1H, d, J=9.0 Hz), 7.24(1H, dd, J=8.7, 2.7 Hz), 7.38(1H, d, J=2.1 Hz), 7.47(1H, dd, J=8.7, 2.7 Hz), 8.00(1H, d, J=2.4 Hz), 10.30(1H, s), 12.01(1H, s).
    • Example 482 Preparation of the Compound of Compound No. 482
  • Using 5-chlorosalicylic acid and 4-aminophenylacetic acid ethyl ester as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 66.1%.
  • 1H-NMR(DMSO-d6): δ 1.19(3H, t, J=7.5 Hz), 3.64(2H, s), 4.08(2H, q, J=7.2 Hz), 7.01(1H, d, J=8.7 Hz), 7.26(2H, d, J=8.7 Hz), 7.47(1H, dd, J=8.7, 3.0 Hz), 7.64(1H, d, J=8.4 Hz), 7.96(1H, d, J=2.4 Hz), 10.40(1H, s), 11.87(1H, s).
    • Example 483 Preparation of the Compound of Compound No. 483
  • Using 5-chlorosalicylic acid and 3-[(trifluoromethyl)sulfanyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 67.1%.
  • 1H-NMR(CDCl3): δ 7.01(1H, d, J=8.9 Hz), 7.42(1H, dd, J=8.9, 2.3 Hz), 7.47-7.53(2H, m), 7.51(1H, d, J=2.3 Hz), 7.76(1H, dt, J=7.6 Hz, 2.0 Hz), 7.88(1H, brs), 7.92(1H, s), 11.64(1H, s).
    • Example 484 Preparation of the Compound of Compound No. 484
  • Using 5-chlorosalicylic acid and 4-[(trifluoromethyl)sulfanyl]aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 63.2%.
  • 1H-NMR(CDCl3): δ 7.01(1H, d, J=8.9 Hz), 7.43(1H, dd, J=8.9, 2.3 Hz), 7.50(1H, d, J=2.3 Hz), 7.70(4H, s), 7.90(1H, brs), 11.60(1H, s).
    • Example 485 Preparation of the Compound of Compound No. 485
  • Using 5-chlorosalicylic acid and 4-(trifluoromethanesulfonyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 38.7%.
  • 1H-NMR(DMSO-d6): δ 7.04(1H, d, J=8.6 Hz), 7.49(1H, dd, J=8.6, 2.6 Hz), 7.80(1H, d, J=2.6 Hz), 8.12(2H, d, J=9.4 Hz), 8.17(2H, d, J=9.4 Hz), 8.16(1H, s), 10.95(1H, s), 11.37(1H, brs).
    • Example 486 Preparation of the Compound of Compound No. 486
  • Using 5-chlorosalicylic acid and 3,4-difluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 75.4%.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.9 Hz), 7.39-7.51(3H, m), 7.85-7.93(2H, m), 10.51, (1H, s), 11.60(1H, s).
    • Example 487 Preparation of the Compound of Compound No. 487
  • Using 5-chlorosalicylic acid and 3-ethynylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 35.8%.
  • 1H-NMR(DMSO-d6): δ 4.22(1H, s), 7.02(1H, d, J=8.6 Hz), 7.25(1H, d, J=7.6 Hz), 7.39(1H, t, J=7.6 Hz), 7.47(1H, dd, J=8.6, 2.6 Hz), 7.70(1H, d, J=7.6 Hz), 7.89(1H, s), 7.91(1H, d, J=2.6 Hz), 10.46(1H, s), 11.69(1H, brs).
    • Example 488 Preparation of the Compound of Compound No. 488
  • Using 5-chlorosalicylic acid and 4-(sec-butyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 40.1%.
  • 1H-NMR(DMSO-d6): δ 0.77(3H, t, 7.4 Hz), 1.19(3H, d, 6.9 Hz), 1.50-1.61(2H, m), 2.52-2.62(1H, m), 7.01(1H, d, J=8.9 Hz), 7.20(2H, d, J=8.6 Hz), 7.47(1H, dd, J=8.9, 2.6 Hz), 7.60(2H, d, J=8.6 Hz), 7.98(1H, d, J=2.6 Hz), 10.36(1H, s), 11.94(1H, brs).
    • Example 489 Preparation of the Compound of Compound No. 489
  • Using 5-chlorosalicylic acid and 3-chloro-4-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 75.7%.
  • 1H-NMR(CDCl3): δ 6.98(2H, t, J=9.2 Hz), 7.38-7.44(2H, m), 7.47(1H, d, J=2.6 Hz), 7.66(1H, d, J=2.6 Hz), 7.73(1H, br.s), 11.81(1H, s).
    • Example 490 Preparation of the Compound of Compound No. 490
  • Using 5-chlorosalicylic acid and 3-aminobenzophenone as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 34.3%.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.6 Hz), 7.48(1H, dd, J=9.1, 2.6 Hz), 7.52-7.62(4H, m), 7.68-7.79(3H, m), 7.93(1H, d, J=2.6 Hz), 8.02(1H, d, J=7.9 Hz), 8.16(1H, s), 10.60(1H, s), 11.68(1H, brs).
    • Example 491 Preparation of the Compound of Compound No. 491
  • Using 5-chlorosalicylic acid and 3-methoxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 23.5%.
  • 1H-NMR(DMSO-d6): δ 3.76(3H, s), 6.69-6.75(1H, m), 7.01(1H, d, J=8.6 Hz), 7.25-7.28(2H, m), 7.39(1H, s), 7.47(1H, dd, J=8.6, 2.6 Hz), 7.94(1H, d, J=2.6 Hz), 10.39(1H, s), 11.81(1H, brs).
    • Example 492 Preparation of the Compound of Compound No. 492
  • Using 5-chlorosalicylic acid and 4′-aminoacetanilide as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 36.2%.
  • 1H-NMR(DMSO-d6): δ 2.50(3H, s), 7.01(1H, d, J=8.6 Hz), 7.47(1H, dd, J=8.6, 2.6 Hz), 7.57(2H, d, J=9.1 Hz), 7.61(2H, d, J=9.1 Hz), 7.98(1H, d, J=2.6 Hz), 9.95(1H, s), 10.38(1H, s), 11.99(1H, brs).
    • Example 493 Preparation of the Compound of Compound No. 493
  • Using 5-chlorosalicylic acid and sulfanilamide as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 25.7%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.9 Hz), 7.31(2H, s), 7.47(1H, dd, J=8.9, 2.3 Hz), 7.81(2H, d, J=8.9 Hz), 7.89(2H, d, J=8.9 Hz), 7.89(1H, d, J=2.3 Hz), 10.70(1H, s), 11.55(1H, brs).
    • Example 494 Preparation of the Compound of Compound No. 494
  • Using 5-chlorosalicylic acid and 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol as the raw materials, the same operation as the Example 16 gave the title compound. (The compound was obtained by separation from the mixture with the compound of Compound No. 498 described in the following Example 498.)
  • Yield: 11.7%.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.6 Hz), 7.47(1H, dd, J=8.6, 2.6 Hz), 7.68(2H, d, J=8.7 Hz), 7.85(2H, d, J=8.7 Hz), 7.91(1H, d, J=2.6 Hz), 8.69(1H, s), 10.62(1H, s).
    • Example 495 Preparation of the Compound of Compound No. 495
  • Using 5-chlorosalicylic acid and 2-chloro-4-nitroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 39.6%.
  • 1H-NMR(CDCl3): δ 7.04(1H, d, J=8.9 Hz), 7.47(1H, dd, J=2.3, 8.9 Hz), 7.54(1H, d, J=2.3 Hz), 8.25(1H, dd, J=2.6, 8.9 Hz), 8.39(1H, d, J=2.3 Hz), 8.73(1H, d, J=9.2 Hz), 8.76(1H, br.s), 11.22(1H, s).
    • Example 496 Preparation of the Compound of Compound No. 496
  • Using 5-chlorosalicylic acid and 2,4-difluoroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 67.8%.
  • 1H-NMR(DMSO-d6): δ 7.05(1H, dd, J=1.7, 8.9 Hz), 7.15(1H, dt, J=1.7, 9.2 Hz), 7.41(1H, ddd, J=2.3, 8.9, 9.2 Hz), 7.51(1H, dt, J=2.3, 8.9 Hz), 7.98(1H, d, J=2.3 Hz), 8.11(1H, dd, J=8.9, 15.1 Hz), 10.59(1H, s), 12.13(1H, s).
    • Example 497 Preparation of the Compound of Compound No. 497
  • Using 5-chlorosalicylic acid and 4-(difluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 85.9%.
  • 1H-NMR(DMSO-d6): δ 7.01(1H, d, J=8.6 Hz), 7.19(1H, t, J=74.2 Hz), 7.20(2H, d, J=8.6 Hz), 7.47(1H, dd, J=8.6, 2.6 Hz), 7.74(2H, d, J=8.9 Hz), 7.94(1H, d, J=2.6 Hz), 10.47(1H, s), 11.80(1H, brs).
    • Example 498 Preparation of the Compound of Compound No. 498
  • This compound was obtained by separation from the mixture with the compound of Compound No. 494 described in the aforementioned Example 494.
  • Yield: 11.6%.
  • 1H-NMR(DMSO-d6): δ 7.02(1H, d, J=8.6 Hz), 7.46(1H, dd, J=8.6, 2.3 Hz), 7.83(2H, d, J=8.1 Hz), 7.88(1H, d, J=2.3 Hz), 7.95(2H, d, J=8.1 Hz), 10.71(1H, s).
    • Example 499 Preparation of the Compound of Compound No. 499
  • Using 5-chlorosalicylic acid and 3-(methylsulfanyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 67.2%.
  • 1H-NMR(DMSO-d6): δ 2.49(3H, s), 7.00-7.05(1H, m), 7.01(1H, d, J=8.9 Hz), 7.31(1H, t, J=7.9 Hz), 7.46(1H, dd, J=8.9, 2.6 Hz), 7.44-7.49(1H, m), 7.68(1H, d, J=1.7 Hz), 7.93(1H, d, J=2.6 Hz), 10.47(1H, s).
    • Example 500 Preparation of the Compound of Compound No. 500
  • Using 5-chlorosalicylic acid and 4-methanesulfonylaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 28.6%.
  • 1H-NMR(DMSO-d6): δ 3.20(3H, s), 7.03(1H, d, J=8.3 Hz), 7.48(1H, dd, J=8.3, 2.6 Hz), 7.87(1H, d, J=2.6 Hz), 7.92(2H, d, J=8.9 Hz), 7.98(2H, d, J=8.9 Hz), 10.75(1H, s), 11.45(1H, brs).
    • Example 501 Preparation of the Compound of Compound No. 501
  • Using 5-chlorosalicylic acid and 2-amino-4-methylbenzophenone as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 8.7%.
  • 1H-NMR(CDCl3): δ 2.50(3H, s), 6.98(1H, d, J=8.3 Hz), 6.99(1H, d, J=7.3 Hz), 7.39(1H, dd, J=2.0, 8.6 Hz), 7.48-7.64(4H, m), 7.72(2H, d, J=7.6 Hz), 7.83(1H, d, J=2.3 Hz), 8.57(1H, s), 12.18(1H, s), 12.34(1H, br.s).
    • Example 502 Preparation of the Compound of Compound No. 502
  • Using 5-chlorosalicylic acid and 3-amino-N-butylbenzenesulfonamide as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 46.7%.
  • 1H-NMR(DMSO-d6): δ 0.80(3H, t, J=7.3 Hz), 1.17-1.41(4H, m), 2.73-2.80(2H, m), 7.03(1H, d, J=8.9 Hz), 7.48(1H, dd, J=8.9, 2.0 Hz), 7.53-7.64(2H, m), 7.87-7.92(1H, m), 7.92(1H, d, J=2.0 Hz), 8.27(1H, s), 10.62(1H, s), 11.63(1H, s).
    • Example 503 Preparation of the Compound of Compound No. 503
  • Using 5-chlorosalicylic acid and 3-(benzyloxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 68.5%.
  • 1H-NMR(DMSO-d6): δ 5.11(2H, s), 6.79-6.83(1H, m), 7.01(1H, d, J=8.9 Hz), 7.27-7.49(9H, m), 7.93(1H, d, J=3.0 Hz), 10.40(1H, s), 11.79(1H, brs).
    • Example 504 Preparation of the Compound of Compound No. 504
  • Using 5-chlorosalicylic acid and N-(4-aminophenyl)-4-methylbenzenesulfonamide as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 40.6%.
  • 1H-NMR(DMSO-d6): δ 2.33(3H, s), 6.99(1H, d, J=8.6 Hz), 7.07(2H, d, J=8.6 Hz), 7.34(2H, d, J=8.3 Hz), 7.45(1H, dd, J=8.6, 2.1 Hz), 7.53(2H, d, J=8.6 Hz), 7.63(2H, d, J=8.3 Hz), 7.90(1H, d, J=2.1 Hz), 10.14(1H, s), 10.33(1H, s), 11.81(1H, brs).
    • Example 505 Preparation of the Compound of Compound No. 505
  • Using 5-chlorosalicylic acid and 4-(morpholino)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 29.8%.
  • 1H-NMR(DMSO-d6): δ 3.09(4H, t, J=4.6 Hz), 3.74(4H, t, J=4.6 Hz), 6.94-7.01(3H, m), 7.46(1H, dd, J=8.9, 2.6 Hz), 7.55(2H, d, J=8.9 Hz), 8.01(1H, d, J=2.6 Hz), 10.29(1H, s), 12.10(1H, brs).
    • Example 506 Preparation of the Compound of Compound No. 506
  • Using 5-chlorosalicylic acid and 3-(tert-butyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 76.1%.
  • 1H-NMR(CDCl3): 5 1.35(9H, s), 6.99(1H, d, J=8.9 Hz), 7.24-7.28(1H, m), 7.32-7.35(1H, m), 7.40(1H, dd, J=8.9, 2.3 Hz), 7.46-7.50(2H, m), 7.51(1H, d, J=2.3 Hz), 7.81(1H, brs), 11.94(1H, s).
    • Example 507 Preparation of the Compound of Compound No. 507
  • Using 5-chlorosalicylic acid and 3-(5-methylfuran-2-yl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 61.1%.
  • 1H-NMR(DMSO-d6): δ 2.36(3H, s), 6.22-6.23(1H, m), 6.81(1H, d, J=3.0 Hz), 7.02(1H, d, J=8.9 Hz), 7.36-7.51(3H, m), 7.58-7.61(1H, m), 7.99-8.01(2H, m), 10.49(1H, s), 11.85(1H, brs).
    • Example 508 Preparation of the Compound of Compound No. 508
  • Using 5-chlorosalicylic acid and 3-(1-hydroxyethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 37.6%.
  • 1H-NMR(DMSO-d6): δ 1.80(3H, d, J=6.6 Hz), 5.33(1H, q, J=6.6 Hz), 7.01(1H, d, J=8.9 Hz), 7.25(1H, d, J=7.9 Hz), 7.38(1H, t, J=7.9 Hz), 7.47(1H, dd, J=8.9, 2.3 Hz), 7.65(1H, d, J=7.9 Hz), 7.85(1H, s), 7.96(1H, d, J=2.3 Hz), 10.48(1H, s), 11.80(1H, brs).
    • Example 509 Preparation of the Compound of Compound No. 509
  • Using 5-chlorosalicylic acid and 3-aminobenzenesulfonamide as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 18.7%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.9 Hz), 7.41(2H, s), 7.48(1H, dd, J=8.9, 2.6 Hz), 7.54-7.62(2H, m), 7.84-7.88(1H, m), 7.93(1H, d, J=2.6 Hz), 8.30(1H, s), 10.64(1H, s), 11.68(1H, brs).
    • Example 510 Preparation of the Compound of Compound No. 510
  • Using 5-chlorosalicylic acid and 3-(trifluoromethanesulfonyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 62.6%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.6 Hz), 7.48(1H, dd, J=8.6, 2.6 Hz), 7.82-7.88(3H, m), 8.23-8.26(1H, m), 8.67(1H, s), 10.88(1H, s), 11.45(1H, brs).
    • Example 511 Preparation of the Compound of Compound No. 511
  • Using 5-chlorosalicylic acid and 2-bromo-4-(trifluoromethoxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 17.1%.
  • 1H-NMR(CDCl3): δ 7.02(1H, d, J=8.9 Hz),7.26-7.31(1H, m), 7.44(1H, dd, J=8.9,2.6 Hz), 7.53(2H, d, J=2.6 Hz), 8.41(1H, brs, ), 8.42(1H, d, J=8.9 Hz), 11.57(1H, s).
    • Example 512 Preparation of the Compound of Compound No. 512
  • Using 5-chlorosalicylic acid and 3,4-(dihexyloxy)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 60.5%.
  • 1H-NMR(CDCl3): δ 0.91(6H, t, J=6.3 Hz), 1.34-1.61(12H, m), 1.76-1.89(4H, m), 3.97-4.04(4H, m), 6.88(1H, d, J=8.9 Hz), 6.97-7.00(2H, m), 7.22(1H, d, J=2.6 Hz), 7.38(1H, dd, J=8.9, 2.6 Hz), 7.47(1H, d, J=2.6 Hz), 7.73(1H, s), 11.97(1H, s).
    • Example 513 Preparation of the Compound of Compound No. 513
  • Using 5-chlorosalicylic acid and 3,4-dichloroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 16.4%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 77.47(1H, dd, J=8.7, 2.7 Hz), 7.61-7.70(2H, m), 7.86(1H, d, J=2.7 Hz), 8.11(1H, d, J=2.1 Hz), 10.56(1H, s), 11.53(1H, s).
    • Example 514 Preparation of the Compound of Compound No. 514
  • Using 5-chlorosalicylic acid and 3-hexyloxyaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 88.2%.
  • 1H-NMR(DMSO-d6): δ 0.89(3H, t, J=7.0 Hz), 1.28-1.47(6H, m), 1.67-1.76(2H, m), 3.95(2H, t, J=6.6 Hz), 6.69-6.73(1H, m), 7.01(1H, d, J=8.8 Hz), 7.21-7.28(2H, m), 7.39-7.40(1H, m), 7.67(1H, dd, J=8.8, 2.6 Hz), 7.94(1H, d, J=2.6 Hz), 10.34(1H, s), 11.80(1H, s).
    • Example 515 Preparation of the Compound of Compound No. 515
  • Using 5-chlorosalicylic acid and 5-ethoxy-4-fluoro-2-nitroaniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 20.2%.
  • 1H-NMR(DMSO-d6): δ 1.43(3H, t, J=7.0 Hz), 4.27(2H, q, J=7.0 Hz), 7.07(1H, d, J=8.8 Hz), 7.52(1H, dd, J=8.8, 2.9 Hz), 7.95(1H, d, J=2.9 Hz), 8.15(1H, d, J=11.4 Hz), 8.57(1H, d, J=8.4 Hz), 12.16(1H, s), 12.26(1H, s).
    • Example 516 Preparation of the Compound of Compound No. 516
  • Using 5-chlorosalicylic acid and 4-hydroxy-3-methyl-1-naphthylamine as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 5.9%.
  • 1H-NMR(DMSO-d6): δ 2.38(3H, s), 7.03(1H, d, J=9.3 Hz), 7.43(2H, s), 7.46(1H, d, J=2.4 Hz), 7.50-7.54(2H, m), 7.67(1H, d, J=2.1 Hz), 7.78(1H, dd, J=6.0, 2.7 Hz), 8.03(1H, brs), 8.18(1H, dd, J=6.0, 3.6 Hz), 11.98(1H, brs).
    • Example 517 Preparation of the Compound of Compound No. 517
  • This compound is a known compound.
  • Reference which describes the preparation method: the pamphlet of International Publication WO99/65449.
    • Example 518 Preparation of the Compound of Compound No. 518
  • This compound is a known compound.
    • Reference which describes the preparation method: the pamphlet of International Publication WO99/65449.
    Example 519 Preparation of the Compound of Compound No. 519
  • This compound is a known compound.
    • Reference which describes the preparation method: the pamphlet of International Publication WO99/65449.
    Example 520 Preparation of the Compound of Compound No. 520
  • This compound is a known compound.
    • Reference which describes the preparation method: the pamphlet of International Publication WO99/65449.
    Example 521 Preparation of the Compound of Compound No. 521
  • This compound is a known compound.
    • Reference which describes the preparation method: the pamphlet of International Publication WO99/65449.
    Example 522 Preparation of the Compound of Compound No. 522
  • This compound is a known compound.
    • Reference which describes the preparation method: the pamphlet of International Publication WO99/65449.
    Example 523 Preparation of the Compound of Compound No. 523
  • This compound is a known compound.
    • Reference which describes the preparation method: the pamphlet of International Publication WO99/65449.
    Example 524 Preparation of the Compound of Compound No. 524
  • Using 5-chlorosalicylic acid and 4-aminobiphenyl as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 52.4%.
  • 1H-NMR(DMSO-d6): δ 7.03(1H, d, J=8.7 Hz), 7.33-7.38(1H, m), 7.44-7.51(3H, m), 7.67-7.72(4H, m), 7.82(2H, d, J=8.7 Hz), 7.98(1H, d, J=2.4 Hz), 10.49(1H, s), 11.84(1H, s).
    • Example 525 Preparation of the Compound of Compound No. 525
  • A mixture of 5-sulfosalicylic acid (218 mg, 1 mmol), 3,5-bis(trifluoromethyl)aniline (229 mg, 1 mmol), phosphorus trichloride (88 μL, 1 mmol) and o-xylene (5 mL) was refluxed for 3 hours. After the reaction mixture was cooled to room temperature, it was purified by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the title compound (29 mg, 9.2%) as a white solid.
  • 1H-NMR(DMSO-d6): δ 7.15(1H, d, J=8.8 Hz), 7.65(2H, s), 7.73(1H, s), 7.81(1H, s), 7.82(1H, dd, J=8.7, 2.5 Hz), 8.23(1H, d, J=2.5 Hz), 8.38(2H, s), 10.87(1H, s), 11.15(1H, brs).
    • Example 526 Preparation of the Compound of Compound No. 526
  • Using 5-chlorosalicylic acid and 2,4-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 6.9%.
  • 1H-NMR(CDCl3): δ 7.03(1H, dd, J=8.7,0.6 Hz), 7.43-7.48(2H, m), 7.91(1H, d, J=9.0 Hz), 7.96(1H, s), 8.42(1H, s), 8.49(1H, d, J=8.7 Hz), 11.26(1H, s).
    • Example 527 Preparation of the Compound of Compound No. 527
  • Using 3-phenylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 64.6%.
  • 1H-NMR(DMSO-d6): δ 7.12(1H, t, J=8.1 Hz), 7.37(1H, tt, J=7.5, 1.5 Hz), 7.43-7.48(2H, m), 7.56-7.60(3H, m), 7.91(1H, s), 8.07, (1H, dd, J=8.1, 1.5 Hz), 8.48(2H, s), 11.00(1H, s), 12.16(1H, s).
    • Example 528 Preparation of the Compound of Compound No. 528
  • Using 4-fluorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 65.7%.
  • 1H-NMR(DMSO-d6): δ 6.81-6.90(2H, m), 7.84(1H, s, ), 7.93-7.98(1H, m,), 8.45(2H, s, ), 10.78(1H, s), 11.81(1H, s,).
    • Example 529 Preparation of the Compound of Compound No. 529
  • This compound was obtained by separation from the mixture with the compound of Compound No. 471 described in the aforementioned Example 471.
  • Yield: 9.4%.
  • 1H-NMR(CD3OD): δ 2.16(3H, s), 2.34(3H, s), 6.69(1H, d, J=8.2 Hz), 6.76(1H, brs)6.95(1H, d, J=8.8 Hz), 7.02(1H, d, J=8.0 Hz), 7.15(1H, d, J=8.2 Hz), 7.29(1H, d, J=8.2 Hz), 7.37(1H, dd, J=8.8, 2.6 Hz), 7.97(1H, d, J=2.6 Hz), 7.98(1H, s).
    • Example 530 Preparation of the Compound of Compound No. 530
  • Using 5-chlorosalicylic acid and 4-amino-3-(trifluoromethoxy)benzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 75.2%.
  • 1H-NMR(DMSO-d6): δ 7.13(1H, d, J=8.8 Hz), 7.54(1H, dd, J=8.8, 2.6 Hz), 7.94(1H, dd, J=8.4, 1.6 Hz), 7.95(1H, d, J=2.6 Hz), 8.15(1H, t, J=1.5 Hz), 8.75(1H, d, J=8.8 Hz), 11.25(1H, s), 12.45(1H, s).
    • Example 531 Preparation of the Compound of Compound No. 531
  • Using 5-chlorosalicylic acid and 4-[2-amino-4-(trifluromethyl)phenoxy]benzonitrile as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 11.6%.
  • 1H-NMR(CD3OD): δ 6.88(1H, d, J=8.6 Hz), 7.19(2H, d, J=8.9 Hz), 7.24(1H, d, J=8.6 Hz), 7.33(1H, dd, J=8.8, 2.8 Hz), 7.46(1H, dd, J=8.9, 1.9 Hz), 7.76(2H, d, J=8.9 Hz), 7.98(1H, d, J=2.7 Hz), 8.96(1H, s).
    • Example 532 Preparation of the Compound of Compound No. 532
  • Using 5-chlorosalicylic acid and 3-amino-4-(4-methoxyphenoxy)-benzotrifluoride as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 88.1%.
  • 1H-NMR(CDCl3): δ 3.85(3H, s) 6.81(1H, d, J=8.5 Hz), 6.97-7.02(3H, m), 7.08(2H, d, J=8.8 Hz), 7.30(1H, m), 7.40(1H, dd, J=8.8, 1.9 Hz), 7.45(1H, d, J=2.2 Hz), 8.70(1H, s), 8.78(1H, d, J=1.6 Hz), 11.76(1H, s).
    • Example 533 Preparation of the Compound of Compound No. 533
  • Using salicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 47.8%.
  • 1H-NMR(CD3OD): δ 7.00-7.06(2H, m), 7.48(1H, dt, J=1.5, 7.5 Hz), 7.74(1H, d, J=8.4 Hz), 8.01-8.08(2H, m), 8.79(1H, s), 11.09(1H, s), 12.03(1H, s).
    • Example 534 Preparation of the Compound of Compound No. 534 (1) 2-Amino-4-(2,4-dichlorophenyl)thiazole
  • Using 2′,4′-dichloroacetophenone and thiourea as the raw materials, the same operation as the Example 395(1) gave the title compound.
  • Yield: 97.1%.
  • 1H-NMR(CDCl3): δ 5.01(2H, s), 7.09(1H, s), 7.28(1H, dd, J=8.4, 2.1 Hz), 7.45(1H, d, J=2.1 Hz), 7.82(1H, d, J=8.4 Hz).
    • (2) 5-Chloro-2-hydroxy-N-[4-(2,4-dichlorophenyl)thiazol-2-yl]benzamide (Compound No. 534)
  • Using 5-chlorosalicylic acid and 2-amino-4-(2,4-dichlorophenyl)thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 8.0%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.7 Hz), 7.50-7.55(2H, m), 7.72-7.76(2H, m), 7.91(1H, d, J=8.4 Hz), 7.95(1H, d, J=2.4 Hz), 11.87(1H, brs), 12.09(1H, brs).
    • Example 535 Preparation of the Compound of Compound No. 535
  • Using 3-isopropylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 99.2%.
  • 1H-NMR(CDCl3): δ 1.26(6H, d, J=6.9 Hz),3.44(1H, Hept, J=6.9 Hz), 6.92(1H, t, J=7.8 Hz), 7.38(1H, dd, J=8.1, 1.2 Hz), 7.44(1H, d, J=7.5 Hz), 7.69(1H, s), 8.13(3H, s), 11.88(1H, s).
    • Example 536 Preparation of the Compound of Compound No. 536
  • Bromine (14.4 μL, 0.28 mmol) and iron powder (1.7 mg, 0.03 mmol) were added to a solution of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-3-isopropylbenzamide (Compound No. 535; 100 mg, 0.26 mmol) in carbon tetrachloride (5 mL) under argon atmosphere, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with ethyl acetate. The ethyl acetate layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was crystallized from n-hexane/ethyl acetate to give the title compound (110 mg, 91.5%) as a white solid.
  • 1H-NMR(CDCl3): δ 1.25(6H, d, J=6.9 Hz), 3.39(1H, Hept, J=6.9 Hz), 7.49-7.51(2H, m), 7.71(1H, brs), 8.11-8.14(3H, m), 11.81(1H, brs).
    • Example 537 Preparation of the Compound of Compound No. 537
  • N-Bromosuccinimide (88.2 mg, 0.50 mmol) was added to a solution of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-3-methylbenzamide (Compound No. 328; 150 mg, 0.41 mmol) in a mixed solvent of methanol/water (3:1; 5 mL), and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was diluted with ethyl acetate. The ethyl acetate layer was washed with 10% aqueous sodium thiosulfate, water and brine, and dried over anhydrous magnesium sulfate. The residue obtained by evaporation under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the title compound (167 mg, 91.5%) as a white powder.
  • 1H-NMR(CDCl3): δ 2.28(3H, s), 7.47(1H, s), 7.50(1H, d, J=2.4 Hz), 7.71(1H, s), 8.08(1H, brs), 8.13(2H, s), 11.71(1H, s).
    • Example 538 Preparation of the Compound of Compound No. 538 (1) 1-(3-Nitrophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole
  • A mixture of 4,4,4-trifluoro-1-phenyl-1,3-butanedione (432.3 mg, 2 mmol), 3-nitrophenylhydrazine hydrochloride (379.2 mg, 2 mmol), concentrated hydrochloric acid (0.2 mL) and ethanol (8 mL) was reflued for 2 hours. After the reaction mixture was cooled to room temperature, it was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water and brine, and dried over anhydrous sodium sulfate. The residue obtained by evaporation under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=4:1→3:1) to give the title compound (631.5 mg, 94.7%) as a light yellowish white powder.
  • 1H-NMR(CDCl3): δ 6.80(1H, s), 7.23-7.26(2H, m), 7.35-7.45(3H, m), 7.54(1H, t, J=8.4 Hz), 7.63(1H, ddd, J=8.1, 1.8, 1.2 Hz), 8.19-8.25(2H, m).
    • (2) 1-(3-Aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole
  • Acetic acid (3 mL) and ethanol (2 mL) were added to 1-(3-nitrophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole (0.59g, 1.77 mmol) and 5% palladium on carbon (0.06g), and the mixture was hydrogenated at room temperature for 2 hours under hydrogen atmosphere. After the insoluble matter was filtered off, the residue obtained by evaporation under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the title compound (491.1 mg, 91.4%) as a white solid.
  • 1H-NMR(CDCl3): δ 3.78(2H, s), 6.54(1H, ddd, J=7.8, 1.8, 0.6 Hz), 6.65(1H, ddd, J=8.4, 2.4, 0.9 Hz), 6.73-6.75(2H, m), 7.07(1H, t, J=8.1 Hz), 7.24-7.36(5H, m).
    • (3) 5-Chloro-2-hydroxy-N-{3-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]phenyl}-benzamide (Compound No. 538)
  • Using 5-chlorosalicylic acid and 1-(3-aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 74.4%.
  • 1H-NMR(CDCl3): δ 6.77(1H, s), 6.97-7.03(2H, m), 7.27-7.45(8H, m), 7.65(1H, ddd, J=8.4, 2.1, 0.9 Hz), 7.74(1H, t, J=2.1 Hz), 7.93(1H, s), 11.63(1H, s).
    • Example 539 Preparation of the Compound of Compound No. 539 (1) 5-(tert-Butyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)pyrazole
  • Using 1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedione and 4-nitrophenylhydrazine hydrochloride as the raw materials, the same operation as the Example 538(1) gave the title compound.
  • Yield: 94.7%.
  • 1H-NMR(CDCl3): δ 1.23(9H, s), 6.51(1H, s), 7.62(2H, d, J=9.0 Hz), 8.37(2H, d, J=9.0 Hz).
    • (2) 1-(4-Aminophenyl)-5-(tert-butyl)-3-(trifluoromethyl)pyrazole
  • Using 5-(tert-butyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)pyrazole as the raw material, the same operation as the Example 538(2) gave the title compound.
  • Yield: 98.9%.
  • 1H-NMR(CDCl3): δ 1.20(9H, s), 4.00(2H, br), 6.40(1H, s), 6.69(2H, d, J=8.7 Hz), 7.14(2H, d, J=9.0 Hz).
    • (3) N-{4-[5-(tert-butyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl}-5-chloro-2-hydroxy-benzamide (Compound No. 539)
  • Using 5-chlorosalicylic acid and 1-(5-aminophenyl)-5-(tert-butyl)-3-(trifluoromethyl)pyrazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 57.6%.
  • 1H-NMR(CDCl3): δ 1.23(9H, s), 6.47(1H, s), 7.00(1H, d, J=9.0 Hz), 7.40-7.44(3H, m), 7.57(1H, d, J=2.4 Hz), 7.72(2H, d, J=8.7 Hz), 8.15(1H, s), 11.58(1H, s).
    • Example 540 Preparation of the Compound of Compound No. 540
  • Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-3-phenylbenzamide (Compound No. 527), the same operation as the Example 537 gave the title compound.
  • Yield: 67.5%.
  • 1H-NMR(DMSO-d6): δ 7.36-7.50(3H, m), 7.55-7.59(2H, m), 7.71(1H, d, J=2.1 Hz), 7.93(1H, brs), 8.28(1H, d, J=2.1 Hz), 8.45(2H, s), 11.06(1H, brs), 12.16(1H, brs).
    • Example 541 Preparation of the Compound of Compound No. 541 (1) 2-Amino-4-(3,4-dichlorophenyl)thiazole
  • Using 3′,4′-dichloroacetophenone and thiourea as the raw materials, the same operation as the Example 395(1) gave the title compound.
  • Yield: 77.8%.
  • 1H-NMR(DMSO-d6): δ 7.17(2H, s), 7.24(1H, s), 7.62(1H, d, J=8.4 Hz), 7.78(1H, dd, J=8.7, 2.7 Hz), 8.22(1H, d, J=2.4 Hz).
    • (2) 5-Chloro-2-hydroxy-N-[4-(3,4-dichlorophenyl)thiazol-2-yl]benzamide (Compound No. 541)
  • Using 5-chlorosalicylic acid and 2-amino-4-(3,4-dichlorophenyl)thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 15.1%.
  • 1H-NMR(DMSO-d6): δ 7.08(1H, d, J=8.7 Hz), 7.52(1H, dd, J=8.7, 2.7 Hz), 7.71(1H, d, J=8.4 Hz), 7.91(1H, d, J=1.8 Hz), 7.94(1H, s), 8.18(1H, d, J=1.5 Hz), 12.09(2H, bs).
    • Example 542 Preparation of the Compound of Compound No. 542 (1) 2-Amino-4-[4-(trifluoromethyl)phenyl]thiazole
  • Using 4′-(trifluoromethyl)acetophenone and thiourea as the raw materials, the same operation as the Example 395(1) gave the title compound.
  • Yield: 77.5%.
  • 1H-NMR(DMSO-d6): δ 7.18(2H, s), 7.26(1H, s), 7.72(2H, d, J=8.4 Hz), 8.00(2H, d, J=8.1 Hz).
    • (2) 5-Chloro-2-hydroxy-N-{4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}benzamide (Compound No. 542)
  • Using 5-chlorosalicylic acid and 2-amino-4-[4-(trifluoromethyl)phenyl]thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 16.0%.
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=9.0 Hz), 7.53(1H, dd, J=8.7, 2.7 Hz), 7.81(2H, d, J=8.4 Hz), 7.96(1H, d, J=2.4 Hz), 7.98(1H, s), 8.16(2H, d, J=8.1 Hz), 11.91(1H, bs), 12.13(1H, bs).
    • Example 543 Preparation of the Compound of Compound No. 543 (1) 2-Acetoxy-N-{4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl)-5-chlorobenzamide
  • Using 2-acetoxy-5-chlorobenzoic acid and 1-(4-aminophenyl)-3,5-bis(trifluoromethyl)pyrazole as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 77.8%.
  • 1H-NMR(CDCl3): δ 2.36(3H, s), 7.78(1H, s), 7.14(1H, d, J=8.7 Hz), 7.48-7.51(3H, m), 7.77(2H, d, J=9.0 Hz), 7.83(1H, d, J=2.7 Hz), 8.25(1H, s).
  • [1-(4-Aminophenyl)-3,5-bis(trifluoromethyl)pyrazole: Refer to “Journal of Medicinal Chemistry”, 2000, Vol. 43, No. 16, p. 2975-2981.]
    • (2) N-{4-[3,5-Bis(trifluoromethyl)pyrazol-1-yl]phenyl}-5-chloro-2-hydroxybenzamide (Compound No. 543)
  • Using 2-acetoxy-N-{4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl}-5-chlorobenzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 73.1%.
  • 1H-NMR(DMSO-d6): o 7.04(1H, d, J=8.7 Hz), 7.48(1H, dd, J=8.7, 2.7 Hz), 7.63(2H, d, J=8.7 Hz), 7.84(1H, s), 7.89(1H, d, J=3.0 Hz), 7.94(2H, d, J=9.0 Hz), 10.65(1H, s), 11.58(1H, s).
    • Example 544 Preparation of the Compound of Compound No. 544 (1) 3,5-Bis(trifluoromethyl)-1-(3-nitrophenyl)pyrazole
  • Using hexafluoroacetylacetone and 3-nitrophenylhydrazine hydrochloride as the raw materials, the same operation as the Example 538(1) gave the title compound.
  • Yield: 94.0%.
  • 1H-NMR(CDCl3): δ 7.16(1H, s), 7.77(1H, dd, J=8.7, 8.1 Hz), 7.88-7.91(1H, m), 8.42-8.45(2H, m).
    • (2) 1-(3-Aminophenyl)-3,5-bis(trifluoromethyl)pyrazole
  • Using 3,5-bis(trifluoromethyl)-1-(3-nitrophenyl)pyrazole as the raw material, the same operation as the Example 538(2) gave the title compound.
  • Yield: 73.1%.
  • 1H-NMR(CDCl3): δ 3.89(2H, s), 6.77-6.87(3H, m), 7.04(1H, s), 7.26(1H, t, J=8.7 Hz).
    • (3) 2-Acetoxy-N-{3-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl}-5-chlorobenzamide
  • Using 2-acetoxy-5-chlorobenzoic acid and 1-(3-aminophenyl)-3,5-bis(trifluoromethyl)pyrazole as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 84.4%.
  • 1H-NMR(CDCl3): δ 2.33(3H, s), 7.09(1H, s),7.11(1H, d, J=9.0 Hz), 7.30(1H, d, J=7.8 Hz), 7.45-7.52(2H, m), 7.67(1H, d, J=8.4 Hz), 7.78(1H, d, J=2.4 Hz), 7.95(1H, s), 8.29(1H, s).
    • (4) N-{3-[3,5-Bis(trifluoromethyl)pyrazol-1-yl]phenyl}-5-chloro-2-hydroxybenzamide (Compound No. 544)
  • Using 2-acetoxy-N-{3-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl}-5-chlorobenzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 69.9%.
  • 1H-NMR(CDCl3): δ 7.01(1H, d, J=8.7 Hz), 7.10(1H, s), 7.34-7.37(1H, m), 7.42(1H, dd, J=8.7, 2.4 Hz), 7.50(1H, d, J=2.4 Hz), 7.56(1H, t, J=8.1 Hz), 7.69-7.73(1H, m), 7.95-7.98(2H, m), 11.57(1H, s).
    • Example 545 Preparation of the Compound of Compound No. 545 (1) Methyl 2-methoxy-4-phenylbenzoate
  • Dichlorobis(triphenylphosphine)palladium (29 mg, 0.04 mmol) was added to a solution of methyl 4-chloro-2-methoxybenzoate (904 mg, 4.5 mmol), phenylboronic acid (500 mg, 4.1 mmol) and cesium carbonate (2.7g, 8.2 mmol) in N,N-dimethylformamide (15 mL) under argon atmosphere, and the mixture was stirred at 120° C. for 8 hours. After the reaction mixture was cooled to room temperature, it was diluted with ethyl acetate. The ethyl acetate layer was washed successively with water and brine, and dried over anhydrous sodium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=10:1) to give the title compound (410 mg, 41.2%) as a colourless oil.
  • 1H-NMR(CDCl3): δ 3.91(3H, s), 3.98(3H, s), 7.17(1H, d, J=1.5 Hz), 7.20(1H, dd, J=8.1, 1.5 Hz), 7.31-7.50(3H, m), 7.59-7.63(2H, m), 7.89(1H, d, J=8.1 Hz).
    • (2) 2-Methoxy-4-phenylbenzoic acid
  • 2N Aqueous sodium hydroxide (5 mL) was added to a solution of methyl 2-methoxy-4-phenylbenzoate (410 mg, 1.69 mmol) in methanol (5 mL), and the mixture was refluxed for 1 hour. After the reaction mixture was cooled to room temperature, the solvent was evaporated under reduced pressure. 2N hydrochloric acid was added to the obtained residue and the separated crystal was filtered to give the title compound (371 mg, 96.0%) as a crude product.
  • 1H-NMR(DMSO-d6): δ 3.93(3H, s), 7.29(1H, dd, J=8.1, 1.5 Hz), 7.34(1H, d, J=1.5 Hz), 7.40-7.53(3H, m), 7.73-7.77(3H, m), 12.60(1H, s).
    • (3) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxy-4-phenylbenzamide
  • Using 2-methoxy-4-phenylbenzoic acid and 3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 97.5%.
  • 1H-NMR(CDCl3): δ 4.19(3H, s), 7.25(1H, m), 7.38-7.53(4H, m), 7.62-7.65(3H, m), 8.12(2H, s), 8.35(1H, d, J=8.1 Hz), 10.15(1H, brs).
    • (4) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-4-phenylbenzamide (Compound No. 545)
  • 1M Boron tribromide-dichloromethane solution (0.71 mL, 0.71 mmol) was added to a solution of N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-4-phenylbenzamide (100 mg, 0.24 mmol) in dichloromethane (5 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with water and brine, and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the title compound (69.3 mg, 71.6%) as a white powder.
  • 1H-NMR(DMSO-d6): δ 7.20(1H, dd, J=8.4.1.8 Hz), 7.30(1H, d, J=1.8 Hz), 7.39-7.51(3H, m), 7.60-7.64(3H, m), 7.70(1H, brs), 8.15(2H, s), 8.19(1H, brs), 11.59(1H, s).
    • Example 546 Preparation of the Compound of Compound No. 546 (1) 2-Amino-4-(2,5-difluorophenyl)thiazole
  • Using 2′,5′-difluoroacetophenone and thiourea as the raw materials, the same operation as the Example 395(1) gave the title compound.
  • Yield: 77.8%.
  • 1H-NMR(DMSO-d6): δ 7.45(1H, d, J=2.7 Hz), 7.11-7.17(1H, m), 7.19(2H, s), 7.28-7.36(1H, m), 7.65-7.71(1H, m).
    • (2) 5-Chloro-2-hydroxy-N-[4-(2,5-difluorophenyl)thiazol-2-yl]benzamide (Compound No. 546)
  • Using 5-chlorosalicylic acid and 2-amino-4-(2,5-difluorophenyl)thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 36.5%.
  • 1H-NMR(DMSO-d6): δ 7.09(1H, d, J=8.7 Hz), 7.22-7.30(1H, m), 7.37(1H, m), 7.53(1H, dd, J=8.7, 3.0 Hz), 7.72(1H, d, J=2.4 Hz), 7.77-7.84(1H, m), 7.94(1H, d, J=3.0 Hz), 11.89(1H, bs), 12.12(1H, bs).
    • Example 547 Preparation of the Compound of Compound No. 547 (1) 2-Acetoxy-4-chlorobenzoic acid
  • Using 4-chlorosalicylic acid, concentrated sulfuric acid and acetic anhydride as the raw materials, the same operation as the Example 34(1) gave the title compound.
  • Yield: 88.1%.
  • 1H-NMR(DMSO-d6): δ 2.25(3H, s), 7.42(1H, d, J=1.8 Hz), 7.48(1H, dd, J=8.4, 2.4 Hz), 7.94(1H, d, J=8.1 Hz), 13.31(1H, s).
    • (2) 2-Acetoxy-N-{4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl}-4-chlorobenzamide
  • Using 2-acetoxy-4-chlorobenzoic acid and 1-(4-aminophenyl)-3,5-bis(trifluoromethyl)pyrazole as the raw materials, the same operation as the Example 24 gave the title compound.
  • Yield: 74.0%.
  • 1H-NMR(CDCl3): δ 2.37(3H, s), 7.08(1H, s), 7.23(1H, d, J=1.8 Hz), 7.37(1H, dd, J=8.1, 2.1 Hz), 7.50(2H, d, J=8.7 Hz), 7.77(2H, d, J=8.7 Hz), 7.82(1H, d, J=8.1 Hz), 8.23(1H, s).
    • (3) N-{4-[3,5-Bis(trifluoromethyl)pyrazol-1-yl]phenyl}-4-chloro-2-hydroxybenzamide (Compound No. 547)
  • Using 2-acetoxy-N-{4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl}-4-chlorobenzamide as the raw material, the same operation as the Example 2(2) gave the title compound.
  • Yield: 56.6%.
  • 1H-NMR(DMSO-d6): δ 7.03-7.06(2H, m), 7.61(2H, d, J=8.7 Hz), 7.81(1H, s), 7.89-7.95(3H, m), 10.62(1H, s), 11.82(1H, s).
    • Example 548 Preparation of the Compound of Compound No. 548 (1) 1-(4-Nitrophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole
  • Using 4,4,4-trifluoro-1-phenyl-1,3-butanedione and 4-nitrophenylhydrazine hydrochloride as the raw materials, the same operation as the Example 538(1) gave the title compound.
  • Yield: 95.2%.
  • 1H-NMR(CDCl3): δ 6.80(1H, s), 7.22-7.26(2H, m), 7.37-7.45(3H, m), 7.51(2H, d, J=9.3 Hz), 8.22(2H, d, J=9.0 Hz).
    • (2) 1-(4-Aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole
  • Using 1-(4-nitrophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole as the raw material, the same operation as the Example 538(2) gave the title compound.
  • Yield: 73.0%.
  • 1H-NMR(CDCl3): δ 3.80(2H, s), 6.62(2H, d, J=8.7 Hz),6.72(1H, s), 7.08(2H, d, J=8.7 Hz), 7.22-7.26(2H, m), 7.30-7.33(3H, m).
    • (3) 5-Chloro-2-hydroxy-N-{4-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]phenyl}-benzamide (Compound No. 548)
  • Using 5-chlorosalicylic acid and 1-(4-aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 73.2%.
  • 1H-NMR(CDCl3): δ 7.02(1H, d, J=8.7 Hz), 7.21(1H, s), 7.30-7.42(7H, m), 7.47(1H, dd, J=8.7, 2.7 Hz), 7.79(2H, d, J=8.7 Hz), 7.89(1H, d, J=2.7 Hz), 10.56(1H, s), 11.61(1H, s).
    • Example 549 Preparation of the Compound of Compound No. 549 (1) 2-Amino-4-(4-methoxyphenyl)thiazole
  • Using 4′-methoxyacetophenone and thiourea as the raw materials, the same operation as the Example 395(1) gave the title compound.
  • Yield: 85.2%.
  • 1H-NMR(DMSO-d6): δ 3.76(3H, s), 6.82(1H, s), 6.92(2H, d, J=9.0 Hz), 7.01(2H, s), 7.72(2H, d, J=8.7 Hz).
    • (2) 5-Chloro-2-hydroxy-N-[4-(4-methoxyphenyl)thiazol-2-yl]benzamide (Compound No. 549)
  • Using 5-chlorosalicylic acid and 2-amino-4-(4-methoxyphenyl)thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 16.4%.
  • 1H-NMR(DMSO-d6): δ 3.80(3H, s), 7.01(2H, d, J=9.0 Hz), 7.07(1H, d, J=8.7 Hz), 7.50-7.55(2H, m), 7.86(2H, d, J=9.0 Hz), 7.96(1H, d, J=2.7 Hz), 11.90(1H, bs), 12.04(1H, bs).
    • Example 550 Preparation of the Compound of Compound No. 550 (1) 2-Amino-4-[3-(trifluoromethyl)phenyl]thiazole
  • Using 3′-(trifluoromethyl)acetophenone and thiourea as the raw materials, the same operation as the Example 395(1) gave the title compound.
  • Yield: 94.1%.
  • 1H-NMR(DMSO-d6): δ 7.19(2H, s), 7.27(1H, s), 7.61(2H, dd, J=3.9, 1.5 Hz), 8.07-8.13(2H, m).
    • (2) 5-Chloro-2-hydroxy-N-{4-[3-(trifluoromethyl)phenyl]thiazol-2-yl}benzamide (Compound No. 550)
  • Using 5-chlorosalicylic acid and 2-amino-4-[3-(trifluoromethyl)phenyl]thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 31.0%.
  • 1H-NMR(DMSO-d6): δ 7.13(1H, d, J=8.7 Hz), 7.53(1H, dd, J=9.0, 2.7 Hz), 7.70(1H, d, J=2.4 Hz), 7.71(1H, d, J=1.2 Hz), 7.95(1H, d, J=2.7 Hz), 8.00(1H, s), 8.24-8.27(2H, m), 12.16(2H, bs).
    • Example 551 Preparation of the Compound of Compound No. 551 (1) 2-Amino-4-(2,3,4,5,6-pentafluorophenyl)thiazole
  • Using 2′,3′,4′,5′,6′-pentafluoroacetophenone and thiourea as the raw materials, the same operation as the Example 395(1) gave the title compound.
  • Yield: 86.7%.
  • 1H-NMR(CDCl3): δ 5.19(2H, s), 6.83(1H, s).
    • (2) 5-Chloro-2-hydroxy-N-[4-(2,3,4,5,6-pentafluorophenyl)thiazol-2-yl]benzamide (Compound No. 551)
  • Using 5-chlorosalicylic acid and 2-amino-4-(2,3,4,5,6-pentafluorophenyl)-thiazole as the raw materials, the same operation as the Example 16 gave the title compound.
  • Yield: 23.8%.
  • 1H-NMR(DMSO-d6): o 7.08(1H, d, J=8.7 Hz), 7.53(1H, dd, J=8.7, 2.7 Hz), 7.73(1H, s), 7.93(1H, d, J=2.7 Hz), 11.85(1H, bs), 12.15(1H, bs).
    • Example 552 Preparation of the Compound of Compound No. 552
  • Iron (3 mg, 0.05 mmol) and bromine (129 μl, 2.5 mmol) were added to a solution of 2-hydroxy-N-[2,5-bis(trifluoromethyl)phenyl]benzamide (Compound No. 533; 175 mg, 0.5 mmol) in carbon tetrachloride (5 mL), and the mixture was stirred at 50° C. for 12 hours. After the reaction mixture was cooled to room temperature, it was washed with saturated aqueous sodium hydrogen carbonate, water and brine, and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the title compound (184.2 mg, 72.7%) as a white crystal.
  • 1H-NMR(DMSO-d6): δ 7.92-7.98(1H, m), 8.06(1H, d, J=2.1 Hz), 8.09(1H, d, J=8.4 Hz), 8.22(1H, d, J=2.1 Hz), 8.27-8.32(1H, m), 11.31(1H, s).
    • Example 553 Preparation of the Compound of Compound No. 553
  • Using 2,3-dihydroxybenzaldehyde and 3-[3,5-bis(trifluoromethyl)benzyl]-thiazolidine-2,4-dione(compound of Example 319(1)) as the raw materials, the same operation as the Example 319(2) gave the title compound.
  • Yield: 88.5%.
  • 1H-NMR(DMSO-d6): δ 5.02(2H, s), 6.88(1H, d, J=7.8 Hz), 7.00-7.04(2H, m), 7.79(1H, s), 8.03(2H, s), 8.07(1H, s), 9.49(1H, s), 9.91(1H, s).
    • Example 554 Preparation of the Compound of Compound No. 554
  • A mixture of 5-chlorosalicylaldehyde (157 mg, 1 mmol), 2-amino-4-tert-amylphenyl phenyl ether (255 mg, 1 mmol) and ethanol (2 mL) was stirred at room temperature for 18 hours. The residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel(n-hexane:ethyl acetate=100:1) to give the title compound (57 mg, 14.4%) as a white solid.
  • 1H-NMR(CDCl3):δ 0.66(3H, t, J=7.5 Hz), 1.26(6H, s), 1.61(2H, q, J=7.5 Hz), 6.88-6.94(3H, m), 7.04(1H, dd, J=8.0, 1.6 Hz), 7.15-7.32(7H, m), 8.61(1H, s), 13.20(1H, s).
    • Example 555 Preparation of the Compound of Compound No. 555
  • A mixture of 4-chloro-2-({[2-phenoxy-5-(tert-amyl)phenyl]imino}-methyl)phenol (Compound No. 554; 13 mg, 0.03 mmol), sodium borohydride (1.2 mg, 0.03 mmol) and methanol (1 mL) was stirred at room temperature for 5 minutes. The residue obtained by evaporation of the solvent under reduced pressure was purified by thin layer chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the title compound (13 mg, 100%) as a colourless oil.
  • 1H-NMR(CDCl3): δ 0.69(3H, t, J=7.6 Hz), 1.28(6H, s), 1.63(2H, q, J=7.6 Hz), 4.41(2H, s), 6.78(1H, m), 6.93-6.83(5H, m), 7.03(1H, m), 7.15(2H, m), 7.28(3H, m).
    • Test Example 1 Proliferation Inhibitory Test of Mast Cell under stimulation by SCF and IL-3
  • Bone marrow-derived cultured mast cells (105 cells/ml) of NC/Nga mouse were cultured with rmIL-3 (100 U/ml) and SCF (100 ng/ml) in the presence or absence of a test drug in α-Modified Eagle's Medium containing 10% of bovine fetal serum without phenol red, and then stained with trypan blue, and the number of living cells was counted. The results are shown in the following table.
    Number of Cell (×105/ml)
    Compound Culture Time
    Number Concentration(μM) 0 hr 24 hr 48 hr 72 hr
    — 0 1.0 1.3 1.7 2.6
    50 1 1.0 0.86 0.84 1.16
    5 1.0 0.7 0.52 0.22
    • Test Example 2 Degranulation Inhibitory Test of Mast Cell
  • Anti DNP IgE was added to mouse bone marrow-derived cultured mast cells (BMCMC) which were treated beforehand with anti DNP IgE for 4 days for expression of IgE receptor. The cells were cultured for 3 days, and treated for 1 hour with or without the addition of a test substance. Then, the medium was changed to a -Modified Eagle's Medium containing 10% of bovine fetal serum without phenol red. After cultivation for 60 minutes with rmIL-3 (100 U/ml) and DNP-BSA (50ng/ml) in the presence or absence of the test substance, the concentrations of β-hexosaminidase in the culture medium and in the cells were determined, and the progress of degranulation was measured from a ratio of the amounts. The inhibitory ratio of the degranulation by the drug was calculated when degranulation in the absence of the test substance was taken as 100%, and degranulation in the presence of anti DNP-IgE only and in the absence of the test substance was taken as 0%. The results are shown in the following table.
    Inhibitory Ration of Degranulation(%)
    Compound Number at 10 μM Drug Concentration
    50 >99
    56 92
    63 62
    73 91
    100 83
    101 90
    113 93
    114 88
    122 91
    163 88
    195 72
    • Test Example 3 IgE Production Inhibitory Test of Spleen B Cell
  • B cells isolated from mouse spleen were cultured with 200 U/ml of rmIL-4 and 100 ng/ml of soluble mCD40 ligand in the presence or absence of a test drug in PRMI 1640 medium containing 10% of bovine fetal serum for 9 days, and the amount of IgE in the culture medium was measured by ELISA method. The results are shown in the following table
    Amount of IgE(ng/ml)
    Concentration(μM)
    Compound Number 0 0.1 1.0
    — 45.6 — —
    50 — 24 ND

    ND = not detected
    • Test Example 4 Immediate Type Allergy Reaction Inhibitory Test (Ear Swelling Test)
  • To NC/Nga mouse sensitized by an intravenous administration of anti DNP-IgE, a diluent with a test compound for the drug administered group or that without a test drug for the control group was intraperitoneally administered. Two hours after the administration, picryl chloride dissolved in olive oil was applied to auricle to induce immediate allergy, and then swelling of the auricle was measured with passage of time for comparison of the drug administered group and the control group. The results of Compound 50 (dose: 15 mg/kg) are shown in FIG. 1.
    • Test Example 5 Dermatitis Inhibitory Test by Atopic Dermatitis Model Using NC/Nga Mouse
  • To the conventional NC/Nga mouse with the onset of severe dermatitis, an ointment containing 1% of a test substance for the drug treated group or a base material of the ointment for the control group was applied once a day, and clinical symptoms were recorded as scores with passage of day. Furthermore, the amounts of IgE in blood before and after the test were measured by ELISA. The results for Compound 50 are shown in FIG. 2.
    • Test Example 6 Proliferation Inhibitory Test of Fibrosarcoma (HT-1080) Under PDGF Stimulation
  • HT-1080 cells were cultured for 2 hours in EMEM medium containing 1% of FBS and NEAA in the presence or absence of a test substance. PDGF was added and the cells were cultured for 48 hours, and the proliferation of the cells was measured by MTT assay. The results are shown in the following table.
    Inhibitory Ratio of Proliferation(%)
    Compound Drug Concentration
    Number 500 nM 250 nM
    50 96.6 65.4
    51 97.6 62.4
    67 70.9 38.5
    73 84.9 52.0
    63 77.9 48.3
    114 95.7 48.8
    163 80.8 16.9
    71 83.1 57.9
    56 96.9 37.5
    98 59.4 26.4
    196 80.2 47.3
    122 51.1 32.9
    195 81.7 44.7
    199 24.2 26.2
    201 76.2 60.3
    532 91.8 42.2
    552 19.4 24.0
    101 80.0 53.2
    • INDUSTRIAL APPLICABILITY
  • The medicaments of the present invention are useful for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma.

Claims (23)

1. A medicament for the preventive and/or therapeutic treatment of an allergic disease and/or endometriosis and/or hysteromyoma, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:
Figure US20060122243A1-20060608-C01049
wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted),
A represents hydrogen atom or acetyl group,
E represents an aryl group which may be substituted or a heteroaryl group which may be substituted,
ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
2. The medicament according to claim 1, wherein X is a group selected from the following connecting group α (said group may be substituted): [Connecting Group α] The groups of the following formulas:
Figure US20060122243A1-20060608-C01050
wherein a bond at the left end binds to ring Z and a bond at the right end binds to E.
3. The medicament according to claim 2, wherein X is a group represented by the following formula (said group may be substituted):
Figure US20060122243A1-20060608-C01051
wherein a bond at the left end binds to ring Z and a bond at the right end binds to E.
4. The medicament according to claim 1, wherein A is a hydrogen atom.
5. The medicament according to claim 1, wherein ring Z is a C6 to C10 arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I), or a 5 to 1 3-membered heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I).
6. The medicament according to claim 5, wherein ring Z is a ring selected from the following ring group β:
[Ring Group β] benzene ring, naphthalene ring, thiophene ring, pyridine ring, indole ring, quinoxaline ring, and carbazole ring wherein said ring may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I).
7. The medicament according to clam 6, wherein ring Z is a benzene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I).
8. The medicament according to claim 7, wherein ring Z is a benzene ring which is substituted with halogen atom(s) in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I).
9. The medicament according to claim 6, wherein ring Z is a naphthalene ring which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined in the general formula (I).
10. The medicament according to claim 1, wherein E is a C6 to C10 aryl group which may be substituted or a 5 to 13-membered heteroaryl group which may be substituted.
11. The medicament according to claim 10, wherein E is a phenyl group which may be substituted.
12. The medicament according to claim 11, wherein E is 3,5-bis(trifluoromethyl)phenyl group.
13. The medicament according to claim 10, wherein E is a 5-membered heteroaryl group which may be substituted.
14. The medicament according to claim 1, having inhibitory activity against production of IgE, inhibitory activity against degranulation from activated a mast cell, and/or inhibitory activity against proliferation of a mast cell.
15. A compound represented by the general formula (I-1) or a salt thereof, or a hydrate thereof or a solvate thereof:
Figure US20060122243A1-20060608-C01052
wherein Z1 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, and E1 represents a phenyl group which may be substituted.
16. The compound according to claim 15 or a salt thereof, or a hydrate thereof or a solvate thereof, wherein E1 is 2,5-bis(trifluoromethyl)phenyl group or 3,5-bis(trifluoromethyl)phenyl group, provided that the following compounds are excluded:
N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide,
N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide,
N-[3,5-bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide,
N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide, and
N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-nitrobenzamide.
17. The compound according to claim 16 or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z1 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
18. A compound represented by the general formula (I-2) or a salt thereof, or a hydrate thereof or a solvate thereof:
Figure US20060122243A1-20060608-C01053
wherein Z2 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, E2 represents a 2,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group or a 3,5-di-substituted phenyl group wherein one of said substituents is trifluoromethyl group, provided that the following compounds are excluded:
5-chloro-N-[5-chloro-3-(trifluoromethyl)phenyl]-2-hydroxybenzamide,
5-fluoro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]benzamide,
5-fluoro-2-hydroxy-N-[2-(6,6,6-trifluorohexyloxy)-5-(trifluoromethyl)phenyl]benzamide,
5-chloro-N-[2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide,
5-chloro-2-hydroxy-N-[2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl]benzamide,
5-chloro-N-[2-(4-chlorophenyl)sulfanyl-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide,
5-chloro-2-hydoxy-N-[2-(1-naphthyloxy)-5-(trifluoromethyl)phenyl]benzamide, and
5-chloro-2-hydoxy-N-[2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl]benzamide.
19. The compound according to claim 18 or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z2 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
20. The compound represented by the general formula (I-3) or a salt thereof, or a hydrate thereof or a solvate thereof:
Figure US20060122243A1-20060608-C01054
wherein Z3 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, E3 represents a group represented by the following formula:
Figure US20060122243A1-20060608-C01055
wherein one of R3e2 and R3e3 represents hydrogen atom and the other represents a hydrocarbon group which may be substituted or hydroxyl group which may be substituted, and R3e5 represents a C2 to C6 hydrocarbon group which may be substituted.
21. The compound according to claim 20 or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z3 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
22. A compound represented by the general formula (I-4) or a salt thereof, or a hydrate thereof or a solvate thereof:
Figure US20060122243A1-20060608-C01056
wherein Z4 represents 2-hydroxyphenyl group which may be substituted in the 5-position or 2-acetoxyphenyl group which may be substituted in the 5-position, E4 represents a group represented by the following formula:
Figure US20060122243A1-20060608-C01057
wherein R4e4 represents a hydrocarbon group which may be substituted, R4e5 represents a halogen atom, cyano group, an acyl group which may be substituted, or a heterocyclic group which may be substituted.
23. The compound according to claim 22 or a salt thereof, or a hydrate thereof or a solvate thereof, wherein Z4 is 2-hydroxyphenyl group which is substituted with a halogen atom in the 5-position or 2-acetoxyphenyl group which is substituted with a halogen atom in the 5-position.
US10/515,623 2002-06-06 2003-06-05 Antiallergic Abandoned US20060122243A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/783,324 US7700655B2 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/783,325 US20070185059A1 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/952,686 US20080090779A1 (en) 2002-06-06 2007-12-07 Antiallergic agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-165148 2002-06-06
JP2002165148 2002-06-06
PCT/JP2003/007120 WO2003103665A1 (en) 2002-06-06 2003-06-05 Antiallergic

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/783,325 Division US20070185059A1 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/783,324 Division US7700655B2 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/952,686 Continuation US20080090779A1 (en) 2002-06-06 2007-12-07 Antiallergic agents

Publications (1)

Publication Number Publication Date
US20060122243A1 true US20060122243A1 (en) 2006-06-08

Family

ID=29727583

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/515,623 Abandoned US20060122243A1 (en) 2002-06-06 2003-06-05 Antiallergic
US11/783,325 Abandoned US20070185059A1 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/783,324 Expired - Fee Related US7700655B2 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/952,686 Abandoned US20080090779A1 (en) 2002-06-06 2007-12-07 Antiallergic agents

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/783,325 Abandoned US20070185059A1 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/783,324 Expired - Fee Related US7700655B2 (en) 2002-06-06 2007-04-09 Antiallergic agents
US11/952,686 Abandoned US20080090779A1 (en) 2002-06-06 2007-12-07 Antiallergic agents

Country Status (10)

Country Link
US (4) US20060122243A1 (en)
EP (1) EP1514544A4 (en)
JP (2) JP4660674B2 (en)
KR (1) KR101054562B1 (en)
CN (1) CN1658872B (en)
AU (1) AU2003242103A1 (en)
CA (1) CA2488367A1 (en)
EA (1) EA009701B1 (en)
TW (1) TW200402291A (en)
WO (1) WO2003103665A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211680A1 (en) * 2003-09-17 2006-09-21 Yoshitaka Tomigahara Cinnamoyl compound and use of the same
US20070123521A1 (en) * 2003-09-17 2007-05-31 Yoshitaka Tomigahara Cinnamoyl derivatives and use thereof
US20070259886A1 (en) * 2006-03-01 2007-11-08 Astex Therapeutics, Ltd. Dihydroxyphenyl isoindolylmethanones
US20070259871A1 (en) * 2005-04-13 2007-11-08 Astex Therapeutics Limited Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90
US20080153812A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Novel compounds
US20080311074A1 (en) * 2002-06-10 2008-12-18 Institute Of Medical Molecular Design Inc. Inhibitors against activation of NF-kappaB
US20090318468A1 (en) * 2008-06-19 2009-12-24 Astrazeneca Ab Pyrazole compounds 436
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US20100092474A1 (en) * 2006-10-12 2010-04-15 Neil James Gallagher Pharmaceutical combinations
US20100152184A1 (en) * 2006-10-12 2010-06-17 Astex Therapeutics Limited Pharmaceutical compounds
US20100179145A1 (en) * 2006-10-12 2010-07-15 Neil James Gallagher Pharmaceutical combinations
US20100274051A1 (en) * 2000-12-18 2010-10-28 Institute Of Medicinal Molecular Design. Inc. Inflammatory cytokine release inhibitor
US20110046155A1 (en) * 2006-10-12 2011-02-24 Martyn Frederickson Hydrobenzamide derivatives as inhibitors of hsp90
US20110098290A1 (en) * 2008-04-11 2011-04-28 Brian John Williams Pharmaceutical compounds
US20110105501A1 (en) * 2006-10-12 2011-05-05 Astex Therapeutics Limited Pharmaceutical combinations
WO2015037659A1 (en) 2013-09-13 2015-03-19 株式会社医薬分子設計研究所 Aqueous solution formulation, and manufacturing method for same
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
US10420764B2 (en) 2012-12-21 2019-09-24 Astrazeneca Ab Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US11529361B2 (en) 2015-05-29 2022-12-20 UNION therapeutics A/S Halogenated salicylanilides for treating Clostridium infections

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4743382B2 (en) * 2002-06-06 2011-08-10 株式会社医薬分子設計研究所 O-substituted hydroxyaryl derivatives
WO2003103665A1 (en) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Antiallergic
EP1535610A4 (en) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc Therapeutic agent for cancer
AU2003251944B2 (en) 2002-07-15 2008-06-26 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
WO2005007151A1 (en) * 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. Chromatosis remedies
WO2006013873A1 (en) * 2004-08-05 2006-02-09 Institute Of Medicinal Molecular Design. Inc. Drugs having cyclooxygenase inhibiting activity
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
WO2006077901A1 (en) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf expression inhibitor
DE102011083271A1 (en) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatic amidothiazoles, their cosmetic or dermatological use and cosmetic or dermatological preparations containing such aromatic amidothiazoles
AU2013259526B2 (en) 2012-05-08 2018-02-15 Aeromics, Inc. New methods
WO2015069948A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel methods
US20170258816A1 (en) 2014-09-12 2017-09-14 Antibiotx Aps Antibacterial Use of Halogenated Salicylanilides
EP3313388A4 (en) 2015-06-24 2019-05-15 Duke University Chemical modulators of signaling pathways and therapeutic use
AR126669A1 (en) * 2021-08-02 2023-11-01 Eurofarma Laboratorios S A N-ACYLYDRAZONIC COMPOUNDS INHIBITORS OF Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS OF THESE AND KITS
CN117105810B (en) * 2023-10-23 2024-02-09 中国农业大学 Compound with broad-spectrum antibacterial activity and antibacterial composition thereof

Citations (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2199A (en) * 1841-07-29 Improvement in the manufacture of buttons
US19412A (en) * 1858-02-23 Improvement in shovel-plows
US19958A (en) * 1858-04-13 Improvement in raking attachments to harvesters
US48891A (en) * 1865-07-25 Improved vessel for holding petroleum
US69267A (en) * 1867-09-24 Improved means for extinguishing fire in steamships
US87650A (en) * 1869-03-09 Improvement in the manufacture of artificial fuel
US122244A (en) * 1871-12-26 Improvement in fire-extinguishers
US141811A (en) * 1873-08-12 Improvement sn reefing fore and aft sails
US157844A (en) * 1874-12-15 Improvement in steam x c cylinder lubricators
US165398A (en) * 1875-07-06 Improvement in processes for cleansing gas-retorts
US259877A (en) * 1882-06-20 Under-garment for infants
US3332996A (en) * 1961-03-25 1967-07-25 Cassella Farbwerke Mainkur Ag Trifluoromethyl-substituted salicylanilides
US3906023A (en) * 1971-04-28 1975-09-16 Bayer Ag Substituted-2-alkoxycarbonyloxy benzoic acid anilides
US4358443A (en) * 1980-04-14 1982-11-09 The Research Foundation Of State University Of New York Method and composition for controlling the growth of microorganisms
US4560549A (en) * 1983-08-24 1985-12-24 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4659710A (en) * 1985-04-17 1987-04-21 Ss Pharmaceutical Co., Ltd. 1,7-Naphthyridine derivatives and pharmaceutical compositions
US4661630A (en) * 1982-12-27 1987-04-28 Eisai Co., Ltd. Carboxylic acid amides and their derivatives
US4725590A (en) * 1983-08-24 1988-02-16 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
US4952588A (en) * 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) * 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US5126341A (en) * 1990-04-16 1992-06-30 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory 1,8-naphthyridin-2-one derivatives
US5589514A (en) * 1992-01-16 1996-12-31 Hoechst Aktiengesellschaft Arylcycloalkyl derivatives, their production and their use
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6117859A (en) * 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
US6159988A (en) * 1992-01-16 2000-12-12 Hoeschst Aktiengesellschaft Arylcycloalkyl derivatives, their production and their use
US6166028A (en) * 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US20030083386A1 (en) * 1999-12-13 2003-05-01 Junying Yuan Small molecules used to increase cell death
US6566394B1 (en) * 1999-08-11 2003-05-20 Mercian Corporation Salicylamide derivatives
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US6734180B1 (en) * 1998-07-22 2004-05-11 Daiichi Suntory Pharma Co., Ltd. NF-κB inhibitor comprising an indan derivative as an active ingredient
US6787652B1 (en) * 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1017606B (en) 1951-12-29 1957-10-17 Geigy Ag J R Process for the preparation of bactericidal salicylanilides
JPS37225B1 (en) 1958-07-23 1962-01-23
GB996074A (en) * 1962-02-27 1965-06-23 Herbert Christian Stecker Improvements in or relating to germicidal compositions
NL292958A (en) * 1962-05-29 1900-01-01
GB1079177A (en) 1963-06-11 1967-08-16 Stecker Internat S P A Improvements in pesticide composition for destroying internal worm parasites in animals
FR1481713A (en) 1965-10-11 1967-05-19 Stecker Internat S P A Benzoazinediones and germicidal compositions which contain them
GB1099865A (en) 1965-10-11 1968-01-17 Stecker Internat S P A Benzoazinediones and germicidal compositions made therewith
JPS52110835A (en) 1976-03-11 1977-09-17 Microbial Chem Res Found Remedy for immunological diseases containing benzanilide derivative as active ingredient
FR2434158A1 (en) 1978-08-25 1980-03-21 Esteve Int Prod NOVEL 1,3-BENZOXAZINE-2,4-DIONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
JPS57112360A (en) * 1980-08-08 1982-07-13 Risaachi Fuandeeshiyon Obu Sut Microbe growth controlling compound and method
CA1219587A (en) 1981-12-14 1987-03-24 Norman P. Jensen Hydroxybenzylaminobenzenes as anti-inflammatory agents
JPS6299329A (en) * 1983-08-24 1987-05-08 ユニリ−バ−・ナ−ムロ−ゼ・ベンノ−トシヤ−プ Antiinflammatory composition for skin
JPH0755902B2 (en) 1986-10-21 1995-06-14 株式会社ツムラ Aldo-reductase inhibitor
JPS6487491A (en) 1987-09-30 1989-03-31 Hitachi Ltd Guide apparatus for passenger conveyor
JPH04217916A (en) 1990-06-21 1992-08-07 Japan Tobacco Inc Anti-inflammatory agent
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5661153A (en) 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
JPH08175990A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Pi3 kinase-inhibiting agent and its production
JPH09169747A (en) 1995-12-18 1997-06-30 Kyorin Pharmaceut Co Ltd New substituted phenylthiazolidine-2,4-dione derivative and its production
JPH09203951A (en) 1996-01-26 1997-08-05 Minolta Co Ltd Waterproof mechanism for cartridge holder
JPH09227561A (en) 1996-02-21 1997-09-02 Tanabe Seiyaku Co Ltd Xanthine derivative
JPH1045738A (en) 1996-07-29 1998-02-17 Microbial Chem Res Found Antibiotic substance epoxyquinomicin c and d, its production and antirheumatic agent
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DK0960335T3 (en) * 1997-01-15 2005-06-20 Telik Inc Modulators of insulin receptor activity
JPH1121243A (en) 1997-05-06 1999-01-26 Tanabe Seiyaku Co Ltd Medicinal composition
JPH1121225A (en) 1997-06-27 1999-01-26 Tanabe Seiyaku Co Ltd Ingredient for beautifying and whitening and skin preparation for external use for beautifying and whitening containing the same ingredient
JPH11180873A (en) * 1997-12-22 1999-07-06 Kaken Shoyaku Kk Nf-kappa b activity inhibitor
AU2662899A (en) * 1998-02-13 1999-08-30 Medinox, Inc. Methods for the controlled delivery of carbon disulfide for the treatment of inflammatory conditions
US20020019412A1 (en) * 1998-03-12 2002-02-14 Henrik Sune Andersen Modulators of protein tyrosine phosphatases (ptpases)
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
ATE308546T1 (en) 1998-03-12 2005-11-15 Novo Nordisk As MODULATORS OF PROTEIN TYROSINE PHOSPHATASE (PTPASES)
AU2713699A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
AU2713799A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
CN1181817C (en) * 1998-03-20 2004-12-29 第一三得利制药株式会社 NF-KB inhibitors containing as active ingredient phenylmethyl benzoquinone
AU3665199A (en) * 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
CA2343101A1 (en) 1998-09-11 2000-03-23 Ajinomoto Co., Inc. Benzene derivatives and medicinal use thereof
JP2000169479A (en) 1998-12-09 2000-06-20 Kyowa Hakko Kogyo Co Ltd Nf-kappa b activation inhibitor
WO2001010865A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
EP1088819B1 (en) 1999-09-30 2005-06-15 Pfizer Products Inc. 6-azauracil derivatives as thyroid receptor ligands
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
ATE356798T1 (en) * 2000-10-02 2007-04-15 Univ New York State Res Found NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTI-INFLAMMATORY AGENTS
UA82827C2 (en) 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
JP4083422B2 (en) * 2000-12-22 2008-04-30 石原産業株式会社 Aniline derivatives or salts thereof, and cytokine production inhibitors containing them
CA2432713C (en) * 2000-12-22 2009-10-27 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
JPWO2002076918A1 (en) * 2001-03-27 2004-07-15 第一サントリーファーマ株式会社 NF-κB inhibitor comprising a substituted benzoic acid derivative as an active ingredient
US20040025987A1 (en) * 2002-05-31 2004-02-12 Bhagwat Anand W. High carbon steel wire with bainitic structure for spring and other cold-formed applications
AU2003242131A1 (en) 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Immunity-related protein kinase inhibitors
AU2003242127A1 (en) 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
WO2003103665A1 (en) 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Antiallergic
EP1535610A4 (en) 2002-06-10 2008-12-31 Inst Med Molecular Design Inc Therapeutic agent for cancer
CA2489091A1 (en) 2002-06-10 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibitors against activation of nf-kappab
AU2003242124A1 (en) 2002-06-11 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of neurodegenerative diseases
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
WO2005007151A1 (en) 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. Chromatosis remedies
US7059195B1 (en) * 2004-12-02 2006-06-13 Honeywell International Inc. Disposable and trimmable wireless pressure sensor for medical applications
JP4217981B2 (en) 2005-02-08 2009-02-04 Ｓｍｃ株式会社 Combined linear / rotary actuator
JP4217916B2 (en) 2006-02-15 2009-02-04 三菱ふそうトラック・バス株式会社 Control device for hybrid electric vehicle

Patent Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US259877A (en) * 1882-06-20 Under-garment for infants
US69267A (en) * 1867-09-24 Improved means for extinguishing fire in steamships
US2199A (en) * 1841-07-29 Improvement in the manufacture of buttons
US48891A (en) * 1865-07-25 Improved vessel for holding petroleum
US19412A (en) * 1858-02-23 Improvement in shovel-plows
US87650A (en) * 1869-03-09 Improvement in the manufacture of artificial fuel
US122244A (en) * 1871-12-26 Improvement in fire-extinguishers
US141811A (en) * 1873-08-12 Improvement sn reefing fore and aft sails
US157844A (en) * 1874-12-15 Improvement in steam x c cylinder lubricators
US165398A (en) * 1875-07-06 Improvement in processes for cleansing gas-retorts
US19958A (en) * 1858-04-13 Improvement in raking attachments to harvesters
US3332996A (en) * 1961-03-25 1967-07-25 Cassella Farbwerke Mainkur Ag Trifluoromethyl-substituted salicylanilides
US3906023A (en) * 1971-04-28 1975-09-16 Bayer Ag Substituted-2-alkoxycarbonyloxy benzoic acid anilides
US4358443A (en) * 1980-04-14 1982-11-09 The Research Foundation Of State University Of New York Method and composition for controlling the growth of microorganisms
US4661630A (en) * 1982-12-27 1987-04-28 Eisai Co., Ltd. Carboxylic acid amides and their derivatives
US4560549A (en) * 1983-08-24 1985-12-24 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4725590A (en) * 1983-08-24 1988-02-16 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4659710A (en) * 1985-04-17 1987-04-21 Ss Pharmaceutical Co., Ltd. 1,7-Naphthyridine derivatives and pharmaceutical compositions
US4690924A (en) * 1985-04-17 1987-09-01 Ss Pharmaceutical Co., Ltd. 1,7-Naphthyridine derivatives and medicinal preparations containing same
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US4966906A (en) * 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) * 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US5126341A (en) * 1990-04-16 1992-06-30 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory 1,8-naphthyridin-2-one derivatives
US5589514A (en) * 1992-01-16 1996-12-31 Hoechst Aktiengesellschaft Arylcycloalkyl derivatives, their production and their use
US5776977A (en) * 1992-01-16 1998-07-07 Hoechst Aktiengesellschaft Arylcycloalkyl derivatives, their production and their use
US6159988A (en) * 1992-01-16 2000-12-12 Hoeschst Aktiengesellschaft Arylcycloalkyl derivatives, their production and their use
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US6117859A (en) * 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6410586B1 (en) * 1998-03-12 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6734180B1 (en) * 1998-07-22 2004-05-11 Daiichi Suntory Pharma Co., Ltd. NF-κB inhibitor comprising an indan derivative as an active ingredient
US6166028A (en) * 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US6566394B1 (en) * 1999-08-11 2003-05-20 Mercian Corporation Salicylamide derivatives
US6787652B1 (en) * 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
US20030083386A1 (en) * 1999-12-13 2003-05-01 Junying Yuan Small molecules used to increase cell death
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097759B2 (en) 2000-12-18 2012-01-17 Institute Of Medicinal Molecular Design, Inc. Inflammatory cytokine release inhibitor
US20100274051A1 (en) * 2000-12-18 2010-10-28 Institute Of Medicinal Molecular Design. Inc. Inflammatory cytokine release inhibitor
US20080311074A1 (en) * 2002-06-10 2008-12-18 Institute Of Medical Molecular Design Inc. Inhibitors against activation of NF-kappaB
US7989478B2 (en) 2003-09-17 2011-08-02 Sumitomo Chemical Company, Limited Cinnamoyl compound and use of the same
US20070123521A1 (en) * 2003-09-17 2007-05-31 Yoshitaka Tomigahara Cinnamoyl derivatives and use thereof
US20060211680A1 (en) * 2003-09-17 2006-09-21 Yoshitaka Tomigahara Cinnamoyl compound and use of the same
US8524729B2 (en) 2003-09-17 2013-09-03 Sumitomo Chemical Company, Limited Cinnamoyl derivatives and use thereof
US7700625B2 (en) 2005-04-13 2010-04-20 Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
US8530469B2 (en) 2005-04-13 2013-09-10 Astex Therapeutics Ltd. Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90
US8816087B2 (en) 2005-04-13 2014-08-26 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
US20090215772A1 (en) * 2005-04-13 2009-08-27 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of HSP90
US9914719B2 (en) 2005-04-13 2018-03-13 Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors of HSP90
US20100216782A1 (en) * 2005-04-13 2010-08-26 Gianni Chessari Hydroxybenzamide derivatives and their use as inhibitors of hsp90
US8101648B2 (en) 2005-04-13 2012-01-24 Astex Therapeutics, Ltd. Hydroxybenzamide derivatives and their use as inhibitors of HSP90
US20070259871A1 (en) * 2005-04-13 2007-11-08 Astex Therapeutics Limited Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US8106057B2 (en) 2006-03-01 2012-01-31 Astex Therapeutics, Ltd. Dihydroxyphenyl isoindolylmethanones
US20100286167A1 (en) * 2006-03-01 2010-11-11 Gianni Chessari Dihydroxyphenyl isoindolylmethanones
US20070259886A1 (en) * 2006-03-01 2007-11-08 Astex Therapeutics, Ltd. Dihydroxyphenyl isoindolylmethanones
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US20100152184A1 (en) * 2006-10-12 2010-06-17 Astex Therapeutics Limited Pharmaceutical compounds
US9428439B2 (en) 2006-10-12 2016-08-30 Astex Therapeutics Ltd. Hydrobenzamide derivatives as inhibitors of Hsp90
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
US20110046155A1 (en) * 2006-10-12 2011-02-24 Martyn Frederickson Hydrobenzamide derivatives as inhibitors of hsp90
US20110105501A1 (en) * 2006-10-12 2011-05-05 Astex Therapeutics Limited Pharmaceutical combinations
US20100179145A1 (en) * 2006-10-12 2010-07-15 Neil James Gallagher Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8779132B2 (en) 2006-10-12 2014-07-15 Astex Therapeutics Limited Pharmaceutical compounds
US20100092474A1 (en) * 2006-10-12 2010-04-15 Neil James Gallagher Pharmaceutical combinations
US8653084B2 (en) 2006-10-12 2014-02-18 Astex Therapeutics Ltd. Hydrobenzamide derivatives as inhibitors of Hsp90
US10301267B2 (en) 2006-12-21 2019-05-28 Astrazeneca Ab Compounds
US20080153812A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Novel compounds
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8604022B2 (en) 2006-12-21 2013-12-10 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
US9688640B2 (en) 2006-12-21 2017-06-27 Astrazeneca Ab Methods of treating cancer with a pyrazole derivative
US8129391B2 (en) 2006-12-21 2012-03-06 Astrazeneca Ab N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
US20100273811A1 (en) * 2006-12-21 2010-10-28 Astrazeneca Ab N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof
US8383619B2 (en) 2008-04-11 2013-02-26 Astex Therapeutics Limited Pharmaceutical compounds
US20110098290A1 (en) * 2008-04-11 2011-04-28 Brian John Williams Pharmaceutical compounds
US8664218B2 (en) 2008-04-11 2014-03-04 Astex Therapeutics Ltd. Pharmaceutical compounds
US20090318468A1 (en) * 2008-06-19 2009-12-24 Astrazeneca Ab Pyrazole compounds 436
US10420764B2 (en) 2012-12-21 2019-09-24 Astrazeneca Ab Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
WO2015037659A1 (en) 2013-09-13 2015-03-19 株式会社医薬分子設計研究所 Aqueous solution formulation, and manufacturing method for same
US9974860B2 (en) 2013-09-13 2018-05-22 Akiko Itai Aqueous solution formulation and method for manufacturing same
US11529361B2 (en) 2015-05-29 2022-12-20 UNION therapeutics A/S Halogenated salicylanilides for treating Clostridium infections
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide

Also Published As

Publication number Publication date
CN1658872B (en) 2010-09-22
AU2003242103A1 (en) 2003-12-22
TW200402291A (en) 2004-02-16
KR101054562B1 (en) 2011-08-04
US20070185059A1 (en) 2007-08-09
EP1514544A1 (en) 2005-03-16
CA2488367A1 (en) 2003-12-18
JPWO2003103665A1 (en) 2005-10-06
US20070185110A1 (en) 2007-08-09
EA009701B1 (en) 2008-02-28
WO2003103665A1 (en) 2003-12-18
KR20050023287A (en) 2005-03-09
CN1658872A (en) 2005-08-24
JP2010215644A (en) 2010-09-30
US20080090779A1 (en) 2008-04-17
US7700655B2 (en) 2010-04-20
EA200401612A1 (en) 2005-08-25
EP1514544A4 (en) 2009-01-07
JP4660674B2 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
US7700655B2 (en) Antiallergic agents
US20060111409A1 (en) Medicament for treatment of diabetes
US20060100257A1 (en) Inhibitors against the activation of ap-1 and nfat
US20060019958A1 (en) Immunity-related protein kinase inhibitors
US20060014811A1 (en) Medicament for treatment of cancer
US20080234233A1 (en) Medicament for treatment of neurodegenerative diseases
US20080311074A1 (en) Inhibitors against activation of NF-kappaB
US20080318956A1 (en) Inflammatory cytokine release inhibitor
KR20050023286A (en) Inhibitors against the activation of AP-1 and NFAT
KR20050023284A (en) Therapeutic drug for diabetes

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC., JAP

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER LISTED ON THE NOTICE OF RECORDATION PREVIOUSLY RECORDED ON REEL 016709 FRAME 0934;ASSIGNORS:MUTO, SUSUMU;ITAI, AKIKO;REEL/FRAME:022085/0434

Effective date: 20050530